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ABSTRACT 
Human papillomavirus (HPV) is the etiologic agent for cervical cancer with HPV 
type 16 (HPV16) being found in about 50% of cervical cancers worldwide. HPVs vary in 
genomic (DNA) sequence not only between types, but also within types, known as variants. 
Variants of a particular HPV type may differ by up to 2% in nucleotide sequence in the 
coding region and up to 5% in the noncoding region. Variants within HPV16 have been 
identified and grouped into six distinct phylogenetic branches, which segregate 
geographically: European (E), Asian-American (As.A), African-1 (Af-1), African-2 (Af-
2), Asian (As), and North American (NA). However, there remains an unclear relationship 
of HPV variants as they pertain to viral infection, HPV persistence, and the risk of 
developing cervical cancer. Thus, we studied HPV16 variants from exfoliated cervical cells 
obtained from women enrolled in the Carolina Women’s Care Study (CWCS). 
The CWCS followed the HPV status of freshman female students attending the 
University of South Carolina (UofSC) from enrollment at UofSC until graduation. 
Exfoliated cervical cells were collected from CWCS participants every 6-months and 
analyzed for the presence and type of HPV using real-time PCR and a commercial line-
blot assay (INNO-LiPA). HPV16 positive cervical DNA samples were amplified by PCR 
using specific primers for the Long Control Region (LCR) of the HPV16 genome, the DNA 
sequence of the PCR product was determined, and the HPV16 variant identified.  
Of the 467 CWCS participants, 160 participants (365 samples) were HPV16 
positive at some point during the study. We obtained informative HPV16 variant results on 
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74 participants (160 samples). Our results determined that the E variant is by far the most 
common amongst the participants (77%). However, the Af-2 variant was much more 
common in African American CWCS participants (24% of HPV16 positive samples) than 
in European American CWCS participants (4% of HPV positive samples). Unfortunately, 
due to small sample size and the predominance of the E variant, it was not possible to 
determine what role, if any; the different variants play in HPV persistence. 
In the second part of this thesis we present data from microarray studies comparing 
the gene expression profiles in RNA isolated from exfoliated cervical cells from CWCS 
participants who either clear an HPV16 infection or have a persistent HPV16 infection. 
HPV infection is very common but HPV infections in most women are cleared by the 
immune system in a period of 12-24 months. However, about 10% of HPV infections 
persist, leading to cytological abnormalities of the squamous epithelium of the cervix, 
lesions which can ultimately progress to cervical cancer. Most cervical premalignant 
lesions are currently treated since there are no diagnostic tools available to predict which 
lesions will progress or regress. This leads to expensive and painful procedures and over 
treatment. Thus, the identification of potential biomarkers that could predict which women 
are more likely to have a persistent HPV infection would we extremely useful, as these 
would be the women most likely to experience cervical disease.  
RNA was isolated from exfoliated cervical cells collected as part of the CWCS and 
gene expression profiles determined using Human Clariom S arrays (Affymetrix/Thermo 
Fisher Scientific). These arrays contain probes for over 20,000 well-annotated genes. We 
compared gene expression profiles in HPV16 negative samples (N=10) to cervical cell 
 viii 
samples collected from women that were HPV16 positive and cleared (N=10) or did not 
clear (persistor, N=10) the HPV16 infection.   
Differentially expressed genes were determined and the data subjected to Ingenuity 
Pathway Analysis (IPA, Qiagen). The IPA results determined that pathways involved in 
cellular immune response were activated in women who cleared the HPV infection but not 
in women who were HPV persistent. Thus, no immune response to the HPV16 infection is 
elicited in women with a persistent HPV16 infection and somehow the HPV “hides” from 
the immune system in these women.
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PART 1 
ANALYSIS OF HPV16 VARIANTS IN THE CAROLINA WOMEN’S 
CARE STUDY 
 2  
  
CHAPTER 1: INTRODUCTION 
1.1 Overview 
To date, more than 200 types of human papillomaviruses (HPV) have been 
identified. HPVs are classified not by antigens on their cell surface, but by genotype (DNA 
sequence). HPVs have been identified by sequencing the gene encoding the major capsid 
protein L1 (de Villiers et al. 2004). The L1 open reading frame (ORF) is the most conserved 
gene within the HPV genome and has been used for identification of HPVs for over 15 
years (de Villiers et al. 2004). HPVs vary genetically not only between types but also 
within types: a new HPV type is recognized when the complete genome has been cloned 
and the DNA sequence of the L1 ORF differs by more than 10% from that of a known HPV 
type. Differences between 2% and 10% homology define a subtype, and less than 2% 
sequence differences define a variant (Yamada et al. 1997).  The first worldwide study of 
HPV variants was published by Ho and colleagues (Ho et al. 1993). 
HPV is the primary etiologic agent for cervical cancer. Worldwide, cervical cancer 
is the fourth most frequent cancer in women with an estimated 570,000 new cases in 2018 
representing 6.6% of all female cancers, and the second most frequent cause of cancer-
related death (WHO 2018 & NIH 2018). Approximately 90% of deaths from cervical 
cancer occur in low- and middle-income countries, accounting for nearly 300,000 deaths 
annually (WHO 2018 & NIH 2018). The American Cancer Society (ACS) predicts that in 
2019 about 13,170 new cases of invasive cervical cancer will be diagnosed and about 4,250  
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women will die from cervical cancer in the United States (ACS, 
https://cancerstatisticscenter.cancer.org 2019).  
Investigations have evaluated associations of specific HPV16 variants with viral 
persistence and may prove important for the determination of the risk of cervical neoplasia. 
For example, one study suggested an association between HPV16 variants and persistence 
of infection or development of cervical intraepithelial neoplasia 2-3 (CIN 2-3) (Xi et al. 
1997). Their results also showed that those in the study with HPV16 non-prototype-like 
variants (designated, Af1, Af2, AA, As, and NA branches) were 6.5 (95% CI = 1.6-27.2) 
times more likely to develop CIN 2-3 than those with prototype-like variants (designated 
as the E branch) (Xi et al. 1997). In 2006, the same group of investigators published data 
suggesting there was a relationship between the distribution of race and persistence to not 
only HPV16, but also HPV18 variants (Xi et al. 2006).  
In Part 1 of this thesis, we will investigate HPV16 variants from exfoliated cervical 
cells from the Carolina Women’s Care Study (CWCS).  
1.2 Papillomaviridae Family 
The Papillomaviridae is a family of small, non-enveloped viruses with a double-
stranded DNA genome varying in size from 5,748 to 8,607 base pairs (bp). Their 
classification is based on the nucleotide sequence of the L1 ORF, leading to over 200 types. 
Members of this family primarily infect mucosal and keratinized epithelia, and have been 
isolated from fish, reptiles, birds, and mammals. Papillomavirus (PV) are both species and 
tissue-tropic, and are hardly ever transmitted between species (van Doorslaer et al. 2018). 
The PV family includes two subfamilies: Firstpapillomavirinae, that includes over 50 
genera and over 130 species, and Secondpapillomavirinae, with a single genus and species 
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(Van Doorslaer et al. 2018). Human papillomavirus (HPV) only infects human epithelia, 
and can be put into two general classes, low or high-risk types, depending on their 
oncogenic potential. Low-risk types are generally associated with skin or genital warts, 
while high-risk types are associated with pre- or malignant lesions that within years can 
develop into cancer. The HPV low risk types are 6, 11, 42, 43, 44, 54, 61, 70, 72, and 81. 
Type 6 and 11 are the most common types that cause genital warts (LabCE 2018). The 
HPV high risk types are 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82. Types 
16 and 18 are the most common types and cause about 70% of all cervical cancer world-
wide (LabCE 2018). 
Structurally, the papillomaviruses’ viral capsid is approximately 600 Å in diameter 
and consists of 360 copies, arranged as 72 pentamers of the major capsid protein L1 and 
approximately 12 molecules of the L2 minor capsid (Finnen et al. 2003) (Figure 1.1). Each 
capsid houses a single copy of the viral circular dsDNA. The packaged viral DNA is 
associated with core histone proteins (Larsen et al. 1987).  
The PV genome is conserved across all types containing three domains: early and 
late regions, and the noncoding upstream regulatory region (URR)/long control region 
(LCR) (Stanley 2007). The URR/LCR is the promoter region where enhancer elements 
bind; the E5, E6, and E7 gene products modulate the transformation process (i.e. the viral 
oncoproteins); the E1 and E2 gene products modulate transcription and replication; and the 
L1 and L2 proteins make up the viral capsid (Stanley et al. 2007) (Figure 1.2). Specifically, 
the only viral DNA helicase (E1) is essential for replication and amplification of the viral 
genome in the nucleus of infected cells (Bergvall et al. 2013). E2 has been shown to play 
a pivotal role in the viral life cycle. It functions in transcriptional regulation, initiation of 
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DNA replication and partitioning the viral genome (McBride et al. 2013). E4 contributes 
to genome amplification success and virus synthesis. E4 protein can also serve as a 
biomarker of active virus infection, and in the case of high-risk human types also disease 
severity (Doorbar et al. 2013). E5 is localized to the endoplasmic reticulum (ER). It plays 
a role in trafficking cytoplasmic membrane proteins, such as growth factor receptors and 
molecules involved in immune control through the cellular compartment (Paolini et al. 
2017). Upon initial infection, viral expression is tightly controlled, especially for E6 and 
E7 expression.  
Figure 1.1 Papillomaviridae. Adapted from van Doorslaer 2018.  (Left) 3D structure of a 
papillomavirus capsid. Derived from an image reconstruction from Cryo-electron 
microscopy of human papillomavirus type 16 at 4.5 Å resolution and colored according to 
the radial coloring scheme shown (PDB: 5KEP; (Guan 2017). (Center) Schematic diagram 
representing the 72 capsomers in a T=7 arrangement of a papillomavirus capsid. The 
icosahedral structure is composed solely of pentameric capsomeres for a total of 360 capsid 
proteins. (Right) Negative-contrast electron micrograph of human papillomavirus 1 




































Figure 1.2 Genomic Structure of Human Papillomavirus Type 16 along with  
their brief respective functions. Adapted from Trimble & Katzenellenbogen 2015).  
The Upstream Regulatory Region (URR), also known as the Long Control Region  
(LCR) is displayed. Early genes E1-E5 are displayed in green and red (E6 & E7)  
colors. Capsid late genes L1 and L2 are displayed in yellow.   
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E6 and E7, along with E5, are considered the HPV oncoproteins (able to transform 
normal cells to tumor cells). Up-regulation of E6 and E7 expression occurs in differentiated 
cells that have exited the cell cycle. E6 binds to the tumor suppressor protein p53 and 
directs it for ubiquitin-mediated degradation. E7 binds to the retinoblastoma (Rb) protein 
that deregulates the G1/S checkpoint.  Together, E6 and E7 immortalize primary 
keratinocytes (Hawley-Nelson et al. 1989 and Pirisi et al. 1987). 
The papillomavirus infectious cycle involves an immune-evasion mechanism 
inhibiting host detection of the virus. The terminal squamous differentiation pathway of 
keratinocytes is required for HPV to establish a productive infection (Stanley et al. 2007). 
During differentiation, keratinocytes will permanently withdraw from the cell cycle, 
initiate expression of epidermal differentiation markers, and move suprabasally as they 
become part of the stratum spinosum, stratum granulosum and eventually become 
corneocytes in the stratum corneum (van Doorslaer et al. 2018) (Figure 1.3).  
HPV does not cause inflammation because it is not found in the bloodstream nor 
does it cause cell death, which in turn does not activate or alert the host cell immune 
response. Initially HPV replicates as an episome, independent of the host chromosomes. 
Initial infection establishes a latent infection with a low level of replication of the viral 
genome (<10 copies/cell) and minimal viral protein expression. Upon differentiation of the 
keratinocytes, early HPV genes are expressed and viral genome copy number increases 
(>1000 copies/cell) (Stanley et al. 2007). Late viral protein expression and viral assembly 
occur only during terminal differentiation of keratinocytes, where newly assembled viruses 
are shed from the outermost layer of the cells to infect other neighboring cells (Stanley et 
al. 2007) (Figure 1.3). The HPV infectious cycle can take up to three weeks from the time 
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of infection to the release of virus, but the period between infection and the appearance of 
cervical lesions is variable, taking from several weeks to months, while cervical cancer 
development usually takes at least a decade from the time of infection (Stanley et al. 2007) 
 
Figure 1.3 Organization of HPV16 Viral Lifecycle. Adapted from van Doorslaer et al. 
2018. The different layers of the epithelium are shown on the left. The timing of expression 
and associated protein levels are summarized using triangles. Viral genome maintenance 
is facilitated by the expression of E6 and E7 together with E1 and E2. Increased levels of 
the viral replication proteins facilitate viral genome amplification. The expression of L1 
and L2 allows for the formation of infectious virions (virus assembly).   
 9 
1.3 HPV16 Variants 
 The first worldwide study of HPV variants was published in 1993 by Ho et al (Ho 
et al. 1993). The overall goal of this study was to determine the genomic diversity of 
HPV16 by comparing different types and within each type. The segment of the HPV16 
genome they decided to investigate was the non-coding LCR segment, which has a much 
higher degree of diversity than the coding regions. For the LCR region, differences can 
reach up to 5%, rather than the 2% observed in other regions of the HPV genome. The 
investigators collected 301 isolates from 25 geographic regions and/or ethnic groups in 
Africa, Eurasia, and the Americas (Ho et al. 1993). After analysis, their data suggested that 
HPV16 evolved along five major branches: two predominantly present in Africa (Af1 and 
Af2), two found mainly in Asia (AA and As.) and one found mainly in Europe (E) (Ho et 
al. 1993). However, the study did not address whether molecular variation may correlate 
with changes in biological functions and whether certain variants may be more frequent in 
patients with disease than in those without disease (Ho et al. 1993). 
In 1997, Yamada et al. published a paper that further investigated HPV16 variants 
(Yamada et al. 1997). They collected and analyzed tumor samples from 22 countries in 
five continents and investigated the E6, L1 and LCR segments of the HPV genome. See 
Figure 1.4, which shows 26 nucleotides that are different from the reference sequence, 
therefore allowing identification of particular HPV16 variants based on DNA sequence 
from the LCR segment alone. It was the 26 nucleotides from Yamada et al.  that were used 
to determine the HPV16 variant status for the current study. Including the five branches 
from Ho et al. 1993, an additional branch, North American (NA) was distinguished in the 





































Figure 1.4 URR/LCR Sequences of representative  
HPV16 Variants from Nucleotides 7485 to 7842.  
Adapted from Yamada et al. 1997.  
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Cornet et al.  aimed to improve the classification of HPV16 variant linages (Cornet 
et al. 2012). They did so not only by using a much larger sample size than previous studies, 
but also by utilizing samples from geographically diverse populations. In this study they 
sequenced the entire E6 and LCR segments of the HPV16 genome of 953 HPV16 isolates 
from 27 different countries. In addition to their phylogenetic analyses confirming 
previously described variant lineages and sub-classifications, they were able to characterize 
two new sub-lineages within both Af1 and Af2. In total, they were able to distinguish nine 
HPV16 variant sub-lineages (EUR, As, AFR1a, AFR1b, AFR2a, AFR2b, NA, AA1, and 
AA). Similar sequences were observed as in Yamada et al. with the addition of several new 
nucleotide changes in the LCR region (Cornet et al. 2012, Yamada et al. 1997). To 
strengthen the concept that HPV16 variants segregate geographically, the investigators also 
determined the distribution of HPV16 variants by geographic region (Figure 1.5). 
 
Figure 1.5 Distribution of HPV16 Sub-lineages by region. Adapted from Cornet et al. 
2012.  
 12 
1.4 HPV16 Variants and Viral Persistence   
 
Factors favoring HPV persistence are not fully understood, but several studies have 
suggested that HPV16 genetic variation may play a role. Providing a short-handed way to 
classify HPV16 variants, currently HPV16 variants are classified into four major lineages 
based on whole-genome sequencing: Lineage A includes A1–A3 (European), and A4 
(Asian); lineage B includes B1-B2 (African 1); lineage C is the African 2 variants; and 
lineage D includes D1 (North American) and D2-D3 (Asian-American 1 and 2) (Burk et 
al. 2013). Epidemiological studies have reported that HPV16 variants may play a role in 
viral persistence and/or progression to pre-cancer and cancer (Hildesheim et al. 2001, Xi 
2006, and Sichero et al. 2007) For example, Sichero et al. 2007, reported that non-
European (A4, B1-B2, C, and D2-D3) HPV16 and HPV18 variants lead to a higher risk of 
viral persistence and tend to cause more high-grade cervical lesions than European (A1-
A3) HPV16 and HPV18 variants.  
In this study we used exfoliated cervical cells from the Carolina Women’s Care 
Study (CWCS), which was the first study designed specifically to compare HPV incidence, 
prevalence, and persistence between African American and European American women in 
South Carolina, to identify HPV16 variants (see section 1.5 below for a detailed description 
of the CWCS). Previous studies reported an association between certain HPV16 variants 
and viral persistence and ethnicity. It was reported that A1–3 variants were associated with 
persistent infection in white women, while infection with B or C variants tended to be 
persistent in African-American women (Xi et al. 2006). However, it was reported that 
European variants of HPV16 were the most prevalent in tumors from Northern, Central, 
and Southern Tunisia (KrennHrubec et al. 2011). These inconsistent results demonstrate 
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the need to investigate the distribution of HPV16 variants according to geography and 
ethnicity. 
Interestingly, it was reported that HPV16 E6 variants were sufficient to alter the 
overall gene expression profile in C33-A cells, suggesting different oncogenic potential of 
HPV16 variants (Zacapala-Gómez et al. 2016). Specifically, not only the Asian-American 
E6 variant alone was sufficient to promote immortalization, transformation, and migration 
of primary human foreskin keratinocytes in culture, but it was more efficiently able to do 
so than the E6 prototype/European variant (Niccoli et al. 2012).  
1.5 The Carolina’s Women Care Study 
The Carolina Women’s Care Study (CWCS) is a longitudinal study that recruited 
freshmen females between the ages of 18 and 25 years attending the University of South 
Carolina in Columbia, South Carolina. The CWCS was initiated by Drs. Kim E. Creek, 
Lucia Pirisi-Creek, Carolyn Banister and their collaborators in November 2004 and 
completed in April 2011. The two overall goals of the CWCS were to asses HPV status 
and type in female college students and to define the determinants and identify biomarkers 
of persistent high-risk HPV infection in college-aged women. The types of potential 
biomarkers that were assessed included: life style factors (from a self-administered survey), 
genetic determinates (single-nucleotide polymorphisms (SNPs) in DNA), immunological 
factors (cytokine levels in cervical mucus), and gene expression profiles (from RNA 
isolated from Pap test samples). Four-hundred and sixty-seven women were recruited and 
293 women completed four or more visits for a total of 2,274 participant visits. For the first 
visit only, blood specimens were collected from which genomic DNA was extracted. Each 
participant during their enrollment at USC returned for biannual visits, one each during the 
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fall and spring semesters. At each visit, participants were given pelvic examinations that 
included the collection of cervical mucus and two Pap tests. Each participant also 
completed a self-administered survey assessing their nutritional, exercise, sexual history, 
and their emotional/psychosocial profile (Banister et al. 2013).  
DNA were extracted from exfoliated cervical cells collected at each visit and tested 
for the presence of HPV by real-time polymerase chain reaction (PCR) using degenerate 
primers against the L1 region of the HPV genome. Commercial INNO-LiPA assay kits 
were used to determine the type(s) of HPV present in each sample that was found to be 
HPV positive by real-time PCR. The INNO-LiPA assay is a reverse hybridization line blot 
assay designed to detect and identify 27 HPV types by amplifying the L1 region of the 
HPV genome: 7 low-risk types, 15 high-risk types, and 5 probable high-risk types. At 
enrollment, 32% of the CWCS participants were HPV-positive, with HPV16 being the 
most common at 18% of all HPV infections detected. Sixty-four percent of all HPV-
positive samples contained more than one HPV type. There was also a notable difference 
between African American (AA) and European American (EA) women in the prevalence 
of HPV infections (38% and 31% respectively) and an abnormal Pap test (10% and 6% 
respectively) (Banister et al. 2013). 
The rates of clearance of the HPV infection in AA and EA CWCS participants was 
also studied. It was determined that the time required for 50% of participants to clear a HR-
HPV infection was almost twice as long in AA women (601 days) as in EA women (316 
days). AA participants were also more likely than EA women to have an abnormal Pap test 
(Banister et al. 2015). These results raised the possibility that the longer time to clearance 
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of HR-HPV among AA women leads to increase rates of abnormal Pap tests and may 
contribute to the increased rates of cervical cancer observed in AA women. 
In this study we explored HPV16 variants using DNA isolated from exfoliated 
cervical cells collected from CWCS participants. Over the course of the CWCS  160 
participants (365 total samples) tested positive for HPV16 at some point during the study 
and were used for HPV16 variant analysis. 
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CHAPTER 2: MATERIAL AND METHODS 
2.1 Study Population  
A cohort of 467 female freshmen aged 18-25 years was included in the CWCS from 
November 2004 through May 2009. The study participants were followed through April 
2011. The study is described in detail in previous publications from our laboratory 
(Banister et al. 2013, Banister et al. 2015). Approval for this study was obtained from the 
University of South Carolina Institutional Review Board. Of the CWCS participants, 160 
tested positive for HPV16 at some point during the study and were used for HPV16 variant 
analysis.  
2.2 Study Samples 
DNA was extracted from exfoliated cervical cells collected in PreservCyt using 
sodium dodecyl sulfate/proteinase K digestion, followed by phenol/chloroform extraction 
and ethanol precipitation. Purified DNA was resuspended in 0.1 mL of 10 mM Tris HCL 
pH 8.0. 
The presence of HPV was determined by real-time polymerase chain reaction 
(PCR) against the L1 region of the HPV genome using PGMY09/11 primers (Gravitt et al. 
2000). Each sample was amplified using a final concentration of 200 pM of each primer in 
the presence of 1× BV buffer (16.6 mM ammonium sulfate, 67 mM Tris-HCl pH 8.8, 6.7 
mM MgCl2, 10 mM β-mercaptoethanol), 1 mM each of dNTP and 6% dimethyl sulfoxide, 
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1-unit Platinum Taq (Invitrogen, Carlsbad CA, USA), and 1× Sybr dye (Invitrogen). 
Amplifications were performed on a MyIQ thermocycler (BioRad Hercules, CA, USA) 
with initial incubation at 94°C for two min, then 50 cycles of 94°C for 10 sec, 57°C for 50 
sec, and 68°C for 50 sec. The melt curve initiated at 52°C for 10 sec, increasing by 0.5°C 
to 92°C. A 1.5 µL aliquot of each real-time PCR was separated by electrophoresis on a 
1.5% agarose gel to visualize the 450 bp product expected in HPV-positive samples. In 
addition to the HPV PCR primers, PCR primers that amplified line DNA (F 5′-
TTTTGAGTTAGGTGTGGGATATA-3′, R 5′-AAAATCAAAAAATTCCCTTTC-3′) or 
the human beta-globin gene (GH20 and PC04) were used to confirm the presence of 
amplifiable human DNA in the samples (Gravitt et al. 2000). 
The INNO-LiPa HPV AMP kit (INNO-LiPA, Innogenetics, Gent, Belgium) and 
the INNO-LiPA genotyping extra kit (INNO-LiPA) were used to determine the type of 
HPV present in the samples found to be positive by real-time PCR screening. This reverse 
hybridization line blot assay is designed to detect and identify 27 HPV types utilizing 
amplification of the L1 region of the HPV genome. This test allows for the identification 
of seven low-risk (HPV 6, 11, 40, 43, 44, 54, and 70) and 15 high-risk (HPV16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) HPV types. It also detects five HPV types of 
probable high-risk (HPV26, 53, 66, 69, and 74). In addition to the type-specific probes, the 
linear array contains two “generic” HPV probe mixtures that hybridize with virtually any 
HPV-derived amplification product. Samples that tested positive for one or both of the 
generic HPV bands on the linear array, but were negative for the type-specific bands, were 
considered HPV-positive and included in the analysis for total HPV infections, but were 
excluded from analysis of low-risk and high-risk HPV infections. 
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2.3 Determination of HPV16 Variants 
HPV16 positive cervical DNA samples were used for the determination of HPV16 
variants. In addition to HPV16 positive cervical samples, a positive control (SiHa) and a 
negative control (water) was used. The Long Control Region (LCR) of the HPV genome 
is a hypervariable region and is the target of amplification. HPV16 primers were used to 
amplify a 600-base pair (bp) and a 1,087 bp region of the LCR: Forward (5’- GCC ATT 
TTG TAG CTT CAA CCG -3’) and Reverse (5- GTC GCT CCT GTG GGT CCT-3’); 
Forward (5'- ACC TCC AGC ACC TAA AGA AG -3') and Reverse (5'- ACC TCC AGC 
ACC TAA AGA AG -3'), respectively (Cornet et al. 2012). A Biometra TGradient PCR 
instrument was used to carry out the PCR reactions under the following conditions: 
denaturation at 94° for 30 sec, anneal at 62° (for 600 bp) or 58.3° (for 1,087 bp) for 30 sec, 
extension at 72° for 45 sec with an initial denaturation at 94° for 6 min and final extension 
at 72° for 7 min 1X buffer containing 0.05% DMSO, 3 mM MgCl2,  dNTPs at  200 uM, 
forward and reverse primers at 1 uM each,  and Platinum Taq DNA polymerase at 0.25 
units/uL was used per master mix. Two uL of sample were used per reaction, with a final 
total PCR volume of 25 uL.  
2.4 Agarose Gel Electrophoresis  
To confirm that PCR amplification had occurred and to directly visualize the 
amplified HPV16 product, each sample was run on a 1.5% agarose gel. Once the 
agarose gel solidified, the well comb was removed, and the gel was placed in 1X 
TAE buffer solution with electrodes.  Ten microliters of amplified HPV16 PCR 
product from each sample was mixed with two microliters of loading dye, and added 
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to one well. The gel was run at 100 volts for about one hour. Ethidium bromide was 
the intercalating agent added to the agarose gel, which allowed visualization of the 
HPV16 DNA band under UV light.  
2.5 Sanger Sequencing 
After successful PCR amplification of the target LCR sequences from the HPV16 
positive cervical DNA samples, the DNA sequence of the PCR product was determined 
using Sanger sequencing. The same primers used for the PCR reactions mentioned above 
were also used for DNA sequencing by Eton Biosciences (North Carolina, USA). Three 
tubes were sent for sequencing: 8 µL of PCR amplicon and 11 uL of forward and reverse 
primers between 5-10 uM as requested by the vendor.  
2.6 Statistical Methods 
The statistical difference between percentages was determined by the user-friendly 
tool, StatPac for a small fee available for download at: https://statpac.com/products.htm. 
Two sample t-test between percentages was used to compare subgroups from a single 
sample.  
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CHAPTER 3: RESULTS 
3.1 Amplification of URR Sequences in Exfoliated Cervical Cells from the CWCS 
The CWCS recruited a total of 467 women, 293 of whom completed four or more 
visits for a total of 2,274 participant visits. The CWCS subgroup used for this project 
included 160 women who tested positive for HPV16, for a total of 365 HPV positive visits. 
We conducted HPV16 variant analysis using DNA from exfoliated cervical cells 
collected from each of the 365 HPV16 positive visits.  After PCR, each sample was 
subjected to agarose gel electrophoresis to visually confirm amplification of a 600 bp 
product from the URR. We successfully amplified HPV16 sequences from DNA isolated 
from exfoliated cervical cells in some of the CWCS samples but many samples did not give 











Figure 3.1 Agarose Gel Electrophoresis of selected CWCS Samples. Samples from the 
CWCS were amplified using HPV16 specific primers in the URR region of the HPV16 
genome. The PCR product amplified was about 600 base pairs. A positive control (SiHa) 
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Although real time PCR and INNO-LiPA had confirmed the presence of HPV16 
DNA in the CWCS samples, we had difficulty amplifying the HPV16 LCR region in many 
of the samples. We attempted PCR amplification of the LCR sequences at least twice in all 
365 HPV16 positive CWCS samples. In addition, a considerable effort was expended to 
further optimize the PCR reaction conditions in the hope of getting successful amplification 
in more of the samples. I initially started using our laboratory standard PCR conditions 
which included 2 mM MgCl2, 0.2 mM dNTPs, and 2 µL of sample. We decided to try to 
optimize the dNTP and MgCl2 concentration, along with sample volume. I conducted a 
series of PCR optimizations by increasing just the concentration of the dNTPs by 0.2 mM 
increments with a fixed MgCl2 concentration (1.5 mM). The best results were at 0.2 mM 
dNTPs. I then increased the concentration of MgCl2 by 0.25 mM increments with a fixed 
dNTPs concentration (0.2 mM).  The best results were at 3.0 mM MgCl2. I then tested 
which amount (1 µL or 2 µL) of sample would be best for amplification. Overall 2 µL of 
the samples gave the best result.  
To examine why many of the samples did not yield an amplification product we 
decided to use a very sensitive assay to determine the amount of DNA in each of the CWCS 
samples.  PicoGreen (ThermoFisher Scientific) is an ultra-sensitive fluorescent nucleic 
acid stain for quantitating dsDNA. Results from the PicoGreen DNA assay determined that 
CWCS samples with a DNA concentration below about 5 ng/µL seldom yielded a PCR 
product. However, samples with a DNA concentration over 10 ng/uL almost always were 
successfully amplified. Samples with DNA concentrations between 5-10 ng/uL gave 
variable results.  In summary, of the 365 samples from the CWCS that were HPV16 
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positive we were able to successfully amplify HPV16 DNA and get Sanger sequencing 
data on 160 of these samples (43.8%). 
 
3.2 Determining HPV16 Variant Status of Exfoliated Cervical Cells from the 
CWCS 
 
After successful PCR amplification of the target LCR sequences from the HPV16 
positive cervical DNA samples, the DNA sequence of the PCR product was determined 
using Sanger sequencing. Not every sample that was sent for DNA sequencing yielded 
complete or usable results. There were 26 nucleotides in the amplified sequences that were 
specifically examined to determine the HPV16 variant status of each sample (see Figure 
1.4). If the DNA sequence was incomplete or of insufficient quality, it was considered 
inconclusive and variant status was not reported. Samples with complete and sufficient 
DNA sequencing results were used to determine their HPV16 variant status. Comparison 
of those 26 key nucleotides of the sequencing results with that of the HPV16 reference 
genome (accession number: KF880690) was accomplished using the Sequencher program. 
To illustrate how we determined HPV16 variants from the DNA sequencing results see 
Table 3.1.  
3.3 Distribution of HPV16 Variants in HPV16 Positive CWCS Participants 
We obtained successful LCR amplification, DNA sequencing, and variant 
identification for 160 of the 365 HPV16 positive samples (43.8%) which represents 74 of 
the 160 participants (46.3%) that were HPV16 positive at some point in the CWCS. 
Unfortunately, our inability to get definitive HPV16 variant identification in over half of 
our HPV16 positive samples was disappointing and limited our analyses.





 Table 3.1 Sequencing Data of Selected CWCS samples: Samples derived from 
the same participant at multiple visits have been grouped together. The data 
show that the nucleotide variation is the same for that participant with each visit 
they had.  Sample ID is defined as: “A” reflects the study site, three-digit 
participant number and “-#” is the participant’s visit number. Nucleotide 
variation (highlighted yellow), No sequence (black boxes), and red letters 







































































































WILD TYPE A G T A G G C C T T A A T A T C A T C C G G A A G
Sample Ethnicity HPV-16 Variant
A145-3 A G T A G G C C T T A A T A T G A T C C G G A A C
A145-4 A G T A G G C C T T A A T A T C A T C C G G A A C
A171-3             T C T T A A T A T C A T C C           
A171-4 A G T A G G T C T T A A T A T C A T C C G G A A G 
A171-5 A G T A G G T C T T A A T A T C A T C C G G A A G 
A171-6 A G T A G G T C T T A A T A T C A T C C G G A A G 
A171-7 A G T A G G T C T T A A T A T C A T C C G G A A G 
A171-8 A G T A G G T C T T A A T A T C A T C C G G A A G 
A173-2 A G T A A G C C T T A A T A T C A T C C G G A A G 
A173-3 A G T A A G C C T T A A T A T C A T C C G G A A G 
A173-4 A G T A A G C C T T A A T A T C A T C C G G A A G
A173-5 A G T A A G C C T T A A T A T C A T C C G G A A G 
A173-7 A G T A G G C C T T A A T A T C A T C C G G A A G
A173-6 A G T A A G C C T T A A T A T C A T C C G G A A G
A173-8 A G T A A G C C T T                               
A217-3 A G T A G G C C T T A A T A T C A T C C G G A A G
A217-5 A G T A G G C C T T A A T A T C A T C C G G A A G
A217-6 A G T A G G C C T T A A T A T C A T C C G G A A G
A452-1 A G T A G G C C T T A A T A T C A T C C G G A A G
A452-3 A G T A G G C C T T A A T A T C A T C C G G A A G
A452-4 A G T A G G C C T T A A T A T C A T C C G G A A G
A452-5 A G T A G G C C T T A A T A T C A T C C G G A A G
A194-1 Hispanic A G T A G G C C T T A A T A T C A T C C G G A A G E
A127-4 A G T A A G C C T T A C T A T C A T C C G G A A A 
A127-6 A G T A A G C C T T A C T A T C A T C C G G A A A 
A127-8 A G T A A G C C T T A C T A T C A T C C G G A A A 
A127-9             C C T T A C T A T C A T C C G G A A A 
A127-10 A G T A A G C C T T A C T A T C A T C C G G A A A 
A162-1 A A T A A G C A T T A A T C T T A T T C G T A A G Af-1
A162-3 C A T A A G T A T T C A G A T T A T T C G G A A G
A162-5 C A T A A G T A T T C A G A T T A T T C G G A A G 
A162-6 C A T A A G T A T T C A G A T T A T T C G G A A G
A162-7             T A T T C A G A T T A T T C G G A A G 
A229-5 European American C A T A A G T A T T C A G A T T A T T C G G A A G As. A
A273-2 C A T A A G T A T T C A G A T T A T T C G G A A G
A273-3 C A T A A G T A T T C A G A T T A T T C G G A A G
A313-1 C A T A A G T A T T C A G A T T A T T C G G A A G
A313-2 C A T A A G T A T T C A G A T T A T T C G G A A G
A313-3 C A T A A G T A T T C A G A T T A T T C G G A A G
A313-4 C A T A A G T A T T C A G A T T A T T C G G A A G
A313-5 C A T A A G T A T T C A G A T T A T T C G G A A G
A353-7 A A T A A G C A T A A A T A T T A T T C G T A A G
A353-8 A A T A A G C A T A A A T T T T A T T C G T A A G
A183-3 African American C A T A A G T C T T A A T A T T A T T C A T C G G Af-2
A184-1 C A T A A G T C T T A A T A T T A T T C A T C G G 
A184-4 C A T A A G T C T T A A T A T T A T T C A T C G G 
A188-4 C A T A A G T A T T A A T A T T A T T C A T C G





















A detailed summary of the results from our HPV16 variant analysis in the CWCS 
is presented in Table 3.2. Table 3.2 lists all 74 participants that were successfully sequenced 
and had their HPV16 variant identified. The table includes; ethnicity, all visits for that 
participant in the study, HPV16 variant type, and whether or not that participant had a 
persistent HPV infection (see Table 3.2 legend for details). 
The HPV16 European (E) variant was by far the most common variant, accounting 
for 77% of all HPV16 positive samples analyzed, followed by the African-2 (Af-2) variant 
(11%), Asian American (As.A) variant (10%), and the African-1 (Af-1) and Asian (As) 
variants both at 1% (Figure 3.2 and Table 3.3).  Since the majority of the CWCS study 
population was European Americans (EA) and African-Americans (AA), our HPV16 
variant analysis will focus on EA and AA participants. Our HPV16 variant data, which 
agrees with the literature, found that the distribution of HPV16 variants detected within a 
population may be distributed among the infected individuals whose race indicates an 
ancestral geographic distribution that was once shared with that of the variant (Ho et al. 
1993, Xi et al. 2006, and Cornet et al. 2012). Of HPV16 positive EA participants: 84% 
have the E variant, 0% the Af-1 variant, 4% the Af-2 variant, 10% the As.A variant, and 
2% the As variant (Figure 3.3 and Table 3.3). Of HPV16 positive AA participants: 66% 
have the E variant, 5% the Af-1 variant, 24% the Af-2 variant, 5% the As.A variant and 
0% the As variant (Figure 3.4 and Table 3.3).  Interestingly, there was an important 
difference in the overall distribution of the HPV16 Af-2 variant between EA and AA 
HPV16 positive CWCS participants. Of AA participants 24% (5 of 21) have the Af-2 
variant, while only 4% (2 out of 50) of EA participants have the Af-2 variant (Table 3.3).  
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EA = European American, AA = African American, E = European Variant, Af-1 = African-1 Variant
Af-2 = African-2 Variant, As.A = Asian American, As.A = Asian American, As = Asian Variant
NS =   Not Successful PCR, but HPV16 (+) Sample, HPV (─) = HPV Negative Sample
● = Not a HPV16 (+) Sample, X = No visit/No sample
NA = Not Applicable (indicates sample was thrown out due to neg. for human DNA and HPV (-) or HPV (X)
P = Persistor, NP = Non-Persistor, CC = Can't call due to Participant having only one HPV16 (+) sample/visit
Participant # Participant ID Ethnicity HPV16 Infection Status
1 2 3 4 5 6 7 8 9 10 11 12 13
1 A104 EA HPV (-) HPV (-) HPV (-) HPV (-) HPV (-) ● E X X X X X X CC
2 A106 EA HPV (-) HPV (-) HPV (-) E E E NS X X X X X X P
3 A127 EA HPV (-) HPV (-) HPV (-) As NS As NS As As As ● X X P
4 A138 EA NS NS NS E NS NS E E X X X X X P
5 A145 EA ● ● E E NA NA X X X X X X X NP
6 A151 EA HPV (-) E E HPV (-) HPV (-) HPV (-) X X X X X X X NP
7 A162 AA Af-1 NS As.A As.A As.A As.A As.A As.A NA X X X X P
8 A171 AA HPV (-) ● E E E E E E X X X X X P
9 A173 EA NS E E E E E E E NS E NS NS NS P
10 A183 AA HPV (-) NS Af-2 X X X X X X X X X X NP
11 A184 Asian Af-2 NS Af-2 Af-2 X X X X X X X X X P
12 A188 EA HPV (-) HPV (-) HPV (-) Af-2 Af-2 ● ● ● X X X X X NP
13 A192 EA NS E X X X X X X X X X X X NP
14 A194 Hispanic E NS X X X X X X X X X X X NP
15 A199 EA HPV (-) ● ● ● NS E E X X X X X X P
16 A212 AA ● ● ● ● NS Af-2 ● ● NA NA X X X NP
17 A215 AA HPV (-) HPV (-) ● ● ● ● NS E X X X X X NP
18 A217 EA ● ● E E E E NS NS X X X X X P
19 A228 AA ● HPV (-) HPV (-) HPV (-) E E NS E E X X X X P
20 A229 EA HPV (-) ● ● HPV (-) As.A ● NS HPV (-) X X X X X P
21 A231 EA HPV (-) HPV (-) HPV (-) NS NS NS E X X X X X X P
22 A237 EA E E E E E NS X X X X X X X P
23 A256 EA HPV (-) HPV (-) HPV (-) HPV (-) HPV (-) HPV (-) NS E HPV (-) HPV (-) HPV (-) X X NP
24 A264 EA HPV (-) HPV (-) HPV (-) HPV (-) HPV (-) HPV (-) HPV (-) E X X X X X CC
25 A267 EA HPV (-) HPV (-) ● E E E X X X X X X X P
26 A273 EA NS As.A As.A X X X X X X X X X X P
27 A285 AA HPV (-) HPV (-) E NS ● ● ● X X X X X X NP
28 A290 EA HPV (-) E E NS NS NS NS X X X X X X P
29 A291 EA E E E NS E NS E X X X X X X P
30 A296 AA HPV (-) NS Af-2 Af-2 NS NS X X X X X X X P
31 A304 EA HPV (-) ● ● ● ● E E X X X X X X NP
32 A313 EA As.A NS As.A As.A As.A As.A X X X X X X X P
33 A317 EA E ● ● ● ● X X X X X X X X CC
34 A332 EA HPV (-) HPV (-) HPV (-) HPV (-) HPV (-) HPV (-) E X X X X X X CC
35 A334 EA E E NS NS NS E NS X X X X X X P
36 A353 AA ● HPV (-) HPV (-) ● ● ● Af-1 Af-1 X X X X X NP




Participant # Participant ID Ethnicity HPV16 Infection Status
38 A373 EA HPV (-) HPV (-) ● ● ● E ● ● X X X X X CC
39 A376 EA E X X X X X X X X X X X X CC
40 A378 Hispanic HPV (-) HPV (-) HPV (-) HPV (-) HPV (-) E X X X X X X X CC
41 A383 AA Af-2 ● X X X X X X X X X X X CC
42 A388 EA HPV (-) HPV (-) ● NS NS ● E NS X X X X X P
43 A390 EA E NS NS NS NS NS NS HPV (-) X X X X X P
44 A396 AA HPV (-) ● E X X X X X X X X X X CC
45 A399 EA As.A NS NS X X X X X X X X X X NP
46 A408 EA HPV (-) HPV (-) ● ● NS NS E ● X X X X X P
47 A417 EA HPV (-) HPV (-) E ● ● X X X X X X X X CC
48 A418 EA E E X X X X X X X X X X X NP
49 A422 EA HPV (-) NS E E E NS E X X X X X X P
50 A424 EA NS E E E NS NS NS X X X X X X P
51 A430 EA ● E X X X X X X X X X X X CC
52 A440 AA E NS E E E E NS X X X X X X P
53 A445 EA ● E E E NS NS NS X X X X X X P
54 A450 AA NS NS NS NS E NS E X X X X X X P
55 A452 EA E NS E E E NA NS NA NS X X X X P
56 A456 AA ● ● E E NS NA NS NS X X X X X P
57 A460 EA HPV (-) HPV (-) HPV (-) ● ● E E  NS X X X X X NP
58 A466 EA E E HPV (-) HPV (-) HPV (-) HPV (-) HPV (-) X X X X X X NP
59 A470 EA HPV (-) HPV (-) HPV (-) HPV (-) ● ● E X X X X X X CC
60 A471 AA E E X X X X X X X X X X X NP
61 A472 EA HPV (-) HPV (-) E E HPV (-) HPV (-) HPV (-) HPV (-) X X X X X NP
62 A473 AA E E E NS NA NS NS X X X X X X P
63 A474 EA E X X X X X X X X X X X X CC
64 A478 AA HPV (-) HPV (-) Af-2 ● HPV (-) HPV (-) HPV (-) X X X X X X CC
65 A489 EA ● E X X X X X X X X X X X CC
66 A514 AA ● E ● HPV (-) HPV (-) HPV (-) HPV (-) X X X X X X CC
67 A515 EA E E E NS ● NS X X X X X X X P
68 A517 EA ● ● Af-2 HPV (-) HPV (-) HPV (-) ● X X X X X X CC
69 A525 EA ● NS E HPV (-) HPV (-) HPV (-) X X X X X X X NP
70 A533 AA E ● HPV (-) HPV (-) X X X X X X X X X CC
71 A536 AA ● ● ● E ● X X X X X X X X CC
72 A547 EA HPV (-) HPV (-) HPV (-) As.A HPV (-) X X X X X X X X CC
73 A556 EA NS E NS E X X X X X X X X X P
74 A564 AA HPV (-) HPV (-) E X X X X X X X X X X CC
 Visit #









































Figure 3.3 Distribution of HPV16 Variants amongst  







































Figure 3.4 Distribution of HPV16 Variants amongst  
AA CWCS Participants. 
 
 
Table 3.3 Distribution of HPV16 Variants between EA and AA Overall Population. 








E Af-1 Af-2 As. A As
n % n % n %
E 57 77 E 42 84 E 14 66
Af-1 1 1 Af-1 0 0 Af-1 1 5
Af-2 8 11 Af-2 2 4 Af-2 5 24
As. A 7 10 AA 5 10 As.A 1 5
As 1 1 As 1 2 As 0 0
Total 74 Total 50 Total 21
EA AA
HPV16 Variant Distribution By 
Participant
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3.4 Comparing HPV16 Variant Status Among CWCS Participants either 
Clearing or having a Persistent HPV16 Infection 
 
For the purpose of this study we define a persistent HPV infection (referred to as a 
“persistor”) as a participant who has the same HPV type infection (i.e. HPV16) for 365 
days or more as determined by the length of time between study visits. Those participants 
that clear the HPV infection in less than 365 days are referred to either as “clearers” or 
“non-persistors”. Of the 74 participants for which we obtained HPV16 variant data we 
could not determine whether 21 of the participants fit into persistors or clearers since they 
did not have a sufficient number of HPV16 positive visits to make that determination. Of 
the remaining 53 participants, 33 were persistors of HPV16 infection (62%) and 20 were 
non-persistors (clearers) (38%).  
It has been suggested that the non-European variants (i.e. Af-1, Af-2, As, and As.A) 
are more common amongst persistors than European variants (Niccoli et al. 2012 and 
Freitas et al. 2014). However, we did not find this to be the case in our CWCS population. 
The most common HPV16 variant amongst persistors was the E variant at 79%, followed 
by the As.A variant at 12%, Af-2 at 6%, and As at 3%. No persistors had the Af-1 variant.  
Overall, we could not find any consistent differences in the distribution of the variants 
among all CWCS participants that either cleared or did not clear an HPV16 infection. Table 
3.4 show the distribution of all HPV16 variants observed based on persistors, non-
persistors/clearers, and those who could not be placed in either group. Unfortunately, we 
did not have sufficient data to make any comparisons of HPV16 variant distribution among 
EA and AA participants that had either cleared or had persistent HPV16 infections.  
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Of the 33 participants that had persistent HPV16 infection, in which we were able 
to determine HPV16 variant status on multiple visits, there was only a single case where 
the variant status changed. This participant (A162) had the Af-1 variant on the first visit 
and was found to be As.A on subsequent visits (Table 3.1). This is strong evidence that the 
individuals that we are calling “persistent” truly had a persistent HPV16 infection and were 
not cases of “clearance” and reinfection. Our results are consistent with previously 
published data (Geraets et al. 2013). 
 
Table 3.4 Distribution of all HPV16 Variants Observed in the CWCS.  
Persistors (P), non-persistors (NP) and those samples that could not be called (CC)  
neither P or NP.  
 
 
HPV16 Variant n % n of P % n of NP % n of CC %
E 57 77 26 79 15 75 16 76
Af-1 1 1 0 0 1 5 0 0
Af-2 8 11 2 6 3 15 3 14
As.A 7 10 4 12 1 5 2 10
As 1 1 1 3 0 0 0 0
Total 74 33 20 21
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
In this study we determined HPV16 variants present in exfoliated cervical cells 
obtained in college-aged women from the University of South Carolina as part of the 
CWCS. We found that the HPV16 E variant was by far the most common variant in this 
study population (77% of all variants identified). The E variant was also the most 
predominant variant among HPV infected women from Northern Brazil at 87.5% 
(Tamegão-Lopes et al. 2014), 97.3% among Danish women (Gheit et al. 2011), and 47% 
in South African women (Tu et al. 2006). Distribution of the remaining HPV16 variants in 
the CWCS included the Af-2 variant (11%), As.A variant (10%), and the Af-1 and As 
variants both at 1% (Figure 3.2). The majority of these studies have looked at HPV16 
variants using cervical cancer samples, while our study analyzed HPV16 variants in 
exfoliated cervical cells obtained from Pap test samples.  
It has previously been reported that HPV16 and 18 variants may play a role in HPV 
persistence, that seemed to be race-related (Xi et al. 2006). African variants were more 
common among African American women than among white women and the E variant was 
more common among white women than among African American women (Xi et al. 2006). 
Our data showed that for both EA and AA participants, the E variant was the most common, 
representing 84% and 66% respectively of all variants present. However, the Af-2 variant 
was much more common in HPV16 positive AA participants (24%) than in EA participants 
(4%). However, there are published data suggesting that infections that cross racial lines 
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may be more oncogenic. For example, a strong correlation was found between cancer and 
European variants that are more common in cervical cancer among African women. There 
also was a stronger association between cancer and non-European variants in white women 
(Burk et al. 2003) and in women from Mexico (Hildesheim et al. 2001) and Costa Rica 
(Berumen et al. 2001). We found in our study in that European Americans not only 
persisted with the E variant, but also with the Af-2 and As.A variants. African Americans 
mostly persisted with the E variant rather than any of the African origin variants. One could 
conclude here that HPVs that did not coevolve with a specific race are more pathogenic 
(Burk & DeSalle 2006). Interestingly, the same correlation is seen with animal 
papillomavirus: Cottontail rabbit cutaneous papillomavirus causes carcinomas in domestic 
rabbits but not in cottontail rabbits, and bovine papillomavirus causes sarcoid lesions in 
horses (Campo 2002).  
Although it has been reported that the non-European variants (i.e. Af-1, Af-2, As, 
and As.A) are more common amongst persistors than European variants (Niccoli et al. 
2012 and Freitas et al. 2014), we did not find this to be the case in the CWCS. The E variant 
was the most common variant found among HPV16 persistors (79%) and clearers (75%).  
Importantly, we found no major differences in the distribution of the five HPV16 variants 
we studied among CWCS participants that either cleared or did not clear an HPV16 
infection.   
In the 33 participants that had persistent HPV16 infection there was only a single 
case where the variant status changed from one visit to the next. Participant A162 had the 
Af-1 variant on the first visit and was found to be As.A on subsequent visits. This is strong 
evidence that the individuals that we are calling “persistent” truly had a persistent HPV16 
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infection and were not cases of “clearance” and reinfection. Our results are consistent with 
previously published data (Geraets et al. 2013). 
A major limitation to this study was the small sample and population sizes that were 
successful in LCR amplification and HPV16 variant determination (160 samples from 74 
participants). It was thus not possible to determine what role, if any, different variants 
played in HPV persistence when comparing AA and EA CWCS participants. Although not 
conclusive, our data does indicate that the As.A variant may be more common in persistors. 
For example, overall 5 participants that we could classify as persistors or clearers had the 
As.A variant, with 4 of the 5 participants (80%) being persistors. This finding is consistent 
with a report that suggested the As.A variant having more oncogenic potential than the 
HPV16 E variant (Niccoli et al. 2012).  
Those women identified as a persistor of a HPV16 infection are the ones truly at 
risk of developing cervical premalignant lesions and thus ultimately cervical cancer. It 
would be useful to identify biomarkers which could predict HPV persistence, which could 
reduce overtreatment, health care costs, and long-term medical consequences. While this 
study did not find that any particular HPV16 variant that had a strong association with HPV 
persistence, future studies will look towards identifying genetic markers, including single 
nucleotide polymorphisms (SNPs), that may be predictive of persistence. Since we have 
DNA isolated from all CWCS participants it may be fruitful to conduct genome-wide 
association studies (GWAS) comparing CWCS participants that either had persistent HPV 
infections or were able to clear the virus. These studies are currently in progress. 
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PART 2 
A COMPARISON OF GENE EXPRESSION PROFILES OF 
EXFOLIATED CERVICAL CELLS FROM WOMEN WHO EITHER 
CLEAR OR DO NOT CLEAR AN HPV16 INFECTION 
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CHAPTER 5: INTRODUCTION 
5.1 Cervical Cancer Burden 
Globally, the burden of cancer is high and rising. This year alone, there are 18.1 
million new cancer cases worldwide with an expected 9.6 million deaths from cancer 
(Figure 5.1) (WHO 2018). One in five men and one in six women worldwide will be 
diagnosed with cancer in their life time and one in eight men and one in 11 women will die 
from cancer (WHO 2018).  Globally the cancer burden is increasing due to population 
growth and because people are living longer. Early diagnosis, effective screening and 
detection initiatives have resulted in a global decrease in incidence rates of some cancers, 
such as cervical cancer, but yet some countries still face increasing numbers of cancer 
diagnoses that require treatment and care.  
Figure 5.1 Incidence and Mortality of Cancers Worldwide in both males and females. 
Adapted from Bray 2018. 
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Breast cancer is the mostly commonly diagnosed, as well as the leading cause of 
cancer death among women worldwide. Following lung and colorectal cancers, cervical 
cancer ranks fourth for both incidence (6.6%) and mortality (7.5%) among women 
worldwide. There were 569,847 new cervical cancer cases in 2018 (Figure 5.2): 315,346 
in Asia, 119,284 in Africa, 61,072 in Europe, 56,187 in Latin America and the Caribbean, 
15,502 in North America, and 2,456 in Oceania (WHO: Global Cancer Observatory 2018). 
There are currently vaccines (Gardasil 9 and Cervarix) available to protect against cancer-
causing (high-risk) types of human papillomavirus (HPV) that will reduce the burden of 
cervical cancer, yet 311,365 women died of cervical cancer in 2018 (Figure 5.2); 168,411 
died in Asia, 81,687 in Africa, 28,318 in Latin America and the Caribbean, 25,829 in 
Europe, 5,852 in North America, and 1,268 in Oceania (WHO: Global Cancer Observatory 
2018). Approximately 90% of those deaths occurred in low- and middle-income countries. 
In comparison, in most developed counties the incidence rates and death from cervical 
cancer is much lower. For example, in the United States there were about 14,065 new 
cervical cancer cases and 5,266 cervical cancer deaths in 2018.  
As stated above, the distribution and risk of cervical cancer incidence and mortality 
varies by region and country. In addition to early diagnoses and effective screening, income 
levels, and changes in cervical cancer risk factors such as sexual behavior and HPV 
exposure, could explain these distributions. Without effective screening methods, cervical 
cancer is often found at an advanced stage and almost always fatal. 
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Figure 5.2: Estimated number of incident Cancer cases and deaths worldwide, females, all 
ages. Adapted from Bray 2018. 
 
5.2 The Human Papillomavirus (HPV) - Cervical Cancer Connection 
The first description of cervical cancer was more than 2,000 years ago by 
Hippocrates (Bordet et al. 2018). Aretaeus, a Greek physician, described uterine cancer as 
superficial and deep ulcers, which later infiltrate the uterus (Bordet et al. 2018). He also 
described another type of cancer that grew outside of the uterus (Bordet et al. 2018). In 
1842, Rigoni-Stern observed that cancer of the uterine cervix rarely occurred among 
celibate nuns (Rigoni-Stern et al. 1842). From 1977 to 1987 Harald zur Hausen and his 
team of researchers collaborated with several institutions in Germany to investigate 
whether HPV caused cervical cancer. One of his first experiments tested the hypothesis 
that HPV caused cervical cancer rather than the herpes simplex virus type 2 (HSV-2) (Kim 
2017). From 1972 to 1977 he analyzed cervical samples from women for HSV-2 DNA 
using nucleic acid hybridization (Kim 2017). When he introduced a single strand of HSV-
2 DNA into cervical tumor samples, if HSV-2 was already in the sample, the single strand 
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would bind to its complementary strand in the sample, which he did not detect, even after 
multiple repeats. Therefore, zur Hausen concluded that HSV-2 did not cause cervical 
cancer. Zur Hausen than began reviewing medical reports about patients who had genital 
warts. He formally published his hypothesis that HPV caused cervical cancer and described 
his experiment that failed to link HSV-2 to cervical cancer in 1976 (zur Hausen et al. 1976). 
He also hypothesized that HPV caused genital warts like condylomata acuminata (zur 
Hausen et al. 1976).  He then proposed his theory that viruses can induce cancer, and if 
analyzed, the tumors would contain viral DNA. From 1980 to 1982, zur Hausen led his 
team to determine whether HPV DNA was present in genital wart samples. They received 
genital wart and cervical cancer biopsies. They compared the DNA from wart samples and 
cervical cancer tumors. They identified HPV6 and HPV11 as the two types that caused 
genital warts (Kim 2017).  
Building on that research, in 1983, zur Hausen and his team investigated the 
presence of HPV6 and 11 in cervical cancer biopsies, using blot hybridization and cloning 
techniques. The scientists screened a large number of cervical carcinomas under low 
stringency of 40o C below the melting temperature (Tm) and hybridized with HPV type 11. 
There was one sample of invasive cancer of the cervix that was found to harbor an HPV 
sequence detectable under low stringency, but it was not detectable under the more 
stringent condition of 20o C below the Tm. After the DNA was molecularly cloned into a 
lambda phage, it cross-hybridized to a minor extent (<0.1%) to HPV types 10, 14, and 15, 
but showed no homology with DNA of other HPV types. Zur Hausen and Gissmann 
isolated the first cervical cancer-linked HPV, tentatively naming it type 16 at the time 
(Schwarz et al. 1985). They then used the newly discovered HPV16 DNA as a probe to 
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test additional biopsies from cervical, vulvar, and penile cancers, as well as benign genital 
warts. Eleven out of 18 cervical carcinoma samples obtained from German patients 
contained HPV16, but only eight out of 23 cervical cancer samples from Kenya/Brazilian 
women were HPV16 positive, indicative of geographic differences in the incidence of 
HPV16 infections. They also concluded that a high percentage of HPV16 negative non-
European tumors may contain other HPV types prevalent only in those areas. Only two out 
of the 33 genital wart samples contained HPV16 DNA, but they all contained HPV type 6 
or 11. It was then concluded that HPV16 was specifically associated with malignant 
cervical disease. He also suggested that other HPV types may cause cervical cancer in those 
samples that did not test positive for HPV16 (Schwarz et al. 1985). It was here that zur 
Hausen and Gissmann provided the first concrete evidence that specific HPV types were 
linked to cancer of the cervix (Schwarz et al. 1985). The publication did not say that HPV 
type 16 was the etiologic agent of cervical cancer at that time.  
A year later in 1984, zur Hausen and his team identified another new HPV strain in 
cervical cancer cells, HPV18 (De Villier et al. 1987). They found HPV18 DNA in nine out 
of 36 cervical cancer biopsies from African and Brazilian patients, and only two out of 13 
cervical cancer biopsies from German patients. This observation further supported the 
concept that cervical cancer might be caused by multiple types of HPV. In 1987, zur 
Hausen analyzed HPV types 6, 11, 16, and 18 in over 9,000 Pap smears obtained from 
three gynecological hospitals and compared the presence of HPV with both cytological 
findings from the Pap tests and staging (CIN I-III and invasive cancer) determined from 
cervical biopsies obtained from women with abnormal Pap tests. They found that over 
8,000 Pap smear samples were normal, but later 15% of them were found to test positive 
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for HPV DNA, indicating that other types of HPV are present in cervical cells, but do not 
necessarily always cause cancer. HPV infection was detected in 35-40% of women with 
abnormal smears. There were 162 Pap smear samples that were abnormal and identified as 
mild cervical dysplasia. There were 120 Pap smear samples that had a high grade of 
cervical dysplasia, and 62 Pap smear samples showed invasive cervical cancer. They found 
strong evidence of HPV 16 and 18 DNA and little evidence of HPV 6 and 11 DNA in the 
Pap smears where mild or moderate stages of cervical dysplasia was present. About 80% 
of the abnormal Pap smear samples that were identified as cervical dysplasia or cancer by 
biopsy, tested positive for HPV DNA (De Villier et al. 1987). They concluded that HPV 6 
and 11 caused genital warts, while HPV 16 and 18 caused cervical cancer (De Villier et al. 
1987). Thanks to zur Hausen’s studies as well as those of others, many more HPV types 
were identified. In 2008, zur Hausen received the Nobel Prize in Physiology or Medicine 
for discovering that HPV caused cervical cancer.  
The findings of zur Hausen and his research team created the basis for subsequent 
studies that ultimately led to the development of three prophylactic vaccines against both 
low and high-risk types of HPV. Specifically, in the US, Gardasil®9 protects against nine 
types of HPV; two low-risk (LR) (types 6 and 11) and seven high-risk (HR) (types 16, 18, 
31, 33, 45 and 52). The HR-HPV can cause cervical, vaginal, and vulvar cancers in females 
and anal cancer in women and men and the LR-HPV types cause genital warts in both 
males and females (Gupta et al. 2017). About 80% of Americans will get an HPV infection 
in their lifetime, but since 2006 when the vaccine was approved, HPV infections have 
dropped by 71% in teen girls (PatientPoint 2018).  The vaccine was initially recommended 
for persons of age 9-26, but recently the Food and Drug Administration (FDA) has 
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extended the approval of the vaccine for persons of age 27-45 (FDA 2017). The vaccine is 
given in 2 or 3 shots depending on age. Contrary to some popular beliefs, the vaccine is 
very safe. Since 2006, more than 270 million doses of an HPV vaccine have been given, 
with only 0.0003% of patients reporting mild side effects, such as nausea and dizziness. 
There is no evidence linking serious side effects to the vaccine (PatientPoint 2018).  
Globally, 71 countries (37% of all countries) have introduced the HPV vaccine in 
their national immunization program for girls and 11 countries (6% of all countries) for 
boys as of March 2017 (WHO 2017). In the US, in 2017, 63% of eligible girls and 50% of 
eligible boys got the vaccine, making it the most underutilized immunization available for 
children (DiSalvo 2017). This vaccine saves lives, so why aren’t more children getting it? 
A meta-analysis study from over 50 published articles on PubMed summarized the barriers 
of the HPV vaccine among US adolescents from the following target populations: Health 
care professionals, parents, underserved and disadvantaged populations, and males. Health 
care professionals cited financial concerns and parental attitudes as barriers (Holman et al. 
2014). Parents reported needing more information before vaccinating their children since 
the vaccine is not required to attend school. Parents were also concerned about the 
vaccine’s effect on sexual behavior and whether it would lead to increased sexual 
promiscuity. However, a study has shown that young women who received the HPV 
vaccine before or at the same age of sexual debut did not engage more in sexual risk-taking 
behavior than women who did not receive the HPV vaccine (Hansen et al. 2014). Parents 
also had concerns of the low perceived risk of HPV infection, social influences, irregular 
preventative care and vaccine cost, which is about $130-170 per dose. Some parents of 
sons reported not vaccinating their young boys because they do not see the benefit for them 
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to get it. One of more important barriers parents reported was health care professional 
recommendations. Minorities with low household incomes and without health insurance 
reported limited knowledge about the vaccine, a lack of health insurance, distrust of the 
health care system, cultural factors, and immigration status (Holman et al. 2014). Males 
reported lack of benefit from the vaccine as well as not knowing the vaccine should be 
given to them. Males also were not being recommended the vaccine from health care 
professionals and the cost of the vaccine was a deterrent (Holman et al. 2014). 
5.3 HPV Prevalence 
Most sexually active individuals will come into contact with a sexually transmitted 
infection (STI) at some point in their lives. HPV is the most common sexually transmitted 
infection in the U.S. (Satterwhite et al. 2008). Globally, about 570,000 cases of cancer per 
year in women and 60,000 cases of cancer in men are attributable to HPV (WHO 2018). 
The proportion of all cancers in a population caused by HPV, the attributable fraction (AF), 
can vary widely. For example, HPV AF in women ranges from less than 3% in 
Australia/New Zealand and the U.S. to 26% in sub-Saharan Africa (de Martel et al. 2017). 
Globally, the relative contribution of HR-HPV types 16 and 18 are 460,000 cases (72%) 
of all HPV-attributable cancer cases (de Martel et al. 2017). All nine HPV types covered 
by Gardasil®9 are 570,000 cases (90%) of all HPV-attributable cancer cases (de Martel et 
al. 2017).  
In the U.S. during 2013-2014, the prevalence of any HPV and high-risk genital 
HPV for adults aged 18-59 was 45.2% and 25.1% respectively in men and 39.9% and 
20.4% respectively in women (McQuillan et al. 2017). Prevalence of any HPV and high- 
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risk genital HPV was lower among non-Hispanic Asians and higher among non-Hispanic 
blacks than both non-Hispanic whites and Hispanic men and women. The prevalence of 
any oral HPV for adults aged 18-59 was 7.3% and was 4.0% for HR-HPV. Overall, the 
prevalence of any HPV and high-risk oral HPV was lowest among non-Hispanic Asian 
adults and highest among non-Hispanic black adults. Prevalence of any HPV and high-risk 
oral HPV was higher in men than in women, except for high-risk HPV among Asian adults 
(McQuillan et al. 2017). 
5.4 HPV-Associated Cancers 
Approximately 79 million Americans in their late teens and early 20s are currently 
infected with HPV (CDC 2018). Fourteen million people in the US become newly infected 
each year (CDC 2018). As mentioned, HPV is the most common sexually transmitted 
infection in that most people that are sexually active will get an HPV infection at some 
point in their life, especially if they do not get the HPV vaccine. There are several HPV-
associated cancers, but the most common in women is cervical cancer, in which HPV is 
responsible for most all cases and oropharyngeal cancer is the most common HPV-
mediated cancer in men. Oropharyngeal cancer is cancer in the back of the throat, including 
the tonsils and tongue and until rather recently tobacco and alcohol were considered the 
primary risk factors.  However, studies have now shown that HPV causes about 70% of 
cancer cases of the tonsils and tongue and these cases are rising (CDC 2018). HPV is also 
responsible for about 75% of vaginal cancers, 69% of vulvar cancers, 63% of penile 
cancers, and 91% of anal cancers. There were 42,671 new cases of HPV-associated cancers 
in the U.S. from 2011-2015: 24,391 among women and over 18,280 among men (Figure 
5.3). The incidence rate of HPV-associated cancers varied by cancer type, sex, and 
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race/ethnic group (Figure 5.4 and Figure 5.5). In each race/ethnic group, women had a 
higher incidence than men. As for cancer site, men have a much higher incidence of HPV-
associated cancers of the oropharynx than women. Of the new cases of HPV-associated 





Figure 5.3 Number of new HPV-associated Cancer cases in females and males (2011-




























Figure 5.4 Rate of HPV-associated Cancers by sex and cancer site. Adapted from CDC 





















Figure 5.5 Rate of HPV-associated Cancers by sex and race/ethnic group. Adapted from 




5.5 HPV Clearance & Persistence 
 
Figure 5.6 illustrates the natural history of HR-HPV infection and progression to 
cervical cancer. Important to note is that there is a high possibility of clearing a HR-HPV 
infection within about one-two years and that it is a persistent HR-HPV infection that 
ultimately increases the risk of cervical cancer, especially infection with HPV types 16 and 
18 (Ho et al. 1998, Walboomers et al. 1999 and Dalstein et al. 2003). The natural history 
of HPV clearance needs to be better understood in order to better predict and understand 
clinical outcomes.  
Up until 2015, there were no reports of comparisons of HR-HPV clearance times 
between African American (AA) and European American (EA) women (Banister et al. 
2015). Banister et al., (2015) found that the time required to clear 50% of HR-HPV 
infections in college-age AA women was much longer (601 days) than that for college-age 
EA women (316 days). Furthermore, the odds of an AA woman not clearing HR-HPV are 
1.61 times those for an EA woman (Figure 5.7). This study also found that having a HR-
HPV was strongly associated with an abnormal Pap test result. The results of Banister et 
al. (2015) are consistent with other studies that also looked at the time of clearance of a 
HR-HPV infection. In a study out of Arizona, a predominately white, non-Hispanic cohort 
aged 18-35 reported the median clearance time was 298 days (Giuliano et al. 2002). A 
study of female university students in Montreal reported their median clearance time was 
495 days (Richardson et al. 2003). The reported median HR-HPV clearance time from 
women in a study in Oahu, Hawaii was 224 days (Goodman et al. 2008). A study involving 
a college-aged cohort out of New Jersey reported the median duration of new HPV 
infections was 243 days (Ho et al. 1998). Interesting, Banister et al. (2015) reported that 
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the increased risked of an abnormal Pap test observed among AA women and the increased 
likelihood of being HR-HPV positive at any one visit is not due to the differences in 
exposure to HPV, rather it is indeed due to the increased duration of HR-HPV infections.  
 
Figure 5.6 The natural history of HR-HPV infection and progression to Cervical Cancer. 































Figure 5.7 HR-HPV infection clearance in college-age females.  
Adapted from Banister et al. 2015. 
 
 
Another question to consider is why are some individuals able to clear a HR-HPV 
infection while in other individuals the HR-HPV infection persists? The mechanism 
involved in viral persistence is complex and not yet fully understood. None of the genes 
encoded by HPV have regulation of the immune system as their primary function, but there 
are several mechanisms that suggests how HPV escapes the host cell immune response 
system (Kanodia et al. 2007). HPV has evolved to avoid detection to maintain a very low 
profile in terms of its species specificity and tissue-tropism. HPV replicates in terminally 
differentiated cells which are no longer dividing, therefore reducing exposure to the host 
immune system. The virus is also non-lytic and does not elicit any pro-inflammatory signs 
that activate dendritic cells (DC) and induce migration to the local environment. Having a 
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non-lytic nature limits the production of antigens that are processed and presented to the 
adaptive immune system. The virus encodes only non-secreted proteins, in which the early 
(E) proteins are expressed at low levels and reside mostly in the nucleus (Crum et al. 1986, 
Stoler et al. 1992 and Greenfield et al. 1991). The expression of the late (L) proteins, highly 
immunogenic capsid proteins, are limited to cells in the terminally differentiated outer layer 
of the epithelium, which are shed (Cason et al. 1989 and Rudolf et al. 1999). Lastly, there 
is no blood-born phase of the HPV life cycle and only minimal amounts of replicating virus 
are exposed to the immune system, allowing them to be invisible to the host.  
Molecular mimicry is the process in which structural properties of an introduced 
molecule imitate or simulate molecules of the host. For example, HPV16 E7 shares a 
common structural motif with xeroderma pigmentosum group G complementing protein 
(XPGC) and the retinoblastoma binding protein 1 (RBP-1), in which a cell-mediated 
response that targets the common motifs of these proteins would result in inhibition of 
excision repair (Scherly et al. 1993 and O'Donovan et al. 1993) and derangement of cell 
cycle regulation (Lai et al. 1999), respectively.  
Neutralizing antibodies are an effective way to prevent HPV infection and control 
the spread of HPV and T-cells are important in controlling HPV infections and HPV-
induced tumors. T-cells recognize infected cells through interactions of their receptors with 
viral peptides bound to major histocompatibility complexes (MHC) om the surface of the 
infected cells. HPV-mediated dysregulation of the antigen processing machinery would 
result in down regulation of peptide-MHC complexes on the surface of infected cells and 
protect from immune attack and HPV associated tumors exhibit loss of MHC class I 
(Cromme et al. 1994, Hilders et al. 1995, Keating et al. 1995, and Bontkes et al. 1998). 
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For example, HPV E5 and E7 specifically play a role in the disruption of antigen 
presentation. The HPV E5 protein possesses mitogenic activity that acts synergistically 
with the epidermal growth factor (EFG) receptor in human keratinocytes and inhibits the 
degradation of the EGF receptor in the endosomal compartment. The HPV E7 protein is 
mostly found in the nucleus of infected cells and can regulate transcription (Greenfield et 
al. 1991). For example, E7 regulates transcription of genes associated with antigen 
presentation and inhibits their function, which thereby reduces viral peptides presented on 
the surface of infected cells and helps the virus escape detection by cytotoxic T-cells 
(CTL).  
Immunogenic peptides from E6 (Evans et al. 2001) and E7 (Bauer et al. 2000) 
proteins are not efficiently processed and presented by HPV positive tumor cells, which 
correlates with reduced expression of human leukocyte antigen (HLA) class I, proteasome 
subunits low molecular mass proteins (LMP) 2 and 7, and the transporters of antigenic 
peptides (TAP) 1 and 2 in cervical carcinoma cell lines (Evans et al. 2001). HPV16 E5 
down-regulates surface expression of HLA-A and HLA-B, which present viral peptides to 
MHC class-restricted CTL. Down-regulation of MHC class I may allow HPV to establish 
infection by avoiding CTL and natural killer (NK) cells (Straight et al. 1995). E5 also 
interferes with MHC class II antigen presentation by inhibiting CD4 positive T-cell 
recognition through down regulation of MHC class II molecules. CD4 positive helper T 
cells are functionally polarized into two subsets that produce different patterns of 
cytokines: Th1 and Th2. Th1 cells are mostly involved in cell-mediated reactions and 
produce mainly IL-2 and IFN-gamma. Th2 cells are commonly found in association with 
strong antibody and allergic response and produce IL-4, IL-5, IL-6, IL-10, and IL-13. The 
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characteristic cytokine products of Th1 and Th2 cells are inhibitory for the differentiation 
and effector function of the opposite subset (Romagnani et al. 1994). Skewing of the 
cytokine profile would lead to an inappropriate immune response, which may result in the 
inability of the host to clear infection. CTL responses are essential in controlling HPV 
infections and since Th1 responses favor the development of CTL, it is possible that HPV 
has evolved mechanisms to disfavor the induction of Th1 responses. Studies have shown 
in HPV-associated cancers that the presence of Th2 cytokines correlated with the 
progression to invasive tumors (Bonagura et al. 1998, Mota et al. 1999, Warrino et al. 
2004, and Bais et al. 2005). For example, a study compared cytokine profiles in cervical 
secretions either negative or positive for HPV DNA. These studies found elevated levels 
of IL-10 in cervical secretions positive for HPV DNA, suggesting elevated IL-10 in early 
cervical lesions may inhibit the immune response against an HPV infection (Azar et al. 
2004). 
Interferons are soluble factors that interfere with viral replication (Schneider et al. 
1983) and limit both lytic and non-lytic viral infections, as well as activate or attract cells 
of the immune system (i.e. neutrophils, macrophages, NK cells, DC). There are two classes 
of interferons: type I (IFN-alpha/beta) and type II (IFN-gamma). Type I IFN is produced 
by infected cells, have anti-viral, anti-proliferative, anti-angiogenic and immune-
stimulatory activities. IFN-regulatory factors (IRF) are a family of transcription factors that 
mediate both virus and IFN signaling pathways, which are involved in anti-viral defense 
immune response and cell growth regulation. Many viruses have evolved mechanisms to 
disrupt the IFN pathway. For example, HPV E6 targets the IFN pathway. cDNA microarray 
analysis of gene expression showed that HPV16 E6 altered expression of three classes of 
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genes; IFN-responsive genes, NF-kappaB stimulated genes, and cell cycle regulation genes 
(Nees et al. 2001).  
Cytokines, chemokines, adhesion molecules, and proteases are all molecules that 
direct the migration of cells of the immune system and elicit local infiltration of 
inflammatory and immune cells. Altered expression of these proteins would hinder and 
may even inhibit immune responses that would help clear HPV infections. MCP-1 was the 
first chemokine identified (Yoshimura et al. 1989 and Leonard et al. 1990) and attracts a 
variety of cell types including monocytes, memory T cells and NK cells (Baggiolini et al. 
1995). MCP-1 expression is suppressed after an HPV infection. The mechanism is not 
known, but E6 and E7 from HR-HPV have been shown to suppress MCP-1 expression in 
epithelial cells lining the female genital tract (Kleine-Lowinski et al. 2003). Interluekin-8 
(IL-8) is another chemokine and is produced by a wide variety of cell types, including all 
nucleated cells within the body (mainly monocytes and macrophages) (Oppenheim et al. 
1991). IL-8 is downregulated when E6 and E7 are expressed (Huang et al. 2002). 
Interluekin-18 (IL-18) is a pro-inflammatory cytokine defined by its ability to stimulate the 
expression of genes associated with inflammation. IL-18 is downregulated by E6 via a p53 
independent pathway (Cho et al. 2001). 
Apoptosis, or programmed cell death, is initiated by specific biological signals and 
two main apoptotic routes have been identified: the extrinsic death receptor pathway and 
the intrinsic mitochondrial pathway (Budihardjo et al. 1999 and Hengartner et al. 2000). 
Extrinsic receptors are activated specifically by their cognate ligands such as Fas-Fas 
(FasL) and the intrinsic pathway is used in response to many nonspecific stimuli such as 
DNA damage, radiation, and osmotic stress (Rich et al. 2000), resulting in cytochrome c 
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release from the mitochondrial inter-membrane space. Both pathways unite at the level of 
capase-3 activation. E6 prevents the intrinsic pathway, p53-dependent apoptosis of infected 
cells and E5 suppresses FasL mediated-apoptosis, reducing Fas expression two-fold 
(Kabsch et al. 2002).  
There are diverse immunogenic associations that play a role in HPV infection, HPV 
persistence, and ultimately cervical cancer. There are several single nucleotide 
polymorphisms (SNPs) in genes encoding cytokines, chemokines, receptors, and antigen-
processing machinery (AMP) components and association with cervical carcinoma risk, 
progression, and/or outcome. Certain SNPs in APM components, HLA genes, cytokine 
genes and receptor genes will lead to a less effective overall local immune response, which 
will impact the development and progression of malignant cells, ultimately leading to 
cervical carcinoma (Mehta et al. 2017). An increasing number of investigators are using a 
genome-wide association study (GWAS) approach for the purpose of identifying SNPs that 
may serve as markers for the susceptibility to persistent HPV infection and ultimately 
cervical neoplasia (Chen et al. 2013 and Chen et al. 2015). 
5.6 The Cervix  
The cervix is a cylinder-shape fibromuscular organ that connects the vagina and 
uterus. It is a part of the female reproductive system. It is approximately 4 cm in length and 
3 cm in diameter. The cervix has two main parts: the endocervix and the ectocervix (ACS 
2016). The endocervix is the inner part of cervix lining the canal leading to the uterus.  The 
ectocervix is the outer part of the cervix facing the vagina. During a gynecologic 
examination, the ectocervix is the part of the cervix that can be seen from inside the vagina. 
There lies an opening in the center of the ectocervix, known as the external os, which allows 
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passage between the uterus and vagina, called the endocervical canal. The two parts of the 
cervix are made up of different cells: glandular and squamous cells. Glandular cells are tall 
and shaped like columns and line the endocervical canal. Squamous cells are flat and thin 
like fish scales and line the ectocervix and vagina. Where the squamous and glandular cells 
join is called the squamocolumnar junction (SCJ), also known as the transformation zone 
because the columnar cells are constantly being changed into squamous cells (Figure 5.8). 
This occurs especially during puberty and child-bearing years.  
One of the main functions of the cervix is to make and release mucus, which 
consistently changes to prevent or promote pregnancy (ACS 2016). The mucus is thick and 
stops sperm from entering the uterus during pregnancy and for most of the menstrual cycle. 
The mucus also helps to protect the uterus and upper female reproductive organs from 
harmful bacteria. The mucus changes and becomes thinner, allowing sperm to pass through 
the cervix into the uterus when a mature egg is released from an ovary each month. The 
lining of the uterus is shed through the cervix into the vagina, then out of the body every 
month, except during pregnancy and menopause. During childbirth, the cervix dilates, 
allowing the baby to pass through the birth canal.  
5.7 Cervical Abnormalities 
Precancerous changes in the cervix and cervical cancer generally begin in the 
transformation zone (ACS-2 2016).  Squamous cell carcinoma (SCC) and adenocarcinoma 
are the two most common tumors of the cervix (ACS-2 2016). SCC originates from the 
squamous cells that line the ectocervix and adenocarcinoma starts in the glandular cells of 
the endocervix. Adenosquamous carcinoma is a mixture of both squamous and glandular 
cells. Over 50% of the time these precancerous changes occur because of an infection with 
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HPV. However, over 90% of these precancerous changes do not progress into cervical 
cancer and if cervical cancer should develop, it can take up to a decade.  
 
Figure 5.8 Schematic of the Cervix and its major parts. Adapted from WebMD 2015-2015. 
 
While precancerous conditions of the cervix are not yet cancer, they must be 
treated. Persistent abnormal changes can develop into cancer if left untreated. Based upon 
how abnormal the exfoliated cervical cells look under a microscope and how severe the 
cell changes are, allow a trained cytologist to classify the stage of the abnormality.  
Two essential components of a cell are the nucleus and the cytoplasm. The nucleus 
gives information about the health of the cell and the cytoplasm gives clues about the type 
of cell and its degree of maturation (Eurocytology 2014). There are criteria that a cytologist 
must follow to distinguish benign and neoplastic, such as the variation in nuclear size and 
shape, chromatin, and nuclear membrane. These variations are indicative of the abnormal 
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mitotic activity of precancerous cells. The Bethesda System terminology is used for 
cervical cytological classification (Nayar et al. 2015). Cervical intraepithelial neoplasia 
(CIN) is the precancerous changes of cervical cells that if left untreated can ultimately lead 
to invasive squamous cell carcinoma of the cervix. CIN may be present in the cervix for 
many years before an invasive lesion develops. CIN also may regress, persist, or progress. 
There are three grades of CIN: CIN1, CIN2, and CIN3 (Eurocytology 2014). These grades 
increase the risk of progression and decrease the likelihood of regression. Glandular 
intraepithelial neoplasia (CGIN) is the precancerous changes of adenocarcinoma of the 
cervix, which is rare compared to squamous cell carcinoma (Eurocytology 2014). 
CIN is described cytologically as squamous intraepithelial lesion (SIL). SILs are 
divided into low-grade (LSIL), atypical squamous cells of undetermined significance 
(ASC-US) and high-grade (HSIL). LSIL only affects cells on the surface of the cervical 
lining and compares to CIN1 (Figure 5.10). The cervical dysplasia is mild, with cells 
looking only slightly different from the normal cells (Figure 5.9). The cells will be mature 
and polygonal in shape and can be single or in sheets and the nucleus will take up about 
40% of the volume of the cell (Eurocytology-2 2014.) ASC-US lie between normal and 
LSIL and equates to a small proportion of cases (Eurocytology-3 2014). HSIL compares 
to CIN2 and CIN3 (Figure 5.11). The changes to the cells are deeper in the cervical lining 
and the cervical dysplasia is moderate to severe, and the cells are much more abnormal. 
The cells will be immature and appear mostly as crowded groups of proliferating cells 
(Eurocytology-4 2014). The higher the grade the greater the risk of cervical cancer. 
Cervical polyp, Nabothian cyst, and cervical fibroids are non-cancerous lesions of the 
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cervix that do not spread to other parts of the body (ACS-3 2016). They are usually not 





















































Figure 5.11 HSIL. Adapted from Eurocytology-4 2014.  
 
5.8 Development of the Pap Test 
 
In the early 1900s, cervical cancer was the number one killer of women in the U.S. 
The death rate from cervical cancer has deceased over 60% between 1955-1992 due to 
cervical cancer screening. Known initially as the Pap smear, this test was developed by 
George Papanicolaou (1883-1962) (Figure 5.12), which has been the basis of the 
significant decline in deaths related to cervical cancer. Upon moving to the U.S. in 1913, 
Papanicolaou’s main area of research was on oocytes collected from guinea pigs, which 
had to be collected at certain stages of development before use. The collection of these 
cells was difficult because female guinea pigs do not have external bleeding or a mensural 
cycle. In 1916 Papanicolaou thought to put a nasal speculum in the vagina of a guinea pig 
in the hope of identifying any bleeding, and sure enough every 15-16 days, slight bleeding 
occurred. At this time, he was interested in being able to approximate the best time for 
oocyte collection. He then decided to view the cells under a microscope. What he found 
was that he was able to view cyclic ovarian changes from the scraped cells. The changes 
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in the hormonal status of the ovary could be interpreted from the scraped cells and led 




















In 1920, he started observing vaginal scrapes from humans. He knew he was on to 
a breakthrough when he saw his first malignant cells from one of the vaginal smears.  He 
started collecting data on cervical carcinoma and presented his findings at a conference in 
1928. Unfortunately, his findings did not impress his colleagues, leading Papanicolaou to 
abandon the subject for many years! He went on to focus again on hormonal changes, but 
found himself returning to cancer detection, and after years of observations, he was able to 
show the correlation between scraped cells and the detection of carcinoma of the cervix. 
He published his findings in a manuscript titled “The diagnostic value of vaginal smears 
in carcinoma of the uterus” in 1941 (Papanicolaou et al. 1941). He describes in detail the 
technique for collecting the cells, smearing the cells on the surface of glass slides, and 
staining it in such a way to view the components of the cell. The vaginal smear method 
Figure 5.12: Dr. George Papanicolaou. Adapted from Shots: Health 
News from NPR 2015.  
 60 
was accurate for the diagnosis of carcinoma of the cervix, and he had realized the need for 
early detection of cancer, and emphasized the need for a simple, inexpensive method for 
its diagnosis. Fortunately, this time his method was well accepted and the training of 
cytopathologists to interpret the cellular characteristics of Pap smears was initiated 
(Michalas et al. 2000). 
The Pap smear has saved the lives of millions of women by early diagnosis of 
cervical cancer, which still remains one of the most common cancers in women in 
developing countries.  In 1942, he published his book titled “Diagnosis of Uterine Cancer 
by the Vaginal Smear.” Papanicolaou, known as “the greatest medical researcher of our 
century without a Nobel prize”, did receive many awards and honors including, but not 
limited to, the publication of two commemorative stamps in Greece and the U.S. (Anand 
et al. 2015). 
5.9 Cervical Cancer Screening Guidelines 
New cervical cancer screening guidelines were published in 2013, since new 
information became available since the publication of the 2006 consensus guidelines. The 
new guidelines are based on a systematic review, contributions from six working groups 
and a symposium co-sponsored by the American Cancer Society (ACS), American Society 
for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical 
Pathology (ASCP) in 2011-2012 (Massad et al. 2013). These new guidelines include 
updated screening guidelines for the early detection of cervical cancer and its precursors. 
The new screening recommendations address age-appropriate screening strategies. The use 
of cytology and HR-HPV testing, follow-up of women after screening (management of 
screen positives and screening interval for screen negatives), age at which to exit screening, 
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future considerations regarding HPV testing alone as a primary screening approach and 
screening strategies for women vaccinated against HPV16/18 infections are addressed in 
the new guidelines. For example, women under the age of 21 are no longer receiving 
cervical cancer screening and co-testing with a HR-HPV type assay, and cervical cytology 
is being used to screen women 30 years and older. Table 5.1 summarizes these new 
screening recommendations.  
Table 5.1 Summary of Cervical Cancer Screening Recommendations. Adapted from 
Saslow et al. 2012. 
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As stated above, the current guidelines recommend cytology and co-testing with a 
HR-HPV testing assay, but there is now growing evidence for screening with HR-HPV 
testing alone as a primary screening approach (Huh et al. 2015). Current guidelines suggest 
women 30-65 years of age should not been be screened with HR-HPV testing alone, but 
every three years for cytology and every five years for co-testing. The guidelines did not 
suggest any setting where the use of HR-HPV testing alone would be appropriate. There 
are concerns about the specificity of HR-HPV screening and the potential harms, such as 
excess colposcopy and treatment for non-neoplastic HPV lesions in women testing HPV 
positive by HR-HPV screening (Saslow et al. 2012). 
Also, there is a lack of a well-defined and evaluated strategy to manage HR-HPV-
positive women, including cost-effectiveness, and the lack of data on testing errors due to 
specimen inadequacy. Although the majority of the current studies that strengthen the 
evidence supporting primary HR-HPV screening were conducted in Europe (Ronco et al. 
2014, Rijkaart et al. 2012, Leinonen et al. 2012, Malila et al. 2013, Gyllensten et al. 2012, 
and Ogilvie et al. 2012), a large prospectively-conducted US FDA registration trial of 
primary HR-HPV screening was published with end-of-study results (Ronco et al. 2010 
and Anttila et al. 2010), demonstrating improved sensitivity against CIN2 and CIN3 over 
cytology alone in a single round of screening. Another important concern was how to 
manage a positive HR-HPV result. Figure 5.13 demonstrates triage for a positive HR-HPV 
test with HPV types 16 and 18, as well as for the 12 other HR-HPV genotypes based from 
the three-year ATHENA trial (Ronco et al. 2010 and Anttila et al. 2010). Other key 
evaluations include, but are not limited to: 1. A negative HR-HPV test provides less risk 
of CIN3+ than a negative cytology result. 2. Rescreening after a negative primary HR-HPV 
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screen should occur no sooner than every 3 years. 3. Primary HR-HPV screening should 
not be initiated prior to 25 years of age. More data is expected on triage options which will 
lead to an update on the current triage recommendations. HR-HPV testing has the potential 










5.10 Early DNA Arrays 
Gene expression can be studied at the messenger ribonucleic acid (mRNA) or 
protein levels. For many years, gene expression studies were limited since genes had to be 
studied individually at the mRNA level using the Northern blot technique developed in 
1977 (Alwine et al. 1977). Briefly, RNA is extracted from the sample and separated by size 
via agarose gel electrophoresis. The RNA is then transferred to a membrane that is then 
hybridized with labeled probes, and then the labeled RNA is visualized on a film. One of 
the key points of a Northern blot is the specific hybridization of the labeled oligonucleotide 
with its complementary target mRNA sequence, thus allowing the investigation of the 
specific gene of interest. The relative expression level of the gene of interest is proportional 
Figure 5.13 Recommended primary HPV screening algorithm. Adapted 
from Ronco et al. 2010 and Anttila et al. 2010.  
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to the intensity of the hybridization band viewed on the film. In 1975, Grunstein and 
Hogness published one of the first examples of a DNA array (Grunstein and Hogness 
1975). They applied the process of molecular hybridization to DNA released from blotted 
microbial colonies, which was a useful process for screening bacteria clones. In this 
procedure, the DNA of interest was cloned into plasmids. The plasmids were used to 
transform E. coli, that were plated onto agar Petri plates covered with nitrocellulose filters. 
A radioactively labeled probe that would bind to complimentary DNA within the plasmid 
was then added. Replica plating was used to produce additional agar plates. The colonies 
on the filter were lysed and their DNA was denatured and fixed to the filter to produce a 
random and unordered collection of DNA spots that represented the cloned fragments. This 
procedure was used to rapidly screen thousands of colonies to identify clones containing 
DNA that was complementary to the probe.  
A similar methodology was used to produce arrays in 1979 (Gergen et al. 1979). 
Researchers created a mechanical 144 pin device and a jig that allowed them to replicate 
multiple microtiter plates on agar and produce arrays of 1728 different colonies in a 26 x 
38 cm region. The colonies could be easily transferred to squares of Whatman filter paper 
for lysis, denaturing, and fixing steps for producing hybridized DNA and allowed the 
production of DNA arrays on filters that could be used multiple times.  Filter based arrays 
were used in a variety of applications including: cloning genes of specific interest, 
identifying SNPs (Miller and Barnes 1986), cloning genes that are differentially expressed 
between two samples (Crampton et al. 1980), and physical mapping (Craig et al. 1990).  
Importantly, the process was then automated using robotic systems to rapidly array 
clones from microtiter plates onto filters (Craig et al. 1990 and Lennon and Lehrach 1991). 
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The arrays created a defined pattern allowing parallel hybridization and efficiency was 
increased. Errors that occur during repetitive procedures was reduced through the 
automated placing of samples on the array (Bumgarner et al. 2013). The development of 
complimentary DNA (cDNA) cloning led to the creation of reference sets of cDNA and 
corresponding filter arrays for entire genomes (Auffray et al. 1980). By the late 1990’s, 
sets of non-redundant cDNA’s became widely available, along with the complete genome 
sequences of some organisms.  
5.11 Modern Day DNA Arrays 
A microarray is defined as a collection of probes immobilized on a solid material 
in microscopic features known as spots that can be hybridized to target molecules 
(Altomare 2010). The first study that used the word “microarray” and explaining this new 
technology was published in 1995 (Schena et al. 1995). The  array was carried out on a 
high capacity system that was developed to monitor the expression of many genes in 
parallel, which was the first miniaturized microarray printed on glass (Schena et al. 1995). 
DNA array technology progressed rapidly as both new methods of production and 
fluorescent detection were introduced. Also, arrays transitioned from the spots on the 
microarrays being relatively long pieces of DNA to arrays containing much shorter 
oligonucleotides, 25-60 nucleotides in length (Bumgarner et al. 2013). The first whole 
eukaryotic genome (Saccharomyces cerevisiae) on a microarray was reported two years 
later by researchers at Stanford University (Stanford, California, USA) (Lashkari et al. 
1997). While today, there are many commercial microarray options with high sensitivity, 
the technology was not commercialized right away and in their initial publication the 
authors included instructions for producing the robotics necessary for printing a 
 66 
microarray, allowing laboratories to produce their own customizable microarray 
experiments (Stoakes et al. 2018 and Altomare 2010).  
Messenger RNA expression analysis is now routinely done on thousands of genes 
and the entire genome of complex organisms, providing a valuable tool for biomarker 
detection, disease sub-classification, and identification of causal mechanisms. Microarray 
results can produce either quantitative (gene expression) or qualitative (diagnostics) data. 
5.12 Types and Classifications of Microarrays 
Based on the mode of preparation of the array, microarrays are divided into three 
subtypes: (1) spotted arrays, (2) in situ synthesized arrays and (3) self-assembled arrays. 
Spotted arrays are often made on poly-lysine coated glass microscope slides (DeRisi et al. 
1996). The poly-lysine coating provides superior binding of DNA. Also, the use of slotted 
pins for spotting, allows a single dip of a pin in a DNA solution to spot multiple slides. 
This type of microarray also allows the use of fluorescent labeling of the sample.  
In situ synthesized arrays are made by chemical synthesis on a solid substrate. This 
method was first published in 1991 (Fodor et al. 1991). The chemical synthesis combines 
photolabile protecting groups with photolithography to perform the insitu synthesis. In 
initial studies, investigators demonstrated the feasibility of producing arrays of 
oligopeptides of a length of 10-amino acids and also arrays of di-nucleotides. In 1994, the 
same group at the recently formed company, Affymetrix, demonstrated the ability to use 
this technology to generate DNA arrays consisting of 256 different octa-nucleotides (Pease 
et al. 1994). By 1995-1996, Affymetrix arrays were being used to detect mutations in the 
reverse transcriptase and protease genes of the highly polymorphic HIV-1 genome 
(Lipshutz et al. 1995) and to measure variation in the human mitochondrial genome (Chee 
 67 
et al. 1996). Later on, Affymetrix would use this technology in gene expression analysis, 
genotyping, and sequencing. 
In 1996, a new method was developed to use inkjet printing technology and 
standard oligonucleotide synthesis chemistry to produce oligonucleotide arrays (Blanchard 
et al. 1996). Briefly, inkjet type printing is used to deposit liquid droplets onto a substrate. 
In this case, the inkjet printer heads were adapted to deliver the four different nucleotide 
phosphonamidites to a glass slide that was pre-patterned to contain hydrophilic regions 
surrounded by hydrophobic regions. This technology was eventually commercialized and 
licensed to Agilent Technologies.  
Self-assembled arrays are fiber optic arrays made by the deposition of DNA 
synthesized on small polystyrene beads.  This approach to the construction of arrays was 
developed by the group of David Walt at Tufts University (Massachusetts, USA) (Ferguson 
et al. 2000) and ultimately licensed to Illumina. The beads are deposited on the etched ends 
of the array to provide a well slightly larger than one bead. Different DNA can be 
synthesized on different beads and applying a mixture of beads to the fiber optic cable will 
make a randomly assembled array. Based on the probes used, microarrays come in many 
different types, including: DNA microarrays, MMChips, peptide, tissue, cellular, chemical 
compound, antibody, carbohydrate, phenotype, reverse phase protein microarrays and 
interferometric reflectance imaging senor (IRIS) arrays.  
In my research I used DNA microarrays. DNA microarrays are also known as gene 
chips, DNA chips, or biochips. The chips either measure DNA or uses DNA as a part of its 
detection system. There are four major types of DNA microarrays: cDNA microarrays, 
oligo DNA microarrays, BAC microarrays and SNP microarrays (Stoakes 2018).  These 
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arrays allow for the analysis of expression patterns of genes across the entire genome, in 
which thousands of genes can be studied at the same time. The following steps are required, 
as showed in Figure 5.14: messenger RNA (mRNA) is isolated from the sample and 
converted into complimentary DNA (cDNA). The cDNA is then labeled with a fluorescent 
dye or a biotin labeled nucleotide, which is then loaded or hybridized onto the microarray, 
where thousands of single-stranded DNA oligonucleotides, each that correspond to a single 
gene, are arranged as spots in a grid formation. Each spot corresponds to a different gene. 
The fluorescently labeled cDNA will only bind to its complimentary base pairs within the 
sample spot and any unbound cDNA will be washed off. The microarray is then scanned 
by a laser scanner in order to detect and quantify the fluorescent label, which can be used 
to determine levels of gene expression.   
 
Figure 5.14 Schematic of DNA Microarray steps. Adapted from 
Grigoryev 2017.  
 69  
  
CHAPTER 6: MATERIALS AND METHODS 
6.1 Collection of Samples 
The Pap test samples used in these experiments were collected as part of the CWCS 
study described in the first part of this thesis. CWCS participants were given two Pap tests 
annually and during each pelvic examination, cervical mucus and two exfoliated cervical 
cell (ECC) samples were collected. The first ECC sample was taken with a spatula and 
cytobrush, rinsed in 20 ml of PreservCyt solution and 15 ml was used in ThinPrep imaging 
for diagnostic cytology at LabCorp and the other 5 ml was used for HPV testing/typing. 
The second ECC sample was taken with a spatula and cytobrush as well. The brush was 
rolled over the spatula in an effort to transfer the complete sample onto the brush and then 
placed in a 15 ml conical tube containing 2 ml of RNAlater, a solution that stabilizes RNA 
and prevents its degradation. The cytobrush’s handle was cut with scissors in order for the 
tube to be capped.  The second ECC sample was used for isolation of total RNA and for 
the gene expression profiling studies using microarrays that I performed. All samples were 
properly labeled and stored immediately in a -20o C freezer until used. A blood or saliva 
specimen was collected at the participant’s first visit and used for DNA isolation and 
genomic studies such as SNP analysis. Cervical mucus samples were also collected at each  
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visit and were used for cytokine profiling experiments (Messersmith 2010 and Banister 
2009). 
6.2 Database Management 
Data generated from CWCS participant surveys and several laboratory tests were 
entered into an Access database, the CWCS Database. Through surveys given to the 
participants, demographic information and their ethnicity were collected. Additional 
information including stress, frequency and quantity of alcohol usage, tobacco and 
marijuana smoking, sexual behavior, diet, exercise, measures of depression and 
medications/supplements being taken were collected from the surveys. Tests that generated 
data were also uploaded into the CWCS database. Those tests included: Pap test result, 
HPV testing and typing, cytokine quantitation, and HPV16 variant information that I 
collected (see first part of this thesis). The database also contained information about 
unprocessed and processed samples (DNA, RNA, and cytokine extracts) and the initials of 
who was responsible for processing the samples. The database provided critical 
information of HPV persistence/clearance as well as for selecting and retrieving specific 
sets of samples for this study, as well as past and potential future studies. 
6.3 RNA Isolation from Exfoliated Cervical Cells  
ECC stored in RNAlater were thawed and mucus was dislodged from the cytobrush 
using a clean 200 uL pipette tip. Cytobrushes were maneuvered accordingly to maximize 
the recovery of suspension.   Ice-cold tissue-culture grade PBS (4.0 ml) was added to each 
sample and inverted. The ECC were collected by centrifugation in a clinical-type 
centrifuge, full-speed for about three min, and the supernatant was aspirated. The RNeasy 
Micro Kit (Qiagen Cat. No. 74004) was used to isolate RNA from the samples. The 
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protocol from the kit suitable for fibrous tissue was used according to the manufacturer’s 
recommendations. Samples were labeled and stored at -80o C until used. RNA quality and 
quantity were evaluated in an Agilent 2100 Bioanalyzer using RNA 6000 Pico chips 
(Agilent, Part No. 5067-1513), according to the manufacturer’s recommendations. RNA 
sample storage locations and data were uploaded into the CWCS database. 
6.4 RNA Quantitation  
After RNA samples were chosen from the database based on the estimated amount 
of initial RNA and the RNA integrity number (RIN) obtained from the Agilent 2100 
Bioanalyzer, we used the Quant-iT™ RiboGreen® RNA Reagent Kit (ThermoFisher 
Scientific, Cat. No. R11491) to quantify the amount of RNA. The RIN had to be 4.5 and 
higher and at least 5 uL of initial RNA had to be available.  RiboGreen® is an ultrasensitive 
fluorescent nucleic acid stain used for quantitating RNA in solution. We used the low-
range assay (1 ng/mL to 50 ng/mL RNA), in which we used about 50 ng/mL RNA for the 
assay.   
6.5 GeneChip® Pico Reagent Kit 
The Pico Reagent Kit (Applied Biosystems, Cat. No. 902929) allows one to prepare 
hybridization ready targets from picogram to nanogram quantities of total RNA for gene 
expression profiling analysis. Because total RNA in the CWCS samples was very limited, 
we choose to use the Pico Reagent Kit. Reverse transcription is initiated at the poly-A tail 
as well as throughout the entire length of RNA to capture both coding and multiple forms 
of non-coding RNA. The kit is ideal for amplification of intact, partially degraded, and 
compromised RNA samples. The kit is also optimized to work with a wide range of samples 
including tissue, cell lines, whole blood, and formalin-fixed paraffin-embedded (FFPE) 
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tissues. Hybridization-ready DNA could be produced using 100 picogram (pg) to 10 
nanogram (ng) of total RNA from cells. We used the maximum of 10 ng of purified RNA 
from our samples. 
Briefly, complementary RNA (cRNA) or cDNA is amplified using low-cycle PCR 
followed by linear amplification using T7 in vitro transcription (IVT) technology. The 
cRNA is then converted into biotinylated double-stranded cDNA hybridization targets for 
unbiased coverage of the transcriptome. Figure 6.1 displays the workflow for amplification 
and the labeling process.  
6.6 Microarray Hybridization and Analysis 
RNA samples (10 ng total RNA) were amplified, fragmented and biotinylated using 
GeneChip WT Pico Reagent Kit (Applied Biosystems, Cat. No. 902929) as described 
above. Amplified fragment size distribution was assessed before and after the 
fragmentation step using an Agilent 2100 Bioanalyzer. Amplified and labeled samples 
were hybridized to Clariom S, human arrays (Applied Biosystems, Cat. No. 902929) for 
16 h at 45°C using a GeneChip Hybridization Oven 645 and a GeneChip Hybridization, 
Wash, and Stain Kit (Applied Biosystems, Cat. No. 900720). Hybridized arrays were 
washed and stained using GeneChip Fluidics Stations 450 (Applied Biosystems) according 
to the manufacturer’s protocol. Chip arrays were scanned using a GeneChip Scanner 3000 
7G system and computer workstation equipped with GeneChip Command Console 4.0 
software (Affymetrix). Scanner-generated probe cell intensity (CEL) files were imported 
into Transcriptome Analysis Console (TAC) Software version 4.0 and processed at the 
gene-level using the SST-Robust Multichip Analysis (SST-RMA) algorithm to generate 
CHP files. To analyze sample specific transcriptional responses, we used empirical Bayes-
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corrected analysis of variance. Figure 6.2 show similar distributions amongst the 
hybridized arrays indicative of the samples being suitable for gene expression profiling 
analysis.  
 
Figure 6.1 Workflow assay for amplification and the labeling process. 
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Figure 6.2 Normalization amongst the arrays of CWCS samples. p<0.05 – FC≥1.5. 
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CHAPTER 7: RESULTS 
7.1 Introduction 
  HR-HPVs are the main etiologic agent in the development of cervical cancer (De 
Villier et al. 1987). There are also additional factors, such as smoking and early onset of 
sexual activity that increase the risk of developing cervical cancer.  Cervical cancer is a 
rare outcome of a HR-HPV infection and only women with a persistent HPV infection are 
truly at risk of developing cervical cancer. An abnormal Pap test is often followed by 
colposcopy. For example, having a low-grade lesion would call for a biopsy, but having a 
high-grade lesion would call for an excisional treatment. Such treatments are painful, 
costly, and may lead to infertility. There is currently no test to determine which patients 
with HR-HPV infection require treatment and which do not. The identification of 
biomarkers would be helpful to predict which women with a HR-HPV infection should be 
treated and those that do not need treatment, as the HPV infection will be cleared and any 
abnormal cervical cytology will regress, rather than progress. Such information would 
reduce overtreatment and long-term medical consequences. 
In this thesis, we present a study of gene expression profiles of RNA samples 
isolated from exfoliated cervical cells using microarray technology. Through analysis of 
samples that were either HPV negative, HPV16 positive, but cleared or did not clear an 
HPV16 infection, we identified gene expression profiles distinguishing these conditions.  
 76  
  
7.2 Preliminary Results  
Previous microarray studies, conducted in the laboratory by Dr. Diego Altomare, 
using RNA isolated from HPV16 negative and HPV16 positive exfoliated cervical cell 
samples from the CWCS yielded very interesting results, warranting more samples and 
further validation (Altomare 2010). In these pilot studies an in-house spotted array was 
used. This array had a total of 1,204 spots that were printed in four subarrays, each of whom 
had a 24 x 13 format, covering about 1,000 genes whose expression had been reported in 
the scientific literature as being altered in cervical cancer.  Preliminary results obtained by 
Dr. Altomare using the in-house arrays determined that there were 39 differentially 
expressed genes in samples from participants with HPV16 persistent infections compared 
to those that cleared the HPV16 infection (17 were up-regulated and 22 were down-
regulated). Nine genes were ultimately identified that showed the highest power in 
predicting if HPV16 infections will be persistent or will be cleared. A further interesting 
observation was that samples from the HPV16 persistor group and samples from the 
HPV16 negative group shared very similar gene expression profiles, indicating that the 
body did not recognize the HPV16 infection in these women with a persistent infection and 
therefore these individuals did not mount an immune response against the virus (Altomare 
2010).  Thus, the in-house array yielded a clear separation between HPV16 persistors and 
HPV16 non-persistors. However, the microarray used in these studies contained a 
relatively small number of genes and thus it is likely that we can identify additional 
important genes using the very high-density microarrays that are currently available 
commercially. Furthermore, expansion of Dr. Altomare’s previous work should enhance 
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our understanding of the biologic mechanisms leading to HR-HPV persistence in young 
college-aged women. 
7.3 Samples Used in Current Microarray Study 
In my thesis studies I conducted gene expression profiles using microarray 
technology on RNA isolated from exfoliated cervical cells that were classified into three 
groups. The first group are 10 CWCS participants with cervical cell samples that were HPV 
negative and these women never were HPV positive on any visit (referred to as HPV 
Negative). The second group are 10 CWCS participants with cervical samples that were 
HPV16 positive, but the participant subsequently cleared the infection, and became HPV16 
negative in subsequent visits (referred to as HPV16 Clearer). The third group are 10 CWCS 
participants with cervical samples that were HPV16 positive and the participant had the 
HPV16 infection for 365 days or more as determined by the length of time between study 
visits (referred to as HPV16 Persistor). It is important to note that the HPV16 positive 
groups may also be co-infected with other HPV types. A summary of the three groups of 
RNA samples is shown in Table 7.1.  
7.4 Comparison of HPV16 Clearer to HPV16 Negative 
A comparison of gene expression profiles between exfoliated cervical cells from 
HPV16 clearer’s to HPV16 negative was made and genes with a p-value less than 0.05 and 
fold-change (FC) greater or equal to 1.5 (up or down) were considered to be statistically 
significant and differentially expressed, respectively. As shown in Table A.1- Appendix A, 
using these cut-offs, 676 genes were found to be differentially expressed, with 484 up-
regulated (72%) and 192 down-regulated (28%). In addition, of the 676 genes, there were 
573 genes that were less than or equal to 0.03 p-value. This comparison determined the 
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genes whose RNA expression is altered due to HPV16 infections in CWCS participants 
that later cleared the virus. A scatter plot of the average expression levels of DEGs for 
HPV16 clearer and HPV16 negative samples is shown in Figure 7.1. Figure 7.2 is a Venn 
Diagram that visually illustrates DEGs that are unique to each comparison and the 
overlapping of DEGs between comparisons. 
 
 
 Group Sample HPV Type (s) Persistor RIN
A107-3 NEG NO 7.5
A115-5 NEG NO 7.1
A121-2 NEG NO 7.2
A172-1 NEG NO 7.6
A180-3 NEG NO 7.0
A198-3 NEG NO 8.7
A226-3 NEG NO 7.5
A239-1 NEG NO 7.7
A301-2 NEG NO 8.7
A385-1 NEG NO 8.4
A110-2 16,40,18,59 NO 6.7
A284-1 16,31,51,66,73 NO Good
A323-5 6,16,18,51,66 NO 4.6
A328-4 16,31 NO 4.7
A336-3 16,18,53,73 NO 7.0
A375-4 16 NO 4.6
A476-2 16 NO 6.9
A512-1 16,53,68 NO 6.6





A127-4 6,16 YES 4.8
A138-2 16,39,59 YES 4.9
A228-7 16,51,70,73 YES 4.9
A237-3 16 YES 5.5
A290-4 16,53,74 YES 6.5
A291-3 16,18 YES 5.3
A307-2 16,40,66 YES 6.8
A424-3 16 YES 7.4
A452-4 16 YES 7.0




Table 7.1: RNA samples used for Gene Expression Profiling.  RNA 
integrity number (RIN) obtained from the Agilent 2100 Bioanalyzer is 
an assessment of RNA quality using a scale from 1 to 10. 
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After determining which genes were differentially expressed in exfoliated cervical 
cells from those women that cleared their HPV16 infection to cells collected from women 
that are HPV16 negative, we conducted pathway analysis using WikiPathway, which is 
provided though TAC. Although TAC provides data of gene expression directionality (i.e. 
up or down), it does not indicate how the direction of those genes effect the pathways that 
the gene may be involved with. Table 7.2 lists the pathways most affected. Since the present 
study used whole genome arrays, this provides a complete view and detailed understanding 
of all pathways affected. WikiPathways’ most relevant include IL-3, IL-6, IL-7, IL-9, IL-
11 and TGF-beta.  
 
Figure 7.1 Scatter plot of the average DEGs expression of the HPV16 Clearer 
vs. HPV16 Negative Comparison. Red dots represented upregulated genes 
and green dots represent down-regulated genes in HPV16 clearer as 
compared to HPV16 negative samples. p<0.05 – FC≥1.5. 
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Figure 7.2 Venn Diagram of DEGs unique to each comparison and the overlapping of 
DEGs between comparisons. A = HPV16 Clearer vs HPV16 Negative, B = HPV16 






WikiPathway Significance p-value # Total  Up Down 
Regulation of Actin Cytoskeleton 5.13 0.0000070 12 6 6 
Pancreatic adenocarcinoma 
pathway 4.82 0.0000150 9 7 2 
Focal Adhesion 4.62 0.0000240 13 6 7 
PI3K-Akt Signaling Pathway 4.31 0.0000490 17 9 8 
IL-6 signaling pathway 4.18 0.0000670 6 5 1 
TGF-beta Signaling Pathway 4.11 0.0000770 10 7 3 
Photodynamic therapy-induced 
AP-1 survival signaling. 3.80 0.0001580 6 2 4 
JAK/STAT 3.42 0.0003760 8 4 4 
Lung fibrosis 3.21 0.0006170 6 3 3 
Non-small cell lung cancer 3.17 0.0006700 6 4 2 
Hypothesized Pathways in 
Pathogenesis of Cardiovascular 
Disease 3.17 0.0006760 4 1 3 
AGE/RAGE pathway 3.14 0.0007270 6 3 3 
MAPK Signaling Pathway 3.13 0.0007470 12 7 5 
G Protein Signaling Pathways 3.11 0.0007820 7 5 2 
Vitamin D Receptor Pathway 3.00 0.0010090 10 10 0 
Wnt Signaling Pathway and 
Pluripotency 2.87 0.0013560 7 4 3 
Focal Adhesion-PI3K-Akt-mTOR-
signaling pathway 2.83 0.0014890 13 7 6 
Leptin signaling pathway 2.76 0.0017460 6 4 2 
Type 2 papillary renal cell 
carcinoma 2.66 0.0022090 4 4 0 
Hepatitis C and Hepatocellular 
Carcinoma 2.63 0.0023660 5 3 2 
ACE Inhibitor Pathway 2.60 0.0024840 3 3 0 
Signaling Pathways in 
Glioblastoma 2.59 0.0025460 6 5 1 
Table 7.2 WikiPathways that were significantly regulated (p < 0.05) for HPV16 Clearer 
vs. HPV16 Negative Comparison. TAC ranked the WikiPathways based on a significant 
score. Note: Significance is calculated using a 2x2 contingency in a Fisherʹs Exact Test 
(Two Sided). Fisherʹs Exact Test is a statistical significance test used in the analysis of 
contingency table(s). After a p-value is established using Fisherʹs Exact Test, it is 





WikiPathway Significance p-value # Total  Up Down 
Senescence and Autophagy in 
Cancer 2.55 0.0028470 7 3 4 
Protein alkylation leading to liver 
fibrosis 2.53 0.0029660 5 3 2 
Simplified Interaction Map 
Between LOXL4 and Oxidative 
Stress Pathway 2.53 0.0029440 3 1 2 
Pathways in clear cell renal cell 
carcinoma 2.52 0.0030370 6 4 2 
G13 Signaling Pathway 2.48 0.0033410 4 2 2 
Ras Signaling 2.47 0.0033700 9 6 3 
BMP Signaling Pathway in Eyelid 
Development 2.40 0.0040150 3 2 1 
Oncostatin M Signaling Pathway 2.35 0.0044840 5 5 0 
Corticotropin-releasing hormone 
signaling pathway 2.33 0.0046920 6 5 1 
VEGFA-VEGFR2 Signaling 
Pathway 2.21 0.0061630 10 6 4 
Circadian rhythm related genes 2.18 0.0065690 9 7 2 
Envelope proteins and their 
potential roles in EDMD 
physiopathology 2.18 0.0066700 4 3 1 
IL1 and megakaryocytes in obesity 2.17 0.0067940 3 3 0 
Chromosomal and microsatellite 
instability in colorectal cancer  2.16 0.0068720 5 4 1 
DNA Damage Response (only 
ATM dependent) 2.14 0.0072550 6 4 2 
IL-7 Signaling Pathway 2.12 0.0076280 3 3 0 
Glycosaminoglycan metabolism 2.10 0.0079740 1 0 1 
IL-3 Signaling Pathway 2.08 0.0083360 4 4 0 
Angiogenesis 2.07 0.0085200 3 2 1 
Wnt Signaling Pathway 2.02 0.0095860 4 2 2 
ESC Pluripotency Pathways 1.92 0.0120740 6 3 3 
Spinal Cord Injury 1.90 0.0125570 6 3 3 
Overview of leukocyte-intrinsic 
Hippo pathway functions 1.90 0.0126820 3 2 1 
Extracellular vesicle-mediated 
signaling in recipient cells 1.90 0.0126820 3 2 1 
Development and heterogeneity of 
the ILC family 1.82 0.0151270 3 2 1 
Epithelial to mesenchymal 
transition in colorectal cancer 1.79 0.0163620 7 4 3 
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WikiPathway Significance p-value # Total  Up Down 
Complement and Coagulation 
Cascades 1.78 0.0166930 4 1 3 
Serotonin HTR1 Group and FOS 
Pathway 1.78 0.0164420 3 2 1 
Signal transduction through IL1R 1.78 0.0164420 3 2 1 
Alpha 6 Beta 4 signaling pathway 1.78 0.0164420 3 1 2 
Deubiquitination 1.77 0.0171720 1 1 0 
Dengue-2 Interactions with 
Complement and Coagulation 
Cascades 1.75 0.0176410 4 1 3 
Endometrial cancer 1.71 0.0196350 4 3 1 
Nuclear Receptors Meta-Pathway 1.65 0.0221630 11 9 2 
Pathways Regulating Hippo 
Signaling 1.65 0.0224020 5 2 3 
Photodynamic therapy-induced 
HIF-1 survival signaling 1.65 0.0223260 3 3 0 
Human Thyroid Stimulating 
Hormone (TSH) signaling pathway 1.64 0.0228780 4 2 2 
Sleep regulation 1.62 0.0239530 3 2 1 
Regulation of sister chromatid 
separation at the metaphase-
anaphase transition 1.61 0.0243110 2 2 0 
PDGF Pathway 1.59 0.0256430 3 3 0 
Ebola Virus Pathway on Host 1.58 0.0260620 7 2 5 
Oxidative Damage 1.56 0.0273960 3 1 2 
Osteoblast Signaling 1.51 0.0308230 2 1 1 
IL-9 Signaling Pathway 1.51 0.0308230 2 2 0 
Multi Drug Resistance Protein 1 
(Glycoprotein 1) Regulation 1.49 0.0324280 1 1 0 
Brain-Derived Neurotrophic Factor 
(BDNF) signaling pathway 1.48 0.0330660 6 5 1 
Deregulated CDK5 triggers 
multiple neurodegenerative 
pathways in Alzheimer's disease 
models 1.48 0.0330250 3 2 1 
RORA activates gene expression 1.48 0.0330250 3 3 0 
Interleukin-11 Signaling Pathway 1.46 0.0350250 3 3 0 
Serotonin Receptor 4/6/7 and 
NR3C Signaling 1.46 0.0343070 2 2 0 
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WikiPathway Significance p-value # Total  Up Down 
Inhibition of exosome biogenesis 
and secretion by Manumycin A in 
CRPC cells 1.46 0.0343070 2 1 1 
Serotonin Receptor 2 and ELK-
SRF/GATA4 signaling 1.42 0.0379370 2 2 0 
Class I MHC mediated antigen 
processing &amp; presentation 1.42 0.0382990 2 0 2 
Calcium Regulation in the Cardiac 
Cell 1.41 0.0390510 6 4 2 
miRNA targets in ECM and 
membrane receptors 1.41 0.0392090 3 0 3 
Myometrial Relaxation and 
Contraction Pathways 1.36 0.0434000 6 4 2 
Aryl Hydrocarbon Receptor 
Pathway 1.36 0.0436340 3 2 1 
Differentiation Pathway 1.36 0.0436340 3 2 1 
Thymic Stromal LymphoPoietin 
(TSLP) Signaling Pathway 1.36 0.0436340 3 2 1 
Cell Cycle Checkpoints 1.32 0.0477740 1 1 0 
Bile Acids synthesis and 
enterohepatic circulation  1.32 0.0482470 1 0 1 
Transcription factor regulation in 
adipogenesis 1.30 0.0496400 2 1 1 
 
 
Because of TAC’s limitation of pathway directionality, after DEGs were identified, 
along with respective p-value and fold change, the 676 DEGs identified (Appendix A) were 
uploaded into Ingenuity Pathway Analysis (IPA) (Qiagen) to analyze directionality of the 
pathways of interest. Pathways with a Z-Score larger than 1.5 or smaller than -1.5 were 
considered altered. These pathways are shown in Table 7.3. Several pathways associated 
with the host cell immune response were upregulated, such as IL-6, NF-κB signaling, toll-
like receptor signaling, and p38 MAPK signaling. Significant pathways with a p-value less 
than 0.05 are shown below.  
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It is important to note that a pathway with a Z-Score of 0 or close to 0 indicates that 
the similarities and the dissimilarities between the user’s dataset measurements and known 
information about the activity of the pathway balances out, so that no statistically 
significant predication of activity can be made. Also, a Z-Score of N/A indicates that the 
pathway does not have enough overlapping modules with the user’s dataset that contribute 
towards the Z-Score calculation, in which that calculation needs a minimum of four genes 
associated with a pathway included in the analyzed dataset.  
 





Cholecystokinin/Gastrin-mediated Signaling 0.0000 2.32 
Glioma Invasiveness Signaling 0.0000 -0.90 
Atherosclerosis Signaling 0.0001 N/A 
Neuroprotective Role of THOP1 in Alzheimer's Disease 0.0001 3.05 
PPAR Signaling 0.0001 -2.31 
Role of Macrophages, Fibroblasts and Endothelial Cells in 
Rheumatoid Arthritis 0.0001 N/A 
IL-8 Signaling 0.0001 0.73 
Thrombin Signaling 0.0002 1.29 
Actin Cytoskeleton Signaling 0.0002 0.77 
α-Adrenergic Signaling 0.0002 1.13 
Gαq Signaling 0.0002 0.53 
Phospholipase C Signaling 0.0003 1.29 
Graft-versus-Host Disease Signaling 0.0005 N/A 
Triacylglycerol Biosynthesis 0.0005 0.38 
Glioma Signaling 0.0005 0.90 
Macropinocytosis Signaling 0.0005 0.38 
Table 7.3 Pathways that were significantly regulated (p<0.05) for HPV16 Clearer vs 
HPV16 Negative Comparison from IPA. IPA analysis provides Z-Score for the 
pathways affected. Highlighted in red are upregulated significant (Z-Score > 1.5) 
pathways and highlighted in green are down-regulated significant pathways (Z-Score 
< -1.5). p<0.05 – FC≥1.5. N/A indicates that no Z-Score was provided.  
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ErbB Signaling 0.0006 1.51 
Breast Cancer Regulation by Stathmin1 0.0006 N/A 
Sperm Motility 0.0006 0.90 
Germ Cell-Sertoli Cell Junction Signaling 0.0007 N/A 
Acute Phase Response Signaling 0.0007 1.51 
Adrenomedullin signaling pathway 0.0007 2.00 
Neuregulin Signaling 0.0009 1.26 
Cardiac Hypertrophy Signaling 0.0009 1.21 
CDP-diacylglycerol Biosynthesis I 0.0009 -0.45 
Protein Kinase A Signaling 0.0010 0.00 
HER-2 Signaling in Breast Cancer 0.0010 N/A 
UVC-Induced MAPK Signaling 0.0010 1.13 
CCR3 Signaling in Eosinophils 0.0013 1.13 
Phosphatidylglycerol Biosynthesis II (Non-plastidic) 0.0014 -0.45 
Role of Cytokines in Mediating Communication between Immune 
Cells 0.0014 N/A 
Semaphorin Signaling in Neurons 0.0014 N/A 
CXCR4 Signaling 0.0014 1.15 
IL-6 Signaling 0.0015 1.73 
Integrin Signaling 0.0017 1.07 
HGF Signaling 0.0017 1.00 
HMGB1 Signaling 0.0019 1.15 
Axonal Guidance Signaling 0.0019 N/A 
Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis 
of Influenza 0.0020 N/A 
Intrinsic Prothrombin Activation Pathway 0.0020 2.24 
STAT3 Pathway 0.0020 1.90 
Synaptic Long Term Potentiation 0.0024 0.90 
PAK Signaling 0.0025 1.00 
Ephrin B Signaling 0.0026 0.38 
Insulin Receptor Signaling 0.0026 0.30 
Chemokine Signaling 0.0029 -0.71 
GNRH Signaling 0.0036 1.15 
Colorectal Cancer Metastasis Signaling 0.0036 -0.26 
Signaling by Rho Family GTPases 0.0039 0.53 
Actin Nucleation by ARP-WASP Complex 0.0041 0.82 
Relaxin Signaling 0.0051 0.00 
NRF2-mediated Oxidative Stress Response 0.0054 1.51 
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Ephrin Receptor Signaling 0.0056 0.90 
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 0.0058 N/A 
Non-Small Cell Lung Cancer Signaling 0.0058 0.00 
Heme Degradation 0.0062 N/A 
P2Y Purigenic Receptor Signaling Pathway 0.0062 1.26 
Rac Signaling 0.0069 -0.33 
CDK5 Signaling 0.0071 -1.00 
IL-10 Signaling 0.0072 N/A 
Renal Cell Carcinoma Signaling 0.0072 0.45 
HIPPO signaling 0.0072 -2.00 
Melatonin Signaling 0.0079 1.89 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid 
Arthritis 0.0083 N/A 
Thrombopoietin Signaling 0.0085 1.13 
Cancer Drug Resistance By Drug Efflux 0.0089 N/A 
Lactose Degradation III 0.0100 N/A 
Endothelin-1 Signaling 0.0110 1.94 
Regulation of the Epithelial-Mesenchymal Transition Pathway 0.0112 N/A 
Bladder Cancer Signaling 0.0112 0.82 
NF-κB Activation by Viruses 0.0112 0.00 
VEGF Family Ligand-Receptor Interactions 0.0120 1.13 
ErbB4 Signaling 0.0123 1.13 
PPARα/RXRα Activation 0.0123 -0.63 
Gap Junction Signaling 0.0132 N/A 
VDR/RXR Activation 0.0132 -1.00 
RhoGDI Signaling 0.0135 0.00 
Regulation of Cellular Mechanics by Calpain Protease 0.0145 -0.45 
GM-CSF Signaling 0.0148 1.13 
Hepatic Cholestasis 0.0151 N/A 
Acute Myeloid Leukemia Signaling 0.0151 1.13 
Role of NFAT in Cardiac Hypertrophy 0.0151 0.83 
Cardiac β-adrenergic Signaling 0.0170 -1.67 
Pancreatic Adenocarcinoma Signaling 0.0174 1.41 
IL-15 Signaling 0.0178 N/A 
NF-κB Signaling 0.0182 1.73 
Pyridoxal 5'-phosphate Salvage Pathway 0.0182 1.63 
Phagosome Formation 0.0200 N/A 
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Sphingosine-1-phosphate Signaling 0.0209 1.00 
UVB-Induced MAPK Signaling 0.0209 0.82 
Leptin Signaling in Obesity 0.0214 0.00 
Glioblastoma Multiforme Signaling 0.0219 0.90 
PTEN Signaling 0.0219 -1.67 
Epithelial Adherens Junction Signaling 0.0229 N/A 
Role of Tissue Factor in Cancer 0.0229 N/A 
Erythropoietin Signaling 0.0240 N/A 
Renin-Angiotensin Signaling 0.0240 1.13 
fMLP Signaling in Neutrophils 0.0251 0.71 
CREB Signaling in Neurons 0.0263 0.90 
IL-3 Signaling 0.0269 1.13 
Prolactin Signaling 0.0269 1.13 
JAK/Stat Signaling 0.0269 0.38 
Endometrial Cancer Signaling 0.0269 0.00 
Gαs Signaling 0.0269 0.00 
MSP-RON Signaling Pathway 0.0302 N/A 
Molecular Mechanisms of Cancer 0.0316 N/A 
Agrin Interactions at Neuromuscular Junction 0.0324 0.45 
Leucine Degradation I 0.0331 N/A 
LPS-stimulated MAPK Signaling 0.0331 1.13 
PEDF Signaling 0.0331 0.38 
Glucocorticoid Receptor Signaling 0.0339 N/A 
ErbB2-ErbB3 Signaling 0.0339 0.82 
Telomerase Signaling 0.0339 0.71 
14-3-3-mediated Signaling 0.0355 1.41 
Androgen Signaling 0.0355 0.82 
ERK/MAPK Signaling 0.0355 0.58 
Toll-like Receptor Signaling 0.0363 2.45 
Salvage Pathways of Pyrimidine Ribonucleotides 0.0363 1.89 
p70S6K Signaling 0.0363 1.00 
Apoptosis Signaling 0.0363 -1.13 
Role of MAPK Signaling in the Pathogenesis of Influenza 0.0380 N/A 
PDGF Signaling 0.0380 0.38 
Oncostatin M Signaling 0.0407 1.00 
Xenobiotic Metabolism Signaling 0.0427 N/A 
Antiproliferative Role of Somatostatin Receptor 2 0.0427 0.45 
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G-Protein Coupled Receptor Signaling 0.0437 N/A 
p38 MAPK Signaling 0.0437 2.65 
G Beta Gamma Signaling 0.0437 1.41 
Mechanisms of Viral Exit from Host Cells 0.0447 N/A 
Role of NFAT in Regulation of the Immune Response 0.0447 0.63 
LXR/RXR Activation 0.0457 -1.13 
tRNA Splicing 0.0479 -1.00 
RhoA Signaling 0.0479 -1.63 
Granulocyte Adhesion and Diapedesis 0.0490 N/A 
Aldosterone Signaling in Epithelial Cells 0.0490 1.13 
Melanoma Signaling 0.0490 0.45 
 
7.5 Comparison of HPV16 Persistor vs HPV16 Negative 
We next compared gene expression profiles from exfoliated cervical cells from 
CWCS participants that had a persistent HPV16 infection to those participants that were 
always HPV16 negative. Using a p-value less than 0.05 and FC equal to or greater than 
1.5, 1,370 genes were found to be differentially expressed, with 548 up-regulated (40%) 
and 822 down-regulated (60%) (Table B.1-Appendix B and Figure 7.2). Although our 
preliminary studies showed that HPV16 persistors and HPV16 negative participants had 
similar gene expression profiles, I did not find that to be the case in this analysis. In fact, 
there was 1,240 genes that had a p-value less than or equal to 0.03, suggesting that HPV16 
persistors and HPV16 negative participants have very different gene expression profiles.  
A scatter plot of the average expression levels of DEGs for the HPV16 persistor and 
HPV16 negative samples is shown in Figure 7.3.   
After determining which genes were differentially expressed between HPV16 
persistors and HPV16 negatives, WikiPathway data was provided from TAC.  TAC 
provides data of gene directionality but does not indicate how the direction of those gene 
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effect the pathway as a whole. The pathways listed provided a full representation of all 
pathways affected among HPV16 persistors and HPV16 negative samples.  Table 7.4 
shows the effected pathways in this comparison. Relevant pathways include cell cycle 
checkpoints, including the Mitotic G1-G1/S and G2-G2/M phases, T-cell antigen receptor 
(TCR) signaling, chemokine signaling pathway, and the immunoregulatory interactions 
between a Lymphoid and a non-Lymphoid cell. These pathways include gene(s) that are 
down-regulated, suggesting the down-regulation of the pathway. 
 
Figure 7.3 Scatter plot of the average DEGs expression of the HPV16 Persistor vs. 
HPV16 negative comparison. Red dots represented upregulated genes and green 
dots represent down-regulated genes in HPV16 persistor as compared to HPV16 













Deubiquitination 5.66 0.0000020 1 0 1 
Olfactory receptor activity 5.19 0.0000060 1 1 0 
Generic Transcription Pathway 4.74 0.0000180 3 0 3 
Chromatin organization 4.21 0.0000620 1 0 1 
Cell Cycle Checkpoints 4.20 0.0000630 1 0 1 
Chromatin modifying enzymes 3.88 0.0001330 1 0 1 
GPCRs, Class A Rhodopsin-like 3.23 0.0005850 1 1 0 
Proteasome Degradation 3.07 0.0008550 9 1 8 
Mitotic G2-G2/M phases 3.04 0.0009020 1 0 1 
Signaling by the B Cell Receptor 
(BCR) 2.75 0.0017730 1 0 1 
Cilium Assembly 2.75 0.0017840 1 0 1 
Assembly of the primary cilium 2.75 0.0017840 1 0 1 
Cell surface interactions at the 
vascular wall 2.75 0.0017950 2 1 1 
Transcriptional regulation by 
RUNX1 2.58 0.0026120 1 0 1 
Immunoregulatory interactions 
between a Lymphoid and a non-
Lymphoid cell 2.38 0.0041310 3 1 2 
Hypertrophy Model 2.18 0.0065780 4 4 0 
Liver steatosis AOP 2.15 0.0070460 10 1 9 
TCR signaling 2.12 0.0076640 1 0 1 
Fc epsilon receptor (FCERI) 
signaling 2.10 0.0079260 3 1 2 
miR-222 in Exercise-Induced 
Cardiac Growth 2.07 0.0085240 2 0 2 
Energy Metabolism 2.04 0.0091710 6 0 6 
Influenza Life Cycle 1.96 0.0110140 1 0 1 
Table 7.4 WikiPathways that were significantly regulated (p < 0.05) for HPV16 
Persistor vs HPV16 Negative Comparison. TAC ranked the WikiPathways based on 
a significance score. Note: Significance is calculated using a 2x2 contingency in a 
Fisherʹs Exact Test (Two Sided). Fisherʹs Exact Test is a statistical significance test 
used in the analysis of contingency table(s). After a p-value is established using 














Lamin A-processing pathway 1.86 0.0138440 2 0 2 
Ion channel transport 1.85 0.0140630 2 0 2 
C-type lectin receptors (CLRs) 1.71 0.0193900 2 0 2 
One Carbon Metabolism 1.66 0.0217890 4 0 4 
Parkin-Ubiquitin Proteasomal 
System pathway 1.64 0.0226770 7 1 6 
Nucleotide Excision Repair 1.64 0.0228570 1 0 1 
Chemokine signaling pathway 1.63 0.0233570 1 0 1 
HDR through Homologous 
Recombination (HRR) or Single 
Strand Annealing (SSA) 1.63 0.0233570 1 0 1 
Gastric Cancer Network 1 1.61 0.0245220 4 3 1 
Mitotic G1-G1/S phases 1.56 0.0278010 3 1 2 
MAPK6/MAPK4 signaling 1.49 0.0324300 1 0 1 
Oxidative Stress Induced 
Senescence 1.48 0.0327580 1 1 0 
Metabolism of water-soluble 
vitamins and cofactors 1.46 0.0344320 1 1 0 
EGF/EGFR Signaling Pathway 1.44 0.0361990 12 3 9 
Aryl Hydrocarbon Receptor 
Pathway 1.43 0.0373080 5 3 2 
Major pathway of rRNA processing 
in the nucleolus and cytosol 1.43 0.0373390 2 0 2 
Pregnane X Receptor pathway 1.43 0.0374540 4 0 4 
Translation Factors 1.36 0.0433820 5 2 3 
Signaling Pathways in Glioblastoma 1.36 0.0440560 7 2 5 
Wnt Signaling 1.33 0.0463530 9 5 4 
Signaling by FGFR1 1.33 0.0464560 1 0 1 
Transcriptional regulation by 
RUNX3 1.33 0.0468710 1 1 0 
Human Complement System 1.33 0.0468710 1 0 1 
Respiratory electron transport, ATP 
synthesis by chemiosmotic coupling, 
and heat production by uncoupling 
proteins. 1.31 0.0484350 1 0 1 
ncRNAs involved in Wnt signaling 
in hepatocellular carcinoma 1.31 0.0489860 7 5 2 
miR-targeted genes in epithelium - 




Ingenuity Canonical Pathways p-value Z-Score 
Protein Ubiquitination Pathway 0.0000 N/A 
Sirtuin Signaling Pathway 0.0003 -0.38 
Granzyme A Signaling 0.0006 N/A 
autophagy 0.0028 N/A 
Insulin Receptor Signaling 0.0032 0.50 
Assembly of RNA Polymerase I Complex 0.0045 N/A 
RhoA Signaling 0.0072 -2.67 
Triacylglycerol Biosynthesis 0.0079 -0.71 
Aldosterone Signaling in Epithelial Cells 0.0081 -1.41 
Hypoxia Signaling in the Cardiovascular System 0.0089 N/A 
Unfolded protein response 0.0100 N/A 
Protein Kinase A Signaling 0.0105 0.69 
Endoplasmic Reticulum Stress Pathway 0.0110 N/A 
HIPPO signaling 0.0117 -1.63 
Cell Cycle: G1/S Checkpoint Regulation 0.0117 -1.13 
Rac Signaling 0.0158 -2.14 
Intrinsic Prothrombin Activation Pathway 0.0178 2.45 
Epithelial Adherens Junction Signaling 0.0191 N/A 
CDP-diacylglycerol Biosynthesis I 0.0195 -0.45 
Dopamine-DARPP32 Feedback in cAMP Signaling 0.0209 -0.77 
MSP-RON Signaling Pathway 0.0209 N/A 
DNA Methylation and Transcriptional Repression Signaling 0.0234 N/A 
Heme Degradation 0.0245 N/A 
Pentose Phosphate Pathway (Oxidative Branch) 0.0245 N/A 
Calcium Transport I 0.0251 N/A 
Graft-versus-Host Disease Signaling 0.0257 N/A 
Phosphatidylglycerol Biosynthesis II (Non-plastidic) 0.0269 -0.45 
Superpathway of Inositol Phosphate Compounds 0.0331 -2.29 
Estrogen Receptor Signaling 0.0339 N/A 
1D-myo-inositol Hexakisphosphate Biosynthesis II (Mammalian) 0.0347 -1.00 
D-myo-inositol (1,3,4)-trisphosphate Biosynthesis 0.0347 -1.00 
NRF2-mediated Oxidative Stress Response 0.0389 0.00 
Table 7.5 Pathways that were significantly regulated (p<0.05) for HPV16 
Persistor vs HPV16 Negative Comparison from IPA. IPA analysis provides Z-
Scores for the pathways affected. Highlighted in red are upregulated significant 
(Z-Score > 1.5) pathways and highlighted in green are down-regulated pathways 
(Z-Score < -1.5). p<0.05 – FC≥1.5. N/A indicates that no Z-Score was provided.  
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Ingenuity Canonical Pathways p-value Z-Score 
Cyclins and Cell Cycle Regulation 0.0398 0.00 
Assembly of RNA Polymerase III Complex 0.0417 N/A 
Calcium-induced T Lymphocyte Apoptosis 0.0457 -1.89 
Cardiac β-adrenergic Signaling 0.0468 -1.94 
 
7.6 Comparison of HPV16 Persistor vs HPV16 Clearer 
The final analysis we made is to compare gene expression profiles in exfoliated 
cervical cells between CWCS participants that had a persistent HPV infection versus 
participants which cleared an HPV16 infection. We used the same procedures as in the 
previous sections, 659 genes were found to be differentially expressed, with 296 
upregulated (45%) and 363 down-regulated (55%) (Table C.1-Appendix C and Figure 7.2).   
There were 570 genes that had a p-value less than or equal to 0.03. This comparison could 
help in identifying genes in HPV positive women that might be predictive of who would 
clear an HPV infection and who would not. A scatter plot of the average expression levels 
of DEGs for HPV16 persistor and HPV16 clearer samples are shown in Figure 7.4.  
WikiPathways that were significantly regulated when comparing HPV16 persistors 
and HPV16 clearers is shown in Table 7.6. Pathway analysis for HPV16 persistors and 
HPV16 clearers was conducted using IPA and the pathways affected are shown in Table 
7.7, listed in decreasing significance, as indicated by the p-value.  
7.7 Cellular Immune Response 
One of the most likely reasons for an individual to clear or not clear an HPV16 
infection resides in the host cellular immune response (CIR). Earlier in this thesis (section 
5.5) I discussed some ways in which HPV16 escapes the host CIR. At present there has not 
been any reports of gene expression profiling via microarray on exfoliated cervical cells 
during the HPV infection phase. All microarray reports currently in the literature have 
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explored cervical cancer samples and not the early HPV infection stage prior to cancer 
(Song et al. 2008, Mendoza-Villanueva et al. 2008, Martin et al. 2009, Luan et al. 2018, 
Zhu et al. 2018, Yang et al. 2019, and Shen et al. 2019). About 90% of women infected 
with HPV16 will clear the HPV infection and any premalignant lesions caused by the HPV 
infection will regress. However, about 10% of HPV infections will become persistent. It 
would be beneficial to be able to predict which women would be able to clear an HPV 
infection and who will not. Women with persistent HPV16 infections are at greatest risk 
of developing cervical disease.  
Figure 7.4 Scatter plot of the average DEGs expression of the HPV16 
Persistor vs. HPV16 Clearer Comparison. Red dots represented 
upregulated genes and green dots represent down-regulated genes in 





WikiPathway Significance p-value # Total Up Down 
Cytoplasmic Ribosomal 
Proteins 10.99 0.0000000 15 14 1 
Matrix Metalloproteinases 2.83 0.0014750 4 4 0 
TGF-beta Signaling 
Pathway 2.80 0.0015700 8 5 3 
Kit receptor signaling 
pathway 2.59 0.0025840 5 2 3 
Target Of Rapamycin 
(TOR) Signaling 2.59 0.0025920 4 2 2 
Genotoxicity pathway 2.43 0.0036870 5 3 2 
miR-targeted genes in 
muscle cell - TarBase 2.34 0.0045530 15 8 7 
EGF/EGFR Signaling 
Pathway 2.32 0.0048290 8 1 7 
Extracellular vesicles in the 
crosstalk of cardiac cells 2.24 0.0057730 3 2 1 
Generic Transcription 
Pathway 2.08 0.0084120 1 0 1 
miR-targeted genes in 
lymphocytes - TarBase 1.97 0.0107240 16 7 9 
Nonalcoholic fatty liver 
disease 1.89 0.0129550 7 7 0 
TYROBP Causal Network 1.80 0.0158890 4 3 1 
Lung fibrosis 1.71 0.0197000 4 3 1 
Human Thyroid Stimulating 
Hormone (TSH) signaling 
pathway 1.66 0.0217990 4 2 2 
Ferroptosis 1.61 0.0246740 3 2 1 
Electron Transport Chain 
(OXPHOS system in 
mitochondria) 1.58 0.0265390 5 5 0 
Integrated Lung Cancer 
Pathway 1.47 0.0337300 3 0 3 
Glutathione metabolism 1.39 0.0405920 2 2 0 
Table 7.6 WikiPathways that were significantly regulated (p < 0.05) for HPV16 
Persistor vs HPV16 Clearer Comparison. TAC ranked the WikiPathways based on 










Ingenuity Canonical Pathways p-value Z-Score 
EIF2 Signaling 0.0000 2.50 
mTOR Signaling 0.0000 -0.33 
Regulation of eIF4 and p70S6K Signaling 0.0000 -1.00 
Granzyme A Signaling 0.0002 N/A 
Inhibition of Matrix Metalloproteases 0.0002 -1.63 
Protein Ubiquitination Pathway 0.0005 N/A 
Oxidative Phosphorylation 0.0006 2.11 
Mitochondrial Dysfunction 0.0011 N/A 
Sirtuin Signaling Pathway 0.0011 0.00 
Airway Pathology in Chronic Obstructive Pulmonary Disease 0.0017 N/A 
HIF1α Signaling 0.0022 N/A 
Hypoxia Signaling in the Cardiovascular System 0.0026 N/A 
Chemokine Signaling 0.0105 0.38 
RhoGDI Signaling 0.0132 0.63 
Leukocyte Extravasation Signaling 0.0182 0.58 
RhoA Signaling 0.0191 -1.00 
Atherosclerosis Signaling 0.0209 N/A 
DNA Methylation and Transcriptional Repression Signaling 0.0240 N/A 
FLT3 Signaling in Hematopoietic Progenitor Cells 0.0269 -1.13 
Neuregulin Signaling 0.0309 -1.34 
autophagy 0.0316 N/A 
Bladder Cancer Signaling 0.0331 N/A 
Sumoylation Pathway 0.0380 0.45 
Superpathway of Inositol Phosphate Compounds 0.0389 -3.05 
TR/RXR Activation 0.0417 N/A 
Table 7.7 Pathways that were significantly regulated (p<0.05) for HPV16 
Persistor vs HPV16 Clearer Comparison from IPA. IPA analysis provides Z-
Scores for the pathways affected. Highlighted in red are upregulated significant 
(Z-Score > 1.5) pathways and highlighted in green are down-regulated pathways 
(Z-Score < -1.5). p<0.05 – FC≥1.5. N/A indicates that no Z-Score was provided.  
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Because CIR is one of the key areas relevant to this study, we decided to look a 
little deeper into pathways and genes that are associated with CIR, comparing HPV16 
negative, HPV16 clearer, and HPV16 persistor exfoliated cervical cell samples. Pathways 
and genes associated with CIR were pulled from IPA for each comparison discussed above. 
IPA allows the customization of the canonical pathways (CP) in terms of what specifically 
applies to your research. There are two categories that CP fall into: (1) Metabolic Pathways 
and (2) Signaling Pathways. There are 7 and 19 subcategories of metabolic and signaling 
pathways, respectively. CIR falls underneath the signaling pathway category. It is 
important to note that any given CP may also be associated with any other of the 19 
subcategories. The HPV16 clearer vs the HPV16 negative comparison had a total of 78 CP 
altered, 76 altered CP for HPV16 persistor vs. HPV16 negative comparison, and 68 altered 
CP for HPV16 persistor vs. HPV16 clearer comparison. Not all CP for each group had a 
Z-score, which provides pathway directionality (up or down). Table 7.8 summarizes the 
data and Tables 7.9-7.11 show each group and their CIR associated pathways that were 
altered and are displayed by decreasing significance indicated by the p-value. Of all the 
pathways shown, those above the red line are significant (p-value <0.05) and those below 
are not.  The CIR category also shared similar pathways with other categories, such as 
cytokine signaling and apoptosis. 
All three comparisons have similar pathways associated with CIR being altered. 
Thus, we decided to compare HPV16 clearer vs. HPV16 negative to each of the other 
groups. Of the 26 total CP for HPV16 clearer vs. HPV16 negative, 23 (88%) had positive 
Z-Score, indicative of the pathways being upregulated and only 3 (12%) had negative Z-
Score indicative of the CIR pathways being downregulated (Table 7.9). In contrast, of the 
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27 total CP for the HPV16 persistor vs. HPV16 negative comparison, 18 (67%) had 
negative Z-Score indicative of the pathways being down-regulated and only 9 (33%) had a 
positive Z-score indicative of the CIR pathway being upregulated (Table 7.10). Of the total 
15 CP for HPV16 persistor vs. HPV16 clearer comparison, 11 (73%) had negative Z-Score 
and only 4 (27%) had positive Z-Score (Table 7.11). The HPV16 clearer vs. HPV16 
negative and HPV16 persistor vs. HPV16 negative has 14 CP in common. The same 
comparison was done for HPV16 clearer vs. HPV16 negative and HPV16 persistor vs. 
HPV16 clearer, where 9 CP were in common. Interestingly, the direction of those CP that 
were in common with the HPV16 clearer vs HPV16 negative and the HPV16 persistor vs 
HPV16 negative comparisons were in the opposite direction.  Tables 7.12-7.13 summarizes 



















Negative 78 26 3 23 
HPV16 Persistor 
vs. HPV16 
Negative 76 2 18 9 
HPV16 Persistor 
vs. HPV16 
Clearer 68 15 11 4 







HPV16 Clearer vs. HPV16 Negative p-value 
Z-
Score 
IL-8 Signaling 0.0001 0.73 
Graft-versus-Host Disease Signaling 0.0005  N/A 
Macropinocytosis Signaling 0.0005 0.38 
CCR3 Signaling in Eosinophils 0.0013 1.13 
Role of Cytokines in Mediating Communication between 
Immune Cells 0.0014  N/A 
CXCR4 Signaling 0.0014 1.16 
IL-6 Signaling 0.0015 1.73 
HMGB1 Signaling 0.0019 1.16 
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 0.0058  N/A 
IL-10 Signaling 0.0072  N/A 
NF-κB Activation by Viruses 0.0112 0.00 
GM-CSF Signaling 0.0148 1.13 
IL-15 Signaling 0.0178  N/A 
NF-κB Signaling 0.0182 1.73 
Phagosome Formation 0.0200  N/A 
fMLP Signaling in Neutrophils 0.0251 0.71 
IL-3 Signaling 0.0269 1.13 
MSP-RON Signaling Pathway 0.0302  N/A 
Toll-like Receptor Signaling 0.0363 2.45 
p38 MAPK Signaling 0.0437 2.65 
Role of NFAT in Regulation of the Immune Response 0.0447 0.63 
Granulocyte Adhesion and Diapedesis 0.0490  N/A 
Production of Nitric Oxide and Reactive Oxygen Species in 
Macrophages 0.0537 0.91 
Natural Killer Cell Signaling 0.0550  N/A 
Regulation of IL-2 Expression in Activated and Anergic T 
Lymphocytes 0.0603  N/A 
Communication between Innate and Adaptive Immune Cells 0.0661  N/A 
Role of Pattern Recognition Receptors in Recognition of Bacteria 
and Viruses 0.0661 0.82 
PI3K Signaling in B Lymphocytes 0.0692 1.13 
IL-17 Signaling 0.0776  N/A 
Leukocyte Extravasation Signaling 0.0776 -1.00 
IL-2 Signaling 0.0794 0.45 
Dendritic Cell Maturation 0.0832 1.00 
Table 7.9 Pathways associated with CIR for the Comparison of HPV16 Clearer 
vs. HPV16 Negative Samples. (+) Z-Score indicates up-regulation, (-) Z-Score 
indicates down-regulation, and N/A is no available Z-Score. p<0.05 – FC≥1.5. 
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HPV16 Clearer vs. HPV16 Negative p-value 
Z-
Score 
Fcγ Receptor-mediated Phagocytosis in Macrophages and 
Monocytes 0.0851 2.45 
IL-12 Signaling and Production in Macrophages 0.1014  N/A 
Agranulocyte Adhesion and Diapedesis 0.1282  N/A 
Calcium-induced T Lymphocyte Apoptosis 0.1334 0.00 
Inflammasome pathway 0.1384  N/A 
Clathrin-mediated Endocytosis Signaling 0.1403  N/A 
T Cell Receptor Signaling 0.1714  N/A 
IL-4 Signaling 0.1841  N/A 
Lipid Antigen Presentation by CD1 0.1849  N/A 
CCR5 Signaling in Macrophages 0.1897 0.00 
T Helper Cell Differentiation 0.1901  N/A 
Caveolar-mediated Endocytosis Signaling 0.2032  N/A 
Antiproliferative Role of TOB in T Cell Signaling 0.2089  N/A 
IL-15 Production 0.2333  N/A 
CD27 Signaling in Lymphocytes 0.2421  N/A 
4-1BB Signaling in T Lymphocytes 0.2825  N/A 
TREM1 Signaling 0.4036  N/A 
Granzyme B Signaling 0.4130  N/A 
iNOS Signaling 0.4256  N/A 
PKCθ Signaling in T Lymphocytes 0.4276 0.00 
Granzyme A Signaling 0.4325  N/A 
CD40 Signaling 0.4732  N/A 
Nur77 Signaling in T Lymphocytes 0.5224  N/A 
Neuroinflammation Signaling Pathway 0.5272 -0.33 
IL-7 Signaling Pathway 0.5383  N/A 
IL-22 Signaling 0.5508  N/A 
Tumoricidal Function of Hepatic Natural Killer Cells 0.5508  N/A 
OX40 Signaling Pathway 0.5521  N/A 
Activation of IRF by Cytosolic Pattern Recognition Receptors 0.5984  N/A 
Allograft Rejection Signaling 1.0000  N/A 
Antigen Presentation Pathway 1.0000  N/A 
Autoimmune Thyroid Disease Signaling 1.0000  N/A 
CD28 Signaling in T Helper Cells 1.0000  N/A 
Crosstalk between Dendritic Cells and Natural Killer Cells 1.0000  N/A 
CTLA4 Signaling in Cytotoxic T Lymphocytes 1.0000  N/A 
Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells 1.0000  N/A 
iCOS-iCOSL Signaling in T Helper Cells 1.0000  N/A 
IL-9 Signaling 1.0000  N/A 
MIF Regulation of Innate Immunity 1.0000  N/A 
MIF-mediated Glucocorticoid Regulation 1.0000  N/A 
Phagosome Maturation 1.0000  N/A 
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HPV16 Clearer vs. HPV16 Negative p-value 
Z-
Score 
Primary Immunodeficiency Signaling 1.0000  N/A 
Role of RIG1-like Receptors in Antiviral Innate Immunity 1.0000  N/A 
Th1 and Th2 Activation Pathway 1.0000  N/A 











Granzyme A Signaling 0.0006  N/A 
MSP-RON Signaling Pathway 0.0209  N/A 
Graft-versus-Host Disease Signaling 0.0257  N/A 
Calcium-induced T Lymphocyte Apoptosis 0.0457 -1.89 
NF-κB Signaling 0.0676 0.00 
IL-4 Signaling 0.0871  N/A 
Clathrin-mediated Endocytosis Signaling 0.0955  N/A 
Toll-like Receptor Signaling 0.1268 0.71 
Phagosome Maturation 0.1324  N/A 
Nur77 Signaling in T Lymphocytes 0.1406  N/A 
iNOS Signaling 0.1683  N/A 
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 0.1892  N/A 
Caveolar-mediated Endocytosis Signaling 0.1950  N/A 
Macropinocytosis Signaling 0.2244 -0.71 
Antiproliferative Role of TOB in T Cell Signaling 0.2500  N/A 
Fcγ Receptor-mediated Phagocytosis in Macrophages and 
Monocytes 0.2818 0.00 
IL-10 Signaling 0.3133  N/A 
Granulocyte Adhesion and Diapedesis 0.3251  N/A 
Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells 0.3428  N/A 
T Cell Receptor Signaling 0.3516  N/A 
Communication between Innate and Adaptive Immune Cells 0.3622  N/A 
IL-3 Signaling 0.3846 -1.13 
Agranulocyte Adhesion and Diapedesis 0.4027  N/A 
Table 7.10 Pathways associated with CIR for the Comparison of HPV16 Persistor 
vs. HPV16 Negative Samples. (+) Z-Score indicates up-regulation, (-) Z-Score 
indicates down-regulation, and N/A is no available Z-Score. p<0.05 – FC≥1.5. 
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IL-6 Signaling 0.4055 1.27 
p38 MAPK Signaling 0.4102 1.00 
Production of Nitric Oxide and Reactive Oxygen Species in 
Macrophages 0.4150 -0.54 
CD27 Signaling in Lymphocytes 0.4613 1.00 
Role of Cytokines in Mediating Communication between Immune 
Cells 0.4613  N/A 
Antigen Presentation Pathway 0.4710  N/A 
CD28 Signaling in T Helper Cells 0.4775 -2.65 
Lipid Antigen Presentation by CD1 0.4831  N/A 
CTLA4 Signaling in Cytotoxic T Lymphocytes 0.4842  N/A 
fMLP Signaling in Neutrophils 0.4864 -2.33 
Regulation of IL-2 Expression in Activated and Anergic T 
Lymphocytes 0.5058  N/A 
Leukocyte Extravasation Signaling 0.5129 -2.11 
PI3K Signaling in B Lymphocytes 0.5248 -1.00 
CCR3 Signaling in Eosinophils 0.5248 -0.45 
Autoimmune Thyroid Disease Signaling 0.5383  N/A 
Th2 Pathway 1.0000 -2.45 
iCOS-iCOSL Signaling in T Helper Cells 1.0000 -1.89 
CXCR4 Signaling 1.0000 -1.67 
Role of Pattern Recognition Receptors in Recognition of Bacteria 
and Viruses 1.0000 -1.63 
Th1 Pathway 1.0000 -1.63 
PKCθ Signaling in T Lymphocytes 1.0000 -1.27 
NF-κB Activation by Viruses 1.0000 -1.00 
Role of NFAT in Regulation of the Immune Response 1.0000 -0.91 
IL-8 Signaling 1.0000 -0.58 
Neuroinflammation Signaling Pathway 1.0000 0.00 
HMGB1 Signaling 1.0000 0.33 
Dendritic Cell Maturation 1.0000 0.91 
Activation of IRF by Cytosolic Pattern Recognition Receptors 1.0000  N/A 
Allograft Rejection Signaling 
1.0000 
   N/A 
CCR5 Signaling in Macrophages 1.0000  N/A 
CD40 Signaling 1.0000  N/A 
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Crosstalk between Dendritic Cells and Natural Killer Cells 1.0000  N/A 
GM-CSF Signaling 1.0000  N/A 
Granzyme B Signaling 1.0000  N/A 
IL-12 Signaling and Production in Macrophages 1.0000  N/A 
IL-15 Signaling 1.0000  N/A 
IL-17 Signaling 1.0000  N/A 
IL-2 Signaling 1.0000  N/A 
IL-22 Signaling 1.0000  N/A 
IL-7 Signaling Pathway 1.0000  N/A 
IL-9 Signaling 1.0000  N/A 
MIF Regulation of Innate Immunity 1.0000  N/A 
MIF-mediated Glucocorticoid Regulation 1.0000  N/A 
Natural Killer Cell Signaling 1.0000  N/A 
OX40 Signaling Pathway 1.0000  N/A 
Phagosome Formation 1.0000  N/A 
Primary Immunodeficiency Signaling 1.0000  N/A 
Role of PKR in Interferon Induction and Antiviral Response 1.0000  N/A 
Role of RIG1-like Receptors in Antiviral Innate Immunity 1.0000  N/A 
T Helper Cell Differentiation 1.0000  N/A 
Th1 and Th2 Activation Pathway 1.0000  N/A 
TREM1 Signaling 1.0000  N/A 












Granzyme A Signaling 0.0002  N/A 
Leukocyte Extravasation Signaling 0.0182 0.58 
IL-8 Signaling 0.0692 -0.91 
Clathrin-mediated Endocytosis Signaling 0.0759  N/A 
Granulocyte Adhesion and Diapedesis 0.0977  N/A 
p38 MAPK Signaling 0.1000 0.45 
Table 7.11 Pathways associated with CIR for the Comparison of 
HPV16 Persistor vs. HPV16 Clearer Samples. (+) Z-score indicates 
up-regulation, (-) Z-score indicates down-regulation, and N/A is no 









Inflammasome pathway 0.1380  N/A 
CCR3 Signaling in Eosinophils 0.1422  N/A 
Macropinocytosis Signaling 0.1560 0.00 
Role of RIG1-like Receptors in Antiviral Innate Immunity 0.1574  N/A 
Fcγ Receptor-mediated Phagocytosis in Macrophages and 
Monocytes 0.1888 -2.24 
Agranulocyte Adhesion and Diapedesis 0.2244  N/A 
PI3K Signaling in B Lymphocytes 0.2642 -1.00 
Role of NFAT in Regulation of the Immune Response 0.2698 -0.38 
Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells 0.2698  N/A 
Phagosome Maturation 0.2979  N/A 
Calcium-induced T Lymphocyte Apoptosis 0.3133  N/A 
Activation of IRF by Cytosolic Pattern Recognition Receptors 0.3221  N/A 
Th2 Pathway 0.3443 -1.00 
IL-4 Signaling 0.3548  N/A 
CCR5 Signaling in Macrophages 0.3622  N/A 
Phagosome Formation 0.3758  N/A 
fMLP Signaling in Neutrophils 0.4083 -1.34 
Caveolar-mediated Endocytosis Signaling 0.4111  N/A 
Graft-versus-Host Disease Signaling 0.4246  N/A 
iNOS Signaling 0.4246  N/A 
Production of Nitric Oxide and Reactive Oxygen Species in 
Macrophages 0.4446 -0.38 
Toll-like Receptor Signaling 0.4467  N/A 
CXCR4 Signaling 0.4842 -1.00 
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 0.5129  N/A 
Neuroinflammation Signaling Pathway 0.5260 1.41 
Th1 and Th2 Activation Pathway 0.5395  N/A 
Communication between Innate and Adaptive Immune Cells 0.5458  N/A 
OX40 Signaling Pathway 0.5508  N/A 
IL-3 Signaling 0.5610  N/A 
IL-17 Signaling 0.5754  N/A 
NF-κB Signaling 1.0000 -1.34 
Th1 Pathway 1.0000 -1.00 
Dendritic Cell Maturation 1.0000 -0.45 
Allograft Rejection Signaling 1.0000  N/A 
Antigen Presentation Pathway 1.0000  N/A 
Autoimmune Thyroid Disease Signaling 1.0000  N/A 
CD27 Signaling in Lymphocytes 1.0000  N/A 
CD28 Signaling in T Helper Cells 1.0000  N/A 
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Crosstalk between Dendritic Cells and Natural Killer Cells 1.0000  N/A 
CTLA4 Signaling in Cytotoxic T Lymphocytes 1.0000  N/A 
GM-CSF Signaling 1.0000  N/A 
HMGB1 Signaling 1.0000  N/A 
iCOS-iCOSL Signaling in T Helper Cells 1.0000  N/A 
IL-10 Signaling 1.0000  N/A 
IL-12 Signaling and Production in Macrophages 1.0000  N/A 
IL-15 Signaling 1.0000  N/A 
IL-2 Signaling 1.0000  N/A 
IL-6 Signaling 1.0000  N/A 
MIF Regulation of Innate Immunity 1.0000  N/A 
MIF-mediated Glucocorticoid Regulation 1.0000  N/A 
MSP-RON Signaling Pathway 1.0000  N/A 
Natural Killer Cell Signaling 1.0000  N/A 
NF-κB Activation by Viruses 1.0000  N/A 
Nur77 Signaling in T Lymphocytes 1.0000  N/A 
PKCθ Signaling in T Lymphocytes 1.0000  N/A 
Primary Immunodeficiency Signaling 1.0000  N/A 
Regulation of IL-2 Expression in Activated and Anergic T 
Lymphocytes 1.0000  N/A 
Role of Cytokines in Mediating Communication between Immune 
Cells 1.0000  N/A 
Role of Pattern Recognition Receptors in Recognition of Bacteria 
and Viruses 1.0000  N/A 
T Cell Receptor Signaling 1.0000  N/A 
T Helper Cell Differentiation 1.0000  N/A 
TREM1 Signaling 1.0000  N/A 
 
We also looked at the pathways that were associated with CIR that was not altered 
in the other two groups. For example, there were two pathways that were altered and both 
had negative Z-Score in the HPV16 persistor vs. HPV16 negative comparison: CD28 
signaling in T-helper cells and iCOS-iCOSL signaling in T-helper cells. T-helper cells play 
a major role in the immune system, with these pathways being down-regulated and not 
altered in the other two groups, this provides strong evidence that HPV16 persistors do not 
elicit an immune response upon HPV16 infection. Another example is from the HPV16 
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clearer vs. HPV16 negative comparison. There were also two pathways that was altered in 
this comparison, but not in the other two groups: Interleukin-2 (IL-2) signaling and (GM-
CSF) signaling, which both had positive Z-Score. IL-2 is a key cytokine in the immune 
system and GM-CSF also functions as a cytokine that is secreted by immune cells such as 
macrophages and natural killer cells. Upregulation of these pathways is likely key to being 
able to clear the HPV16 infection.  There were no pathways that were unique in the HPV16 
persistor vs. HPV16 clearer group alone.   
 





Calcium-induced T Lymphocyte Apoptosis 0.00 0.1334 
CCR3 Signaling in Eosinophils 1.13 0.0013 
CD28 Signaling in T Helper Cells  N/A 1.0000 
CXCR4 Signaling 1.16 0.0014 
Dendritic Cell Maturation 1.00 0.0832 
fMLP Signaling in Neutrophils 0.71 0.0251 
IL-3 Signaling 1.13 0.0269 
IL-8 Signaling 0.73 0.0001 
Macropinocytosis Signaling 0.38 0.0005 
NF-κB Activation by Viruses 0.00 0.0112 
Table 7.12 HPV16 Clearer vs. HPV16 Negative and HPV16 Persistor vs. 
HPV16 Negative CIR CP that were in common. Highlighted in red are 
pathways upregulated and highlighted in green are pathways down-




PI3K Signaling in B Lymphocytes 1.13 0.0692 
PKCθ Signaling in T Lymphocytes 0.00 0.4276 
Production of Nitric Oxide and Reactive Oxygen Species in 
Macrophages 0.91 0.0537 
Role of NFAT in Regulation of the Immune Response 0.63 0.0447 
Role of Pattern Recognition Receptors in Recognition of Bacteria 
and Viruses 0.82 0.0661 





Calcium-induced T Lymphocyte Apoptosis -1.89 0.0457 
CCR3 Signaling in Eosinophils -0.45 0.5248 
CD28 Signaling in T Helper Cells -2.65 0.4775 
CXCR4 Signaling -1.67 1.0000 
Dendritic Cell Maturation 0.91 1.0000 
fMLP Signaling in Neutrophils -2.33 0.4864 
IL-3 Signaling -1.13 0.3846 
IL-8 Signaling -0.58 1.0000 
Macropinocytosis Signaling -0.71 0.2244 
NF-κB Activation by Viruses -1.00 1.0000 
PI3K Signaling in B Lymphocytes -1.00 0.5248 
PKCθ Signaling in T Lymphocytes -1.27 1.0000 
















Role of NFAT in Regulation of the Immune Response -0.91 1.0000 
Role of Pattern Recognition Receptors in Recognition of Bacteria and 
Viruses -1.63 1.0000 





CXCR4 Signaling 1.16 0.0014 
Dendritic Cell Maturation 1.00 0.0832 
Fcγ Receptor-mediated Phagocytosis in Macrophages and 
Monocytes 2.45 0.0851 
fMLP Signaling in Neutrophils 0.71 0.0251 
IL-8 Signaling 0.73 0.0001 
NF-κB Signaling 1.73 0.0182 
PI3K Signaling in B Lymphocytes 1.13 0.0692 
Production of Nitric Oxide and Reactive Oxygen Species in 
Macrophages 0.91 0.0537 
Role of NFAT in Regulation of the Immune Response 0.63 0.0447 





CXCR4 Signaling -1.00 0.4842 
Dendritic Cell Maturation -0.45 1.0000 
Fcγ Receptor-mediated Phagocytosis in Macrophages and 
Monocytes -2.24 0.1888 
fMLP Signaling in Neutrophils -1.34 0.4083 
IL-8 Signaling -0.91 0.0692 
NF-κB Signaling -1.34 1.0000 
PI3K Signaling in B Lymphocytes -1.00 0.2642 
Production of Nitric Oxide and Reactive Oxygen Species in 
Macrophages -0.38 0.4446 
Role of NFAT in Regulation of the Immune Response -0.38 0.2698 
Table 7.13 HPV16 Clearer vs. HPV16 Negative and HPV16 Persistor vs. HPV16 
C1learer CIR CP that were in common. Highlighted in red are pathways 
upregulated and heighted in green are pathways down-regulated. p<0.05 – FC≥1.5.  
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CHAPTER 8: DISCUSSION 
The first comparison we made in our analyses was to explore gene expression in 
exfoliated cervical cells collected from young women that cleared an HPV16 infection to 
gene expression in cervical cells collected from women that were always HPV negative. 
This comparison yielded 676 differentially expressed genes (Table A.1-Appendix A). 
Using WikiPathways we were able to identify several cellular pathways to which these 
differentially expressed genes belonged, (Table 7.2). These pathways and genes were 
mostly involved in immune response and were upregulated in women that cleared an HPV 
infection compared to women without an HPV infection. Those pathways included the 
following cytokines/chemokines:  
• IL-6, which acts as both a pro-inflammatory cytokine and anti-inflammatory 
myokine. IL-6 also plays a role in the maturation of B cells.  
• TGF-beta is involved in many cellular functions, such as cell growth and 
differentiation and apoptosis.  
• IL-7 is a glycoprotein involved in the establishment and maintenance of normal 
immune functions. It is also important for B and T cells development. 
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• IL-3 is a potent growth promoting cytokine produced by T-cells and mast cells 
and regulates formation of blood cells in the body. It also plays a role in cell 
growth, differentiation, and apoptosis.  
• IL-9 is a cytokine that play an important role in the expansion and recruitment 
of mast cells to sites of inflammation. It also plays a role in cell proliferation.  
• IL-11 is a cytokine produced by activated T lymphocytes. IL-11 also plays an 
important role in the synthesis, maturation and differentiation of hematopoietic 
cells. 
GeneCards Human Gene Database was used to help identify the function of genes 
that were differentially expressed in our analyses. This database consists of human genes 
and provides genomic, proteomic, transcriptomic, genetic, and functional information on 
all known and predicted human genes (Rebhan et al. 1997). There was a total of six genes 
regulated in the IL-6 signaling pathway. The TGF-beta signaling pathway has 10 genes 
regulated. The IL-7 signaling pathway has three genes regulated, all upregulated. The IL-
3 signaling pathway had four differentially expressed genes, all upregulated. The IL-9 
signaling pathway had two differentially expressed genes, both upregulated.  The IL-11 
signaling pathway has three altered genes, all upregulated. There was one gene up-
regulated from the cell cycle checkpoints pathway. The genes associated with each of these 
pathways are summarized in Table 8.1 There are no published studies to date that have 
compared gene expression profiles in exfoliated cervical cells from women who clear an 
HPV infection to uninfected women. My studies are the first to make such a comparison.  
These studies show that the immune system is activated in the cervical cells of HPV16 
infected individuals that are able to “clear” the HPV infection. 
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Pathway #Total #Up Up List #Down Down List 
IL-6 
signaling 




1,JUNB 1 IL6 
TGF-beta 
Signaling 










Pathway 3 3 
MAP2K1,B
CL2L1,MA
PK3 0  
IL-3 
Signaling 




3 0  
IL-9 
Signaling 
Pathway 2 2 
MAPK3,M
AP2K1 0  
Interleukin-
11 Signaling 
Pathway 3 3 
MAPK3,M
AP2K1,TG
FB1 0  
Cell Cycle 
Checkpoints 1 1 BUB1B 0  
 
We also used the Ingenuity Pathway Analysis (IPA) (Qiagen) software to 
specifically look at how genes that were being differentially expressed (up or down) 
affected the pathway of interest as a whole. This is not possible with the WikiPathways 
program.  676 genes were uploaded into IPA to analyze directionality of the pathways of 
interest. Pathways with a Z-score larger than 1.5 or smaller than -1.5 were considered 
altered. Several pathways were up-regulated and associated with host cell immune 
response in the HPV16 clearer vs. HPV16 negative comparison. The IL-6 signaling 
pathway, NF-κB signaling pathway, toll-like receptor signaling pathway, and the p38 
Table 8.1 Genes regulated up or down associated with selected WikiPathways 
(p < 0.05) for HPV16 Clearer vs HPV16 Negative Comparison.  
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MAPK signaling pathway all had positive Z-core that thus were upregulated in a 
statistically significant manner.  
The second comparison group was gene expression in cervical cells from young 
women with a persistent HPV16 infection to gene expression in cervical cells from HPV 
negative women.  This comparison yielded 1,370 differentially expressed genes, most 
(60%) which were downregulated (Table B.1-Appendix B). Interestingly, the HPV16 
persistor vs HPV16 negative comparison have the most DEGs. This suggests that persistors 
of HPV16 infection do have a significant alteration in their gene expression profiles 
compared to those women that are HPV negative.  However, unlike in women that clear an 
HPV infection, IPA analyses indicated that most all the pathways altered in this comparison 
were down-regulated rather than up-regulated. These pathways were associated with 
immune response, as well as cytokines and apoptosis. There were two pathways that were 
unique to this comparison and were not found changed in our other comparisons: CD28 
signaling in T-helper cells and iCOS-iCOSL signaling in T-helper cells, which are 
important for immune response.  Most interesting, the role of pattern recognition receptors 
in recognition of bacteria and viruses’ pathway was down-regulated. Overall these results 
strongly suggest that individuals able to clear HPV16 infections respond to viral infection 
by altering several pathways and genes associated with mounting an immune response 
against the virus. However, the immune system in those individuals that have a persistent 
HPV16 infection is somehow dampened by the HPV infection and these women do not 
mount an immune response against the virus.  
The final comparison we made was gene expression profiles in cervical cells from 
women with a persistent HPV16 infection to gene expression profiles in cervical cells from 
 114 
women clearing the HPV16 infection. This comparison yielded 659 differentially 
expressed genes.  Nine pathways associated with cellular immune response were in 
common with the HPV16 clearer vs. HPV16 negative group (Table 7.12). While these 
pathways in the HPV16 clearer vs. HPV16 negative groups were upregulated and had 
positive Z-Score, these same pathways in the HPV16 persistor vs. HPV16 clearer group 
were down-regulated and had negative Z-Score. The same was true for the HPV16 clearer 
vs. negative and HPV16 persistor vs. HPV16 negative comparison, where they had 14 
genes in common. An important point is that although the same pathways are regulated, 
specific genes play an important role in the direction of the pathway. For example, Nuclear 
factor of activated T-cells (NFAT) are a family of transcription factors that play a major 
role in immune response. They are expressed in most cells of the immune system.  Overall 
NFAT upregulated the immune response in HPV16 clearers vs. HPV16 negative group, 
but down-regulated the immune response in the HPV16 persistor vs. HPV16 clearer group. 
While there was no statistically significant -log(p-value) or Z-Score provided from NFAT 
in the HPV16 persistor vs HPV16 negative group, NFAT was down regulating the immune 
response. The genes that drove the pathway up were completely different from the genes 
that drove the pathway down.  NF-κB signaling had a gene that was expressed in both 
comparisons, but again the pathway as a whole was upregulated in one group and down-
regulated in the other group. Table 8.2 summarizes our data. Table 8.2 also includes the 
HPV16 persistor vs HPV16 negative comparison, which was similar to the HPV16 
persistor vs HPV16 clearer comparison. Overall, we can conclude that:  
• Women who clear an HPV infection elicit an immune response to the 
infection. 
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• Women with a persistent HPV infection do not mount an immune response 
to the infection but rather the HPV infection somehow dampens the immune 
response. 
• HPV “hides” from the immune system in women that have a persistent 
infection.














































HMOX1 INPP5D ARF6 
MAPK3 PIP5K1A CBL 




























GNG12 PLCB2 GNAI3 
KL PRKD3 KL 
















IL18 IL33 CREBBP 
IL1RN IRAK4 CSNK2B 




Table 8.2 Pathways, along with the Genes associated with the Cellular 
Immune Response, are shown for HPV16 clearer vs. HPV16 negative, HPV16 
Persistor vs. HPV16 Clearer, and HPV16 Persistor vs HPV16 Negative 
Comparisons. Red highlight is up-regulation, green highlight is down-
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ADCY9 GNA12 ELMO2 
GNA15 GNAI2 GNAI3 
GNG12 PLCB2 KL 
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EGFR IRAK4 GNAI3 
GNG12 LIMK2 HMOX1 
HMOX1 MMP9 IRAK3 
ITGAV MTOR IRAK4 
KL PLCB2 KL 
LIMK1 PRKD3 PIK3C3 


















DOA Dendritic Cell 
Maturation 
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Maturation 
CREBBP 
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CSF1R CSF1R ARF6 
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RAB5A MRAS KL 
















HMGN1 HSPB1 HSPB1 
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P1 CD44 CD99 
CLDN4 CLDN17 CLDN1 
CTNNA1 CLDN7 CLDN17 
GNAI2 KL CTNNA1 
MMP12 MMP2 FER 
MMP8 PRKCE GNAI3 
MMP9 PRKCH KL 
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1 TIMP2 MSN 



























CSF1R HMOX1 CREBBP 
GABRE IL18 GRINA 
GABRP IL6 HLA-B 




MMP9 TGFB1 HMOX1 
































 123  
  
REFERENCES 
Anttila, L. Kotaniemi Talonen, M. Leinonen, M. Hakama, P. Laurila, J. Tarkkanen, et al. 
Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in 
primary HPV DNA screening with cytology triage: randomised study within organised 
screening programme. BMJ, 340 (2010), p. c1804. 
 
Altomare, D. (2010). Smad proteins and the TGF-beta signaling pathway during in vitro 
progression of HPV16-immortalized human keratinocytes and microarray gene expression 
profiling of exfoliated cervical cells (Order No. 3433119). Available from Dissertations & 
Theses @ University of South Carolina. (835065990). Retrieved from 
http://search.proquest.com/docview/835065990?accountid=13965 
 
Alwine JC, Kemp DJ, Stark GR. Method for detection of specific RNAs in agarose gels by 
transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes. Proc Natl 
Acad Sci U S A. 1977 Dec;74(12):5350-4. 
 
















American Cancer Society (ACS). Cancer Facts & Figures 2018. Atlanta, Ga: American 
Cancer Society; 2018. 
 
Anand A, Singh VP, Anand KP. George Nicholas Papanicolaou, Father of Modern 
Cytopathology. J Assoc Physicians India. 2015 Mar;63(3):107-8. 
 124  
  
Auffray C, Nageotte R, Chambraud B, Rougeon F. Mouse immunoglobulin genes: a 
bacterial plasmid containing the entire coding sequence for a pre-gamma 2a heavy 
chain. Nucleic acids research. 1980;8:1231–1241. 
 
Azar, K. K.; Tani, M.; Yasuda, H.; Sakai, A.; Inoue, M.; Sasagawa, T. Increased secretion 
patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous 
intraepithelial lesions. Hum. Pathol. 2004, 35, 1376-1384. 
 
Baggiolini, M.; Loetscher, P.; Moser, B. Interleukin-8 and the chemokine family. Int. J. 
Immunopharmacol. 1995, 17, 103-108. 
 
Bais, A. G.; Beckmann, I.; Lindemans, J.; Ewing, P. C.; Meijer, C. J.; Snijders, P. J.; 
Helmerhorst, T. J. A shift to a peripheral Th2- type cytokine pattern during the 
carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J. Clin. Pathol. 
2005, 58, 1096-1100. 
 
Banister, C. E. (2009). Factors that contribute to human papillomavirus prevalence and 
persistence in female students attending the university of south carolina (Order No. 
3366496). Available from Dissertations & Theses @ University of South Carolina. 
(304995395). Retrieved from https://login.pallas2.tcl.sc.edu/login?url=https://search-
proquest-com.pallas2.tcl.sc.edu/docview/304995395?accountid=13965 
 
Banister CE, Messersmith AR, Cai B, Spiryda LB, Glover SH, Pirisi L, Creek KE. 
Disparity in the persistence of high-risk human papillomavirus genotypes between African 
American and European American women of college age. J Infect Dis. 2015 Jan 
1;211(1):100-8 
 
Banister CE, Messersmith AR, Cai B, Spiryda LB, Glover SH, Pirisi L, Creek KE. 
Disparity in the persistence of high-risk human papillomavirus genotypes between African 
American and European American women of college age. J Infect Dis. 2015 Jan 
1;211(1):100-8. 
 
Banister CE, Messersmith AR, Chakraborty H, Wang Y, Spiryda LB, Glover SH, Pirisi L, 
Creek KE. HPV prevalence at enrollment and baseline results from theCarolina Women's 
Care Study, a longitudinal study of HPV persistence in women of college age. Int J 
Womens Health. 2013 Jul 2;5:379-88. 
 
Bauer, M.; Wagner, H.; Lipford, G. B. HPV type 16 protein E7 HLA-A2 binding peptides 
are immunogenic but not processed and presented. Immunol. Lett. 2000, 71, 55-59. 
 
Bergvall M, Melendy T, Archambault J. The E1 proteins. Virology. 2013 Oct;445(1-2):35-
56. 
 
Berumen J, Ordoñez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, Yunes E, 
Garcia-Carranca A, Gonzalez-Lira G, Madrigal-de la Campa A. Asian-American variants 
 125 
of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl 
Cancer Inst. 2001 Sep 5;93(17):1325-30. 
 
Blanchard AP, Kaiser RJ, Hood LE. High-density oligonucleotide arrays. Biosensors and 
Bioelectronics. 1996;11:687–690. 
 
Bonagura, V. R.; Hatam, L.; DeVoti, J.; Zeng, F.; Steinberg, B. M. Recurrent respiratory 
papillomatosis: altered CD8(+) T-cell subsets and T(H)1/T(H)2 cytokine imbalance. Clin. 
Immunol. 1999, 93, 302-311. 
 
Bontkes, H. J.; Walboomers, J. M.; Meijer, C. J.; Helmerhorst, T. J.; Stern, P. L. Specific 
HLA class I down-regulation is an early event in cervical dysplasia associated with clinical 
progression. Lancet 1998, 351, 187-188. 
 
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 
2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 
countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. 
 
Budihardjo, I.; Oliver, H.; Lutter, M.; Luo, X.; Wang, X. Biochemical pathways of caspase 
activation during apoptosis. Annu. Rev. Cell Dev. Biol. 1999, 15, 269-290.  
 
Bumgarner R. Overview of DNA microarrays: types, applications, and their future. Curr 
Protoc Mol Biol. 2013 Jan;Chapter 22:Unit 22.1. 
 
Burk RD, DeSalle R. The tango and tangle of human papillomavirus and the human 
genome. J Natl Cancer Inst. 2006 Aug 2;98(15):1026-7. 
 
Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013 
Oct;445(1-2):232-43. 
 
Burk RD, Terai M, Gravitt PE, Brinton LA, Kurman RJ, Barnes WA, Greenberg MD, 
Hadjimichael OC, Fu L, McGowan L, Mortel R, Schwartz PE, Hildesheim A. Distribution 
of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and 
adenocarcinomas of the cervix. Cancer Res. 2003 Nov 1;63(21):7215-20. 
 
Campo MS. Animal models of papillomavirus pathogenesis. Virus Res 2002 ; 89 : 249 –
61. 
 
Cason J, Patel D, Naylor J, Lunney D, Shepherd PS, Best JM, McCance DJ. Identification 
of immunogenic regions of the major coat protein of human papillomavirus type 16 that 
contain type-restricted epitopes. J Gen Virol. 1989 Nov;70 ( Pt 11):2973-87. 
 
Centers for Disease Control and Prevention (CDC). Cancers associated with human 
papillomavirus, United States—2011–2015 USCS data brief, no. 4. Atlanta, GA: Centers 
for Disease Control and Prevention. 2018. 
 
 126 
Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, WInkler J, Lockhart DJ, Morris 
MS, Fodor SPA. Accessing genetic information with high-density DNA 
arrays. Science. 1996;274:610–614. 
 
Chen D., Gyllensten U. Lessons and implications from association studies and post-GWAS 
analyses of cervical cancer. Trends in Genetics. 2015;31(1):41–54. 
 
Chen D., Juko-Pecirep I., Hammer J., et al. Genome-wide association study of 
susceptibility loci for cervical cancer. Journal of the National Cancer 
Institute. 2013;105(9):624–633. 
 
Cho YS, Kang JW, Cho M, Cho CW, Lee S, Choe YK, Kim Y, Choi I, Park SN, Kim 
S,Dinarello CA, Yoon DY. Down modulation of IL-18 expression by human 
papillomavirus type 16 E6 oncogene via binding to IL-18. FEBS Lett. 2001 Jul 20;501(2-
3):139-45. 
 
Cornet I, Gheit T, Franceschi S, Vignat J, Burk RD, Sylla BS, Tommasino M, Clifford 
GM; IARC HPV Variant Study Group. Human papillomavirus type 16 genetic variants: 
phylogeny and classification based on E6 and LCR. J Virol. 2012 Jun;86(12):6855-61. 
 
Craig AG, Nizetic D, Hoheisel JD, Zehetner G, Lehrach H. Ordering of cosmid clones 
covering the herpes simplex virus type I (HSV-I) genome: a test case for fingerprinting by 
hybridisation. Nucleic acids research. 1990; 18:2653–2660. 
 
Crampton J, Humphries S, Woods D, Williamson R. The isolation of cloned cDNA 
sequences which are differentially expressed in human lymphocytes and 
fibroblasts. Nucleic acids research. 1980;8:6007–6017. 
 
Cromme, F. V.; van Bommel, P. F.; Walboomers, J. M.; Gallee, M. P.; Stern, P. L.; 
Kenemans, P.; Helmerhorst, T. J.; Stukart, M. J.; Meijer, C. J. Differences in MHC and 
TAP-1 expression in cervical cancer lymph node metastases as compared with the primary 
tumours. Br. J. Cancer 1994, 69, 1176-1181.  
 
Crum CP, Nagai N, Levine RU, Silverstein S. In situ hybridization analysis of HPV 16 
DNA sequences in early cervical neoplasia. Am J Pathol. 1986 Apr;123(1):174-82. 
 
D.C. Rijkaart, J. Berkhof, F.J. vanKemenade, V.M. Coupe, L. Rozendaal, D.A. Heidema
n, et al.HPV DNA testing in population-based cervical screening (VUSA-Screen study): 
results and implications. Br J Cancer, 106 (5) (2012), pp. 975-981. 
 
Dalstein V, Riethmuller D, Prétet J-L, et al. Persistence and load of high-risk HPV are 
predictors for development of high-grade cervical lesions: A longitudinal French cohort 
study. Int J Cancer. 2003; 106:396–403.  
 
de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable 
to HPV by site, country and HPV type. Int J Cancer. 2017 Aug 15;141(4):664-670. 
 127 
 
De Villier, Ethel-Michele, Achim Schneider, H. Miklaw, Uwe Papendick, Dieter Wagner, 
H. Wesch, Jürgen Wahrendorf, and Harald zur Hausen. "Human Papillomavirus Infections 
in Women With and Without Abnormal Cervical Cytology." The Lancet (1987): 703–705. 
 
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of 
papillomaviruses. Virology. 2004 Jun 20;324(1):17-27. 
 
DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent 
JM. Use of a cDNA microarray to analyse gene expression patterns in human 
cancer. Nature genetics. 1996;14:457–460. 
 
DiSalvo, David. (2017, July 24). The HPV Vaccine Saves Lives, So Why Aren't More Kids 
Getting It? Retrieved from: https://www.forbes.com/sites/daviddisalvo/2017/07/24/why-
are-so-few-kids-getting-a-vaccine-we-know-saves-lives/#4123eb7d7c06. 
 
Doorbar J. The E4 protein; structure, function and patterns of expression. Virology. 2013 
Oct;445(1-2):80-98. 
 
Eurocytology-2.2014. Cervical Cytology. Retrieved from: 
https://www.eurocytology.eu/en/course/1289  
 
Eurocytology-3.2014. Cervical Cytology. Retrieved from: 
https://www.eurocytology.eu/en/course/1290 
 
Eurocytology-4.2014. Cervical Cytology. Retrieved from: 
https://www.eurocytology.eu/en/course/1297 
 
Eurocytology.2014. Cervical Cytology. Retrieved from: 
https://www.eurocytology.eu/en/course/1125 
  
Evans, M.; Borysiewicz, L. K.; Evans, A. S.; Rowe, M.; Jones, M.; Gileadi, U.; Cerundolo, 
V.; Man, S. Antigen processing defects in cervical carcinomas limit the presentation of a 
CTL epitope from human papillomavirus 16 E6. J. Immunol. 2001, 167, 5420-5428. 
 
Ferguson JA, Steemers FJ, Walt DR. High-density fiber-optic DNA random microsphere 
array. Analytical chemistry. 2000;72:5618–5624. 
 
Finnen RL, Erickson KD, Chen XS, Garcea RL. Interactions between papillomavirus L1 
and L2 capsid proteins. J Virol. 2003 Apr;77(8):4818-26. 
 
Fodor SPA, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D. Light-directed, spatially 
addressable parallel chemical synthesis. Science. 1991; 251:767–773. 
 
 128 
Food and Drug Administration (FDA). (2017, October). FDA approves expanded use of 
Gardasil 9 to include individuals 27 through 45 years old. Retrieved from: 
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622715.htm  
 
Freitas LB, Chen Z, Muqui EF, Boldrini NA, Miranda AE, Spano LC, Burk RD. Human 
papillomavirus 16 non-European variants are preferentially associated with high-grade 
cervical lesions. PLoS One. 2014 Jul 1;9(7). 
 
G. Ronco, J. Dillner, K.M. Elfström, S. Tunesi, P.J. Snijders, M. Arbyn, et al. Efficacy of 
HPV-based screening for prevention of invasive cervical cancer: follow-up of four 
European randomised controlled trials. Lancet, 383 (9916) (2014), pp. 524-532. 
 
G. Ronco, P. Giorgi-Rossi, F. Carozzi, M. Confortini, Palma P. Dalla, A. Del Mistro, et 
al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers 
and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet 
Oncol, 11 (3) (2010), pp. 249-257. 
 
GeneChipTM WT Pico Reagent Kit User Guide (Pub. No. MAN0017893 Rev A.0). 
Affymetrix Inc. | 3450 Central Expressway | Santa Clara, CA 95051 | USA. July 10, 2018. 
Accessed on October 10, 2017 (Online). Available: 
https://www.thermofisher.com/order/catalog/product/902622 
 
G.S. Ogilvie, M. Krajden, D.J. van Niekerk, R.E. Martin, T.G. Ehlen, K. Ceballos, et al. 
Primary cervical cancer screening with HPV testing compared with liquid-based cytology: 
results of round 1 of a randomised controlled trial — the HPV FOCAL Study. Br J 
Cancer, 107 (12) (2012), pp. 1917-1924. 
 
Geraets DT, van Doorn LJ, Kleter B, Colau B, Harper DM, Quint WG. Long-term follow-
up of HPV16-positive women: persistence of the same genetic variant and low prevalence 
of variant co-infections. PLoS One. 2013 Nov 11;8(11). 
 
Gergen JP, Stern RH, Wensink PC. Filter replicas and permanent collections of 
recombinant DNA plasmids. Nucleic Acids Res. 1979 Dec 20;7(8):2115-36. 
 
Gheit T, Cornet I, Clifford GM, Iftner T, Munk C, Tommasino M, Kjaer SK. Risks for 
persistence and progression by human papillomavirus type 16 variant lineages among a 
population-based sample of Danish women. Cancer Epidemiol Biomarkers Prev. 2011 
Jul;20(7):1315-21. 
 
Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-
specific human papillomavirus infections: The Young Women's Health Study. J Infect 
Dis. 2002;186:462–9. 
 
Goodman MT, Shvetsov YB, McDuffie K, et al. Prevalence, acquisition, and clearance of 
cervical human papillomavirus infection among women with normal cytology: Hawaii 
Human Papillomavirus Cohort Study. Cancer Res. 2008;68:8813–24. 
 129 
 
Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human 
papillomaviruses. J Clin Microbiol. 2000;38(1):357–361. 
 
Greenfield, I.; Nickerson, J.; Penman, S.; Stanley, M. Human papillomavirus 16 E7 protein 
is associated with the nuclear matrix. Proc. Natl. Acad. Sci. USA 1991, 88, 11217-11221. 
 
Grigoryev, Yevgeniy. 2017. Introduction to DNA Microarrays. BiteSizeBio. Retrieved 
from  https://bitesizebio.com/7206/introduction-to-dna-microarrays/  
 
Grunstein M, Hogness DS. Colony hybridization: a method for the isolation of cloned 
DNAs that contain a specific gene. 1975. Biotechnology. 1992;24:117-21. 
 
Guan J, Bywaters SM, Brendle SA, Ashley RE, Makhov AM, et al. Cryoelectron 
microscopy maps of human papillomavirus 16 reveal L2 densities and heparin binding site. 
Structure. 2017;25:253–263. 
 
Gupta G, Glueck R, Patel PR. HPV vaccines: Global perspectives. Hum Vaccin 
Immunother. 2017 Jun 3;13(6):1-4. 
 
Hansen BT, Kjær SK, Arnheim-Dahlström L, Liaw KL, Jensen KE, Thomsen LT, Munk 
C, Nygård M. Human papillomavirus (HPV) vaccination and subsequent sexual behaviour: 
evidence from a large survey of Nordic women. Vaccine. 2014 Sep3;32(39):4945-53. 
 
Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 
proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989 Dec 
1;8(12):3905-10. 
 
Hengartner, M. O. The biochemistry of apoptosis. Nature 2000, 407, 770-776. 
 
Hilders, C. G.; Munoz, I. M.; Nooyen, Y.; Fleuren, G. J. Altered HLA expression by 
metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol. 
Oncol. 1995, 57, 366-375. 
 
Hildesheim A, Schiffman M, Bromley C, Wacholder S, Herrero R, Rodriguez A, Bratti 
MC, Sherman ME, Scarpidis U, Lin QQ, Terai M, Bromley RL, Buetow K, Apple RJ, Burk 
RD. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst. 
2001 Feb 21;93(4):315-8. 
 
Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal 
papillomavirus infection in young women. N Engl J Med. 1998;338:423–8. 
 
Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP, Kahn T, Kiviat N, Lancaster 
W, Mavromara-Nazos P, et al. The genetic drift of human papillomavirus type 16 is a 
means of reconstructing prehistoric viral spread and the movement of ancient human 
populations. J Virol. 1993 Nov;67(11):6413-23. 
 130 
 
Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human 
papillomavirus vaccination among US adolescents: a systematic review of the literature. 
JAMA Pediatr. 2014 Jan;168(1):76-82. 
 
Huang, S. M.; McCance, D. J. Down regulation of the interleukin8 promoter by human 
papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and 
P/CAF. J. Virol. 2002, 76, 8710-8721. 
 
Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad 
LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH. Use 
of primary high-risk human papillomavirus testing for cervical cancer screening: interim 
clinical guidance. Obstet Gynecol. 2015 Feb;125(2):330-7. 
 










Institut Jules Bordet. The history of cancer. Available at 
http://www.bordet.be/en/presentation/history/cancer-e/cancer2.htm [last accessed: 
January 2018] 
 
Kabsch K, Alonso A. The human papillomavirus type 16 E5 protein impairs TRAIL-and 
FasL-mediated apoptosis in HaCaT cells by different mechanisms. J Virol. 2002 
Dec;76(23):12162-72. 
 
Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape 
the host immune response. Curr Cancer Drug Targets. 2007 Feb;7(1):79-89. 
 
Keating, P. J.; Cromme, F. V.; Duggan-Keen, M.; Snijders, P. J.; Walboomers, J. M.; 
Hunter, R. D.; Dyer, P. A.; Stern, P. L. Frequency of down-regulation of individual HLA-
A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br. J. Cancer 1995, 
72, 405-411. 
 
Kim, Grace, "Harald zur Hausen's Experiments on Human Papillomavirus Causing 
Cervical Cancer (1976–1987)". Embryo Project Encyclopedia (2017-03-09). ISSN: 1940-
5030 http://embryo.asu.edu/handle/10776/11444. 
 
Kleine-Lowinski K, Rheinwald JG, Fichorova RN, Anderson DJ, Basile J, Münger K, Daly 
CM, Rösl F, Rollins BJ. Selective suppression of monocyte chemoattractant protein-1 
 131 
expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial 
and epidermal cells. Int J Cancer. 2003 Nov 10;107(3):407-15. 
 
KrennHrubec K, Mrad K, Sriha B, Ben Ayed F, Bottalico DM, Ostolaza J, Smith B, 
Tchaikovska T, Soliman AS, Burk RD. HPV types and variants among cervical cancer 
tumors in three regions of Tunisia. J Med Virol. 2011 Apr;83(4):651-7. 
 
LabCE. (2001-2018). Low-Risk and High-Risk HPV Types. 
https://www.labce.com/spg1074398_low_risk_and_high_risk_hpv_types.aspx . 
 
Lai A, Lee JM, Yang WM, DeCaprio JA, Kaelin WG Jr, Seto E, Branton PE. RBP1 recruits 
both histone deacetylase-dependent and -independent repression activities to 
retinoblastoma family proteins. Mol Cell Biol. 1999 Oct;19(10):6632-41. 
 
Larsen PM, Storgaard L, Fey SJ. Proteins present in bovine papillomavirus particles. J 
Virol. 1987 Nov;61(11):3596-601. 
 
Lashkari DA, DeRisi JL, McCusker JH, Namath AF, Gentile C, Hwang SY, Brown 
PO,Davis RW. Yeast microarrays for genome wide parallel genetic and gene expression 
analysis. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13057-62. 
 
Lennon GG, Lehrach H. Hybridization analyses of arrayed cDNA libraries. Trends in 
genetics: TIG. 1991;7:314–317. 
 
Leonard, E. J.; Yoshimura, T. Human monocyte chemoattractant protein-1 (MCP-1). 
Immunol. Today 1990, 11, 97-101. 
 
Lipshutz RJ, Morris D, Chee M, Hubbell E, Kozal MJ, Shah N, Shen N, Yang R, Fodor 
SP. Using oligonucleotide probe arrays to access genetic 
diversity. Biotechniques. 1995;19:442–427. 
 
Luan S, An Z, Bi S, Chen L, Fan J. Interleukin 6 receptor (IL-6R) was an independent 
prognostic factor in cervical cancer. Histol Histopathol. 2018 Mar;33(3):269-276. 
 
M.K. Leinonen, P. Nieminen, S. Lönnberg, N. Malila, M. Hakama, A. Pokhrel, et al. 
Detection rates of precancerous and cancerous cervical lesions within one screening round 
of primary human papillomavirus DNA testing: prospective randomised trial in Finland. 
BMJ, 345 (2012), p. e7789. 
 
Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ. Gene expression 
profiling in cervical cancer: identification of novel markers for disease diagnosis and 
therapy. Methods Mol Biol. 2009;511:333-59. 
 
Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, 
Wentzensen N, Lawson HW; 2012 ASCCP Consensus Guidelines Conference. 2012 
 132 
updated consensus guidelines for the management of abnormal cervical cancer screening 
tests and cancer precursors. J Low Genit Tract Dis. 2013 Apr;17(5 Suppl1):S1-S27. 
 
McBride AA. The papillomavirus E2 proteins. Virology. 2013 Oct;445(1-2):57-79.  
 
McQuillan G, Kruszon-Moran D, Markowitz LE, Unger ER, Paulose-Ram R. Prevalence 
of HPV in Adults Aged 18-69: United States, 2011-2014. NCHS Data Brief. 2017 
Apr;(280):1-8. 
 
Messersmith, A. R. (2010). Cytokine dysregulation promotes HPV persistence (Order No. 
3413231). Available from Dissertations & Theses @ University of South Carolina. 
(746178747). Retrieved from https://login.pallas2.tcl.sc.edu/login?url=https://search-
proquest-com.pallas2.tcl.sc.edu/docview/746178747?accountid=13965 
 
Mehta AM, Mooij M, Branković I, Ouburg S, Morré SA, Jordanova ES. Cervical 
Carcinogenesis and Immune Response Gene Polymorphisms: A Review. J Immunol 
Res.2017;2017:8913860. 
 
Mendoza-Villanueva D, Diaz-Chavez J, Uribe-Figueroa L, Rangel-Escareão C, Hidalgo-
Miranda A, March-Mifsut S, Jimenez-Sanchez G, Lambert P, Gariglio P. Gene expression 
profile of cervical and skin tissues from human papillomavirus type 16 E6 transgenic mice. 
BMC Cancer. 2008 Nov 26;8:347. 
 
Michalas SP. The Pap test: George N. Papanicolaou (1883-1962). A screening test for the 
prevention of cancer of uterine cervix. Eur J Obstet Gynecol Reprod Biol. 2000 
Jun;90(2):135-8. 
 
Miller JK, Barnes WM. Colony probing as an alternative to standard sequencing as a means 
of direct analysis of chromosomal DNA to determine the spectrum of single-base changes 
in regions of known sequence. Proceedings of the National Academy of Sciences of the 
United States of America. 1986;83:1026–1030. 
 
Mota, F.; Rayment, N.; Chong, S.; Singer, A.; Chain, B. The antigen-presenting 
environment in normal and human papillomavirus (HPV)-related premalignant cervical 
epithelium. Clin. Exp. Immunol. 1999, 116, 33-40.  
 
N. Malila, M. Leinonen, L. Kotaniemi-Talonen, P. Laurila, J. Tarkkanen, M. HakamaThe 
HPV test has similar sensitivity but more overdiagnosis than the Pap test — a randomised 
health services study on cervical cancer screening in Finland. Int J Cancer, 132 (9) (2013), 
pp. 2141-2147. 
 




Nayar R, Wilbur DC (2015).  The Bethesda System for Reporting Reporting Cervical 
Cytology: Definitions, Criteria and Explanatory Notes, 3nd Edn. New York: Springer; 
2015. 
 
Nees, M.; Geoghegan, J. M.; Hyman, T.; Frank, S.; Miller, L.; Woodworth, C. D. 
Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes 
and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical 
keratinocytes. J. Virol. 2001, 75, 4283-4296. 
 
Niccoli S, Abraham S, Richard C, Zehbe I. The Asian-American E6 variant protein of 
human papillomavirus 16 alone is sufficient to promote immortalization, transformation, 
and migration of primary human foreskin keratinocytes. J Virol. 2012 Nov;86(22):12384-
96. 
 
O'Donovan A, Wood RD. Identical defects in DNA repair in xeroderma pigmentosum 
group G and rodent ERCC group 5. Nature. 1993 May 13;363(6425):185-8. 
 
Oppenheim, J. J.; Zachariae, C. O.; Mukaida, N.; Matsushima, K. Properties of the novel 
proinflammatory supergene "intercrine" cytokine family. Annu. Rev. Immunol. 1991, 9, 
617-648. 
 
Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus 
vaccine introduction. Vaccine. 2004 Dec 16;23(5):569-78. Review. PubMed PMID: 
15630792. 
 
Paolini F, Curzio G, Cordeiro MN, Massa S, Mariani L, Pimpinelli F, de Freitas AC, 
Franconi R, Venuti A. HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis 
and can be a target of immunotherapy. Hum Vaccin Immunother. 2017 Feb;13(2):291-297. 
 
Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the 
uterus. 1941. Arch Pathol Lab Med. 1997 Mar;121(3):211-24. 
 
PatientPoint. The HPV Vaccine and Your Child. June 2018. 1-24. Print. 
 
Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SPA. Light generated 
oligonucleotide arrays for rapid DNA sequence analysis. Proc. Natl. Acad. Sci., 
USA. 1994;91:5022–5026. 
 
Pirisi L, Yasumoto S, Feller M, Doniger J, DiPaolo JA. Transformation of human 
fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J Virol. 1987 
Apr;61(4):1061-6. 
 
Rebhan M(1), Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: integrating information 
about genes, proteins and diseases. Trends Genet. 1997 Apr;13(4):163.  
 
 134 
Rich, T.; Allen, R. L.; Wyllie, A. H. Defying death after DNA damage. Nature 2000, 407, 
777-783. 
Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human 
papillomavirus infections in female university students. Cancer Epidem 
Biomar. 2003;12:485–90. 
 
Rigoni-Stern DA. Fatti statistici relativi alle malattie cancerose. Giornale per servire ai 
progressi della Patologia e della Terapia 1842;2:507–17. 
 
Romagnani, S. Lymphokine production by human T cells in disease states. Annu. Rev. 
Immunol. 1994, 12, 227-257. 
 
Rudolf MP, Nieland JD, DaSilva DM, Velders MP, Müller M, Greenstone HL, Schiller JT, 
Kast WM. Induction of HPV16 capsid protein-specific human T cell responses by virus-
like particles. Biol Chem. 1999 Mar;380(3):335-40. 
 
Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, Garcia FA, 
Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki 
AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER, Chelmow D,Herzig A, 
Kim JJ, Kinney W, Herschel WL, Waldman J. American Cancer Society, American 
Society for Colposcopy and Cervical Pathology, and American Society for Clinical 
Pathology screening guidelines for the prevention and early detection of cervical cancer. J 
Low Genit Tract Dis. 2012 Jul;16(3):175-204. 
 
Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, Su J, Xu F, 
Weinstock H. Sexually transmitted infections among US women and men: prevalence and 
incidence estimates, 2008. Sex Transm Dis. 2013 Mar;40(3):187-93. 
 
Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression 
patterns with a complementary DNA microarray. Science. 1995 Oct 20;270(5235):467-70. 
 
Scherly D, Nouspikel T, Corlet J, Ucla C, Bairoch A, Clarkson SG. Complementation of 
the DNA repair defect in xeroderma pigmentosum group G cells by a human cDNA related 
to yeast RAD2. Nature. 1993 May 13;363(6425):182-5. 
 
Schneider, V.; Kay, S.; Lee, H. M. Immunosuppression as a highrisk factor in the 
development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol. 
1983, 27, 220-224. 
 
Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur Hausen 
H. Structure and transcription of human papillomavirus sequences in cervical carcinoma 
cells. Nature. 1985 Mar 7-13;314(6006):111-4. 
 
Shen F, Zheng H, Zhou L, Li W, Liu J, Xu X. Identification of CD28 and PTEN as novel 
prognostic markers for cervical cancer. J Cell Physiol. 2019 May;234(5):7004-7011. 
 
 135 
Shots: Health News from NPR. 2015, April 30th. The Great Success and Enduring 





Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, Villa LL. High 
grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 
18. Int J Cancer. 2007 Apr 15;120(8):1763-8. 
 
Song JY, Lee JK, Lee NW, Jung HH, Kim SH, Lee KW. Microarray analysis of normal 
cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in 
pathogenesis of invasion in cervical cancer. Int J Gynecol Cancer. 2008 Sep-
Oct;18(5):1051-9. 
 
Stanley MA, Pett MR, Coleman N. HPV: from infection to cancer. Biochem Soc Trans. 
2007 Dec;35(Pt 6):1456-60. 
 
Stoakes, Shelley. 2000-2019. History of Microarrays. Retrieved from: https://www.news-
medical.net/life-sciences/History-of-Microarrays.aspx . 
 
Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human 
papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol. 1992 
Feb;23(2):117-28. 
 
Straight, S. W.; Herman, B.; McCance, D. J. The E5 oncoprotein of human papillomavirus 
type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 1995, 69, 
3185-3192. 
 
Tamegão-Lopes BP, Sousa-Júnior EC, Passetti F, Ferreira CG, de Mello WA,Duarte 
Silvestre RV. Prevalence of human papillomavirus infection and phylogenetic analysis of 
HPV-16 E6 variants among infected women from Northern Brazil. Infect Agent Cancer. 
2014 Aug 5;9:25. 
 
Trimble, Cornelia L and Rachel Katzenellenbogen. June 30th, 2015. Biology of Cervical 
Sqamous Neoplasia. Retrieved from https://clinicalgate.com/biology-of-cervical-
squamous-neoplasia/.  
 
Tu JJ, Kuhn L, Denny L, Beattie KJ, Lorincz A, Wright TC Jr. Molecular variants of human 
papillomavirus type 16 and risk for cervical neoplasia in South Africa. Int J Gynecol 
Cancer. 2006 Mar-Apr;16(2):736-42. 
 
U. Gyllensten, I. Gustavsson, M. Lindell, E. Wilander. Primary high-risk HPV screening 




Van Doorslaer K, Chen Z, Bernard HU, Chan PKS, DeSalle R, Dillner J, Forslund O, Haga 
T, McBride AA, Villa LL, Burk RD, Ictv Report Consortium. ICTV Virus Taxonomy 
Profile: Papillomaviridae. J Gen Virol. 2018 Aug;99(8):989-990. 
 
Walboomers JM, Marcel VJ, Manos MM, et al. Human papillomavirus is a necessary cause 
of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9. 
 
Warrino, D. E.; Olson, W. C.; Knapp, W. T.; Scarrow, M. I.; D'Ambrosio-Brennan, L. J.; 
Guido, R. S.; Edwards, R. P.; Kast, W. M.; Storkus, W. J. Disease-stage variance in 
functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region 
presented human papillomavirus-16 E7 epitopes. Clin. Cancer Res. 2004, 10, 3301-3308.  
 




World Health Organization (WHO). (2018). Cervical Cancer. Retrieved from 
https://www.who.int/cancer/prevention/diagnosis-screening/cervical-cancer/en/. 
 
World Health Organization (WHO). Electronic address: sageexecsec@who.int. Human 
papillomavirus vaccines: WHO position paper, May 2017-Recommendations. 
Vaccine.2017 Oct 13;35(43):5753-5755. 
 
World Health Organization. Global Cancer Observatory. 2019. Retrieved from: 
http://gco.iarc.fr/  
 
World Health Organizaton. Cerivcal Cancer. 2019. Retrieved from: 
https://www.who.int/cancer/prevention/diagnosis-screening/cervical-cancer/en/  
 
Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, Koutsky LA. Human 
papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl 
Cancer Inst. 2006 Aug 2;98(15):1045-52. 
 
Xi LF, Koutsky LA, Galloway DA, Kuypers J, Hughes JP, Wheeler CM, Holmes KK, 
Kiviat NB. Genomic variation of human papillomavirus type 16 and risk for high grade 
cervical intraepithelial neoplasia. J Natl Cancer Inst. 1997 Jun4; 89(11):796-802. 
 
Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, Wheeler CM. Human 
papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J 
Virol. 1997 Mar;71(3):2463-72. 
 
Yang XF, Shen DF, Zhao S, Ren TR, Gao Y, Shi S, Wu JC, Sun HZ, Zheng HC. Expression 




Yoshimura, T.; Yuhki, N.; Moore, S. K.; Appella, E.; Lerman, M. I.; Leonard, E. J. Human 
monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in 
mitogenstimulated blood mononuclear leukocytes, and sequence similarity to mouse 
competence gene JE. FEBS Lett. 1989, 244, 487-493. 
 
Zacapala-Gómez AE, Del Moral-Hernández O, Villegas-Sepúlveda N, Hidalgo-Miranda 
A, Romero-Córdoba SL, Beltrán-Anaya FO, Leyva-Vázquez MA,  Alarcón-Romero Ldel 
C, Illades-Aguiar B. Changes in global gene expression profiles induced by HPV 16 E6 
oncoprotein variants in cervical carcinoma C33-Acells. Virology. 2016 Jan 15; 488:187-
95. 
 
Zhu L, Zheng X, Du Y, Xing Y, Xu K, Cui L. Matrix metalloproteinase-7 may serve as a 
novel biomarker for cervical cancer. Onco Targets Ther. 2018 Jul 20;11:4207-4220. 
 
zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res. 1976 
Feb;36(2 pt 2):794.
 138  
  













PRSS3 10.07 0.0002 protease, serine, 3 
ALOX12 9.94 0.0013 arachidonate 12-lipoxygenase 
LCE3D 9.65 0.0017 late cornified envelope 3D 
LY6K 9.02 0.0015 lymphocyte antigen 6 complex, locus K 
FLG 8.50 0.0078 filaggrin 
LCE3E 8.10 0.0040 late cornified envelope 3E 
SEMA7A 7.99 0.0005 
semaphorin 7A, GPI membrane anchor (John 
Milton Hagen blood group) 
IL36A 7.93 0.0006 interleukin 36, alpha 
KRT78 7.65 0.0006 keratin 78, type II 
GRPEL2 7.36 0.0054 GrpE-like 2, mitochondrial (E. coli) 
KPRP 7.35 0.0020 keratinocyte proline-rich protein 
UPK1A 7.33 0.0039 uroplakin 1A 
YOD1 7.18 0.0031 YOD1 deubiquitinase 
A2ML1 7.10 0.0011 alpha-2-macroglobulin-like 1 
CLIC3 6.87 0.0009 chloride intracellular channel 3 
SBSN 6.59 0.0014 suprabasin 
C6orf132 6.48 0.0006 chromosome 6 open reading frame 132 
HILPDA 6.34 0.0034 hypoxia inducible lipid droplet-associated 
UPP1 6.20 0.0027 uridine phosphorylase 1 
TMEM40 6.19 0.0002 transmembrane protein 40 
CST6 6.10 0.0014 cystatin E/M 
CRNN 5.95 0.0026 cornulin 
DUSP5 5.91 0.0002 dual specificity phosphatase 5 
Table A.1 DEGs for the HPV16 clearer vs HPV16 negative comparison. As 
indicated by the fold change, numbers in red are upregulated genes and numbers 
in green are down-regulated genes. p<0.05 – FC≥1.5. 
 







RGS2 5.86 0.0336 regulator of G-protein signaling 2 
GPAT3 5.84 0.0023 glycerol-3-phosphate acyltransferase 3 
UPK1A-AS1 5.84 0.0067 UPK1A antisense RNA 1 
S100A12 5.70 0.0182 S100 calcium binding protein A12 
DKK4 5.68 0.0002 dickkopf WNT signaling pathway inhibitor 4 
KRT80 5.55 0.0010 keratin 80, type II 
C18orf25 5.54 0.0017 chromosome 18 open reading frame 25 
GCOM1; 
MYZAP; 
POLR2M 5.49 0.0011 
GRINL1A complex locus 1; myocardial zonula 
adherens protein; polymerase (RNA) II (DNA 
directed) polypeptide M 
KLK5 5.45 0.0031 kallikrein related peptidase 5 
EMP1 5.35 0.0033 epithelial membrane protein 1 
SPINK7 5.21 0.0130 
serine peptidase inhibitor, Kazal type 7 
(putative) 
ATP6V1C2 5.18 0.0008 
ATPase, H+ transporting, lysosomal 42kDa, 
V1 subunit C2 
ESAM 5.11 0.0002 endothelial cell adhesion molecule 
FAM84A 5.06 0.0005 family with sequence similarity 84, member A 
PPP1R3C 4.97 0.0002 protein phosphatase 1, regulatory subunit 3C 
PITX1 4.91 0.0003 paired-like homeodomain 1 
KLK10 4.89 0.0006 kallikrein related peptidase 10 
RNASE7 4.88 0.0135 ribonuclease, RNase A family, 7 
SULT2B1 4.84 0.0011 sulfotransferase family 2B member 1 
ADGRG6 4.79 0.0013 adhesion G protein-coupled receptor G6 
KRT15; 
MIR6510 4.75 0.0010 keratin 15, type I; microRNA 6510 
FAM83A 4.68 0.0070 family with sequence similarity 83, member A 
EPHA2 4.61 0.0022 EPH receptor A2 
TPRG1 4.61 0.0096 tumor protein p63 regulated 1 
LOR 4.56 0.0427 loricrin 
FAM25G; 
FAM25C; 
FAM25BP 4.51 0.0076 
family with sequence similarity 25, member G; 
family with sequence similarity 25, member C; 
protein FAM25 
IL36RN 4.47 0.0424 interleukin 36 receptor antagonist 
RNF222 4.42 0.0018 ring finger protein 222 
PPL 4.41 0.0034 periplakin 







AIM1 4.33 0.0039 absent in melanoma 1 
RHCG 4.32 0.0013 Rh family, C glycoprotein 
JUNB 4.28 0.0108 jun B proto-oncogene 
CNFN 4.27 0.0037 cornifelin 
SESN2 4.23 0.0016 sestrin 2 
IVL 4.22 0.0062 involucrin 
BNIPL 4.21 0.0034 
BCL2/adenovirus E1B 19kD interacting 
protein like 
CCNG2 4.20 0.0004 cyclin G2 
TSC22D2 4.19 0.0022 TSC22 domain family, member 2 
SNRK 4.17 0.0032 SNF related kinase 
HCG22 4.16 0.0036 HLA complex group 22 
ERRFI1 4.14 0.0009 ERBB receptor feedback inhibitor 1 
CPA4 4.14 0.0012 carboxypeptidase A4 
GYS2 4.10 0.0202 glycogen synthase 2 (liver) 
PPARD 4.04 0.0045 
peroxisome proliferator-activated receptor 
delta 
TSPAN5 4.02 0.0046 tetraspanin 5 
CHAC1 3.93 0.0081 
ChaC glutathione-specific gamma-
glutamylcyclotransferase 1 
ANKRD37 3.92 0.0014 ankyrin repeat domain 37 
UGCG 3.92 0.0047 UDP-glucose ceramide glucosyltransferase 
PRDM1 3.88 0.0009 PR domain containing 1, with ZNF domain 
ARL4C 3.83 0.0101 ADP-ribosylation factor like GTPase 4C 
MAP3K9 3.81 0.0046 
mitogen-activated protein kinase kinase kinase 
9 
LPIN1; 
MIR548S 3.81 0.0050 lipin 1; microRNA 548s 
PROK2 3.81 0.0349 prokineticin 2 
GALNT1 3.80 0.0015 
polypeptide N-acetylgalactosaminyltransferase 
1 
FAM83D 3.75 0.0011 family with sequence similarity 83, member D 
TGM3 3.75 0.0371 transglutaminase 3 
EPHX3 3.74 0.0112 epoxide hydrolase 3 
ATG9B 3.71 0.0012 autophagy related 9B 
TMEM159 3.71 0.0033 transmembrane protein 159 







SPRR1B 3.67 0.0085 small proline-rich protein 1B 
AIF1L 3.65 0.0255 allograft inflammatory factor 1-like 
RNF39 3.64 0.0073 ring finger protein 39 
PRSS27 3.61 0.0016 protease, serine 27 
CRYM 3.61 0.0199 crystallin mu 
SCEL 3.54 0.0031 sciellin 
SPNS2 3.54 0.0073 spinster homolog 2 (Drosophila) 
TICAM1 3.52 0.0060 toll-like receptor adaptor molecule 1 




zawskaw 3.49 0.0148 
Transcript Identified by AceView; family with 
sequence similarity 25, member D 
[Source:HGNC Symbol;Acc:23588]; family 
with sequence similarity 25, member E 
[Source:HGNC Symbol;Acc:HGNC:23587] 
RASGEF1B 3.49 0.0189 RasGEF domain family member 1B 
TMPRSS11D 3.49 0.0427 transmembrane protease, serine 11D 
SERTAD2 3.47 0.0012 SERTA domain containing 2 
B3GNT8 3.45 0.0014 
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 8 
TMPRSS11E 3.44 0.0134 transmembrane protease, serine 11E 
KLK13 3.39 0.0099 kallikrein related peptidase 13 
LOC441178; 
RP11-351J23.1 3.39 0.0188 uncharacterized LOC441178; novel tanscript 
FBXO32 3.39 0.0201 F-box protein 32 
IL1RN 3.37 0.0387 interleukin 1 receptor antagonist 
PAX9 3.36 0.0008 paired box 9 
DUSP14 3.35 0.0061 dual specificity phosphatase 14 
ZNF185 3.34 0.0008 zinc finger protein 185 (LIM domain) 
RMND5A 3.34 0.0059 
required for meiotic nuclear division 5 
homolog A 
XG; XGY2 3.33 0.0042 Xg blood group; Xg pseudogene, Y-linked 2 
SASH1 3.32 0.0029 SAM and SH3 domain containing 1 
TRIP10 3.26 0.0028 thyroid hormone receptor interactor 10 
FAM25C 3.26 0.0299 family with sequence similarity 25, member C 
PDLIM2 3.25 0.0062 PDZ and LIM domain 2 (mystique) 
LNX1 3.25 0.0106 
ligand of numb-protein X 1, E3 ubiquitin 
protein ligase 







TTC9 3.23 0.0008 tetratricopeptide repeat domain 9 
C5orf66-AS1 3.21 0.0000 C5orf66 antisense RNA 1 
CNST 3.21 0.0149 consortin, connexin sorting protein 
USP2 3.20 0.0007 ubiquitin specific peptidase 2 
KLK7 3.20 0.0138 kallikrein related peptidase 7 
SLCO4A1 3.20 0.0281 
solute carrier organic anion transporter family, 
member 4A1 
METRNL 3.19 0.0253 
meteorin, glial cell differentiation regulator-
like 
FAM129B 3.16 0.0019 
family with sequence similarity 129, member 
B 
SERPINB13 3.16 0.0106 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 13 
KRT4 3.16 0.0257 keratin 4, type II 
NCCRP1 3.15 0.0044 
non-specific cytotoxic cell receptor protein 1 
homolog (zebrafish) 
LMO7 3.13 0.0071 LIM domain 7 
PLBD1 3.12 0.0098 phospholipase B domain containing 1 
RAP2B 3.06 0.0008 RAP2B, member of RAS oncogene family 
TMPRSS11A 3.06 0.0492 transmembrane protease, serine 11A 
OVOL1 3.04 0.0011 ovo-like zinc finger 1 
TCP11L2 3.04 0.0044 t-complex 11, testis-specific-like 2 
PKP1 3.03 0.0017 plakophilin 1 
SDCBP2 3.03 0.0034 syndecan binding protein (syntenin) 2 
GLTP 3.02 0.0029 glycolipid transfer protein 
ABLIM3 3.02 0.0182 actin binding LIM protein family, member 3 
HMOX1 3.02 0.0265 heme oxygenase 1 
FUT6 3.00 0.0007 
fucosyltransferase 6 (alpha (1,3) 
fucosyltransferase) 
SPINK6 3.00 0.0279 serine peptidase inhibitor, Kazal type 6 
RUSC2 2.99 0.0025 RUN and SH3 domain containing 2 
ITPKC 2.97 0.0033 inositol-trisphosphate 3-kinase C 
USP6NL 2.96 0.0085 USP6 N-terminal like 
MXD1 2.96 0.0120 MAX dimerization protein 1 
CLDN17 2.95 0.0268 claudin 17 
LYPD2 2.93 0.0035 LY6/PLAUR domain containing 2 
ABTB2 2.92 0.0092 








SNX9 2.91 0.0040 sorting nexin 9 
PADI1 2.91 0.0200 peptidyl arginine deiminase, type I 
KAZN 2.90 0.0154 kazrin, periplakin interacting protein 
KLK11 2.88 0.0014 kallikrein related peptidase 11 
PRDM4 2.87 0.0072 PR domain containing 4 
C1orf116 2.85 0.0023 chromosome 1 open reading frame 116 
CRCT1 2.83 0.0008 cysteine rich C-terminal 1 
NR1D1 2.83 0.0212 
nuclear receptor subfamily 1, group D, member 
1 
MAL 2.82 0.0009 mal, T-cell differentiation protein 
MALL 2.82 0.0044 mal, T-cell differentiation protein-like 
C16orf52 2.82 0.0310 chromosome 16 open reading frame 52 
RANBP9 2.81 0.0015 RAN binding protein 9 
SPRR2E 2.81 0.0361 small proline-rich protein 2E 
GDPD3 2.80 0.0013 
glycerophosphodiester phosphodiesterase 
domain containing 3 
ZNF426 2.80 0.0076 zinc finger protein 426 
RASAL2 2.79 0.0033 RAS protein activator like 2 
CSTA 2.78 0.0325 cystatin A (stefin A) 
ABHD17B 2.76 0.0023 abhydrolase domain containing 17B 
FAM25A 2.76 0.0133 family with sequence similarity 25, member A 
AGFG2 2.76 0.0404 ArfGAP with FG repeats 2 
C2orf54 2.75 0.0074 chromosome 2 open reading frame 54 
ADIPOR2 2.74 0.0029 adiponectin receptor 2 
ABCA13 2.74 0.0184 
Memczak2013 ALT_ACCEPTOR, 
ALT_DONOR, coding, INTERNAL, intronic 
best transcript NM_152701 
CCDC127 2.73 0.0080 coiled-coil domain containing 127 
CITED2 2.68 0.0253 
Cbp/p300-interacting transactivator, with 
Glu/Asp rich carboxy-terminal domain, 2 
CLCA4 2.68 0.0350 chloride channel accessory 4 
DOCK9 2.67 0.0036 dedicator of cytokinesis 9 
GNA15 2.67 0.0312 
guanine nucleotide binding protein (G protein), 
alpha 15 (Gq class) 
TMPRSS11B 2.66 0.0155 transmembrane protease, serine 11B 
ARNTL2 2.66 0.0183 








TGFB1 2.65 0.0123 transforming growth factor beta 1 
PSCA 2.65 0.0232 prostate stem cell antigen 
GABRP 2.61 0.0312 
gamma-aminobutyric acid (GABA) A receptor, 
pi 
FMO2 2.58 0.0018 flavin containing monooxygenase 2 
SPRR1A 2.56 0.0041 small proline-rich protein 1A 
SFTA2 2.56 0.0050 surfactant associated 2 
PLS3 2.54 0.0040 plastin 3 
AIM1L 2.54 0.0108 absent in melanoma 1-like 
ARHGEF4 2.53 0.0185 Rho guanine nucleotide exchange factor 4 
PHACTR2 2.51 0.0110 phosphatase and actin regulator 2 
RAB11FIP1 2.51 0.0360 RAB11 family interacting protein 1 (class I) 
TMEM45B 2.49 0.0088 transmembrane protein 45B 
WFDC12 2.49 0.0188 WAP four-disulfide core domain 12 
SOWAHC 2.49 0.0342 
sosondowah ankyrin repeat domain family 
member C 
FOSL1 2.48 0.0321 FOS-like antigen 1 
CSNK1E 2.47 0.0006 casein kinase 1, epsilon 
EPN3 2.46 0.0069 epsin 3 
VSIG10L 2.46 0.0088 
V-set and immunoglobulin domain containing 
10 like 
NDRG2; 
MIR6717 2.46 0.0182 NDRG family member 2; microRNA 6717 
HMGA1 2.45 0.0058 high mobility group AT-hook 1 
KCTD11 2.45 0.0114 
potassium channel tetramerization domain 
containing 11 
FAM214A 2.45 0.0192 
family with sequence similarity 214, member 
A 
ELF3 2.45 0.0430 
E74-like factor 3 (ets domain transcription 
factor, epithelial-specific ) 
ARHGAP10 2.43 0.0215 Rho GTPase activating protein 10 
PARD6B 2.42 0.0055 par-6 family cell polarity regulator beta 
SPINK5 2.41 0.0169 serine peptidase inhibitor, Kazal type 5 
ABHD5 2.41 0.0296 abhydrolase domain containing 5 
SH3GL1 2.40 0.0009 SH3-domain GRB2-like 1 
YPEL3 2.40 0.0352 yippee like 3 
OSBP2 2.40 0.0398 oxysterol binding protein 2 







PAPL 2.40 0.0472 
iron/zinc purple acid phosphatase-like protein; 
Iron/zinc purple acid phosphatase-like protein  
[Source:UniProtKB/Swiss-Prot;Acc:Q6ZNF0]; 
Transcript Identified by AceView, Entrez Gene 
ID(s) 390928 
C12orf56 2.39 0.0025 chromosome 12 open reading frame 56 
TTC22 2.39 0.0026 tetratricopeptide repeat domain 22 
PTK6 2.37 0.0008 protein tyrosine kinase 6 
KRT13 2.36 0.0013 keratin 13, type I 
VASN 2.36 0.0089 vasorin 
FUT3 2.35 0.0076 
fucosyltransferase 3 (galactoside 3(4)-L-
fucosyltransferase, Lewis blood group) 
DNAJB1 2.35 0.0155 
DnaJ (Hsp40) homolog, subfamily B, member 
1 
PCSK5 2.35 0.0383 proprotein convertase subtilisin/kexin type 5 
ZNF812P 2.35 0.0439 zinc finger protein 812, pseudogene 
DTX2 2.34 0.0004 deltex 2, E3 ubiquitin ligase 
STK24 2.34 0.0196 serine/threonine kinase 24 
CSNK1E 2.32 0.0034 casein kinase 1, epsilon 
GFOD2 2.32 0.0042 
glucose-fructose oxidoreductase domain 
containing 2 
NCK2 2.32 0.0056 NCK adaptor protein 2 
CEACAM6 2.32 0.0107 
carcinoembryonic antigen-related cell adhesion 
molecule 6 (non-specific cross reacting 
antigen) 
GJB6 2.31 0.0115 gap junction protein beta 6 
PLK3 2.31 0.0391 polo-like kinase 3 
PADI1 2.30 0.0213 peptidyl arginine deiminase, type I 
MAPK3 2.30 0.0260 mitogen-activated protein kinase 3 
FGF11 2.29 0.0011 fibroblast growth factor 11 
DMKN 2.29 0.0026 dermokine 
FAM45A 2.27 0.0087 family with sequence similarity 45, member A 
LYPLA1 2.26 0.0360 lysophospholipase I 
NDUFA4L2 2.26 0.0384 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 4-like 2 
RIOK3 2.25 0.0065 RIO kinase 3 
MLLT4 2.24 0.0011 
myeloid/lymphoid or mixed-lineage leukemia; 
translocated to, 4 







KAT2B 2.24 0.0152 K(lysine) acetyltransferase 2B 
SLC20A2 2.23 0.0001 
solute carrier family 20 (phosphate 
transporter), member 2 
PHLDA1 2.23 0.0179 
pleckstrin homology-like domain, family A, 
member 1 
ABLIM1 2.23 0.0286 actin binding LIM protein 1 
PDE4C 2.23 0.0318 phosphodiesterase 4C, cAMP-specific 
CDKN2B 2.23 0.0382 
cyclin-dependent kinase inhibitor 2B (p15, 
inhibits CDK4) 
ZNRF1 2.22 0.0036 
zinc and ring finger 1, E3 ubiquitin protein 
ligase 
PHACTR4 2.22 0.0040 phosphatase and actin regulator 4 
TMOD3 2.22 0.0230 tropomodulin 3 (ubiquitous) 
IL20RB 2.22 0.0287 interleukin 20 receptor beta 
UPK3B 2.21 0.0009 uroplakin 3B 
MUC21 2.20 0.0065 mucin 21, cell surface associated 
IL18 2.20 0.0111 interleukin 18 
RND3 2.20 0.0263 Rho family GTPase 3 
PVRL4 2.19 0.0196 poliovirus receptor-related 4 
UBE2R2 2.19 0.0198 ubiquitin-conjugating enzyme E2R 2 
CEP295NL; 
TIMP2 2.19 0.0340 
CEP295 N-terminal like; TIMP 
metallopeptidase inhibitor 2 
BLNK 2.17 0.0054 B-cell linker 
ACE2 2.17 0.0344 angiotensin I converting enzyme 2 
DENND2C 2.16 0.0076 DENN/MADD domain containing 2C 
AHNAK 2.16 0.0085 AHNAK nucleoprotein 
RDH13 2.16 0.0424 retinol dehydrogenase 13 (all-trans/9-cis) 
TGM5 2.15 0.0008 transglutaminase 5 
SERTAD1 2.15 0.0232 SERTA domain containing 1 
CLN8 2.15 0.0270 ceroid-lipofuscinosis, neuronal 8 
SORT1 2.14 0.0066 sortilin 1 
MIDN 2.14 0.0385 midnolin 
WDR26; 
MIR4742 2.12 0.0062 WD repeat domain 26; microRNA 4742 
UBE2B 2.12 0.0341 ubiquitin conjugating enzyme E2B 
CTTNBP2NL 2.11 0.0051 CTTNBP2 N-terminal like 







SLK 2.10 0.0059 STE20-like kinase 
NDFIP2 2.09 0.0015 Nedd4 family interacting protein 2 
TCTEX1D1 2.09 0.0138 Tctex1 domain containing 1 
POF1B 2.09 0.0216 premature ovarian failure, 1B 
RHOD 2.08 0.0054 ras homolog family member D 
MYO6 2.07 0.0179 myosin VI 
CGNL1 2.07 0.0199 cingulin-like 1 
LPIN1 2.07 0.0310 
Transcript Identified by AceView, Entrez Gene 
ID(s) 23175 
UBE2G1 2.05 0.0123 ubiquitin conjugating enzyme E2G 1 
C3orf67 2.05 0.0293 chromosome 3 open reading frame 67 
STAP2 2.02 0.0018 signal transducing adaptor family member 2 
RIPK4 2.01 0.0216 receptor-interacting serine-threonine kinase 4 
RB1CC1 2.01 0.0466 RB1-inducible coiled-coil 1 






MIR941-5 2.00 0.0089 
DnaJ (Hsp40) homolog, subfamily C, member 
5; microRNA 941-1; microRNA 941-2; 
microRNA 941-3; microRNA 941-4; 
microRNA 941-5 
CCDC172 1.99 0.0167 coiled-coil domain containing 172 
SPRR3 1.99 0.0170 small proline-rich protein 3 
RAPGEF5 1.99 0.0368 Rap guanine nucleotide exchange factor 5 
ALOX12B 1.98 0.0045 arachidonate 12-lipoxygenase, 12R type 
PARD3 1.97 0.0007 par-3 family cell polarity regulator 
ANXA11 1.97 0.0016 annexin A11 
TNFRSF21 1.97 0.0188 
tumor necrosis factor receptor superfamily, 
member 21 
VAT1 1.97 0.0397 vesicle amine transport 1 
MOSPD1 1.96 0.0017 motile sperm domain containing 1 
WASL 1.96 0.0048 Wiskott-Aldrich syndrome-like 
ABHD3 1.96 0.0069 
Transcript Identified by AceView, Entrez Gene 
ID(s) 171586 
CKAP4 1.96 0.0109 cytoskeleton-associated protein 4 
ADCY9 1.96 0.0338 adenylate cyclase 9 







KLF4 1.95 0.0163 Kruppel-like factor 4 (gut) 
PADI1 1.94 0.0027 peptidyl arginine deiminase, type I 
ITSN2 1.94 0.0100 intersectin 2 
HPGD 1.94 0.0360 
hydroxyprostaglandin dehydrogenase 15-
(NAD) 
YTHDC1 1.93 0.0259 YTH domain containing 1 
PLAGL2 1.93 0.0371 pleiomorphic adenoma gene-like 2 
PPP1R14C 1.92 0.0023 
protein phosphatase 1, regulatory (inhibitor) 
subunit 14C 
MUC15 1.92 0.0122 mucin 15, cell surface associated 
ZNF672 1.92 0.0298 zinc finger protein 672 
EPS8L2 1.91 0.0008 EPS8-like 2 
YPEL2 1.91 0.0096 yippee like 2 
SUSD6 1.91 0.0151 sushi domain containing 6 
NPAS2 1.91 0.0278 neuronal PAS domain protein 2 
PLCXD1 1.91 0.0299 
phosphatidylinositol-specific phospholipase C, 
X domain containing 1 
EPS8L1 1.91 0.0448 EPS8-like 1 
SNX33 1.90 0.0011 sorting nexin 33 
SERPINA6 1.89 0.0197 
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 6 
PNLIPRP3 1.89 0.0221 pancreatic lipase-related protein 3 
PLEKHM1; 
MIR4315-1 1.89 0.0346 
pleckstrin homology domain containing, 
family M (with RUN domain) member 1; 
microRNA 4315-1 
MPRIP 1.88 0.0066 myosin phosphatase Rho interacting protein 
PLCXD1 1.88 0.0316 
phosphatidylinositol-specific phospholipase C, 
X domain containing 1 
DSP 1.87 0.0033 desmoplakin 
ERBB3 1.87 0.0079 erb-b2 receptor tyrosine kinase 3 
CAST 1.87 0.0101 calpastatin 
TIAM1 1.87 0.0157 T-cell lymphoma invasion and metastasis 1 
RBMS2 1.87 0.0333 
RNA binding motif, single stranded interacting 
protein 2 
JUP 1.86 0.0007 junction plakoglobin 
EEF1A2 1.86 0.0020 
eukaryotic translation elongation factor 1 alpha 
2 
WWTR1 1.86 0.0131 








CRY1 1.86 0.0314 cryptochrome circadian clock 1 
SECISBP2L 1.86 0.0330 SECIS binding protein 2-like 
DUSP4 1.86 0.0344 dual specificity phosphatase 4 
H1F0 1.85 0.0072 H1 histone family, member 0 
FAM45A 1.85 0.0124 
Transcript Identified by AceView, Entrez Gene 
ID(s) 404636 
RNF169 1.85 0.0186 ring finger protein 169 
PPDPF 1.84 0.0065 
pancreatic progenitor cell differentiation and 
proliferation factor 
OGFR 1.84 0.0101 opioid growth factor receptor 
RNF11 1.84 0.0339 ring finger protein 11 
HEG1 1.84 0.0347 
heart development protein with EGF-like 
domains 1 
FAM102A 1.84 0.0391 
family with sequence similarity 102, member 
A 
CRISP3 1.84 0.0458 cysteine-rich secretory protein 3 
S100A9 1.83 0.0282 S100 calcium binding protein A9 
TMEM57 1.82 0.0098 transmembrane protein 57 
SRGAP1 1.82 0.0408 SLIT-ROBO Rho GTPase activating protein 1 
PQLC1 1.81 0.0011 PQ loop repeat containing 1 
PLEKHA6 1.81 0.0112 
pleckstrin homology domain containing, 
family A member 6 
RNF223 1.81 0.0203 ring finger protein 223 
FOXO3 1.80 0.0031 forkhead box O3 
LAP3 1.80 0.0049 
Transcript Identified by AceView, Entrez Gene 
ID(s) 51056 
RORA 1.80 0.0075 RAR-related orphan receptor A 
TMEM80 1.80 0.0099 transmembrane protein 80 
TP53INP1 1.80 0.0134 tumor protein p53 inducible nuclear protein 1 
ACADM 1.80 0.0261 
acyl-CoA dehydrogenase, C-4 to C-12 straight 
chain 
ANKRD31 1.80 0.0438 ankyrin repeat domain 31 
MAP2K1 1.79 0.0063 mitogen-activated protein kinase kinase 1 
VPS4B 1.79 0.0172 
vacuolar protein sorting 4 homolog B (S. 
cerevisiae) 
SLC6A9 1.79 0.0433 
solute carrier family 6 (neurotransmitter 
transporter, glycine), member 9 







SORBS2 1.79 0.0442 
Transcript Identified by AceView, Entrez Gene 
ID(s) 8470 
MAP1LC3A 1.78 0.0300 
microtubule-associated protein 1 light chain 3 
alpha 
NIPAL3 1.77 0.0017 NIPA-like domain containing 3 
SMURF1 1.76 0.0119 SMAD specific E3 ubiquitin protein ligase 1 
CAMSAP1 1.76 0.0146 
calmodulin regulated spectrin-associated 
protein 1 
UBL3 1.76 0.0170 ubiquitin-like 3 
GTPBP2 1.76 0.0243 GTP binding protein 2 
SLC37A2 1.76 0.0304 
solute carrier family 37 (glucose-6-phosphate 
transporter), member 2 
KRT17 1.76 0.0359 keratin 17, type I 
FKBP1A-
SDCBP2 1.75 0.0211 
FKBP1A-SDCBP2 readthrough (NMD 
candidate) 
TAB3 1.74 0.0100 
TGF-beta activated kinase 1/MAP3K7 binding 
protein 3 
EPG5 1.74 0.0119 
ectopic P-granules autophagy protein 5 
homolog (C. elegans) 
TGFA 1.74 0.0377 transforming growth factor alpha 
SMIM5 1.73 0.0057 small integral membrane protein 5 
MGEA5 1.73 0.0077 
Salzman2013 ALT_ACCEPTOR, 
ALT_DONOR, coding, INTERNAL, intronic 
best transcript NM_012215 
ATP12A 1.73 0.0225 
ATPase, H+/K+ transporting, nongastric, alpha 
polypeptide 
CNKSR3 1.73 0.0267 CNKSR family member 3 
PRSS8 1.73 0.0401 protease, serine, 8 
STRN 1.73 0.0489 striatin, calmodulin binding protein 
BNIP3 1.72 0.0122 
BCL2/adenovirus E1B 19kDa interacting 
protein 3 
SMS 1.72 0.0244 spermine synthase 
KRT16 1.71 0.0038 keratin 16, type I 
WASF2 1.71 0.0118 WAS protein family, member 2 
GRHL3 1.71 0.0455 grainyhead-like transcription factor 3 
SLURP1 1.70 0.0002 secreted LY6/PLAUR domain containing 1 
ALPK3 1.70 0.0331 alpha kinase 3 







DLGAP1 1.69 0.0107 
discs, large (Drosophila) homolog-associated 
protein 1 
CYSRT1 1.69 0.0192 cysteine-rich tail protein 1 
EEPD1 1.69 0.0240 
endonuclease/exonuclease/phosphatase family 
domain containing 1 
HK2 1.69 0.0298 hexokinase 2 
TP53INP2 1.69 0.0310 tumor protein p53 inducible nuclear protein 2 
BCL2L1 1.69 0.0336 BCL2-like 1 
NEIL3 1.69 0.0351 nei-like DNA glycosylase 3 
ZRANB1 1.69 0.0427 zinc finger, RAN-binding domain containing 1 
CYTH2 1.68 0.0063 cytohesin 2 
MGC57346-
CRHR1; RP11-
105N13.4 1.68 0.0085 
Homo sapiens MGC57346-CRHR1 
readthrough (MGC57346-CRHR1), transcript 
variant 5, mRNA.; Homo sapiens MGC57346-
CRHR1 readthrough (MGC57346-CRHR1), 
transcript variant 6, mRNA.; novel transcript 
DOPEY2 1.68 0.0110 dopey family member 2 
HEBP2 1.68 0.0162 heme binding protein 2 
SIK1 1.68 0.0201 salt-inducible kinase 1 
MARCH5 1.68 0.0224 membrane associated ring finger 5 
SMAGP 1.67 0.0194 small cell adhesion glycoprotein 
RUNX1 1.67 0.0206 runt-related transcription factor 1 
WWC2 1.66 0.0078 WW and C2 domain containing 2 
WWC1 1.66 0.0109 WW and C2 domain containing 1 
C15orf59 1.66 0.0114 chromosome 15 open reading frame 59 
MAST4 1.65 0.0026 
microtubule associated serine/threonine kinase 
family member 4 
ZNF398 1.65 0.0110 zinc finger protein 398 
CLTB 1.65 0.0216 clathrin, light chain B 
UBE2H 1.65 0.0317 ubiquitin conjugating enzyme E2H 
MYEOV 1.65 0.0493 myeloma overexpressed 
PRSS1 1.64 0.0032 protease, serine, 1 (trypsin 1) 
USP38 1.64 0.0065 ubiquitin specific peptidase 38 
SLCO4A1-AS1 1.64 0.0115 SLCO4A1 antisense RNA 1 
SH3BGRL2 1.64 0.0324 
SH3 domain binding glutamate-rich protein 
like 2 







CDC42EP1 1.63 0.0086 
CDC42 effector protein (Rho GTPase binding) 
1 
ELK3 1.63 0.0136 
ELK3, ETS-domain protein (SRF accessory 
protein 2) 
RORA 1.63 0.0162 
Jeck2013 ALT_ACCEPTOR, ALT_DONOR, 
coding, INTERNAL, intronic best transcript 
NM_134261 
PI4K2A 1.63 0.0163 phosphatidylinositol 4-kinase type 2 alpha 
CDRT1 1.63 0.0250 CMT1A duplicated region transcript 1 
DCAF12 1.62 0.0242 DDB1 and CUL4 associated factor 12 
GPT2 1.61 0.0152 
glutamic pyruvate transaminase (alanine 
aminotransferase) 2 
HSPB1 1.61 0.0254 heat shock 27kDa protein 1 
RNF10 1.61 0.0468 ring finger protein 10 
ATMIN 1.60 0.0093 ATM interactor 
TMBIM1; 
MIR6513 1.60 0.0234 
transmembrane BAX inhibitor motif 
containing 1; microRNA 6513 
MPZL3 1.60 0.0268 myelin protein zero-like 3 
PRSS2 1.60 0.0435 protease, serine, 2 (trypsin 2) 
ARRDC1 1.59 0.0018 arrestin domain containing 1 
EPB41L5 1.59 0.0134 erythrocyte membrane protein band 4.1 like 5 
AJUBA 1.59 0.0172 ajuba LIM protein 
CDC34 1.59 0.0260 cell division cycle 34 
S100A14 1.59 0.0273 S100 calcium binding protein A14 
ESPL1 1.59 0.0287 extra spindle pole bodies like 1, separase 
CAMSAP3 1.58 0.0015 
calmodulin regulated spectrin-associated 
protein family, member 3 
RAB25 1.58 0.0105 RAB25, member RAS oncogene family 
PHLPP1 1.58 0.0166 
PH domain and leucine rich repeat protein 
phosphatase 1 
PRKCH 1.58 0.0174 protein kinase C, eta 
ZNF431; 
VN1R82P 1.58 0.0280 
zinc finger protein 431; vomeronasal 1 receptor 
82 pseudogene 
FAM107B 1.58 0.0322 
family with sequence similarity 107, member 
B 
ATXN1L 1.58 0.0326 ataxin 1-like 
ZFAND5 1.58 0.0331 zinc finger, AN1-type domain 5 









MYO5B 1.57 0.0088 myosin VB 
FMO6P 1.57 0.0138 
flavin containing monooxygenase 6 
pseudogene 
BDKRB1 1.57 0.0153 bradykinin receptor B1 
ATP13A5 1.57 0.0180 ATPase type 13A5 
TNFRSF11A 1.57 0.0185 
Transcript Identified by AceView, Entrez Gene 
ID(s) 8792 
PDCD6IP 1.56 0.0028 programmed cell death 6 interacting protein 
KPNA7 1.56 0.0030 karyopherin alpha 7 (importin alpha 8) 
DHRS11 1.56 0.0055 
dehydrogenase/reductase (SDR family) 
member 11 
GPSM2 1.56 0.0071 G-protein signaling modulator 2 
GID8 1.56 0.0096 GID complex subunit 8 
TBC1D9 1.56 0.0233 
TBC1 domain family, member 9 (with GRAM 
domain) 
TNK2 1.56 0.0266 tyrosine kinase, non-receptor, 2 
ARF6 1.55 0.0093 ADP-ribosylation factor 6 
DIAPH1 1.55 0.0191 diaphanous-related formin 1 
DNAH5 1.55 0.0196 
Transcript Identified by AceView, Entrez Gene 
ID(s) 1767 
LPIN2 1.55 0.0352 lipin 2 
CYP2A7 1.55 0.0420 
cytochrome P450, family 2, subfamily A, 
polypeptide 7 
NDUFA10 1.55 0.0463 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 10, 42kDa 
WSCD2 1.54 0.0014 WSC domain containing 2 
GNG12 1.54 0.0057 
guanine nucleotide binding protein (G protein), 
gamma 12 
LILRA5 1.54 0.0133 
Memczak2013 ANTISENSE, coding, 
INTERNAL, intronic best transcript 
NM_181985 
MCU 1.54 0.0248 mitochondrial calcium uniporter 
HMOX2 1.54 0.0310 heme oxygenase 2 
PPM1A 1.54 0.0326 
protein phosphatase, Mg2+/Mn2+ dependent, 
1A 
MARCH7 1.54 0.0491 membrane associated ring finger 7 
BCOR 1.54 0.0499 BCL6 corepressor 







SPATA5 1.53 0.0392 
Transcript Identified by AceView, Entrez Gene 
ID(s) 166378 
KLF3 1.53 0.0411 Kruppel-like factor 3 (basic) 
CSTB 1.52 0.0029 cystatin B (stefin B) 
GOLGA6L5P; 
GOLGA6L17P 1.52 0.0062 
golgin A6 family-like 5, pseudogene; golgin 
A6 family-like 17, pseudogene 
PRKCE 1.52 0.0081 protein kinase C, epsilon 
CEP76 1.52 0.0144 centrosomal protein 76kDa 
MED18 1.52 0.0180 mediator complex subunit 18 
LIPE 1.52 0.0190 lipase, hormone-sensitive 
PDGFB 1.52 0.0284 platelet-derived growth factor beta polypeptide 
MTRNR2L6 1.52 0.0337 MT-RNR2-like 6 
EIF4H 1.52 0.0439 eukaryotic translation initiation factor 4H 
NDUFA10 1.51 0.0039 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 10, 42kDa 
PLAC1 1.51 0.0062 placenta specific 1 
GPSM1 1.51 0.0080 G-protein signaling modulator 1 
CLDN7 1.51 0.0155 claudin 7 
USP25 1.51 0.0224 ubiquitin specific peptidase 25 
BUB1B 1.51 0.0238 
BUB1 mitotic checkpoint serine/threonine 
kinase B 
SOX4 1.51 0.0318 SRY box 4 
CNGA4 1.51 0.0459 cyclic nucleotide gated channel alpha 4 
NT5C2 1.50 0.0444 5-nucleotidase, cytosolic II 
HRASLS2 1.50 0.0447 HRAS-like suppressor 2 
SLC38A2 -1.50 0.0138 solute carrier family 38, member 2 
PCYT1A -1.50 0.0150 phosphate cytidylyltransferase 1, choline, alpha 
SCUBE2 -1.50 0.0186 signal peptide, CUB domain, EGF-like 2 
TNFRSF14 -1.50 0.0241 
tumor necrosis factor receptor superfamily, 
member 14 
HGSNAT -1.50 0.0348 
heparan-alpha-glucosaminide N-
acetyltransferase 
PSMF1 -1.50 0.0408 proteasome inhibitor subunit 1 
BNC2 -1.50 0.0440 basonuclin 2 
MYADM -1.50 0.0485 
Memczak2013 ANTISENSE, CDS, coding, 
INTERNAL best transcript NM_001020819 
RABGGTB; 
SNORD45B; -1.51 0.0082 
Rab geranylgeranyltransferase, beta subunit; 









nucleolar RNA, C/D box 45A; small nucleolar 
RNA, C/D box 45C 
LIMK1 -1.51 0.0083 
Memczak2013 ANTISENSE, CDS, coding, 
INTERNAL best transcript NM_001204426 
ABHD16A -1.51 0.0086 abhydrolase domain containing 16A 
DHX58 -1.51 0.0091 DEXH (Asp-Glu-X-His) box polypeptide 58 
UTP14A -1.51 0.0113 
UTP14A small subunit (SSU) processome 
component 
GUK1 -1.51 0.0147 guanylate kinase 1 
PM20D2 -1.51 0.0230 peptidase M20 domain containing 2 
NUDCD2 -1.51 0.0368 NudC domain containing 2 
COPA -1.51 0.0380 coatomer protein complex subunit alpha 
MILR1 -1.51 0.0383 mast cell immunoglobulin-like receptor 1 
CTSB -1.51 0.0443 cathepsin B 
COPS3 -1.52 0.0076 COP9 signalosome subunit 3 
DFFA -1.52 0.0182 
DNA fragmentation factor, 45kDa, alpha 
polypeptide 
FAH -1.52 0.0201 
fumarylacetoacetate hydrolase 
(fumarylacetoacetase) 
LPXN -1.52 0.0210 leupaxin 
ENO1 -1.52 0.0216 enolase 1, (alpha) 
GALNS -1.52 0.0216 galactosamine (N-acetyl)-6-sulfatase 
ITGAV -1.52 0.0281 integrin alpha V 
SNX3 -1.52 0.0310 sorting nexin 3 
BRMS1L -1.52 0.0365 
Transcript Identified by AceView, Entrez Gene 
ID(s) 84312 
EXT1 -1.53 0.0057 exostosin glycosyltransferase 1 
GLB1; TMPPE -1.53 0.0078 
galactosidase beta 1; transmembrane protein 
with metallophosphoesterase domain 
BRD9 -1.53 0.0161 bromodomain containing 9 
C1orf54 -1.53 0.0282 chromosome 1 open reading frame 54 
TTLL4 -1.54 0.0069 tubulin tyrosine ligase-like family member 4 
FXR1 -1.54 0.0095 
fragile X mental retardation, autosomal 
homolog 1 
SEMA4B -1.54 0.0160 
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4B 
FN1 -1.54 0.0251 fibronectin 1 







ETV6 -1.54 0.0445 ets variant 6 
PJA2 -1.55 0.0001 praja ring finger 2, E3 ubiquitin protein ligase 
THBD -1.55 0.0027 thrombomodulin 
ADCY3 -1.55 0.0071 adenylate cyclase 3 
CCDC88A -1.55 0.0117 coiled-coil domain containing 88A 
JAGN1 -1.55 0.0257 jagunal homolog 1 
SFXN3 -1.55 0.0344 sideroflexin 3 
VMO1 -1.55 0.0415 
vitelline membrane outer layer 1 homolog 
(chicken) 
SSR1 -1.55 0.0496 signal sequence receptor, alpha 
ANGEL2 -1.56 0.0037 angel homolog 2 (Drosophila) 
ATP1B3 -1.56 0.0098 
ATPase, Na+/K+ transporting, beta 3 
polypeptide 
EPHX4 -1.56 0.0101 epoxide hydrolase 4 
C1orf131 -1.56 0.0130 chromosome 1 open reading frame 131 
LARP1B -1.56 0.0396 
La ribonucleoprotein domain family, member 
1B 
EMILIN2 -1.57 0.0008 elastin microfibril interfacer 2 
GKN1 -1.57 0.0026 gastrokine 1 
SNAP23 -1.57 0.0062 synaptosome associated protein 23kDa 
LTBP2 -1.57 0.0338 
latent transforming growth factor beta binding 
protein 2 
CBX3 -1.58 0.0023 chromobox homolog 3 
CBWD6; 
CBWD5; 
CBWD7 -1.58 0.0066 
COBW domain containing 6; COBW domain 
containing 5; COBW domain containing 7 
LHFPL2 -1.58 0.0075 lipoma HMGIC fusion partner-like 2 
ANXA5 -1.58 0.0152 annexin A5 
AAED1 -1.58 0.0188 
AhpC/TSA antioxidant enzyme domain 
containing 1 
MRPL32 -1.58 0.0195 mitochondrial ribosomal protein L32 
HLA-DOA -1.58 0.0216 
major histocompatibility complex, class II, DO 
alpha 
EIF2AK3 -1.58 0.0353 
eukaryotic translation initiation factor 2-alpha 
kinase 3 
OLFM2 -1.59 0.0001 olfactomedin 2 
SPPL2A -1.59 0.0006 signal peptide peptidase like 2A 







LGALS1 -1.59 0.0120 lectin, galactoside-binding, soluble, 1 
UST -1.59 0.0208 uronyl-2-sulfotransferase 
EGFR -1.59 0.0328 epidermal growth factor receptor 
MARK1 -1.59 0.0394 MAP/microtubule affinity-regulating kinase 1 
CNTLN -1.59 0.0496 centlein, centrosomal protein 
PLXND1 -1.60 0.0173 plexin D1 
SERPINB6 -1.60 0.0460 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 6 
ASIC1 -1.60 0.0488 acid sensing ion channel 1 
DBNDD2 -1.61 0.0160 
dysbindin (dystrobrevin binding protein 1) 
domain containing 2 
DHRS13 -1.61 0.0209 
dehydrogenase/reductase (SDR family) 
member 13 
WBP5 -1.61 0.0311 WW domain binding protein 5 
STRA6 -1.61 0.0335 stimulated by retinoic acid 6 
ENO1 -1.62 0.0037 
Memczak2013 ANTISENSE, coding, 
INTERNAL, UTR3 best transcript 
NM_001428 
CEP112 -1.62 0.0051 centrosomal protein 112kDa 
MRAS -1.62 0.0106 muscle RAS oncogene homolog 
SNX12 -1.62 0.0110 sorting nexin 12 
SEPT2 -1.62 0.0460 septin 2 
FAM76B -1.63 0.0101 family with sequence similarity 76, member B 
SLC25A6 -1.63 0.0172 
solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 6 
LZIC -1.64 0.0005 
leucine zipper and CTNNBIP1 domain 
containing 
EMD -1.64 0.0029 emerin 
CRTAP -1.64 0.0133 cartilage associated protein 
ADH5 -1.64 0.0144 
alcohol dehydrogenase 5 (class III), chi 
polypeptide 
P2RX4 -1.64 0.0218 
purinergic receptor P2X, ligand gated ion 
channel, 4 
CALM2 -1.65 0.0026 calmodulin 2 (phosphorylase kinase, delta) 
SLC45A3 -1.65 0.0316 solute carrier family 45, member 3 
SSR2 -1.65 0.0322 
signal sequence receptor, beta (translocon-
associated protein beta) 
PDE3A -1.65 0.0353 phosphodiesterase 3A, cGMP-inhibited 







RAB43 -1.67 0.0006 RAB43, member RAS oncogene family 
CAPZA2 -1.68 0.0009 
capping protein (actin filament) muscle Z-line, 
alpha 2 
RPL18A -1.68 0.0057 ribosomal protein L18a 
GATC -1.68 0.0059 
glutamyl-tRNA(Gln) amidotransferase, subunit 
C 
G3BP1 -1.68 0.0085 
GTPase activating protein (SH3 domain) 
binding protein 1 
SLC25A6 -1.68 0.0132 
solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 6 
HTT -1.68 0.0171 huntingtin 
RHOA -1.68 0.0191 ras homolog family member A 
MSR1 -1.68 0.0208 macrophage scavenger receptor 1 
SDC2 -1.68 0.0265 syndecan 2 
TNFRSF18 -1.68 0.0421 
tumor necrosis factor receptor superfamily, 
member 18 
KIF20B -1.69 0.0231 kinesin family member 20B 
LAMC1 -1.69 0.0396 laminin, gamma 1 (formerly LAMB2) 
GPR107 -1.69 0.0412 G protein-coupled receptor 107 
NARS -1.71 0.0015 asparaginyl-tRNA synthetase 
PSAP -1.71 0.0087 prosaposin 
ZDHHC2 -1.71 0.0208 zinc finger, DHHC-type containing 2 
TRIM35 -1.71 0.0250 tripartite motif containing 35 
RPL18A; 
SNORA68 -1.71 0.0322 
ribosomal protein L18a; small nucleolar RNA, 
H/ACA box 68 
MXRA7 -1.72 0.0362 matrix-remodelling associated 7 
TFPI -1.73 0.0018 
tissue factor pathway inhibitor (lipoprotein-
associated coagulation inhibitor) 
LRP6 -1.73 0.0178 LDL receptor related protein 6 
SPRYD3 -1.73 0.0192 SPRY domain containing 3 
P3H1 -1.73 0.0321 prolyl 3-hydroxylase 1 
CTNS -1.73 0.0391 cystinosin, lysosomal cystine transporter 
SIAE -1.73 0.0399 sialic acid acetylesterase 
KIAA0100 -1.73 0.0471 KIAA0100 
MFSD2A -1.74 0.0014 
major facilitator superfamily domain 
containing 2A 
TMEM39A -1.74 0.0163 transmembrane protein 39A 







SCN1A -1.74 0.0345 
sodium channel, voltage gated, type I alpha 
subunit 
SLC25A29 -1.74 0.0386 
solute carrier family 25 (mitochondrial 
carnitine/acylcarnitine carrier), member 29 
DHX33 -1.75 0.0171 DEAH (Asp-Glu-Ala-His) box polypeptide 33 
OLFML2B -1.75 0.0269 olfactomedin like 2B 
ABL2 -1.76 0.0010 
ABL proto-oncogene 2, non-receptor tyrosine 
kinase 
SEC22B -1.76 0.0043 
SEC22 homolog B, vesicle trafficking protein 
(gene/pseudogene) 
LPCAT3 -1.76 0.0158 lysophosphatidylcholine acyltransferase 3 
TMX4 -1.76 0.0359 thioredoxin-related transmembrane protein 4 
TXLNG -1.77 0.0066 taxilin gamma 
REPIN1 -1.77 0.0375 replication initiator 1 
NEK6 -1.78 0.0006 NIMA-related kinase 6 
PDK1 -1.78 0.0239 pyruvate dehydrogenase kinase, isozyme 1 
ATP8B4 -1.79 0.0006 ATPase, class I, type 8B, member 4 
SLC39A14 -1.79 0.0369 
solute carrier family 39 (zinc transporter), 
member 14 
CDC25B -1.81 0.0094 cell division cycle 25B 
GOLIM4 -1.81 0.0160 golgi integral membrane protein 4 
SLC3A2 -1.82 0.0012 
solute carrier family 3 (amino acid transporter 
heavy chain), member 2 
SLC16A10 -1.82 0.0076 
solute carrier family 16 (aromatic amino acid 
transporter), member 10 
C1RL -1.82 0.0080 
complement component 1, r subcomponent-
like 
CRLS1 -1.83 0.0106 cardiolipin synthase 1 
SGCD -1.84 0.0317 sarcoglycan delta 
CDH11 -1.85 0.0011 cadherin 11, type 2, OB-cadherin (osteoblast) 
HIST1H4E -1.85 0.0475 histone cluster 1, H4e 
DPYSL2 -1.86 0.0019 dihydropyrimidinase-like 2 
GRAMD1B -1.86 0.0026 GRAM domain containing 1B 
GPRC5B -1.86 0.0083 
G protein-coupled receptor, class C, group 5, 
member B 
TNS4 -1.86 0.0155 tensin 4 
THEM4 -1.86 0.0382 thioesterase superfamily member 4 







H6PD -1.87 0.0120 
hexose-6-phosphate dehydrogenase (glucose 1-
dehydrogenase) 
FBXL2 -1.87 0.0362 F-box and leucine-rich repeat protein 2 
APLP2 -1.94 0.0003 amyloid beta (A4) precursor-like protein 2 
PDE12 -1.94 0.0028 phosphodiesterase 12 
LAIR2 -1.97 0.0167 
leukocyte-associated immunoglobulin-like 
receptor 2 
PDPN -1.98 0.0074 podoplanin 
GANAB -1.98 0.0418 glucosidase, alpha; neutral AB 
CD44 -2.04 0.0003 CD44 molecule (Indian blood group) 
CDR1 -2.04 0.0363 cerebellar degeneration related protein 1 
CPXM1 -2.05 0.0056 carboxypeptidase X (M14 family), member 1 
ABCA1 -2.05 0.0439 ATP binding cassette subfamily A member 1 
ISLR -2.06 0.0361 
immunoglobulin superfamily containing 
leucine-rich repeat 
CERS2 -2.07 0.0005 ceramide synthase 2 
FBLN5 -2.07 0.0022 fibulin 5 
CSF1R -2.10 0.0456 colony stimulating factor 1 receptor 
KL -2.11 0.0005 klotho 
NRP2 -2.12 0.0117 neuropilin 2 
AGPAT2 -2.15 0.0058 1-acylglycerol-3-phosphate O-acyltransferase 2 
C1R -2.18 0.0241 complement component 1, r subcomponent 
TGFBI -2.21 0.0123 
transforming growth factor, beta-induced, 
68kDa 
SLC43A3 -2.22 0.0169 solute carrier family 43, member 3 
IL6 -2.22 0.0433 interleukin 6 
BCAT1 -2.29 0.0152 
branched chain amino-acid transaminase 1, 
cytosolic 
PMP22 -2.32 0.0148 peripheral myelin protein 22 
IFRD2 -2.33 0.0095 interferon-related developmental regulator 2 
MMP2 -2.38 0.0297 matrix metallopeptidase 2 
FLNA -2.43 0.0338 filamin A, alpha 
SLC26A2 -2.50 0.0060 
solute carrier family 26 (anion exchanger), 
member 2 
SLC6A20 -2.59 0.0063 
solute carrier family 6 (proline IMINO 
transporter), member 20 









C1S -2.61 0.0407 complement component 1, s subcomponent 
SLC7A1 -2.64 0.0078 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1 
KIF26B -2.67 0.0470 kinesin family member 26B 
FAM150B -3.15 0.0013 
family with sequence similarity 150, member 
B 
HABP2 -3.15 0.0390 hyaluronan binding protein 2 
EXOC3 -4.19 0.0178 exocyst complex component 3 
SLC9A3 -6.08 0.0148 
solute carrier family 9, subfamily A (NHE3, 
cation proton antiporter 3), member 3 
RELN -11.49 0.0430 reelin 
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LCE3A 11.08 0.0013 late cornified envelope 3A 
LCE3D 10.93 0.0028 late cornified envelope 3D 
LCE3E 10.63 0.0018 late cornified envelope 3E 
TGM3 10.30 0.0116 transglutaminase 3 
IL36A 9.93 0.0011 interleukin 36, alpha 
SPRR2F 8.26 0.0229 small proline-rich protein 2F 
DEFB103A; 
DEFB103B 8.22 0.0162 defensin, beta 103A; defensin, beta 103B 
DEFB103A 8.14 0.0144 defensin, beta 103A 
C20orf85 7.52 0.0198 chromosome 20 open reading frame 85 
SBSN 7.40 0.0048 suprabasin 
KPRP 7.17 0.0028 keratinocyte proline-rich protein 
KLK13 6.18 0.0080 kallikrein related peptidase 13 
UPP1 5.86 0.0020 uridine phosphorylase 1 
CLIC3 5.76 0.0008 chloride intracellular channel 3 
PRSS3 5.58 0.0011 protease, serine, 3 
FAM25G; 
FAM25C; 
FAM25BP 5.51 0.0050 
family with sequence similarity 25, member 
G; family with sequence similarity 25, 
member C; protein FAM25 
TMEM40 5.37 0.0007 transmembrane protein 40 
SPRR2E 5.28 0.0162 small proline-rich protein 2E 
KRTDAP 5.26 0.0053 
keratinocyte differentiation-associated 
protein 
UPK1A 4.95 0.0213 uroplakin 1A 
SPINK7 4.90 0.0073 
serine peptidase inhibitor, Kazal type 7 
(putative) 
SULT2B1 4.69 0.0004 sulfotransferase family 2B member 1 
Table B.1 DEGs for the HPV16 persistor vs. HPV16 negative 
comparison. As indicated by the fold change, numbers in red highlight 
are upregulated genes and green highlight are down-regulated genes. 
p<0.05 – FC≥1.5. 
 
 







A2ML1 4.69 0.0059 alpha-2-macroglobulin-like 1 
UPK1A-AS1 4.66 0.0138 UPK1A antisense RNA 1 
IL36RN 4.64 0.0471 interleukin 36 receptor antagonist 
ADGRG6 4.60 0.0023 adhesion G protein-coupled receptor G6 
WDR38 4.58 0.0231 WD repeat domain 38 
PITX1 4.46 0.0003 paired-like homeodomain 1 
KRT78 4.42 0.0042 keratin 78, type II 
SEMA7A 4.32 0.0098 
semaphorin 7A, GPI membrane anchor (John 
Milton Hagen blood group) 
C6orf132 4.28 0.0014 chromosome 6 open reading frame 132 
KRT6B 4.23 0.0491 keratin 6B, type II 
CITED2 4.21 0.0001 
Cbp/p300-interacting transactivator, with 
Glu/Asp rich carboxy-terminal domain, 2 
KRT4 4.15 0.0091 keratin 4, type II 
CHAC1 4.13 0.0035 
ChaC glutathione-specific gamma-
glutamylcyclotransferase 1 
HILPDA 4.11 0.0179 hypoxia inducible lipid droplet-associated 
RNASE7 4.08 0.0093 ribonuclease, RNase A family, 7 




zawskaw 4.03 0.0084 
Transcript Identified by AceView; family with 
sequence similarity 25, member D 
[Source:HGNC Symbol;Acc:23588]; family 
with sequence similarity 25, member E 
[Source:HGNC Symbol;Acc:HGNC:23587] 
S100A7 4.01 0.0355 S100 calcium binding protein A7 
KLK5 4.00 0.0084 kallikrein related peptidase 5 
KRT24 3.96 0.0478 keratin 24, type I 
WFDC12 3.95 0.0012 WAP four-disulfide core domain 12 
UGCG 3.95 0.0043 UDP-glucose ceramide glucosyltransferase 
IVL 3.95 0.0144 involucrin 
FAM25C 3.86 0.0161 family with sequence similarity 25, member C 
CRNN 3.84 0.0125 cornulin 
ATP6V1C2 3.78 0.0020 
ATPase, H+ transporting, lysosomal 42kDa, 
V1 subunit C2 
FAM83D 3.77 0.0006 family with sequence similarity 83, member D 
FLG 3.75 0.0308 filaggrin 
SPRR2B 3.71 0.0371 small proline-rich protein 2B 
CST6 3.61 0.0028 cystatin E/M 







GALNT1 3.58 0.0022 
polypeptide N-acetylgalactosaminyltransferase 
1 
CSTA 3.50 0.0055 cystatin A (stefin A) 
SPRR1B 3.47 0.0227 small proline-rich protein 1B 
PAPL 3.45 0.0012 
iron/zinc purple acid phosphatase-like protein; 
Iron/zinc purple acid phosphatase-like protein  
[Source:UniProtKB/Swiss-
Prot;Acc:Q6ZNF0]; Transcript Identified by 
AceView, Entrez Gene ID(s) 390928 
AIM1 3.45 0.0157 absent in melanoma 1 
MMP8 3.43 0.0044 matrix metallopeptidase 8 
KLK10 3.39 0.0048 kallikrein related peptidase 10 
IL1A 3.33 0.0494 interleukin 1 alpha 
MAP3K9 3.32 0.0066 
mitogen-activated protein kinase kinase kinase 
9 
USP53 3.31 0.0011 ubiquitin specific peptidase 53 
KRT15; 
MIR6510 3.22 0.0023 keratin 15, type I; microRNA 6510 
MIDN 3.13 0.0057 midnolin 
OSBP2 3.13 0.0102 oxysterol binding protein 2 
ZNF365 3.12 0.0184 zinc finger protein 365 
LY6K 3.11 0.0156 lymphocyte antigen 6 complex, locus K 
GLTP 3.10 0.0004 glycolipid transfer protein 
PPP1R3C 3.10 0.0039 protein phosphatase 1, regulatory subunit 3C 
GYS2 3.10 0.0423 glycogen synthase 2 (liver) 
AHNAK 3.08 0.0003 AHNAK nucleoprotein 
FAM25A 3.08 0.0123 family with sequence similarity 25, member A 
PAX9 3.02 0.0022 paired box 9 
ARNTL2 2.99 0.0012 
aryl hydrocarbon receptor nuclear translocator-
like 2 
PPL 2.99 0.0124 periplakin 
ANXA9 2.98 0.0038 annexin A9 
S100A7A 2.97 0.0106 S100 calcium binding protein A7A 
HMGA1 2.96 0.0006 high mobility group AT-hook 1 
RNF222 2.96 0.0334 ring finger protein 222 
FAM83A 2.93 0.0341 family with sequence similarity 83, member A 
CNFN 2.91 0.0183 cornifelin 
PVRL1 2.90 0.0059 








XG; XGY2 2.90 0.0077 Xg blood group; Xg pseudogene, Y-linked 2 
PKP1 2.87 0.0019 plakophilin 1 
LOR 2.83 0.0214 loricrin 
C16orf52 2.80 0.0176 chromosome 16 open reading frame 52 
TICAM1 2.77 0.0154 toll-like receptor adaptor molecule 1 
LPIN1; MIR548S 2.74 0.0373 lipin 1; microRNA 548s 
STAP2 2.69 0.0012 signal transducing adaptor family member 2 
CLDN17 2.69 0.0246 claudin 17 
KLK12 2.68 0.0398 kallikrein related peptidase 12 
DSP 2.66 0.0000 desmoplakin 
ARHGEF4 2.66 0.0106 Rho guanine nucleotide exchange factor 4 
C1orf116 2.62 0.0017 chromosome 1 open reading frame 116 
HCG22 2.60 0.0370 HLA complex group 22 
GABARAP 2.59 0.0000 GABA(A) receptor-associated protein 
GDPD3 2.55 0.0084 
glycerophosphodiester phosphodiesterase 
domain containing 3 
LYPD2 2.55 0.0233 LY6/PLAUR domain containing 2 
RUSC2 2.55 0.0299 RUN and SH3 domain containing 2 
ESAM 2.54 0.0060 endothelial cell adhesion molecule 
CCL2 2.53 0.0038 chemokine (C-C motif) ligand 2 
KRT1 2.53 0.0185 keratin 1, type II 
XPO1 2.52 0.0000 exportin 1 
SFTA2 2.52 0.0052 surfactant associated 2 
HIST1H1C 2.51 0.0020 
Memczak2013 ANTISENSE, CDS, coding, 
INTERNAL best transcript NM_005319 
CEACAM6 2.51 0.0026 
carcinoembryonic antigen-related cell 
adhesion molecule 6 (non-specific cross 
reacting antigen) 
CSF1 2.51 0.0100 colony stimulating factor 1 (macrophage) 
RNF223 2.51 0.0190 ring finger protein 223 
CDKN2A 2.50 0.0144 cyclin-dependent kinase inhibitor 2A 
SPINK6 2.49 0.0081 serine peptidase inhibitor, Kazal type 6 
ECM1 2.49 0.0116 extracellular matrix protein 1 
ANKRD37 2.48 0.0085 ankyrin repeat domain 37 
GJB6 2.48 0.0268 gap junction protein beta 6 
ABHD16B 2.47 0.0020 abhydrolase domain containing 16B 
BNIPL 2.47 0.0188 








PPARD 2.46 0.0251 
peroxisome proliferator-activated receptor 
delta 
HLA-C 2.45 0.0017 major histocompatibility complex, class I, C 
KRT17 2.45 0.0120 keratin 17, type I 
USP2 2.45 0.0259 ubiquitin specific peptidase 2 
TTC9 2.44 0.0087 tetratricopeptide repeat domain 9 
ZNF185 2.42 0.0030 zinc finger protein 185 (LIM domain) 
SPRR1A 2.42 0.0429 small proline-rich protein 1A 
PPP1R17 2.40 0.0002 protein phosphatase 1, regulatory subunit 17 
YOD1 2.40 0.0314 YOD1 deubiquitinase 
RMND5A 2.39 0.0204 
required for meiotic nuclear division 5 
homolog A 
CLDN1 2.39 0.0311 claudin 1 
ATXN1L 2.38 0.0000 ataxin 1-like 
DMKN 2.38 0.0022 dermokine 
PDLIM2 2.38 0.0031 PDZ and LIM domain 2 (mystique) 
TTC22 2.38 0.0046 tetratricopeptide repeat domain 22 
GRHL1 2.38 0.0133 grainyhead-like transcription factor 1 
HERC4 2.36 0.0019 
HECT and RLD domain containing E3 
ubiquitin protein ligase 4 
SH3BGRL3 2.36 0.0049 
SH3 domain binding glutamate-rich protein 
like 3 
PLA2G4D 2.36 0.0260 phospholipase A2, group IVD (cytosolic) 
CNST 2.36 0.0444 consortin, connexin sorting protein 
RPS26 2.35 0.0232 
Homo sapiens ribosomal protein S26, mRNA 
(cDNA clone MGC:104291 
IMAGE:4287636), complete cds. 
ZNF426 2.35 0.0247 zinc finger protein 426 
SOWAHC 2.35 0.0359 
sosondowah ankyrin repeat domain family 
member C 
GPAT3 2.34 0.0478 glycerol-3-phosphate acyltransferase 3 
S100A2 2.34 0.0490 S100 calcium binding protein A2 
PRSS27 2.33 0.0086 protease, serine 27 
VSIG10L 2.32 0.0226 
V-set and immunoglobulin domain containing 
10 like 
DTX2 2.31 0.0002 deltex 2, E3 ubiquitin ligase 
PRSS2 2.31 0.0045 protease, serine, 2 (trypsin 2) 
KLK8 2.31 0.0054 kallikrein related peptidase 8 







SERTAD2 2.30 0.0068 SERTA domain containing 2 
RPS26 2.29 0.0267 ribosomal protein S26 
FAM84A 2.29 0.0423 family with sequence similarity 84, member A 
NIPAL3 2.28 0.0000 NIPA-like domain containing 3 
HIST1H4C 2.28 0.0048 
Jeck2013 ANTISENSE, CDS, coding, 
INTERNAL, OVCODE, OVEXON, UTR3 
best transcript NM_003542 
SNRK 2.28 0.0274 SNF related kinase 
RBP7 2.26 0.0491 retinol binding protein 7, cellular 
FAM129B 2.25 0.0063 
family with sequence similarity 129, member 
B 
ZBTB7A 2.23 0.0000 zinc finger and BTB domain containing 7A 
NDUFA11 2.23 0.0000 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 11, 14.7kDa 
EPHA2 2.23 0.0152 EPH receptor A2 
CCDC127 2.23 0.0208 coiled-coil domain containing 127 
DOCK9 2.22 0.0152 dedicator of cytokinesis 9 
KIAA0355 2.21 0.0028 KIAA0355 
SPTLC1 2.19 0.0002 
serine palmitoyltransferase, long chain base 
subunit 1 
C1orf194 2.19 0.0038 chromosome 1 open reading frame 194 
RASAL2 2.19 0.0105 RAS protein activator like 2 
PSIP1 2.17 0.0000 PC4 and SFRS1 interacting protein 1 
PPP1R37 2.17 0.0003 protein phosphatase 1, regulatory subunit 37 
POF1B 2.17 0.0028 premature ovarian failure, 1B 
HIST1H1E 2.16 0.0000 histone cluster 1, H1e 
SDC1 2.16 0.0131 syndecan 1 
CDKN2B 2.16 0.0237 
cyclin-dependent kinase inhibitor 2B (p15, 
inhibits CDK4) 
PPDPF 2.15 0.0022 
pancreatic progenitor cell differentiation and 
proliferation factor 
PLEKHM1; 
MIR4315-1 2.13 0.0039 
pleckstrin homology domain containing, 
family M (with RUN domain) member 1; 
microRNA 4315-1 
AVPI1 2.13 0.0219 arginine vasopressin-induced 1 
ANXA8L1; 
ANXA8 2.13 0.0248 annexin A8-like 1; annexin A8 
C19orf53 2.11 0.0000 chromosome 19 open reading frame 53 
TRIOBP; NOL12 2.11 0.0002 








HEBP1 2.11 0.0149 heme binding protein 1 
KLF11 2.11 0.0446 Kruppel-like factor 11 
MOSPD1 2.10 0.0002 motile sperm domain containing 1 
ANXA8 2.10 0.0339 annexin A8 
KLK11 2.09 0.0008 kallikrein related peptidase 11 
LYPLA1 2.09 0.0055 lysophospholipase I 
GFOD2 2.09 0.0088 
glucose-fructose oxidoreductase domain 
containing 2 
C19orf33 2.09 0.0106 chromosome 19 open reading frame 33 
CRY1 2.09 0.0115 cryptochrome circadian clock 1 
RPS26 2.09 0.0226 
Homo sapiens ribosomal protein S26, mRNA 
(cDNA clone MGC:27148 IMAGE:4807004), 
complete cds.; Homo sapiens ribosomal 
protein S26, mRNA (cDNA clone 
MGC:88201 IMAGE:6388128), complete 
cds.; Homo sapiens ribosomal protein S26, 
mRNA (cDNA clone MGC:104291 
IMAGE:4287636), complete cds.; Homo 
sapiens ribosomal protein S26, mRNA (cDNA 
clone MGC:104292 IMAGE:6726218), 
complete cds. 
RTKN2 2.09 0.0382 rhotekin 2 
CTNNA1 2.06 0.0000 catenin (cadherin-associated protein), alpha 1 
SCEL 2.06 0.0461 sciellin 
HACE1 2.05 0.0005 
HECT domain and ankyrin repeat containing 
E3 ubiquitin protein ligase 1 
HIST1H1C 2.05 0.0028 histone cluster 1, H1c 
DSG1 2.05 0.0029 desmoglein 1 
C3orf67 2.05 0.0049 chromosome 3 open reading frame 67 
SESN2 2.05 0.0203 sestrin 2 
C5orf66-AS1 2.04 0.0015 C5orf66 antisense RNA 1 
S100A14 2.04 0.0209 S100 calcium binding protein A14 
PHACTR2 2.04 0.0372 phosphatase and actin regulator 2 
RHCG 2.04 0.0442 Rh family, C glycoprotein 
RHOD 2.03 0.0064 ras homolog family member D 
SERTAD1 2.03 0.0216 SERTA domain containing 1 
PLK3 2.03 0.0280 polo-like kinase 3 
PQLC1 2.02 0.0001 PQ loop repeat containing 1 







YTHDC1 2.01 0.0035 YTH domain containing 1 
ABHD17B 2.01 0.0195 abhydrolase domain containing 17B 
HECTD2 2.00 0.0007 
HECT domain containing E3 ubiquitin protein 
ligase 2 
CRCT1 2.00 0.0064 cysteine rich C-terminal 1 
SASH1 2.00 0.0243 SAM and SH3 domain containing 1 
SPRED2 1.99 0.0040 sprouty-related, EVH1 domain containing 2 
MUC15 1.99 0.0056 mucin 15, cell surface associated 
FAM166B 1.99 0.0430 
family with sequence similarity 166, member 
B 
RAP2B 1.98 0.0062 RAP2B, member of RAS oncogene family 
SPRR3 1.98 0.0281 small proline-rich protein 3 
CNKSR1 1.97 0.0001 
connector enhancer of kinase suppressor of 
Ras 1 
STXBP5 1.97 0.0229 syntaxin binding protein 5 (tomosyn) 
UBE2S 1.96 0.0020 ubiquitin-conjugating enzyme E2S 
RPL29 1.95 0.0001 ribosomal protein L29 
ALOX12B 1.95 0.0082 arachidonate 12-lipoxygenase, 12R type 
ITPKC 1.95 0.0421 inositol-trisphosphate 3-kinase C 
TNPO1 1.94 0.0000 transportin 1 
MAP1LC3A 1.94 0.0012 
microtubule-associated protein 1 light chain 3 
alpha 
ATG9B 1.94 0.0100 autophagy related 9B 
SMN1 1.93 0.0005 survival of motor neuron 1, telomeric 
MREG 1.93 0.0144 melanoregulin 
LCE3C 1.93 0.0251 late cornified envelope 3C 
PGLS 1.92 0.0000 6-phosphogluconolactonase 
DNAJB13 1.92 0.0277 
DnaJ (Hsp40) homolog, subfamily B, member 
13 
ZC3H4 1.91 0.0000 zinc finger CCCH-type containing 4 
SOX2 1.91 0.0007 SRY box 2 
ABHD5 1.91 0.0221 abhydrolase domain containing 5 
RANBP9 1.91 0.0267 RAN binding protein 9 
TRIP10 1.91 0.0333 thyroid hormone receptor interactor 10 
DUSP14 1.91 0.0362 dual specificity phosphatase 14 
PARD6B 1.90 0.0044 par-6 family cell polarity regulator beta 
PARD3 1.89 0.0011 par-3 family cell polarity regulator 
ATP6V0C 1.88 0.0000 
ATPase, H+ transporting, lysosomal 16kDa, 







HNRNPF 1.88 0.0001 heterogeneous nuclear ribonucleoprotein F 
IL33 1.88 0.0013 interleukin 33 
NDUFA4L2 1.88 0.0169 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 4-like 2 
CRYAB 1.88 0.0273 crystallin alpha B 
AJUBA 1.87 0.0027 ajuba LIM protein 
DKK4 1.87 0.0162 dickkopf WNT signaling pathway inhibitor 4 
RPL28; MIR6805 1.86 0.0000 ribosomal protein L28; microRNA 6805 
JUP 1.86 0.0004 junction plakoglobin 
SNCG 1.86 0.0040 synuclein gamma 
C5orf15 1.85 0.0017 chromosome 5 open reading frame 15 
SH3D19 1.85 0.0086 SH3 domain containing 19 
S100B 1.85 0.0146 S100 calcium binding protein B 
PLCD3 1.85 0.0169 phospholipase C, delta 3 
TMEM159 1.85 0.0272 transmembrane protein 159 
TMEM80 1.85 0.0365 transmembrane protein 80 
EPN3 1.85 0.0425 epsin 3 
TOM1 1.84 0.0003 target of myb1 membrane trafficking protein 
BLVRB 1.84 0.0011 biliverdin reductase B 
HIST1H4F 1.84 0.0014 histone cluster 1, H4f 
KRTAP3-2 1.84 0.0082 keratin associated protein 3-2 
ERBB2IP 1.84 0.0109 erbb2 interacting protein 
MARCH1 1.83 0.0026 
Memczak2013 ANTISENSE, coding, 
INTERNAL, intronic best transcript 
NM_001166373 
CHMP4C 1.83 0.0028 charged multivesicular body protein 4C 
MDK 1.83 0.0247 midkine (neurite growth-promoting factor 2) 
H1FX 1.82 0.0000 H1 histone family, member X 
HMGN3 1.82 0.0003 
high mobility group nucleosomal binding 
domain 3 
BRI3BP 1.82 0.0004 BRI3 binding protein 
B3GNT3 1.82 0.0040 
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 3 
MGST1 1.82 0.0158 microsomal glutathione S-transferase 1 
GPX3 1.82 0.0220 glutathione peroxidase 3 
TAF10 1.81 0.0000 
TAF10 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
30kDa 







HSPB1 1.81 0.0034 heat shock 27kDa protein 1 
CBFB 1.81 0.0050 core-binding factor, beta subunit 
BNIP3 1.81 0.0051 
BCL2/adenovirus E1B 19kDa interacting 
protein 3 
WWTR1 1.81 0.0078 
WW domain containing transcription regulator 
1 
STK33 1.81 0.0105 serine/threonine kinase 33 
CKAP4 1.81 0.0167 cytoskeleton-associated protein 4 
HIST1H2AJ 1.81 0.0184 histone cluster 1, H2aj 
DSC3 1.81 0.0267 desmocollin 3 
DUSP5 1.80 0.0370 dual specificity phosphatase 5 
TMEM38B 1.79 0.0001 transmembrane protein 38B 
WSCD2 1.79 0.0001 WSC domain containing 2 
ZDHHC20 1.79 0.0021 zinc finger, DHHC-type containing 20 
TAF1B 1.79 0.0037 
TATA box binding protein (TBP)-associated 
factor, RNA polymerase I, B, 63kDa 
TCEB2 1.79 0.0042 
transcription elongation factor B (SIII), 
polypeptide 2 (18kDa, elongin B) 
GRHL3 1.79 0.0317 grainyhead-like transcription factor 3 
SEPP1 1.79 0.0384 selenoprotein P, plasma, 1 
ABHD17C 1.79 0.0454 abhydrolase domain containing 17C 
RPS19 1.78 0.0000 ribosomal protein S19 
C1GALT1 1.78 0.0008 
core 1 synthase, glycoprotein-N-
acetylgalactosamine 3-beta-
galactosyltransferase 1 
UBE2R2 1.78 0.0104 ubiquitin-conjugating enzyme E2R 2 
NCK2 1.78 0.0241 NCK adaptor protein 2 
CPA4 1.78 0.0346 carboxypeptidase A4 
ITSN1 1.77 0.0008 
Transcript Identified by AceView, Entrez 
Gene ID(s) 6453 
CBR3 1.77 0.0053 carbonyl reductase 3 
CCPG1; MIR628 1.77 0.0241 cell cycle progression 1; microRNA 628 
NDP 1.77 0.0379 Norrie disease (pseudoglioma) 
CHST9 1.77 0.0476 
carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 9 
GPSM1 1.76 0.0013 G-protein signaling modulator 1 
NTHL1 1.76 0.0021 nth-like DNA glycosylase 1 
MXD4; MIR4800 1.76 0.0021 MAX dimerization protein 4; microRNA 4800 







RBMS2 1.76 0.0063 
RNA binding motif, single stranded interacting 
protein 2 
TEX9 1.76 0.0110 testis expressed 9 
RAB21 1.76 0.0168 RAB21, member RAS oncogene family 
SEMA3C 1.76 0.0387 
sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3C 
FUT6 1.76 0.0466 
fucosyltransferase 6 (alpha (1,3) 
fucosyltransferase) 
DNTTIP1 1.75 0.0071 
deoxynucleotidyltransferase, terminal, 
interacting protein 1 
ARHGAP27 1.75 0.0131 Rho GTPase activating protein 27 
FAM198B 1.75 0.0137 
family with sequence similarity 198, member 
B 
ANKRD31 1.75 0.0254 ankyrin repeat domain 31 
TP53I11 1.75 0.0438 
Memczak2013 ALT_ACCEPTOR, 
ALT_DONOR, coding, INTERNAL, intronic 
best transcript NM_001076787 
NDUFB11 1.74 0.0007 
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 11, 17.3kDa 
UBL3 1.74 0.0073 ubiquitin-like 3 
MAFIP; 
TEKT4P2 1.74 0.0147 
MAFF interacting protein (pseudogene); tektin 
4 pseudogene 2 
PRDM4 1.74 0.0498 PR domain containing 4 
RAB25 1.73 0.0028 RAB25, member RAS oncogene family 
NDUFA2 1.73 0.0037 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 2, 8kDa 
WASF2 1.73 0.0038 WAS protein family, member 2 
BCHE 1.73 0.0061 butyrylcholinesterase 
HBP1 1.73 0.0087 HMG-box transcription factor 1 
PPA1 1.73 0.0106 pyrophosphatase (inorganic) 1 
MAL 1.73 0.0343 mal, T-cell differentiation protein 
UBE2E3 1.72 0.0003 ubiquitin-conjugating enzyme E2E 3 
PHGDH 1.72 0.0003 phosphoglycerate dehydrogenase 
IL22RA1 1.72 0.0045 interleukin 22 receptor, alpha 1 
ITSN2 1.72 0.0102 intersectin 2 
CBFA2T2 1.71 0.0009 
core-binding factor, runt domain, alpha 
subunit 2; translocated to, 2 
EIF2S3 1.71 0.0010 
eukaryotic translation initiation factor 2, 
subunit 3 gamma, 52kDa 







DAAM1 1.71 0.0021 
dishevelled associated activator of 
morphogenesis 1 
EEF1A2 1.71 0.0024 
eukaryotic translation elongation factor 1 
alpha 2 
KRT13 1.71 0.0207 keratin 13, type I 
HIST1H1B 1.71 0.0444 histone cluster 1, H1b 
RFXANK 1.70 0.0005 
regulatory factor X-associated ankyrin-
containing protein 
WWC2 1.70 0.0010 WW and C2 domain containing 2 
TP63 1.70 0.0054 tumor protein p63 
POU2F2 1.70 0.0128 POU class 2 homeobox 2 
CNKSR3 1.70 0.0157 CNKSR family member 3 
PSCA 1.70 0.0497 prostate stem cell antigen 
POLR1D 1.69 0.0025 polymerase (RNA) I polypeptide D 
TUBA4B 1.69 0.0073 tubulin, alpha 4b 
NCKAP1 1.69 0.0126 NCK-associated protein 1 
KAZN 1.69 0.0187 kazrin, periplakin interacting protein 
DENND2C 1.69 0.0267 DENN/MADD domain containing 2C 
MYEOV 1.69 0.0291 myeloma overexpressed 
RAET1E 1.68 0.0002 retinoic acid early transcript 1E 
IRAK1BP1 1.68 0.0074 
interleukin 1 receptor associated kinase 1 
binding protein 1 
HLA-B 1.68 0.0086 major histocompatibility complex, class I, B 
H1F0 1.68 0.0091 H1 histone family, member 0 
MDFIC 1.68 0.0216 MyoD family inhibitor domain containing 
LSM7 1.68 0.0218 
LSM7 homolog, U6 small nuclear RNA and 
mRNA degradation associated 
HMOX1 1.68 0.0334 heme oxygenase 1 
SMS 1.68 0.0352 spermine synthase 
AHCY 1.67 0.0005 adenosylhomocysteinase 
CBX4 1.67 0.0014 chromobox homolog 4 
PCP4 1.67 0.0035 Purkinje cell protein 4 
CSNK1E 1.67 0.0044 casein kinase 1, epsilon 
FAM184A 1.67 0.0155 
family with sequence similarity 184, member 
A 
CFAP44 1.67 0.0163 cilia and flagella associated protein 44 
MRPL40 1.67 0.0189 mitochondrial ribosomal protein L40 







DNAJB1 1.67 0.0365 
DnaJ (Hsp40) homolog, subfamily B, member 
1 
MED18 1.67 0.0402 mediator complex subunit 18 
PHACTR4 1.66 0.0080 phosphatase and actin regulator 4 
EIF4E 1.66 0.0118 eukaryotic translation initiation factor 4E 
NAP1L1 1.66 0.0118 nucleosome assembly protein 1-like 1 
FBXO34 1.66 0.0346 F-box protein 34 
THAP2 1.65 0.0000 
THAP domain containing, apoptosis 
associated protein 2 
UBE2M 1.65 0.0001 ubiquitin-conjugating enzyme E2M 
CST3 1.65 0.0002 cystatin C 
FBXO45 1.65 0.0029 F-box protein 45 
EPN1 1.65 0.0045 epsin 1 
LIPE 1.65 0.0050 lipase, hormone-sensitive 
PITX2 1.65 0.0055 paired-like homeodomain 2 
FCER1A 1.65 0.0087 
Fc fragment of IgE, high affinity I, receptor 
for; alpha polypeptide 
UBE2T 1.65 0.0093 ubiquitin conjugating enzyme E2T 
DAW1 1.65 0.0186 
dynein assembly factor with WDR repeat 
domains 1 
NCLN 1.65 0.0200 nicalin 
CHN2 1.65 0.0380 chimerin 2 
KLF8 1.65 0.0432 Kruppel-like factor 8 
BLOC1S1 1.64 0.0001 
biogenesis of lysosomal organelles complex-1, 
subunit 1 
THAP3 1.64 0.0017 
THAP domain containing, apoptosis 
associated protein 3 
SHARPIN 1.64 0.0024 SHANK-associated RH domain interactor 
PPP1R42 1.64 0.0063 protein phosphatase 1, regulatory subunit 42 
RPS15 1.64 0.0107 ribosomal protein S15 
SH3BGRL2 1.64 0.0241 
SH3 domain binding glutamate-rich protein 
like 2 
STON2 1.64 0.0289 stonin 2 
PRELID1 1.64 0.0359 PRELI domain containing 1 
H2AFJ 1.63 0.0006 H2A histone family, member J 
DEGS2 1.63 0.0031 delta(4)-desaturase, sphingolipid 2 
ASAP2 1.63 0.0067 
ArfGAP with SH3 domain, ankyrin repeat and 
PH domain 2 







EBLN1 1.63 0.0144 endogenous Bornavirus-like nucleoprotein 1 
DENND3 1.63 0.0149 
Memczak2013 ALT_ACCEPTOR, 
ALT_DONOR, coding, INTERNAL, intronic 
best transcript NM_014957 
PPP1R12A 1.63 0.0205 protein phosphatase 1, regulatory subunit 12A 
SH3BP1; PDXP 1.63 0.0220 
SH3-domain binding protein 1; pyridoxal 
(pyridoxine, vitamin B6) phosphatase 
EEPD1 1.63 0.0267 
endonuclease/exonuclease/phosphatase family 
domain containing 1 
GATS 1.63 0.0339 GATS, stromal antigen 3 opposite strand 
TMEM30A 1.63 0.0441 transmembrane protein 30A 
HIST2H2AC 1.62 0.0000 histone cluster 2, H2ac 
PDCD6IP 1.62 0.0003 programmed cell death 6 interacting protein 
ANKRD13C 1.62 0.0113 ankyrin repeat domain 13C 
CCNE1 1.62 0.0130 cyclin E1 
FAT2 1.62 0.0171 FAT atypical cadherin 2 
CAMSAP1 1.62 0.0210 
calmodulin regulated spectrin-associated 
protein 1 
BNIP3L 1.62 0.0237 
BCL2/adenovirus E1B 19kDa interacting 
protein 3-like 
SUGCT 1.61 0.0000 succinyl-CoA:glutarate-CoA transferase 
STRBP; 
MIR600HG; 
MIR600 1.61 0.0012 
spermatid perinuclear RNA binding protein; 
MIR600 host gene; microRNA 600 
SRP72 1.61 0.0047 
Memczak2013 ANTISENSE, coding, 
INTERNAL, intronic best transcript 
NM_006947 
CCDC167 1.61 0.0087 coiled-coil domain containing 167 
GFOD1 1.61 0.0115 







MIR941-5 1.61 0.0237 
DnaJ (Hsp40) homolog, subfamily C, member 
5; microRNA 941-1; microRNA 941-2; 
microRNA 941-3; microRNA 941-4; 
microRNA 941-5 
WDR26; 
MIR4742 1.61 0.0295 WD repeat domain 26; microRNA 4742 
SPANXN4 1.60 0.0002 SPANX family, member N4 







EIF4EBP1 1.60 0.0109 
eukaryotic translation initiation factor 4E 
binding protein 1 
C12orf56 1.60 0.0114 chromosome 12 open reading frame 56 
CYP1B1 1.60 0.0149 
cytochrome P450, family 1, subfamily B, 
polypeptide 1 
FSIP1 1.60 0.0166 fibrous sheath interacting protein 1 
UBA5 1.60 0.0256 ubiquitin-like modifier activating enzyme 5 
CLTB 1.60 0.0343 clathrin, light chain B 
DYNLL1 1.59 0.0001 dynein, light chain, LC8-type 1 
TIGD2 1.59 0.0006 tigger transposable element derived 2 
BAZ2B 1.59 0.0008 
bromodomain adjacent to zinc finger domain 
2B 
ND6 1.59 0.0029 NADH dehydrogenase, subunit 6 (complex I) 
GTF3C3 1.59 0.0065 general transcription factor IIIC subunit 3 
CMBL 1.59 0.0122 
carboxymethylenebutenolidase homolog 
(Pseudomonas) 
ARF6 1.59 0.0174 ADP-ribosylation factor 6 
CTNNBIP1 1.59 0.0176 catenin, beta interacting protein 1 
ALKBH7 1.59 0.0227 alkB homolog 7 
CNN3 1.59 0.0485 calponin 3, acidic 





MIR6820 1.58 0.0005 
polymerase (RNA) II (DNA directed) 
polypeptide F; microRNA 4534; microRNA 
6820 
CSTB 1.58 0.0032 cystatin B (stefin B) 
SYT17 1.58 0.0034 synaptotagmin XVII 
POLR2J3 1.58 0.0049 
polymerase (RNA) II (DNA directed) 
polypeptide J3 
KLF3 1.58 0.0067 Kruppel-like factor 3 (basic) 
PTPRZ1 1.58 0.0087 
protein tyrosine phosphatase, receptor-type, Z 
polypeptide 1 
TMIE 1.58 0.0173 transmembrane inner ear 
DDX5 1.58 0.0205 
Memczak2013 ANTISENSE, CDS, coding, 
INTERNAL best transcript NM_004396 
OVOL1 1.58 0.0217 ovo-like zinc finger 1 
OSBPL1A 1.57 0.0004 oxysterol binding protein-like 1A 
SIGLEC15 1.57 0.0007 sialic acid binding Ig-like lectin 15 
JUND 1.57 0.0008 jun D proto-oncogene 







SAMD4A 1.57 0.0074 sterile alpha motif domain containing 4A 
NBL1 1.57 0.0197 neuroblastoma 1, DAN family BMP antagonist 
MFSD12 1.57 0.0379 
major facilitator superfamily domain 
containing 12 
RNF169 1.57 0.0445 ring finger protein 169 
CSN1S1 1.57 0.0461 casein alpha s1 
BARX2 1.56 0.0004 BARX homeobox 2 
PCDHB11 1.56 0.0011 protocadherin beta 11 
HIST1H2AE 1.56 0.0013 histone cluster 1, H2ae 
HIST2H2AB 1.56 0.0018 histone cluster 2, H2ab 
SMAGP 1.56 0.0041 small cell adhesion glycoprotein 
FILIP1 1.56 0.0061 filamin A interacting protein 1 
SCGB1D4 1.56 0.0094 secretoglobin, family 1D, member 4 
HAPLN1 1.56 0.0109 hyaluronan and proteoglycan link protein 1 
BOK 1.56 0.0124 BCL2-related ovarian killer 
MAST4 1.56 0.0133 
microtubule associated serine/threonine kinase 
family member 4 
APOC2 1.56 0.0138 apolipoprotein C-II 
MAB21L3 1.56 0.0434 mab-21-like 3 (C. elegans) 
FAM120AOS 1.55 0.0000 
family with sequence similarity 120A opposite 
strand 
XPO7 1.55 0.0005 exportin 7 
TMEM134 1.55 0.0024 transmembrane protein 134 
RBPMS 1.55 0.0026 RNA binding protein with multiple splicing 
HIST1H2BF 1.55 0.0031 histone cluster 1, H2bf 
SLPI 1.55 0.0041 secretory leukocyte peptidase inhibitor 
DLX2 1.55 0.0063 distal-less homeobox 2 
FAM208A 1.55 0.0085 
family with sequence similarity 208, member 
A 
CXXC4 1.55 0.0091 CXXC finger protein 4 
HIST1H4D 1.55 0.0096 histone cluster 1, H4d 
TBC1D9 1.55 0.0109 
TBC1 domain family, member 9 (with GRAM 
domain) 
BLOC1S3 1.55 0.0120 
biogenesis of lysosomal organelles complex-1, 
subunit 3 
PTN 1.55 0.0139 pleiotrophin 
TEKT4P2 1.55 0.0196 tektin 4 pseudogene 2 
CIART 1.55 0.0254 circadian associated repressor of transcription 







CCDC172 1.55 0.0408 coiled-coil domain containing 172 
NRTN 1.54 0.0002 neurturin 
SOX7 1.54 0.0004 SRY box 7 
STARD5 1.54 0.0006 
StAR-related lipid transfer domain containing 
5 
ACVR1 1.54 0.0007 activin A receptor type I 
LY6G5B; 
CSNK2B 1.54 0.0007 
lymphocyte antigen 6 complex, locus G5B; 
casein kinase 2, beta polypeptide 
ADK; 
MRPL35P3 1.54 0.0020 
adenosine kinase; mitochondrial ribosomal 
protein L35 pseudogene 3 
STX17 1.54 0.0021 syntaxin 17 
CST7 1.54 0.0041 cystatin F (leukocystatin) 
PPP2R2A 1.54 0.0052 
protein phosphatase 2, regulatory subunit B, 
alpha 
SUZ12 1.54 0.0071 
SUZ12 polycomb repressive complex 2 
subunit 
CDC42EP1 1.54 0.0104 
CDC42 effector protein (Rho GTPase binding) 
1 
PCSK5 1.54 0.0137 proprotein convertase subtilisin/kexin type 5 
ARL6 1.54 0.0142 ADP-ribosylation factor like GTPase 6 
AKAP14 1.54 0.0235 A kinase (PRKA) anchor protein 14 
CCDC96 1.54 0.0249 coiled-coil domain containing 96 
PDIK1L 1.54 0.0438 PDLIM1 interacting kinase 1 like 
HMCN1 1.54 0.0459 hemicentin 1 
C7orf73 1.53 0.0004 chromosome 7 open reading frame 73 
HSBP1L1 1.53 0.0011 heat shock factor binding protein 1-like 1 
GSX1 1.53 0.0028 GS homeobox 1 
CYSRT1 1.53 0.0050 cysteine-rich tail protein 1 
E2F7 1.53 0.0064 E2F transcription factor 7 
MYO1B 1.53 0.0077 myosin IB 
DHX32 1.53 0.0077 DEAH (Asp-Glu-Ala-His) box polypeptide 32 
RAET1G 1.53 0.0112 retinoic acid early transcript 1G 
ME1 1.53 0.0164 
malic enzyme 1, NADP(+)-dependent, 
cytosolic 
ESYT3 1.53 0.0197 extended synaptotagmin-like protein 3 
UBE2C 1.53 0.0219 ubiquitin-conjugating enzyme E2C 
PLS3 1.53 0.0400 plastin 3 
RGS17 1.53 0.0406 regulator of G-protein signaling 17 







MTRNR2L13 1.52 0.0008 MT-RNR2-like 13 
SVIP 1.52 0.0011 small VCP/p97-interacting protein 
YAF2 1.52 0.0020 YY1 associated factor 2 
SLC22A25 1.52 0.0036 solute carrier family 22, member 25 
DNAJC27 1.52 0.0044 
DnaJ (Hsp40) homolog, subfamily C, member 
27 
SPRED1 1.52 0.0127 sprouty-related, EVH1 domain containing 1 
ADCY9 1.52 0.0150 adenylate cyclase 9 
OR8B8 1.52 0.0155 
olfactory receptor, family 8, subfamily B, 
member 8 
SLCO4A1-AS1 1.52 0.0169 SLCO4A1 antisense RNA 1 
PKP4 1.52 0.0283 
Transcript Identified by AceView, Entrez 
Gene ID(s) 8502 
SOX4 1.52 0.0334 SRY box 4 
MYO5C 1.52 0.0448 myosin VC 
RAB9A 1.52 0.0467 RAB9A, member RAS oncogene family 
LRP6 1.52 0.0495 LDL receptor related protein 6 
NELL1 1.51 0.0012 neural EGFL like 1 
SGCA 1.51 0.0013 sarcoglycan alpha 
CPSF3L; 
MIR6727 1.51 0.0021 
cleavage and polyadenylation specific factor 
3-like; microRNA 6727 
CD99 1.51 0.0026 CD99 molecule 
KCNJ3 1.51 0.0034 
potassium channel, inwardly rectifying 
subfamily J, member 3 
FNBP1L 1.51 0.0055 formin binding protein 1-like 
DBP 1.51 0.0057 
D site of albumin promoter (albumin D-box) 
binding protein 
CALR3 1.51 0.0064 calreticulin 3 
CCNI 1.51 0.0066 cyclin I 
MAFB 1.51 0.0076 
v-maf avian musculoaponeurotic fibrosarcoma 
oncogene homolog B 
USP25 1.51 0.0086 ubiquitin specific peptidase 25 
OR52E4 1.51 0.0109 
olfactory receptor, family 52, subfamily E, 
member 4 
LIN9 1.51 0.0112 
lin-9 DREAM MuvB core complex 
component 
SLF1 1.51 0.0138 SMC5-SMC6 complex localization factor 1 
KRTAP1-1 1.51 0.0168 keratin associated protein 1-1 
SNX24 1.51 0.0178 sorting nexin 24 







FAM92B 1.51 0.0324 family with sequence similarity 92, member B 
TRIM64C 1.50 0.0008 tripartite motif containing 64C 
MIEN1 1.50 0.0008 migration and invasion enhancer 1 
SLCO2A1 1.50 0.0111 
solute carrier organic anion transporter family, 
member 2A1 
MRLN 1.50 0.0123 myoregulin 
DAPL1; 
OR7E89P 1.50 0.0213 
death associated protein like 1; olfactory 
receptor, family 7, subfamily E, member 89 
pseudogene 
UACA 1.50 0.0295 
uveal autoantigen with coiled-coil domains 
and ankyrin repeats 
FMNL3 1.50 0.0308 formin like 3 
ANKRD36 1.50 0.0338 
Transcript Identified by AceView, Entrez 
Gene ID(s) 375248 
MEGF11 -1.50 0.0023 multiple EGF-like-domains 11 
MOV10 -1.50 0.0026 Mov10 RISC complex RNA helicase 
MTMR14 -1.50 0.0041 myotubularin related protein 14 
RNF38 -1.50 0.0062 ring finger protein 38 
CECR1 -1.50 0.0065 
cat eye syndrome chromosome region, 
candidate 1 
SAR1B -1.50 0.0088 secretion associated, Ras related GTPase 1B 
VTA1 -1.50 0.0090 vesicle (multivesicular body) trafficking 1 
TRMT44 -1.50 0.0165 
tRNA methyltransferase 44 homolog (S. 
cerevisiae) 
MANSC1 -1.50 0.0198 MANSC domain containing 1 
PPP2R5C -1.51 0.0000 
protein phosphatase 2, regulatory subunit B, 
gamma 
MOB4 -1.51 0.0002 MOB family member 4, phocein 
MYL12A -1.51 0.0005 myosin light chain 12A 
PACSIN2 -1.51 0.0013 
protein kinase C and casein kinase substrate in 
neurons 2 
C5orf51 -1.51 0.0023 chromosome 5 open reading frame 51 
MESDC2 -1.51 0.0036 mesoderm development candidate 2 
DHX57 -1.51 0.0036 
DEAH (Asp-Glu-Ala-Asp/His) box 
polypeptide 57 
DNAJC7 -1.51 0.0046 
DnaJ (Hsp40) homolog, subfamily C, member 
7 
RAB3D -1.51 0.0048 RAB3D, member RAS oncogene family 







VCPKMT -1.51 0.0069 
valosin containing protein lysine (K) 
methyltransferase 
HSPA13 -1.51 0.0073 heat shock protein 70kDa family, member 13 
L3MBTL2 -1.51 0.0076 l(3)mbt-like 2 (Drosophila) 
FCHSD2 -1.51 0.0080 FCH and double SH3 domains 2 
BRPF3 -1.51 0.0103 bromodomain and PHD finger containing 3 
LAMB3; 




228J13.1 -1.51 0.0127 
Homo sapiens TMLHE antisense RNA 1 
(TMLHE-AS1), long non-coding RNA.; 
uncharacterized LOC101927830; Transcript 
Identified by AceView, Entrez Gene ID(s) 
1193; novel transcript 
TBC1D7 -1.51 0.0129 TBC1 domain family, member 7 
JOSD1 -1.51 0.0155 Josephin domain containing 1 
THAP9-AS1 -1.51 0.0270 THAP9 antisense RNA 1 
NEDD9 -1.51 0.0274 
neural precursor cell expressed, 
developmentally down-regulated 9 
SNX12 -1.51 0.0304 sorting nexin 12 
ARL5B -1.51 0.0346 ADP-ribosylation factor like GTPase 5B 
SH3BGRL -1.52 0.0000 
SH3 domain binding glutamate-rich protein 
like 
SLC4A1AP -1.52 0.0004 
solute carrier family 4 (anion exchanger), 
member 1, adaptor protein 
PDE8A -1.52 0.0005 phosphodiesterase 8A 
PRMT7 -1.52 0.0098 protein arginine methyltransferase 7 
MSN -1.52 0.0109 moesin 
GSDMD -1.52 0.0144 gasdermin D 
SYNCRIP -1.52 0.0158 
synaptotagmin binding, cytoplasmic RNA 
interacting protein 
ZUFSP -1.52 0.0161 
zinc finger with UFM1-specific peptidase 
domain 
NPIPB11 -1.52 0.0198 
nuclear pore complex interacting protein 
family, member B11 
HDAC6 -1.52 0.0204 histone deacetylase 6 
KIAA1586 -1.52 0.0219 KIAA1586 
POGZ -1.52 0.0235 pogo transposable element with ZNF domain 
VKORC1L1 -1.52 0.0251 
vitamin K epoxide reductase complex subunit 
1 like 1 
TNFAIP1 -1.52 0.0267 








KLRC1 -1.52 0.0413 
killer cell lectin-like receptor subfamily C, 
member 1 
LINC01189 -1.52 0.0434 long intergenic non-protein coding RNA 1189 
AKAP8 -1.53 0.0002 A kinase (PRKA) anchor protein 8 
SATB1 -1.53 0.0006 SATB homeobox 1 
SYNJ1 -1.53 0.0012 synaptojanin 1 
OLFM2 -1.53 0.0014 olfactomedin 2 
CALM2 -1.53 0.0016 calmodulin 2 (phosphorylase kinase, delta) 
LTA4H -1.53 0.0028 leukotriene A4 hydrolase 
BANP -1.53 0.0053 BTG3 associated nuclear protein 
GNAI3 -1.53 0.0055 
guanine nucleotide binding protein (G 
protein), alpha inhibiting activity polypeptide 
3 
TXLNG -1.53 0.0121 taxilin gamma 
SRP54 -1.53 0.0123 signal recognition particle 54kDa 
ZNF75D -1.53 0.0125 zinc finger protein 75D 
CD2 -1.53 0.0198 CD2 molecule 
TMEM184C -1.53 0.0293 transmembrane protein 184C 
CHD9 -1.53 0.0308 
chromodomain helicase DNA binding protein 
9 
ACADVL -1.53 0.0422 acyl-CoA dehydrogenase, very long chain 
FAM179B -1.53 0.0467 
family with sequence similarity 179, member 
B 
ABL1 -1.53 0.0472 
ABL proto-oncogene 1, non-receptor tyrosine 
kinase 
ZNF280B -1.53 0.0494 zinc finger protein 280B 
MIER1 -1.54 0.0000 
mesoderm induction early response 1, 
transcriptional regulator 
INTS4 -1.54 0.0001 integrator complex subunit 4 
UBA3 -1.54 0.0002 ubiquitin-like modifier activating enzyme 3 
RAB1A -1.54 0.0002 RAB1A, member RAS oncogene family 
TXNDC12; 
KTI12 -1.54 0.0003 
thioredoxin domain containing 12 
(endoplasmic reticulum); KTI12 chromatin 
associated homolog 
KIAA1429 -1.54 0.0004 KIAA1429 
SARAF -1.54 0.0004 
store-operated calcium entry-associated 
regulatory factor 
ADNP -1.54 0.0016 activity-dependent neuroprotector homeobox 
UBE2J2 -1.54 0.0016 
Transcript Identified by AceView, Entrez 







WDR47 -1.54 0.0016 WD repeat domain 47 
DHRS13 -1.54 0.0029 
dehydrogenase/reductase (SDR family) 
member 13 
PVRIG -1.54 0.0035 
poliovirus receptor related immunoglobulin 
domain containing 
POLR3B -1.54 0.0038 
polymerase (RNA) III (DNA directed) 
polypeptide B 




C7orf55 -1.54 0.0053 
C7orf55-LUC7L2 readthrough; LUC7-like 2 
pre-mRNA splicing factor; chromosome 7 
open reading frame 55 
WBSCR22 -1.54 0.0057 
Williams Beuren syndrome chromosome 
region 22 
TBCK -1.54 0.0070 TBC1 domain containing kinase 
NOP14 -1.54 0.0073 NOP14 nucleolar protein 
SPRY3 -1.54 0.0084 sprouty RTK signaling antagonist 3 
SPRY3 -1.54 0.0084 
Homo sapiens sprouty RTK signaling 
antagonist 3 (SPRY3), transcript variant 1, 
mRNA.; sprouty homolog 3 (Drosophila) 
[Source:HGNC Symbol;Acc:HGNC:11271]; 
Homo sapiens sprouty homolog 3 
(Drosophila), mRNA (cDNA clone 
MGC:97072 IMAGE:7262284), complete 
cds.; Homo sapiens sprouty homolog 3 
(Drosophila), mRNA (cDNA clone 
MGC:103904 IMAGE:30915293), complete 
cds.; Homo sapiens sprouty homolog 3 
(Drosophila), mRNA (cDNA clone 
MGC:104063 IMAGE:30915511), complete 
cds. 
SLC25A43 -1.54 0.0105 solute carrier family 25, member 43 
WDR92 -1.54 0.0134 WD repeat domain 92 
HECTD4; 
MIR6861 -1.54 0.0159 
HECT domain containing E3 ubiquitin protein 
ligase 4; microRNA 6861 
GATC -1.54 0.0271 
glutamyl-tRNA(Gln) amidotransferase, 
subunit C 
PSMA3 -1.54 0.0275 proteasome subunit alpha 3 
ICK -1.54 0.0297 intestinal cell (MAK-like) kinase 
ERAP2 -1.54 0.0334 endoplasmic reticulum aminopeptidase 2 









GPRC5B -1.54 0.0377 
G protein-coupled receptor, class C, group 5, 
member B 
DHDDS -1.54 0.0397 dehydrodolichyl diphosphate synthase subunit 
NEO1 -1.54 0.0413 neogenin 1 
CACYBP -1.54 0.0496 calcyclin binding protein 
ATG13 -1.55 0.0000 autophagy related 13 
ZNF207; MIR632 -1.55 0.0001 zinc finger protein 207; microRNA 632 
PSME3 -1.55 0.0001 proteasome activator subunit 3 
ZNF891 -1.55 0.0009 zinc finger protein 891 
ARIH1; MIR630 -1.55 0.0009 
ariadne RBR E3 ubiquitin protein ligase 1; 
microRNA 630 
GDAP2 -1.55 0.0015 
ganglioside induced differentiation associated 
protein 2 
EDRF1 -1.55 0.0018 erythroid differentiation regulatory factor 1 
RRM2B -1.55 0.0020 
ribonucleotide reductase M2 B (TP53 
inducible) 
C2CD3 -1.55 0.0025 C2 calcium-dependent domain containing 3 
PAPD7 -1.55 0.0027 PAP associated domain containing 7 
SLC35B3 -1.55 0.0035 
solute carrier family 35 (adenosine 3-phospho 
5-phosphosulfate transporter), member B3 
SURF4 -1.55 0.0036 surfeit 4 
USPL1 -1.55 0.0037 ubiquitin specific peptidase like 1 
THAP5 -1.55 0.0042 THAP domain containing 5 
EXT1 -1.55 0.0045 exostosin glycosyltransferase 1 
TCF20 -1.55 0.0059 transcription factor 20 (AR1) 
TCF20 -1.55 0.0059 transcription factor 20 (AR1) 
SAFB2 -1.55 0.0064 scaffold attachment factor B2 
FAF2 -1.55 0.0075 Fas associated factor family member 2 
NUFIP2 -1.55 0.0100 
nuclear fragile X mental retardation protein 
interacting protein 2 
ABL2 -1.55 0.0140 
ABL proto-oncogene 2, non-receptor tyrosine 
kinase 
STAG3L1 -1.55 0.0144 stromal antigen 3-like 1 (pseudogene) 
ANGEL2 -1.55 0.0160 angel homolog 2 (Drosophila) 
SPTY2D1 -1.55 0.0170 SPT2 chromatin protein domain containing 1 
SLC9A8 -1.55 0.0172 
solute carrier family 9, subfamily A (NHE8, 
cation proton antiporter 8), member 8 
NR2C2 -1.55 0.0232 
Transcript Identified by AceView, Entrez 
Gene ID(s) 7182 







TRA2B -1.55 0.0420 transformer 2 beta homolog (Drosophila) 
RC3H2 -1.56 0.0011 ring finger and CCCH-type domains 2 
ISY1 -1.56 0.0011 ISY1 splicing factor homolog 
RBSN -1.56 0.0014 rabenosyn, RAB effector 
ZMPSTE24 -1.56 0.0017 zinc metallopeptidase STE24 
RAB6A -1.56 0.0021 RAB6A, member RAS oncogene family 
MFSD9 -1.56 0.0032 
major facilitator superfamily domain 
containing 9 
NPIPB4 -1.56 0.0047 
nuclear pore complex interacting protein 
family, member B4 
NOTCH2 -1.56 0.0049 notch 2 
ABHD2 -1.56 0.0058 abhydrolase domain containing 2 
SLFN11 -1.56 0.0140 schlafen family member 11 
TXNIP -1.56 0.0164 thioredoxin interacting protein 
EXOSC3 -1.56 0.0185 exosome component 3 
SLC3A2 -1.56 0.0200 
solute carrier family 3 (amino acid transporter 
heavy chain), member 2 
HTT -1.56 0.0208 huntingtin 
ZSWIM1 -1.56 0.0286 zinc finger, SWIM-type containing 1 




CYCS -1.56 0.0322 cytochrome c, somatic 
VTI1B -1.56 0.0323 
vesicle transport through interaction with t-
SNAREs 1B 
C9orf64 -1.56 0.0362 chromosome 9 open reading frame 64 
BOLA3 -1.56 0.0403 bolA family member 3 
ZNF148 -1.57 0.0002 zinc finger protein 148 
PIK3C3 -1.57 0.0009 
phosphatidylinositol 3-kinase, catalytic subunit 
type 3 
NFYC -1.57 0.0030 nuclear transcription factor Y subunit gamma 
FOXP1 -1.57 0.0043 forkhead box P1 
DEDD -1.57 0.0059 death effector domain containing 
CHCHD7 -1.57 0.0070 
coiled-coil-helix-coiled-coil-helix domain 
containing 7 
TRMT1L -1.57 0.0081 tRNA methyltransferase 1 like 
PSMD12 -1.57 0.0084 proteasome 26S subunit, non-ATPase 12 
MDM4 -1.57 0.0084 MDM4, p53 regulator 









FOXO1 -1.57 0.0120 
Memczak2013 ALT_ACCEPTOR, 
ALT_DONOR, coding, INTERNAL, intronic 
best transcript NM_002015 
NPIPB3 -1.57 0.0123 
nuclear pore complex interacting protein 
family, member B3 
SETD5 -1.57 0.0202 SET domain containing 5 
ENTPD7 -1.57 0.0244 
ectonucleoside triphosphate 
diphosphohydrolase 7 
TMEM120B -1.57 0.0278 transmembrane protein 120B 
NOP58 -1.57 0.0278 NOP58 ribonucleoprotein 
INTS9 -1.57 0.0317 integrator complex subunit 9 
GPR107 -1.57 0.0455 G protein-coupled receptor 107 
NSFL1C -1.58 0.0001 NSFL1 (p97) cofactor (p47) 
SERINC3 -1.58 0.0002 serine incorporator 3 
TRAFD1 -1.58 0.0003 TRAF-type zinc finger domain containing 1 
RCHY1 -1.58 0.0007 
ring finger and CHY zinc finger domain 
containing 1, E3 ubiquitin protein ligase 
NDST2 -1.58 0.0007 
N-deacetylase/N-sulfotransferase (heparan 
glucosaminyl) 2 
EMC7 -1.58 0.0007 ER membrane protein complex subunit 7 
ATG4B -1.58 0.0017 autophagy related 4B, cysteine peptidase 
SETDB1 -1.58 0.0028 SET domain, bifurcated 1 
DERL1 -1.58 0.0031 derlin 1 
OGT -1.58 0.0039 
O-linked N-acetylglucosamine (GlcNAc) 
transferase 
TCF20 -1.58 0.0060 transcription factor 20 (AR1) 
TCF20 -1.58 0.0060 transcription factor 20 (AR1) 
ASB7 -1.58 0.0071 ankyrin repeat and SOCS box containing 7 
SLC11A2 -1.58 0.0091 
solute carrier family 11 (proton-coupled 
divalent metal ion transporter), member 2 
MAN2A1 -1.58 0.0108 mannosidase, alpha, class 2A, member 1 
MLF2 -1.58 0.0135 myeloid leukemia factor 2 
CBL -1.58 0.0153 
Cbl proto-oncogene, E3 ubiquitin protein 
ligase 
EP400; 
SNORA49 -1.58 0.0165 
E1A binding protein p400; small nucleolar 
RNA, H/ACA box 49 
SURF4 -1.58 0.0261 surfeit 4 
LDLR; MIR6886 -1.58 0.0289 








SLC25A5 -1.58 0.0299 
solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 5 
TMEM176B -1.58 0.0301 transmembrane protein 176B 
ICA1 -1.58 0.0338 islet cell autoantigen 1 
SURF4 -1.58 0.0387 surfeit 4 
XPNPEP1 -1.58 0.0393 
X-prolyl aminopeptidase (aminopeptidase P) 
1, soluble 
CD38 -1.58 0.0469 CD38 molecule 
IQGAP2 -1.58 0.0486 
IQ motif containing GTPase activating protein 
2 
SYNRG -1.59 0.0000 synergin, gamma 
FAM172A; 
POU5F2; 
MIR2277 -1.59 0.0001 
family with sequence similarity 172, member 
A; POU domain class 5, transcription factor 2; 
microRNA 2277 
BRD2 -1.59 0.0001 bromodomain containing 2 
DDX46 -1.59 0.0001 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 
ATG16L1 -1.59 0.0005 autophagy related 16-like 1 
IRAK4 -1.59 0.0005 interleukin 1 receptor associated kinase 4 
CALM1 -1.59 0.0008 calmodulin 1 (phosphorylase kinase, delta) 
WDR55 -1.59 0.0015 WD repeat domain 55 
USP37 -1.59 0.0015 ubiquitin specific peptidase 37 
CYB5B -1.59 0.0032 
cytochrome b5 type B (outer mitochondrial 
membrane) 
RBL2 -1.59 0.0035 retinoblastoma-like 2 
MED8 -1.59 0.0038 mediator complex subunit 8 
KAT6B -1.59 0.0046 K(lysine) acetyltransferase 6B 
DSN1 -1.59 0.0063 
DSN1 homolog, MIS12 kinetochore complex 
component 
GRINA -1.59 0.0104 
glutamate receptor, ionotropic, N-methyl D-
aspartate-associated protein 1 (glutamate 
binding) 
VMO1 -1.59 0.0105 
vitelline membrane outer layer 1 homolog 
(chicken) 
SKP1 -1.59 0.0109 S-phase kinase-associated protein 1 
CDK19 -1.59 0.0163 cyclin-dependent kinase 19 
PPP3CB -1.59 0.0334 
protein phosphatase 3, catalytic subunit, beta 
isozyme 
CA12 -1.59 0.0341 carbonic anhydrase XII 
HSPE1-MOB4 -1.60 0.0003 HSPE1-MOB4 readthrough 







NFX1 -1.60 0.0015 nuclear transcription factor, X-box binding 1 
CHD8 -1.60 0.0017 
chromodomain helicase DNA binding protein 
8 
SPIDR -1.60 0.0030 scaffolding protein involved in DNA repair 
SDCBP -1.60 0.0031 syndecan binding protein 
SLC37A1 -1.60 0.0041 
solute carrier family 37 (glucose-6-phosphate 
transporter), member 1 
CEP104 -1.60 0.0044 centrosomal protein 104kDa 
SMYD4 -1.60 0.0047 SET and MYND domain containing 4 
ACLY -1.60 0.0063 ATP citrate lyase 
METTL2B -1.60 0.0071 methyltransferase like 2B 
TMED2 -1.60 0.0123 transmembrane p24 trafficking protein 2 
EPB41L4A -1.60 0.0135 
erythrocyte membrane protein band 4.1 like 
4A 
GGPS1 -1.60 0.0204 geranylgeranyl diphosphate synthase 1 
LRRC37B -1.60 0.0214 leucine rich repeat containing 37B 
ETV6 -1.60 0.0217 ets variant 6 
VPS18 -1.60 0.0231 VPS18 CORVET/HOPS core subunit 
SLC41A1 -1.60 0.0252 
solute carrier family 41 (magnesium 
transporter), member 1 
NUDCD1 -1.60 0.0256 NudC domain containing 1 
MTR -1.60 0.0285 
5-methyltetrahydrofolate-homocysteine 
methyltransferase 
AGAP4 -1.60 0.0288 
ArfGAP with GTPase domain, ankyrin repeat 
and PH domain 4 
UCP2 -1.60 0.0303 
uncoupling protein 2 (mitochondrial, proton 
carrier) 
SLC22A23 -1.60 0.0341 solute carrier family 22, member 23 
CD36 -1.60 0.0362 CD36 molecule (thrombospondin receptor) 
PHLPP2 -1.60 0.0466 
PH domain and leucine rich repeat protein 
phosphatase 2 
MTMR2 -1.60 0.0471 myotubularin related protein 2 
HHAT -1.60 0.0480 hedgehog acyltransferase 
LRRC8B -1.61 0.0002 
leucine rich repeat containing 8 family, 
member B 
ATE1 -1.61 0.0006 arginyltransferase 1 
DEF8 -1.61 0.0010 
differentially expressed in FDCP 8 homolog 
(mouse) 
TMED8 -1.61 0.0012 








RAB2A -1.61 0.0024 RAB2A, member RAS oncogene family 
FAM134A -1.61 0.0025 
family with sequence similarity 134, member 
A 
UTP23 -1.61 0.0036 
UTP23, small subunit (SSU) processome 
component, homolog (yeast) 
NECAP1 -1.61 0.0054 NECAP endocytosis associated 1 
CARD11 -1.61 0.0069 
caspase recruitment domain family, member 
11 
AP3M2 -1.61 0.0070 
adaptor-related protein complex 3, mu 2 
subunit 
FAM173B -1.61 0.0070 
Transcript Identified by AceView, Entrez 
Gene ID(s) 134145 
AVEN -1.61 0.0088 apoptosis, caspase activation inhibitor 
TMEM181 -1.61 0.0099 transmembrane protein 181 
UBR3 -1.61 0.0127 
ubiquitin protein ligase E3 component n-
recognin 3 (putative) 
STAG3L3; 
STAG3L2 -1.61 0.0127 
stromal antigen 3-like 3 (pseudogene); stromal 
antigen 3-like 2 (pseudogene) 
CHEK2 -1.61 0.0190 checkpoint kinase 2 
AGAP6 -1.61 0.0271 
ArfGAP with GTPase domain, ankyrin repeat 
and PH domain 6 
MIS12 -1.61 0.0279 MIS12 kinetochore complex component 
EMD -1.61 0.0316 emerin 
HLA-DMA -1.61 0.0373 
major histocompatibility complex, class II, 
DM alpha 
STAM -1.62 0.0001 
signal transducing adaptor molecule (SH3 
domain and ITAM motif) 1 
HSP90B1 -1.62 0.0006 
Transcript Identified by AceView, Entrez 
Gene ID(s) 7184 
PIP5K1A -1.62 0.0013 
phosphatidylinositol-4-phosphate 5-kinase, 
type I, alpha 
GPR137 -1.62 0.0027 G protein-coupled receptor 137 
RNASET2 -1.62 0.0036 ribonuclease T2 
MYO10 -1.62 0.0042 myosin X 
PRKAG2 -1.62 0.0044 
protein kinase, AMP-activated, gamma 2 non-
catalytic subunit 
NLK -1.62 0.0078 nemo-like kinase 
LONRF3 -1.62 0.0084 
LON peptidase N-terminal domain and ring 
finger 3 
ZNF175 -1.62 0.0084 zinc finger protein 175 







ANTXR2 -1.62 0.0116 anthrax toxin receptor 2 
LIN7C -1.62 0.0147 lin-7 homolog C (C. elegans) 
ZBTB24 -1.62 0.0196 zinc finger and BTB domain containing 24 
ZMYM4 -1.62 0.0229 zinc finger, MYM-type 4 
WDR45B -1.62 0.0256 WD repeat domain 45B 
CNOT10 -1.62 0.0275 CCR4-NOT transcription complex subunit 10 
ZNF3 -1.62 0.0343 zinc finger protein 3 
KDM3B -1.63 0.0000 lysine (K)-specific demethylase 3B 
LRCH3 -1.63 0.0017 
leucine-rich repeats and calponin homology 
(CH) domain containing 3 
TMEM59 -1.63 0.0044 transmembrane protein 59 
ZFP64 -1.63 0.0088 ZFP64 zinc finger protein 
CPD -1.63 0.0118 carboxypeptidase D 
ZNF451 -1.63 0.0145 zinc finger protein 451 
MPHOSPH8 -1.63 0.0149 M-phase phosphoprotein 8 
PTGFRN -1.63 0.0191 prostaglandin F2 receptor inhibitor 
EVA1C -1.63 0.0199 eva-1 homolog C (C. elegans) 
PIH1D1 -1.63 0.0208 PIH1 domain containing 1 
KRT8 -1.63 0.0280 keratin 8, type II 
SLC45A3 -1.63 0.0385 solute carrier family 45, member 3 
ENTPD4; 
LOXL2 -1.64 0.0001 
ectonucleoside triphosphate 
diphosphohydrolase 4; lysyl oxidase-like 2 
ARFIP1 -1.64 0.0001 ADP-ribosylation factor interacting protein 1 
MED17 -1.64 0.0011 mediator complex subunit 17 
GPN2 -1.64 0.0034 GPN-loop GTPase 2 
PTP4A1 -1.64 0.0045 
protein tyrosine phosphatase type IVA, 
member 1 
CRLF3 -1.64 0.0076 cytokine receptor-like factor 3 
FBXO25 -1.64 0.0093 F-box protein 25 
SNRPE -1.64 0.0150 small nuclear ribonucleoprotein polypeptide E 
EFCAB2 -1.64 0.0152 EF-hand calcium binding domain 2 
SEC23IP -1.64 0.0157 SEC23 interacting protein 
STIP1 -1.64 0.0243 stress-induced phosphoprotein 1 
MFN2 -1.64 0.0263 mitofusin 2 
PIGU -1.64 0.0271 
phosphatidylinositol glycan anchor 
biosynthesis class U 
KL -1.64 0.0314 klotho 







FAM73A -1.64 0.0352 family with sequence similarity 73, member A 
HEATR5A -1.64 0.0353 HEAT repeat containing 5A 
ZFAND4 -1.64 0.0362 zinc finger, AN1-type domain 4 
TTN -1.64 0.0454 titin 
KIAA2026 -1.65 0.0001 KIAA2026 
GTF2H1 -1.65 0.0003 general transcription factor IIH subunit 1 
SLC38A10 -1.65 0.0003 solute carrier family 38, member 10 
KAT6A -1.65 0.0007 K(lysine) acetyltransferase 6A 
SURF4 -1.65 0.0008 surfeit 4 
IP6K1 -1.65 0.0031 inositol hexakisphosphate kinase 1 
PARL -1.65 0.0051 presenilin associated, rhomboid-like 
DIABLO -1.65 0.0069 diablo, IAP-binding mitochondrial protein 
RRBP1 -1.65 0.0232 ribosome binding protein 1 
SURF4 -1.65 0.0396 surfeit 4 
VPS45 -1.65 0.0407 
vacuolar protein sorting 45 homolog (S. 
cerevisiae) 
HPS4 -1.65 0.0461 Hermansky-Pudlak syndrome 4 
ATG101 -1.66 0.0001 autophagy related 101 
MAPK1IP1L -1.66 0.0002 
mitogen-activated protein kinase 1 interacting 
protein 1-like 
RNF145 -1.66 0.0004 ring finger protein 145 
MED1 -1.66 0.0005 mediator complex subunit 1 
PDE4D -1.66 0.0007 phosphodiesterase 4D, cAMP-specific 
GDPGP1 -1.66 0.0011 GDP-D-glucose phosphorylase 1 
ANKRD52 -1.66 0.0021 ankyrin repeat domain 52 
PDCL -1.66 0.0046 phosducin like 
ZNF35 -1.66 0.0048 zinc finger protein 35 
VPS33A -1.66 0.0052 
vacuolar protein sorting 33 homolog A (S. 
cerevisiae) 
ATXN2 -1.66 0.0060 ataxin 2 
TMEM164 -1.66 0.0076 transmembrane protein 164 
PGPEP1 -1.66 0.0151 pyroglutamyl-peptidase I 
GPR132 -1.66 0.0278 G protein-coupled receptor 132 
BCAT1 -1.66 0.0297 
branched chain amino-acid transaminase 1, 
cytosolic 
MAP3K13 -1.66 0.0324 
mitogen-activated protein kinase kinase kinase 
13 







TTC31 -1.67 0.0005 
Memczak2013 ALT_ACCEPTOR, 
ALT_DONOR, coding, INTERNAL, intronic 
best transcript NM_022492 
SCRN3 -1.67 0.0010 secernin 3 
RTF1 -1.67 0.0023 
RTF1 homolog, Paf1/RNA polymerase II 
complex component 
BPTF -1.67 0.0055 bromodomain PHD finger transcription factor 
LARP1B -1.67 0.0076 
La ribonucleoprotein domain family, member 
1B 
LMAN2L -1.67 0.0110 lectin, mannose-binding 2-like 
TFRC -1.67 0.0113 
Transcript Identified by AceView, Entrez 
Gene ID(s) 7037 
TLR5 -1.67 0.0123 toll-like receptor 5 
NPIPB6 -1.67 0.0128 
nuclear pore complex interacting protein 
family, member B6 
TRIM59 -1.67 0.0155 tripartite motif containing 59 
PREB -1.67 0.0222 prolactin regulatory element binding 
ZNF25 -1.67 0.0280 zinc finger protein 25 
TESK1; 
MIR4667 -1.67 0.0391 testis-specific kinase 1; microRNA 4667 
TMC5 -1.67 0.0447 transmembrane channel like 5 
DNMT3A -1.68 0.0004 DNA (cytosine-5-)-methyltransferase 3 alpha 
PCNXL3 -1.68 0.0004 pecanex-like 3 (Drosophila) 
SLC16A3; 
MIR6787 -1.68 0.0006 
solute carrier family 16 (monocarboxylate 
transporter), member 3; microRNA 6787 
CASC4 -1.68 0.0006 cancer susceptibility candidate 4 
SMCR8 -1.68 0.0008 
Smith-Magenis syndrome chromosome region, 
candidate 8 
GAS2L3 -1.68 0.0011 growth arrest-specific 2 like 3 
COPA -1.68 0.0026 coatomer protein complex subunit alpha 
PCNXL4 -1.68 0.0048 pecanex-like 4 (Drosophila) 
CFL1 -1.68 0.0052 cofilin 1 (non-muscle) 
HSPA5 -1.68 0.0067 
heat shock 70kDa protein 5 (glucose-regulated 
protein, 78kDa) 
RNF123 -1.68 0.0096 ring finger protein 123 
UROS -1.68 0.0117 uroporphyrinogen III synthase 
ATG4D -1.68 0.0163 autophagy related 4D, cysteine peptidase 
TNFRSF11A -1.68 0.0186 
Transcript Identified by AceView, Entrez 
Gene ID(s) 8792 







RABAC1 -1.68 0.0399 Rab acceptor 1 (prenylated) 
TRAM2 -1.68 0.0439 translocation associated membrane protein 2 
PIAS2 -1.68 0.0486 protein inhibitor of activated STAT 2 
OSGEPL1 -1.68 0.0489 O-sialoglycoprotein endopeptidase-like 1 
SENP6 -1.69 0.0000 SUMO1/sentrin specific peptidase 6 
TTC17 -1.69 0.0000 tetratricopeptide repeat domain 17 
SLC37A3 -1.69 0.0002 solute carrier family 37, member 3 
CNEP1R1 -1.69 0.0004 
CTD nuclear envelope phosphatase 1 
regulatory subunit 1 
GDI1 -1.69 0.0009 GDP dissociation inhibitor 1 
ZNF200 -1.69 0.0013 zinc finger protein 200 
SRR -1.69 0.0023 serine racemase 
MFSD2A -1.69 0.0024 
major facilitator superfamily domain 
containing 2A 
IGF2R -1.69 0.0072 insulin-like growth factor 2 receptor 
CTC1 -1.69 0.0089 
CTS telomere maintenance complex 
component 1 
HNRNPA0 -1.69 0.0120 heterogeneous nuclear ribonucleoprotein A0 
RASD1 -1.69 0.0243 RAS, dexamethasone-induced 1 
PARP15 -1.69 0.0340 
poly(ADP-ribose) polymerase family member 
15 
CHD3 -1.69 0.0481 
chromodomain helicase DNA binding protein 
3 
TFG -1.70 0.0003 TRK-fused gene 
TNFRSF10D -1.70 0.0006 
tumor necrosis factor receptor superfamily, 
member 10d, decoy with truncated death 
domain 
B4GALT3 -1.70 0.0022 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 3 
OGFOD1 -1.70 0.0022 
2-oxoglutarate and iron-dependent oxygenase 
domain containing 1 
RGL2 -1.70 0.0031 
ral guanine nucleotide dissociation stimulator-
like 2 
PAAF1 -1.70 0.0062 proteasomal ATPase-associated factor 1 
SRPR -1.70 0.0067 
signal recognition particle receptor (docking 
protein) 
TSC1 -1.70 0.0085 tuberous sclerosis 1 
SLCO3A1 -1.70 0.0131 
solute carrier organic anion transporter family, 
member 3A1 







CCDC152 -1.70 0.0137 coiled-coil domain containing 152 
STEAP3 -1.70 0.0151 STEAP family member 3, metalloreductase 
NDUFA10 -1.70 0.0171 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 10, 42kDa 
SGCD -1.70 0.0223 sarcoglycan delta 
BAIAP2 -1.70 0.0225 BAI1-associated protein 2 
PNKD; MIR6810 -1.70 0.0232 
paroxysmal nonkinesigenic dyskinesia; 
microRNA 6810 
VWA5A -1.70 0.0291 
von Willebrand factor A domain containing 
5A 
MEIS1 -1.70 0.0302 Meis homeobox 1 
SURF4 -1.70 0.0348 surfeit 4 
ATF6 -1.71 0.0001 activating transcription factor 6 
WBP1L -1.71 0.0002 WW domain binding protein 1-like 
INIP -1.71 0.0024 INTS3 and NABP interacting protein 
LGALS8 -1.71 0.0047 lectin, galactoside-binding, soluble, 8 
PWWP2A -1.71 0.0058 PWWP domain containing 2A 
NAT10 -1.71 0.0062 N-acetyltransferase 10 (GCN5-related) 
POM121 -1.71 0.0091 POM121 transmembrane nucleoporin 
DHX16 -1.71 0.0095 DEAH (Asp-Glu-Ala-His) box polypeptide 16 
IBTK -1.71 0.0127 
inhibitor of Bruton agammaglobulinemia 
tyrosine kinase 
TMEM138 -1.71 0.0291 transmembrane protein 138 
LRRC4C -1.71 0.0318 leucine rich repeat containing 4C 
C2orf27A -1.71 0.0329 chromosome 2 open reading frame 27A 
GTF3C1 -1.71 0.0414 general transcription factor IIIC subunit 1 
ZBED4 -1.72 0.0002 zinc finger, BED-type containing 4 
TAPT1 -1.72 0.0003 
transmembrane anterior posterior 
transformation 1 
GTF2E1 -1.72 0.0006 general transcription factor IIE subunit 1 
GPATCH8 -1.72 0.0022 G-patch domain containing 8 
ATG2B -1.72 0.0022 autophagy related 2B 
ELK4 -1.72 0.0022 
ELK4, ETS-domain protein (SRF accessory 
protein 1) 
CHCHD4 -1.72 0.0033 
coiled-coil-helix-coiled-coil-helix domain 
containing 4 
AGPAT2 -1.72 0.0109 
1-acylglycerol-3-phosphate O-acyltransferase 
2 







UBE4B -1.73 0.0000 ubiquitination factor E4B 
UBR1 -1.73 0.0004 
ubiquitin protein ligase E3 component n-
recognin 1 
ZNF41 -1.73 0.0008 zinc finger protein 41 
ASB6 -1.73 0.0010 ankyrin repeat and SOCS box containing 6 
FUT8 -1.73 0.0010 
fucosyltransferase 8 (alpha (1,6) 
fucosyltransferase) 
PPFIBP2 -1.73 0.0019 
PTPRF interacting protein, binding protein 2 
(liprin beta 2) 
MAPRE1 -1.73 0.0036 
microtubule-associated protein, RP/EB family, 
member 1 
DIP2B -1.73 0.0055 disco-interacting protein 2 homolog B 
VPS51 -1.73 0.0058 
vacuolar protein sorting 51 homolog (S. 
cerevisiae) 
CCZ1B -1.73 0.0066 
CCZ1 homolog B, vacuolar protein trafficking 
and biogenesis associated 
TMEM39A -1.73 0.0070 transmembrane protein 39A 
GBF1 -1.73 0.0080 
golgi brefeldin A resistant guanine nucleotide 
exchange factor 1 
PRRC2B -1.73 0.0084 proline-rich coiled-coil 2B 
PCCB -1.73 0.0284 propionyl-CoA carboxylase beta subunit 
PDIA6 -1.73 0.0421 
protein disulfide isomerase family A, member 
6 
DDX23 -1.74 0.0000 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 
PSMD4 -1.74 0.0000 proteasome 26S subunit, non-ATPase 4 
DNTTIP2 -1.74 0.0002 
deoxynucleotidyltransferase, terminal, 
interacting protein 2 
FAM160A2 -1.74 0.0012 
family with sequence similarity 160, member 
A2 
TTLL4 -1.74 0.0013 tubulin tyrosine ligase-like family member 4 
ZNF417 -1.74 0.0026 zinc finger protein 417 
HYOU1 -1.74 0.0030 hypoxia up-regulated 1 
ATP2A2 -1.74 0.0045 
ATPase, Ca++ transporting, cardiac muscle, 
slow twitch 2 
RBM47 -1.74 0.0059 RNA binding motif protein 47 
ZNF776 -1.74 0.0060 zinc finger protein 776 
ECT2 -1.74 0.0229 epithelial cell transforming 2 
RNGTT -1.75 0.0000 RNA guanylyltransferase and 5-phosphatase 
ZNF410 -1.75 0.0001 zinc finger protein 410 







FOXO1 -1.75 0.0010 forkhead box O1 
ANKFY1 -1.75 0.0012 ankyrin repeat and FYVE domain containing 1 
DHX9 -1.75 0.0013 DEAH (Asp-Glu-Ala-His) box helicase 9 
MYH9 -1.75 0.0026 myosin, heavy chain 9, non-muscle 
NR2C2 -1.75 0.0030 
nuclear receptor subfamily 2, group C, 
member 2 
IGF1R -1.75 0.0104 insulin-like growth factor 1 receptor 
PTAR1 -1.75 0.0129 
protein prenyltransferase alpha subunit repeat 
containing 1 
C9orf114 -1.75 0.0223 chromosome 9 open reading frame 114 
SMAD5 -1.75 0.0338 SMAD family member 5 
TUBGCP3 -1.75 0.0441 
Memczak2013 ANTISENSE, coding, 
INTERNAL, intronic best transcript 
NM_006322 
PRR14L -1.76 0.0000 proline rich 14-like 
LPAR1 -1.76 0.0000 lysophosphatidic acid receptor 1 
BTN2A2 -1.76 0.0001 butyrophilin, subfamily 2, member A2 
SRSF4 -1.76 0.0003 serine/arginine-rich splicing factor 4 
RRP7A -1.76 0.0005 ribosomal RNA processing 7 homolog A 
IP6K2 -1.76 0.0010 inositol hexakisphosphate kinase 2 
CHST11 -1.76 0.0014 
Transcript Identified by AceView, Entrez 
Gene ID(s) 50515 
SLC35A5 -1.76 0.0014 solute carrier family 35, member A5 
ARMCX5 -1.76 0.0036 armadillo repeat containing, X-linked 5 
FER -1.76 0.0068 fer (fps/fes related) tyrosine kinase 
CDC37; 
MIR1181 -1.76 0.0076 cell division cycle 37; microRNA 1181 
HYOU1 -1.76 0.0084 hypoxia up-regulated 1 
EIF2AK1 -1.76 0.0113 
eukaryotic translation initiation factor 2-alpha 
kinase 1 
GTF3C2 -1.76 0.0147 general transcription factor IIIC subunit 2 
MTRR -1.76 0.0198 
5-methyltetrahydrofolate-homocysteine 
methyltransferase reductase 
MCFD2 -1.76 0.0209 multiple coagulation factor deficiency 2 
ZNF780B -1.76 0.0299 zinc finger protein 780B 
ZNF780B -1.76 0.0299 zinc finger protein 780B 
PPP1CA -1.76 0.0361 
protein phosphatase 1, catalytic subunit, alpha 
isozyme 
POLDIP2 -1.76 0.0387 








MRPS16 -1.76 0.0455 mitochondrial ribosomal protein S16 
CD180 -1.76 0.0460 CD180 molecule 
SSR1 -1.77 0.0020 signal sequence receptor, alpha 
PLIN2 -1.77 0.0024 perilipin 2 
TBC1D9B -1.77 0.0050 
TBC1 domain family, member 9B (with 
GRAM domain) 
WDR41 -1.77 0.0062 WD repeat domain 41 
NDUFA9 -1.77 0.0120 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 9, 39kDa 
FOLH1 -1.77 0.0360 
folate hydrolase (prostate-specific membrane 
antigen) 1 
ASXL2 -1.78 0.0000 
additional sex combs like transcriptional 
regulator 2 
CDC42SE2 -1.78 0.0000 CDC42 small effector 2 
PARN -1.78 0.0002 poly(A)-specific ribonuclease 
MED12 -1.78 0.0003 mediator complex subunit 12 
LRRC28 -1.78 0.0007 leucine rich repeat containing 28 
HDAC1 -1.78 0.0008 histone deacetylase 1 
HIPK1 -1.78 0.0012 homeodomain interacting protein kinase 1 
DBNL; MIR6837 -1.78 0.0014 drebrin-like; microRNA 6837 
PSMC5 -1.78 0.0021 proteasome 26S subunit, ATPase 5 
ACTR3 -1.78 0.0029 ARP3 actin-related protein 3 homolog (yeast) 
PSTPIP2 -1.78 0.0063 
proline-serine-threonine phosphatase 
interacting protein 2 
SLC35A2 -1.78 0.0098 
solute carrier family 35 (UDP-galactose 
transporter), member A2 
SNRPA1 -1.78 0.0134 small nuclear ribonucleoprotein polypeptide A 





RABEP1 -1.79 0.0000 
rabaptin, RAB GTPase binding effector 
protein 1 
OCRL -1.79 0.0008 oculocerebrorenal syndrome of Lowe 
EDEM3 -1.79 0.0016 
ER degradation enhancer, mannosidase alpha-
like 3 
NDUFA12 -1.79 0.0016 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 12 
FAH -1.79 0.0017 
fumarylacetoacetate hydrolase 
(fumarylacetoacetase) 







OGDH -1.79 0.0033 
oxoglutarate (alpha-ketoglutarate) 
dehydrogenase (lipoamide) 
TFCP2 -1.80 0.0000 transcription factor CP2 
ABHD16A -1.80 0.0001 abhydrolase domain containing 16A 
CREBBP -1.80 0.0001 CREB binding protein 
RWDD2B -1.80 0.0016 RWD domain containing 2B 
TIMM17A -1.80 0.0032 
translocase of inner mitochondrial membrane 
17 homolog A (yeast) 
HOXB6 -1.80 0.0049 homeobox B6 
CARS2 -1.80 0.0052 
cysteinyl-tRNA synthetase 2, mitochondrial 
(putative) 
BCORL1 -1.80 0.0058 BCL6 corepressor-like 1 
TMEM8A -1.80 0.0068 transmembrane protein 8A 
REPIN1 -1.80 0.0115 replication initiator 1 
SMG5 -1.80 0.0129 SMG5 nonsense mediated mRNA decay factor 
STT3A -1.80 0.0324 
STT3A, subunit of the 
oligosaccharyltransferase complex (catalytic) 
METTL5 -1.80 0.0331 methyltransferase like 5 
ZKSCAN1 -1.80 0.0333 zinc finger with KRAB and SCAN domains 1 
ZFX -1.81 0.0001 zinc finger protein, X-linked 
SUSD1 -1.81 0.0002 sushi domain containing 1 
THBD -1.81 0.0008 thrombomodulin 
CDC42SE2 -1.81 0.0029 CDC42 small effector 2 
CPT2 -1.81 0.0043 carnitine palmitoyltransferase 2 
PSAP -1.81 0.0062 prosaposin 
SLC5A5 -1.81 0.0103 
solute carrier family 5 (sodium/iodide 
cotransporter), member 5 
GANAB -1.81 0.0142 glucosidase, alpha; neutral AB 
NUP210 -1.81 0.0164 nucleoporin 210kDa 
NR4A2 -1.81 0.0190 
nuclear receptor subfamily 4, group A, 
member 2 
SLC26A2 -1.81 0.0451 
solute carrier family 26 (anion exchanger), 
member 2 
CRIPT -1.82 0.0000 cysteine-rich PDZ-binding protein 
HNRNPC -1.82 0.0000 
heterogeneous nuclear ribonucleoprotein C 
(C1/C2) 
EIF4G3 -1.82 0.0001 
eukaryotic translation initiation factor 4 
gamma, 3 
CRCP -1.82 0.0001 CGRP receptor component 







PTBP1; MIR4745 -1.82 0.0041 
polypyrimidine tract binding protein 1; 
microRNA 4745 
TRIP11 -1.82 0.0197 thyroid hormone receptor interactor 11 
TPRA1 -1.82 0.0238 
transmembrane protein, adipocyte asscociated 
1 
ELOVL1; 
MIR6734 -1.82 0.0281 
ELOVL fatty acid elongase 1; microRNA 
6734 
GORASP1 -1.82 0.0363 golgi reassembly stacking protein 1 
ZNF587 -1.83 0.0008 zinc finger protein 587 
PTPRJ -1.83 0.0035 protein tyrosine phosphatase, receptor type, J 
SERINC5 -1.83 0.0038 serine incorporator 5 
MSTO1; 
MSTO2P -1.83 0.0363 
misato 1, mitochondrial distribution and 
morphology regulator; misato family member 
2, pseudogene 
HGS -1.84 0.0001 
hepatocyte growth factor-regulated tyrosine 
kinase substrate 
TESC -1.84 0.0003 tescalcin 
XPC -1.84 0.0009 
xeroderma pigmentosum, complementation 
group C 
FAM118B -1.84 0.0013 
family with sequence similarity 118, member 
B 
AGO2 -1.84 0.0013 argonaute RISC catalytic component 2 
THOC5 -1.84 0.0016 THO complex 5 
SAE1 -1.84 0.0019 SUMO1 activating enzyme subunit 1 
DPY19L3 -1.84 0.0024 dpy-19-like 3 (C. elegans) 
IRAK3; 
MIR6502 -1.84 0.0043 
interleukin 1 receptor associated kinase 3; 
microRNA 6502 
TTC37 -1.84 0.0050 tetratricopeptide repeat domain 37 
FUZ -1.84 0.0083 fuzzy planar cell polarity protein 
HYOU1 -1.84 0.0299 hypoxia up-regulated 1 
HPS3 -1.85 0.0001 Hermansky-Pudlak syndrome 3 
ANXA5 -1.85 0.0002 annexin A5 
NCOA3 -1.85 0.0004 nuclear receptor coactivator 3 
GRAMD1B -1.85 0.0007 GRAM domain containing 1B 
FBXW2 -1.85 0.0008 F-box and WD repeat domain containing 2 
KPNB1 -1.85 0.0049 karyopherin (importin) beta 1 
VNN3 -1.85 0.0386 vanin 3 
NUP153 -1.86 0.0000 nucleoporin 153kDa 
SMARCC2 -1.86 0.0047 
Memczak2013 ANTISENSE, CDS, coding, 







SIDT1 -1.86 0.0139 SID1 transmembrane family, member 1 
OGFOD3 -1.86 0.0239 
2-oxoglutarate and iron-dependent oxygenase 
domain containing 3 
LYPLA2 -1.86 0.0258 lysophospholipase II 
PPRC1 -1.86 0.0472 
peroxisome proliferator-activated receptor 
gamma, coactivator-related 1 
NUDT13 -1.86 0.0488 nudix hydrolase 13 
BTN3A1 -1.87 0.0002 butyrophilin, subfamily 3, member A1 
SMG6 -1.87 0.0004 SMG6 nonsense mediated mRNA decay factor 
NRDC; MIR761 -1.87 0.0007 nardilysin convertase; microRNA 761 
KCTD10 -1.87 0.0008 
potassium channel tetramerization domain 
containing 10 
INTS8 -1.87 0.0008 integrator complex subunit 8 
RGPD5; RGPD8 -1.87 0.0020 
RANBP2-like and GRIP domain containing 5; 
RANBP2-like and GRIP domain containing 8 
COPG1 -1.87 0.0200 coatomer protein complex subunit gamma 1 
FIP1L1 -1.88 0.0000 factor interacting with PAPOLA and CPSF1 
UBE2Z -1.88 0.0009 ubiquitin-conjugating enzyme E2Z 
DENND2D -1.88 0.0036 DENN/MADD domain containing 2D 
MILR1 -1.88 0.0237 mast cell immunoglobulin-like receptor 1 
PCNXL2 -1.89 0.0002 pecanex-like 2 (Drosophila) 
BAP1 -1.89 0.0003 BRCA1 associated protein 1 
FAM98A -1.89 0.0037 family with sequence similarity 98, member A 
SRP9 -1.89 0.0214 signal recognition particle 9kDa 
AP5M1 -1.89 0.0216 
adaptor-related protein complex 5, mu 1 
subunit 
PVRL3 -1.89 0.0226 poliovirus receptor-related 3 
MARK1 -1.89 0.0280 MAP/microtubule affinity-regulating kinase 1 
TNRC6B -1.90 0.0013 trinucleotide repeat containing 6B 
BAG6 -1.90 0.0017 BCL2 associated athanogene 6 
KCTD13 -1.90 0.0033 
potassium channel tetramerization domain 
containing 13 
RABL3 -1.90 0.0035 RAB, member of RAS oncogene family-like 3 
NOL9 -1.90 0.0046 nucleolar protein 9 
CLASP1 -1.91 0.0000 cytoplasmic linker associated protein 1 
BCAP31 -1.91 0.0001 B-cell receptor-associated protein 31 
SLC12A9 -1.91 0.0021 solute carrier family 12, member 9 







MBTPS2; YY2 -1.91 0.0023 
membrane bound transcription factor 
peptidase, site 2; YY2 transcription factor 
SLC38A5 -1.91 0.0039 solute carrier family 38, member 5 
SLC35A4 -1.91 0.0177 solute carrier family 35, member A4 
LRP8 -1.91 0.0431 LDL receptor related protein 8 
CD96 -1.91 0.0432 CD96 molecule 
STARD13 -1.91 0.0451 
StAR-related lipid transfer domain containing 
13 
MYLIP; 
MIR4639 -1.92 0.0001 
myosin regulatory light chain interacting 
protein; microRNA 4639 
PCYT1A -1.92 0.0005 
phosphate cytidylyltransferase 1, choline, 
alpha 
KCNK1 -1.92 0.0007 
potassium channel, two pore domain 
subfamily K, member 1 
ZNF394 -1.92 0.0010 zinc finger protein 394 
NFATC3 -1.92 0.0035 
nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 3 
AGPAT1; 
MIR6721 -1.92 0.0116 
1-acylglycerol-3-phosphate O-acyltransferase 
1; microRNA 6721 
PSMD11 -1.92 0.0301 proteasome 26S subunit, non-ATPase 11 
LYSMD3 -1.93 0.0001 
LysM, putative peptidoglycan-binding, 
domain containing 3 
SIPA1L1 -1.93 0.0001 signal-induced proliferation-associated 1 like 1 
RBM5 -1.93 0.0001 RNA binding motif protein 5 
TARDBP -1.93 0.0010 TAR DNA binding protein 
BCL2L15 -1.93 0.0017 BCL2-like 15 
SLC17A9 -1.93 0.0181 
solute carrier family 17 (vesicular nucleotide 
transporter), member 9 
RPN2 -1.93 0.0258 ribophorin II 
RAB8A -1.94 0.0000 RAB8A, member RAS oncogene family 
NEDD1 -1.94 0.0003 
neural precursor cell expressed, 
developmentally down-regulated 1 
CRELD1 -1.94 0.0017 cysteine rich with EGF-like domains 1 
RBBP5 -1.94 0.0019 retinoblastoma binding protein 5 
LRRC31 -1.94 0.0027 leucine rich repeat containing 31 
GALNT3 -1.94 0.0051 
polypeptide N-acetylgalactosaminyltransferase 
3 
MOGS -1.94 0.0057 mannosyl-oligosaccharide glucosidase 
PIP5K1B -1.94 0.0151 
phosphatidylinositol-4-phosphate 5-kinase, 
type I, beta 







ADH5 -1.94 0.0192 
alcohol dehydrogenase 5 (class III), chi 
polypeptide 
BCL6 -1.94 0.0449 B-cell CLL/lymphoma 6 
NGLY1 -1.95 0.0000 N-glycanase 1 
INTS4P2 -1.95 0.0000 integrator complex subunit 4 pseudogene 2 
DYNC1H1 -1.95 0.0013 dynein, cytoplasmic 1, heavy chain 1 
ATP11A -1.95 0.0028 ATPase, class VI, type 11A 
SLC30A7 -1.96 0.0002 
solute carrier family 30 (zinc transporter), 
member 7 
PSMD2 -1.96 0.0005 proteasome 26S subunit, non-ATPase 2 
SRSF6 -1.96 0.0019 serine/arginine-rich splicing factor 6 
ENTPD6 -1.96 0.0249 
ectonucleoside triphosphate 
diphosphohydrolase 6 (putative) 
PIGS -1.96 0.0273 
phosphatidylinositol glycan anchor 
biosynthesis class S 
AOC1 -1.96 0.0344 amine oxidase, copper containing 1 
DHRS7 -1.97 0.0001 
dehydrogenase/reductase (SDR family) 
member 7 
SMAP2 -1.97 0.0013 small ArfGAP2 
WDR33 -1.97 0.0047 WD repeat domain 33 
CORO1C -1.97 0.0095 coronin, actin binding protein, 1C 
PRKD3 -1.97 0.0173 protein kinase D3 
PCYT1A -1.98 0.0000 
phosphate cytidylyltransferase 1, choline, 
alpha 
DUS2 -1.98 0.0001 dihydrouridine synthase 2 
FMR1 -1.98 0.0001 fragile X mental retardation 1 
CCT6A -1.98 0.0006 
chaperonin containing TCP1, subunit 6A (zeta 
1) 
DHX33 -1.98 0.0012 DEAH (Asp-Glu-Ala-His) box polypeptide 33 
HUWE1 -1.98 0.0028 
HECT, UBA and WWE domain containing 1, 
E3 ubiquitin protein ligase 
SRC -1.98 0.0031 
SRC proto-oncogene, non-receptor tyrosine 
kinase 
PLPPR2 -1.98 0.0032 phospholipid phosphatase related 2 
COX18 -1.98 0.0045 COX18 cytochrome c oxidase assembly factor 
SLC39A6 -1.98 0.0310 
solute carrier family 39 (zinc transporter), 
member 6 
APLP2 -1.99 0.0001 amyloid beta (A4) precursor-like protein 2 
PIP4K2A -1.99 0.0039 
phosphatidylinositol-5-phosphate 4-kinase, 







TBCE -2.00 0.0001 tubulin folding cofactor E 
ABR -2.00 0.0013 active BCR-related 
NAA35 -2.00 0.0013 
N(alpha)-acetyltransferase 35, NatC auxiliary 
subunit 
METTL2A -2.00 0.0072 methyltransferase like 2A 
SDF2L1 -2.00 0.0187 stromal cell-derived factor 2-like 1 
KDELR2 -2.00 0.0295 
KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 2 
STRAP -2.01 0.0001 
serine/threonine kinase receptor associated 
protein 
VPS8 -2.01 0.0003 
vacuolar protein sorting 8 homolog (S. 
cerevisiae) 
SPECC1 -2.01 0.0013 
sperm antigen with calponin homology and 
coiled-coil domains 1 
IFRD2 -2.01 0.0089 interferon-related developmental regulator 2 
KIAA0513 -2.02 0.0000 KIAA0513 
PEX11B -2.02 0.0146 peroxisomal biogenesis factor 11 beta 
TPM3 -2.03 0.0000 tropomyosin 3 
ABCC10 -2.03 0.0010 ATP binding cassette subfamily C member 10 
MCTP2 -2.03 0.0030 multiple C2 domains, transmembrane 2 
OS9 -2.04 0.0099 
osteosarcoma amplified 9, endoplasmic 
reticulum lectin 
AREL1 -2.05 0.0001 
apoptosis resistant E3 ubiquitin protein ligase 
1 
COPS8 -2.05 0.0049 COP9 signalosome subunit 8 
TMEM220 -2.05 0.0255 transmembrane protein 220 
THOC7 -2.06 0.0000 THO complex 7 
HELZ -2.06 0.0001 helicase with zinc finger 
SMIM8 -2.06 0.0013 small integral membrane protein 8 
CELF2 -2.06 0.0150 
Transcript Identified by AceView, Entrez 
Gene ID(s) 10659 
USO1 -2.07 0.0054 USO1 vesicle transport factor 
SH3RF1 -2.07 0.0345 SH3 domain containing ring finger 1 
MYCBP; GJA9 -2.08 0.0000 
MYC binding protein; gap junction protein 
alpha 9 
MICAL2 -2.08 0.0001 
microtubule associated monooxygenase, 
calponin and LIM domain containing 2 
DNAJC10 -2.08 0.0374 
DnaJ (Hsp40) homolog, subfamily C, member 
10 








MIR640 -2.09 0.0001 
GATA zinc finger domain containing 2A; 
microRNA 640 
DNAJC16 -2.09 0.0003 
DnaJ (Hsp40) homolog, subfamily C, member 
16 
EIF2AK3 -2.09 0.0005 
eukaryotic translation initiation factor 2-alpha 
kinase 3 
APH1A -2.09 0.0021 APH1A gamma secretase subunit 
PTPN23 -2.10 0.0002 
protein tyrosine phosphatase, non-receptor 
type 23 
KAT6B -2.10 0.0007 K(lysine) acetyltransferase 6B 
NCALD -2.10 0.0082 neurocalcin delta 
RASGRP1 -2.10 0.0160 
RAS guanyl releasing protein 1 (calcium and 
DAG-regulated) 
DEPTOR -2.10 0.0421 
DEP domain containing MTOR-interacting 
protein 
CCDC103 -2.10 0.0432 coiled-coil domain containing 103 
TRIP4 -2.11 0.0000 thyroid hormone receptor interactor 4 
SLC39A11 -2.11 0.0044 solute carrier family 39, member 11 
SLC25A11 -2.11 0.0140 
solute carrier family 25 (mitochondrial carrier; 
oxoglutarate carrier), member 11 
GNE -2.11 0.0369 
glucosamine (UDP-N-acetyl)-2-epimerase/N-
acetylmannosamine kinase 
STIM2 -2.12 0.0000 stromal interaction molecule 2 
SDHD -2.12 0.0000 
succinate dehydrogenase complex subunit D, 
integral membrane protein 
NDRG1 -2.12 0.0015 N-myc downstream regulated 1 
EIF4ENIF1 -2.12 0.0146 
eukaryotic translation initiation factor 4E 
nuclear import factor 1 
ZC3H7B -2.12 0.0248 zinc finger CCCH-type containing 7B 
NUP50 -2.13 0.0000 nucleoporin 50kDa 
ANAPC5 -2.13 0.0021 anaphase promoting complex subunit 5 
HIPK2 -2.13 0.0040 homeodomain interacting protein kinase 2 
GMPPB -2.13 0.0076 GDP-mannose pyrophosphorylase B 
SF3A3 -2.14 0.0002 splicing factor 3a subunit 3 
KIAA0430; 
MIR6506 -2.15 0.0000 KIAA0430; microRNA 6506 
IST1 -2.15 0.0010 increased sodium tolerance 1 homolog (yeast) 
SCFD1 -2.15 0.0038 sec1 family domain containing 1 
HYOU1 -2.15 0.0056 hypoxia up-regulated 1 







SLC35C2 -2.16 0.0031 
solute carrier family 35 (GDP-fucose 
transporter), member C2 
SCAP -2.16 0.0187 
Memczak2013 ANTISENSE, CDS, coding, 
INTERNAL best transcript NM_012235 
FADS2 -2.16 0.0407 fatty acid desaturase 2 
DYNC1LI2 -2.17 0.0000 
dynein, cytoplasmic 1, light intermediate chain 
2 
SEC23B -2.17 0.0002 
Sec23 homolog B, COPII coat complex 
component 
RTFDC1 -2.17 0.0004 
replication termination factor 2 domain 
containing 1 
STAT6 -2.18 0.0002 
signal transducer and activator of transcription 
6, interleukin-4 induced 
LATS1 -2.18 0.0022 large tumor suppressor kinase 1 
PDE12 -2.19 0.0001 phosphodiesterase 12 
PCMTD2 -2.20 0.0002 
protein-L-isoaspartate (D-aspartate) O-
methyltransferase domain containing 2 
CDC23 -2.20 0.0010 cell division cycle 23 
TMEM184B -2.20 0.0016 transmembrane protein 184B 
YTHDF3 -2.21 0.0000 
YTH N(6)-methyladenosine RNA binding 
protein 3 
ELMO2 -2.21 0.0000 engulfment and cell motility 2 
PATL1 -2.21 0.0027 
protein associated with topoisomerase II 
homolog 1 (yeast) 
LAIR2 -2.21 0.0057 
leukocyte-associated immunoglobulin-like 
receptor 2 
CTDSPL -2.21 0.0200 CTD small phosphatase like 
SRM -2.22 0.0464 spermidine synthase 
FTO -2.23 0.0108 fat mass and obesity associated 
RAB43 -2.24 0.0000 RAB43, member RAS oncogene family 
C2CD5 -2.24 0.0000 C2 calcium-dependent domain containing 5 
RINT1 -2.24 0.0008 RAD50 interactor 1 
RCC2 -2.24 0.0020 regulator of chromosome condensation 2 
CBX5; MIR3198-
2 -2.24 0.0038 chromobox homolog 5; microRNA 3198-2 
RIMKLB -2.24 0.0048 
ribosomal modification protein rimK-like 
family member B 
SLC7A11 -2.24 0.0191 
solute carrier family 7 (anionic amino acid 










SNHG4 -2.25 0.0005 
matrin 3; small nucleolar RNA, H/ACA box 
74A; small nucleolar RNA host gene 4 
NUMB -2.25 0.0007 numb homolog (Drosophila) 
BTBD3 -2.25 0.0058 BTB (POZ) domain containing 3 
FAM120A -2.26 0.0012 family with sequence similarity 120A 
NCKAP1L -2.26 0.0027 NCK-associated protein 1-like 
PIGN -2.27 0.0005 
phosphatidylinositol glycan anchor 
biosynthesis class N 
SPRYD3 -2.27 0.0008 SPRY domain containing 3 
SLC4A11 -2.27 0.0077 
solute carrier family 4, sodium borate 
transporter, member 11 
MFSD10 -2.28 0.0011 
major facilitator superfamily domain 
containing 10 
LPCAT3 -2.29 0.0000 lysophosphatidylcholine acyltransferase 3 
MIA3 -2.29 0.0003 
melanoma inhibitory activity family, member 
3 
TMEM214 -2.29 0.0039 transmembrane protein 214 
TMEM50B -2.30 0.0004 transmembrane protein 50B 
DCPS -2.30 0.0009 decapping enzyme, scavenger 
HHAT -2.30 0.0018 hedgehog acyltransferase 
ZNF275 -2.30 0.0123 zinc finger protein 275 
C16orf72 -2.31 0.0000 
Memczak2013 ANTISENSE, coding, 
INTERNAL, intronic best transcript 
NM_014117 
CAP1 -2.33 0.0000 
CAP, adenylate cyclase-associated protein 1 
(yeast) 
CDC14B -2.33 0.0009 cell division cycle 14B 
TIMM21 -2.33 0.0105 
translocase of inner mitochondrial membrane 
21 homolog (yeast) 
NAE1 -2.34 0.0000 NEDD8 activating enzyme E1 subunit 1 
BROX -2.35 0.0000 BRO1 domain and CAAX motif containing 
MAVS -2.36 0.0009 mitochondrial antiviral signaling protein 
KIAA0100 -2.36 0.0048 KIAA0100 
CERS2 -2.38 0.0001 ceramide synthase 2 
TRAPPC10 -2.38 0.0002 trafficking protein particle complex 10 
LDAH -2.38 0.0031 lipid droplet associated hydrolase 
CCDC84 -2.39 0.0000 coiled-coil domain containing 84 







PPM1B -2.40 0.0213 
Memczak2013 ANTISENSE, coding, 
INTERNAL, intronic best transcript 
NM_001033556 
DICER1 -2.41 0.0000 dicer 1, ribonuclease type III 
EIF2B1 -2.42 0.0000 
eukaryotic translation initiation factor 2B, 
subunit 1 alpha, 26kDa 
OSTM1 -2.42 0.0001 
osteopetrosis associated transmembrane 
protein 1 
IPO9 -2.42 0.0001 importin 9 
SLC45A4 -2.44 0.0399 solute carrier family 45, member 4 
MYO1D -2.45 0.0219 myosin ID 
PRRC2A -2.49 0.0047 proline-rich coiled-coil 2A 
LCOR -2.51 0.0001 ligand dependent nuclear receptor corepressor 
LMNA -2.51 0.0029 lamin A/C 
FBRS -2.51 0.0113 fibrosin 
UTP20 -2.53 0.0000 
UTP20 small subunit (SSU) processome 
component 
CFTR -2.55 0.0008 
cystic fibrosis transmembrane conductance 
regulator 
ENO1 -2.56 0.0000 enolase 1, (alpha) 
RTN3 -2.56 0.0000 reticulon 3 
H6PD -2.60 0.0016 
hexose-6-phosphate dehydrogenase (glucose 
1-dehydrogenase) 
SEPT2 -2.61 0.0000 septin 2 
SLC6A20 -2.61 0.0052 
solute carrier family 6 (proline IMINO 
transporter), member 20 
EPHB2 -2.64 0.0010 EPH receptor B2 
GLYR1 -2.64 0.0013 glyoxylate reductase 1 homolog (Arabidopsis) 
SLC2A10 -2.64 0.0080 
solute carrier family 2 (facilitated glucose 
transporter), member 10 
ATHL1 -2.65 0.0049 ATH1, acid trehalase-like 1 (yeast) 
MYH10 -2.67 0.0078 myosin, heavy chain 10, non-muscle 
HSP90B1; 
MIR3652 -2.68 0.0002 
heat shock protein 90kDa beta (Grp94), 
member 1; microRNA 3652 
SMAD6 -2.69 0.0027 SMAD family member 6 
PFKP -2.71 0.0095 phosphofructokinase, platelet 
GPAA1 -2.72 0.0036 
glycosylphosphatidylinositol anchor 
attachment 1 
SLC25A44 -2.72 0.0042 solute carrier family 25, member 44 







PVRL2 -2.74 0.0005 
poliovirus receptor-related 2 (herpesvirus entry 
mediator B) 
LAIR1 -2.83 0.0068 
leukocyte-associated immunoglobulin-like 
receptor 1 
CDR1 -2.83 0.0242 cerebellar degeneration related protein 1 
NRP2 -2.91 0.0005 neuropilin 2 
CATSPERB -2.95 0.0019 catsper channel auxiliary subunit beta 
MYRF -3.01 0.0273 myelin regulatory factor 
DHCR7 -3.04 0.0049 7-dehydrocholesterol reductase 
SLC6A6 -3.16 0.0323 
solute carrier family 6 (neurotransmitter 
transporter), member 6 
WSB1 -3.24 0.0000 WD repeat and SOCS box containing 1 
CDR1; CDR1-AS -3.24 0.0134 
Memczak2013 ANTISENSE, CDS, coding, 
downstream_end, upstream_start, UTR3, 
UTR5 best transcript NM_004065; CDR1 
antisense RNA; CDR1 antisense RNA 
[Source:HGNC Symbol;Acc:HGNC:48926] 
MAPKAP1 -3.34 0.0000 
mitogen-activated protein kinase associated 
protein 1 
TMX4 -3.44 0.0002 thioredoxin-related transmembrane protein 4 
SEC16A -3.69 0.0005 
SEC16 homolog A, endoplasmic reticulum 
export factor 
ZBTB20; 
MIR568 -3.75 0.0005 
zinc finger and BTB domain containing 20; 
microRNA 568 
ATP2A3 -3.92 0.0015 ATPase, Ca++ transporting, ubiquitous 
SLC7A1 -3.92 0.0028 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1 
ZBTB38 -4.01 0.0001 zinc finger and BTB domain containing 38 
HABP2 -4.04 0.0077 hyaluronan binding protein 2 
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RPS26 4.90 0.0009 
Homo sapiens ribosomal protein S26, mRNA 
(cDNA clone MGC:27148 IMAGE:4807004), 
complete cds.; Homo sapiens ribosomal protein S26, 
mRNA (cDNA clone MGC:88201 
IMAGE:6388128), complete cds.; Homo sapiens 
ribosomal protein S26, mRNA (cDNA clone 
MGC:104291 IMAGE:4287636), complete cds.; 
Homo sapiens ribosomal protein S26, mRNA 
(cDNA clone MGC:104292 IMAGE:6726218), 
complete cds. 
RPS26 4.65 0.0004 
Homo sapiens ribosomal protein S26, mRNA 
(cDNA clone MGC:104291 IMAGE:4287636), 
complete cds. 
MMP1 4.64 0.0038 matrix metallopeptidase 1 
RPS26 4.23 0.0025 ribosomal protein S26 
MMP9 3.74 0.0257 matrix metallopeptidase 9 
MMP12 3.50 0.0353 matrix metallopeptidase 12 
KRT5 3.30 0.0177 keratin 5, type II 
LGALS1 3.28 0.0001 lectin, galactoside-binding, soluble, 1 
APOC1 3.26 0.0380 apolipoprotein C-I 
CSF1 3.21 0.0034 colony stimulating factor 1 (macrophage) 
CD163 3.12 0.0150 CD163 molecule 
SLC43A3 3.10 0.0256 solute carrier family 43, member 3 
OLFML2B 2.95 0.0027 olfactomedin like 2B 
COL6A1 2.86 0.0108 collagen, type VI, alpha 1 
Table C.1 DEGs for the HPV16 persistor vs HPV16 clearer 
comparison. As indicated by the fold change, numbers in red 
highlight are upregulated genes and green highlight are down-
regulated genes. p<0.05 – FC≥1.5. 
 







ADAMDEC1 2.86 0.0135 ADAM-like, decysin 1 
MAFIP; TEKT4P2 2.69 0.0022 
MAFF interacting protein (pseudogene); 
tektin 4 pseudogene 2 
RNASE1 2.69 0.0144 ribonuclease, RNase A family, 1 (pancreatic) 
FAM150B 2.67 0.0035 
family with sequence similarity 150, member 
B 
S100A2 2.67 0.0283 S100 calcium binding protein A2 
MMP8 2.65 0.0178 matrix metallopeptidase 8 
ANXA8L1; 
ANXA8 2.63 0.0441 annexin A8-like 1; annexin A8 
NCKAP1 2.58 0.0085 NCK-associated protein 1 
LSM7 2.43 0.0097 
LSM7 homolog, U6 small nuclear RNA and 
mRNA degradation associated 
ELP5 2.33 0.0362 
elongator acetyltransferase complex subunit 
5 
CCPG1; MIR628 2.28 0.0006 cell cycle progression 1; microRNA 628 
RUNX3 2.26 0.0251 runt-related transcription factor 3 
SEPP1 2.26 0.0321 selenoprotein P, plasma, 1 
RFXANK 2.24 0.0000 
regulatory factor X-associated ankyrin-
containing protein 
HIST1H1E 2.23 0.0000 histone cluster 1, H1e 
EIF2S3 2.21 0.0003 
eukaryotic translation initiation factor 2, 
subunit 3 gamma, 52kDa 
RPS5 2.18 0.0001 ribosomal protein S5 
HIST1H1C 2.17 0.0116 
Memczak2013 ANTISENSE, CDS, coding, 
INTERNAL best transcript NM_005319 
XPO1 2.16 0.0002 exportin 1 
SH2B2 2.16 0.0292 
Memczak2013 ANTISENSE, CDS, coding, 
INTERNAL best transcript NM_020979 
C19orf70 2.15 0.0384 chromosome 19 open reading frame 70 
RPL28; MIR6805 2.12 0.0000 ribosomal protein L28; microRNA 6805 
TRIOBP; NOL12 2.12 0.0012 
TRIO and F-actin binding protein; nucleolar 
protein 12 
UBE2S 2.07 0.0019 ubiquitin-conjugating enzyme E2S 
CPNE2 2.07 0.0151 copine II 
PSIP1 2.06 0.0000 PC4 and SFRS1 interacting protein 1 
LRP1 2.04 0.0060 LDL receptor related protein 1 
RPS19 2.03 0.0000 ribosomal protein S19 
C19orf53 2.03 0.0000 chromosome 19 open reading frame 53 







MRPL40 2.03 0.0380 mitochondrial ribosomal protein L40 
HACE1 2.02 0.0018 
HECT domain and ankyrin repeat containing 
E3 ubiquitin protein ligase 1 
CSF1R 2.02 0.0089 colony stimulating factor 1 receptor 
HNRNPF 2.01 0.0001 heterogeneous nuclear ribonucleoprotein F 
SH3BGRL3 2.01 0.0043 
SH3 domain binding glutamate-rich protein 
like 3 
FABP5 2.01 0.0179 
fatty acid binding protein 5 (psoriasis-
associated) 
UBR5 2.00 0.0002 
ubiquitin protein ligase E3 component n-
recognin 5 
PDPN 1.99 0.0036 podoplanin 
RPL39L 1.99 0.0067 ribosomal protein L39-like 
HIST1H2BM 1.99 0.0421 histone cluster 1, H2bm 
TNPO1 1.98 0.0000 transportin 1 
TPP1 1.96 0.0019 tripeptidyl peptidase I 
UBA5 1.95 0.0414 ubiquitin-like modifier activating enzyme 5 
NDUFA3 1.94 0.0093 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 3, 9kDa 
HIST1H2AJ 1.92 0.0075 histone cluster 1, H2aj 
HLA-C 1.92 0.0223 major histocompatibility complex, class I, C 
PRCP 1.91 0.0097 prolylcarboxypeptidase 
H1FX 1.90 0.0000 H1 histone family, member X 
SPTLC1 1.90 0.0020 
serine palmitoyltransferase, long chain base 
subunit 1 
CTSB 1.90 0.0136 cathepsin B 
CCDC102B 1.89 0.0040 coiled-coil domain containing 102B 
FAM198B 1.89 0.0068 
family with sequence similarity 198, member 
B 
NDUFB7 1.89 0.0241 
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 7, 18kDa 
ARHGAP1 1.88 0.0044 
Memczak2013 ANTISENSE, CDS, coding, 
INTERNAL, UTR3 best transcript 
NM_004308 
TNC 1.88 0.0127 tenascin C 
SLC41A2 1.88 0.0318 
solute carrier family 41 (magnesium 
transporter), member 2 
NRCAM 1.87 0.0064 neuronal cell adhesion molecule 
DAB2 1.87 0.0099 
Dab, mitogen-responsive phosphoprotein, 







USP34 1.85 0.0008 
Memczak2013 ANTISENSE, CDS, coding, 
INTERNAL best transcript NM_014709 
MDK 1.85 0.0103 midkine (neurite growth-promoting factor 2) 
SMIM12 1.85 0.0109 small integral membrane protein 12 
MXRA7 1.84 0.0239 matrix-remodelling associated 7 
SHARPIN 1.83 0.0013 SHANK-associated RH domain interactor 
GNA12 1.82 0.0016 
guanine nucleotide binding protein (G 
protein) alpha 12 
ZBTB7C 1.82 0.0018 zinc finger and BTB domain containing 7C 
LIN9 1.81 0.0060 
lin-9 DREAM MuvB core complex 
component 
FAM96B 1.81 0.0147 
family with sequence similarity 96, member 
B 
RPS15 1.80 0.0011 ribosomal protein S15 
PPP1R37 1.80 0.0050 protein phosphatase 1, regulatory subunit 37 
NCLN 1.79 0.0017 nicalin 
GPX4 1.79 0.0248 glutathione peroxidase 4 
FAM208A 1.78 0.0018 
family with sequence similarity 208, member 
A 
DHX58 1.78 0.0025 DEXH (Asp-Glu-X-His) box polypeptide 58 
SCAP 1.78 0.0089 SREBF chaperone 
TNS4 1.78 0.0193 tensin 4 
CTNNA1 1.77 0.0005 catenin (cadherin-associated protein), alpha 1 
FAM92A1 1.76 0.0002 
family with sequence similarity 92, member 
A1 
NCS1 1.76 0.0082 neuronal calcium sensor 1 
TMEM25 1.75 0.0004 transmembrane protein 25 
CBFA2T2 1.75 0.0048 
core-binding factor, runt domain, alpha 
subunit 2; translocated to, 2 
ROMO1 1.75 0.0118 reactive oxygen species modulator 1 
CCDC167 1.75 0.0166 coiled-coil domain containing 167 
RPL29 1.74 0.0001 ribosomal protein L29 
TMEM65 1.74 0.0005 transmembrane protein 65 
ITSN1 1.74 0.0006 
Transcript Identified by AceView, Entrez 
Gene ID(s) 6453 
POLE4 1.74 0.0026 
polymerase (DNA-directed), epsilon 4, 
accessory subunit 
MYO1B 1.74 0.0334 myosin IB 
DST 1.74 0.0426 dystonin 







MRPS30 1.72 0.0020 mitochondrial ribosomal protein S30 
NDUFA2 1.72 0.0020 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 2, 8kDa 
NAP1L1 1.72 0.0022 nucleosome assembly protein 1-like 1 
BLOC1S3 1.72 0.0082 
biogenesis of lysosomal organelles complex-
1, subunit 3 
ERBB2IP 1.72 0.0091 erbb2 interacting protein 
DOCK4 1.72 0.0246 dedicator of cytokinesis 4 
SLC38A2 1.72 0.0313 solute carrier family 38, member 2 
RPS29; RPL32P29 1.71 0.0013 
ribosomal protein S29; ribosomal protein 
L32 pseudogene 29 
NAA10 1.71 0.0023 
N(alpha)-acetyltransferase 10, NatA catalytic 
subunit 
DBNDD2 1.71 0.0056 
dysbindin (dystrobrevin binding protein 1) 
domain containing 2 
TMEM160 1.71 0.0313 transmembrane protein 160 
LSM5 1.71 0.0391 
LSM5 homolog, U6 small nuclear RNA and 
mRNA degradation associated 
RPS2; SNORA64; 
SNORA10 1.70 0.0003 
ribosomal protein S2; small nucleolar RNA, 
H/ACA box 64; small nucleolar RNA, 
H/ACA box 10 
CST3 1.70 0.0009 cystatin C 
HIGD2A 1.70 0.0019 
HIG1 hypoxia inducible domain family, 
member 2A 
CCL2 1.70 0.0048 chemokine (C-C motif) ligand 2 
RPL13; SNORD68 1.70 0.0104 
ribosomal protein L13; small nucleolar RNA, 
C/D box 68 
TEKT4P2 1.70 0.0158 tektin 4 pseudogene 2 
AAED1 1.70 0.0300 
AhpC/TSA antioxidant enzyme domain 
containing 1 
OCIAD1 1.70 0.0398 OCIA domain containing 1 
SMARCA5 1.69 0.0000 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily 
a, member 5 
BLOC1S1 1.69 0.0000 
biogenesis of lysosomal organelles complex-
1, subunit 1 
ZC3H4 1.69 0.0003 zinc finger CCCH-type containing 4 
TFRC 1.69 0.0006 transferrin receptor 
GABARAP 1.69 0.0007 GABA(A) receptor-associated protein 











MIR6820 1.69 0.0009 
polymerase (RNA) II (DNA directed) 
polypeptide F; microRNA 4534; microRNA 
6820 
ELMOD2 1.69 0.0015 ELMO/CED-12 domain containing 2 
RPL10A 1.69 0.0015 ribosomal protein L10a 
CFHR2 1.69 0.0081 complement factor H-related 2 
MIF 1.69 0.0086 
macrophage migration inhibitory factor 
(glycosylation-inhibiting factor) 
PHAX 1.69 0.0277 phosphorylated adaptor for RNA export 
PRRT3 1.68 0.0000 proline-rich transmembrane protein 3 
TMEM68 1.68 0.0224 transmembrane protein 68 
MDM1 1.67 0.0108 Mdm1 nuclear protein 
SMIM4 1.67 0.0118 small integral membrane protein 4 
ICE2 1.67 0.0155 
interactor of little elongation complex ELL 
subunit 2 
GNAI2 1.67 0.0229 
guanine nucleotide binding protein (G 
protein), alpha inhibiting activity polypeptide 
2 
LRRN3 1.67 0.0300 leucine rich repeat neuronal 3 
COX6B1 1.66 0.0000 
cytochrome c oxidase subunit VIb 
polypeptide 1 (ubiquitous) 
RPL17-C18orf32 1.66 0.0002 RPL17-C18orf32 readthrough 
ARMC6 1.66 0.0002 armadillo repeat containing 6 
NDUFA11 1.66 0.0037 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 11, 14.7kDa 
IRAK1BP1 1.66 0.0072 
interleukin 1 receptor associated kinase 1 
binding protein 1 
ACE 1.66 0.0143 angiotensin I converting enzyme 
FCER1A 1.66 0.0219 
Fc fragment of IgE, high affinity I, receptor 
for; alpha polypeptide 
RAB13 1.66 0.0251 RAB13, member RAS oncogene family 
DDX59 1.66 0.0327 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
59 
FOXN3 1.66 0.0372 forkhead box N3 
SLCO2B1 1.66 0.0429 
solute carrier organic anion transporter 
family, member 2B1 
RPL32; 
SNORA7A 1.65 0.0001 
ribosomal protein L32; small nucleolar RNA, 
H/ACA box 7A 
VEGFB 1.65 0.0012 vascular endothelial growth factor B 







SRF 1.65 0.0023 
Jeck2013 ANTISENSE, CDS, coding, 
INTERNAL, intronic, OVCODE, OVEXON 
best transcript NM_003131 
VPS13C 1.65 0.0041 
vacuolar protein sorting 13 homolog C (S. 
cerevisiae) 
FSTL4 1.65 0.0093 follistatin-like 4 
SNX7 1.65 0.0427 sorting nexin 7 
MAP4 1.65 0.0453 
Transcript Identified by AceView, Entrez 
Gene ID(s) 4134 
THAP2 1.64 0.0000 
THAP domain containing, apoptosis 
associated protein 2 
PPP6R1 1.64 0.0002 
Memczak2013 ANTISENSE, CDS, coding, 
INTERNAL best transcript NM_014931 
HSPD1 1.64 0.0123 heat shock 60kDa protein 1 (chaperonin) 
C5orf15 1.64 0.0144 chromosome 5 open reading frame 15 
ARPP21 1.64 0.0157 
Transcript Identified by AceView, Entrez 
Gene ID(s) 10777 
CD81 1.64 0.0207 CD81 molecule 
MYO5C 1.64 0.0290 myosin VC 
SPRED1 1.63 0.0008 sprouty-related, EVH1 domain containing 1 
YARS 1.63 0.0012 
Transcript Identified by AceView, Entrez 
Gene ID(s) 8565 
NUP35 1.63 0.0130 nucleoporin 35kDa 
C1RL 1.63 0.0265 
complement component 1, r subcomponent-
like 
RGS17 1.63 0.0289 regulator of G-protein signaling 17 
FKBP1A; 
MIR6869 1.63 0.0339 FK506 binding protein 1A; microRNA 6869 
SMN1 1.63 0.0389 survival of motor neuron 1, telomeric 
TMEM38B 1.62 0.0015 transmembrane protein 38B 
OR52E4 1.62 0.0018 
olfactory receptor, family 52, subfamily E, 
member 4 
HIST1H2AI 1.62 0.0028 histone cluster 1, H2ai 
ALKBH7 1.62 0.0110 alkB homolog 7 
AAMDC 1.62 0.0160 
adipogenesis associated, Mth938 domain 
containing 
TTLL12 1.62 0.0179 
tubulin tyrosine ligase-like family member 
12 
GPX1 1.62 0.0239 glutathione peroxidase 1 







HMGN1 1.61 0.0005 
high mobility group nucleosome binding 
domain 1 
UQCR11 1.61 0.0006 
ubiquinol-cytochrome c reductase, complex 
III subunit XI 
RPL6 1.61 0.0007 ribosomal protein L6 
ADAM17 1.61 0.0012 ADAM metallopeptidase domain 17 
DAW1 1.61 0.0046 
dynein assembly factor with WDR repeat 
domains 1 
PLBD2 1.61 0.0056 phospholipase B domain containing 2 
EMILIN2 1.61 0.0067 elastin microfibril interfacer 2 
COX7A1 1.61 0.0114 
cytochrome c oxidase subunit VIIa 
polypeptide 1 (muscle) 
UPK3BL; 
POLR2J2 1.61 0.0144 
uroplakin 3B-like; polymerase (RNA) II 
(DNA directed) polypeptide J2 
PPP1R14B 1.60 0.0003 
protein phosphatase 1, regulatory (inhibitor) 
subunit 14B 
XPO7 1.60 0.0014 exportin 7 
UBE2E1 1.60 0.0018 ubiquitin conjugating enzyme E2E 1 
TCEB2 1.60 0.0052 
transcription elongation factor B (SIII), 
polypeptide 2 (18kDa, elongin B) 
RGS4 1.60 0.0087 regulator of G-protein signaling 4 
RPL18A; 
SNORA68 1.60 0.0120 
ribosomal protein L18a; small nucleolar 
RNA, H/ACA box 68 
PEX2 1.60 0.0156 peroxisomal biogenesis factor 2 
KBTBD4 1.60 0.0162 
kelch repeat and BTB (POZ) domain 
containing 4 
COPS4 1.60 0.0234 COP9 signalosome subunit 4 
FAM195A 1.60 0.0258 
family with sequence similarity 195, member 
A 
UQCRQ 1.60 0.0330 
ubiquinol-cytochrome c reductase complex 
III subunit VII 
MSR1 1.60 0.0416 macrophage scavenger receptor 1 
ZNF268 1.59 0.0000 zinc finger protein 268 
RPL18A 1.59 0.0010 ribosomal protein L18a 
RPS11; 
SNORD35B 1.59 0.0022 
ribosomal protein S11; small nucleolar RNA, 
C/D box 35B 
EBPL 1.59 0.0134 emopamil binding protein-like 
AHCY 1.59 0.0295 adenosylhomocysteinase 
UACA 1.59 0.0393 
uveal autoantigen with coiled-coil domains 
and ankyrin repeats 







ZMYM2 1.58 0.0003 zinc finger, MYM-type 2 
ACVR1 1.58 0.0015 activin A receptor type I 
WDR87 1.58 0.0022 WD repeat domain 87 
EIF3F 1.58 0.0025 
Eukaryotic translation initiation factor 3 
subunit F  [Source:UniProtKB/Swiss-
Prot;Acc:O00303] 
ZBTB7A 1.58 0.0032 zinc finger and BTB domain containing 7A 
PAFAH1B2 1.58 0.0056 
platelet-activating factor acetylhydrolase 1b, 
catalytic subunit 2 (30kDa) 
GXYLT1 1.58 0.0086 glucoside xylosyltransferase 1 
UQCC2 1.58 0.0104 
ubiquinol-cytochrome c reductase complex 
assembly factor 2 
FAM65A 1.58 0.0237 
family with sequence similarity 65, member 
A 
S100B 1.58 0.0337 S100 calcium binding protein B 
ZNF574 1.58 0.0440 zinc finger protein 574 
HIST2H2AC 1.57 0.0001 histone cluster 2, H2ac 
RCN1 1.57 0.0007 
reticulocalbin 1, EF-hand calcium binding 
domain 
CNTLN 1.57 0.0013 centlein, centrosomal protein 
HIST1H2AE 1.57 0.0013 histone cluster 1, H2ae 
ULK2 1.57 0.0013 unc-51 like autophagy activating kinase 2 
HIST1H2AL; 
HIST1H2BN 1.57 0.0023 
histone cluster 1, H2al; histone cluster 1, 
H2bn 
GTF2IRD2; 
GTF2IRD2B 1.57 0.0076 
GTF2I repeat domain containing 2; GTF2I 
repeat domain containing 2B 
FAM229B 1.57 0.0111 
family with sequence similarity 229, member 
B 
ROR2 1.57 0.0116 
receptor tyrosine kinase-like orphan receptor 
2 
NT5DC1 1.57 0.0119 5-nucleotidase domain containing 1 
TP63 1.57 0.0123 tumor protein p63 
JAGN1 1.57 0.0166 jagunal homolog 1 
HIST1H1B 1.57 0.0255 histone cluster 1, H1b 
HERC4 1.57 0.0257 
HECT and RLD domain containing E3 
ubiquitin protein ligase 4 
ADAP2 1.57 0.0313 ArfGAP with dual PH domains 2 
CITED2 1.57 0.0355 
Cbp/p300-interacting transactivator, with 
Glu/Asp rich carboxy-terminal domain, 2 







ZNRD1 1.57 0.0457 zinc ribbon domain containing 1 





SNORD32A 1.56 0.0029 
ribosomal protein L13a; small nucleolar 
RNA, C/D box 35A; small nucleolar RNA, 
C/D box 34; small nucleolar RNA, C/D box 
33; small nucleolar RNA, C/D box 32A 
THAP3 1.56 0.0036 
THAP domain containing, apoptosis 
associated protein 3 
PLP2 1.56 0.0126 
proteolipid protein 2 (colonic epithelium-
enriched) 
TIMP1 1.56 0.0219 TIMP metallopeptidase inhibitor 1 
FAT2 1.56 0.0310 FAT atypical cadherin 2 
SAFB 1.55 0.0008 scaffold attachment factor B 
MAFB 1.55 0.0036 
v-maf avian musculoaponeurotic 
fibrosarcoma oncogene homolog B 
SLC25A32 1.55 0.0064 
solute carrier family 25 (mitochondrial folate 
carrier), member 32 
SERF2 1.55 0.0091 small EDRK-rich factor 2 
DHX38 1.55 0.0104 
DEAH (Asp-Glu-Ala-His) box polypeptide 
38 
LRRN4 1.55 0.0143 leucine rich repeat neuronal 4 
UQCRB 1.55 0.0167 
ubiquinol-cytochrome c reductase binding 
protein 
NAP1L4 1.55 0.0178 nucleosome assembly protein 1-like 4 
CMBL 1.55 0.0206 
carboxymethylenebutenolidase homolog 
(Pseudomonas) 
TMEM30A 1.55 0.0232 transmembrane protein 30A 
PPP6R1 1.55 0.0291 
Memczak2013 ANTISENSE, CDS, coding, 
INTERNAL best transcript NM_014931 
PPP1R17 1.55 0.0328 protein phosphatase 1, regulatory subunit 17 
PET117; 
CSRP2BP 1.55 0.0342 PET117 homolog; CSRP2 binding protein 
SSBP2 1.55 0.0459 single-stranded DNA binding protein 2 
MAD2L1BP 1.54 0.0005 MAD2L1 binding protein 
DGKE 1.54 0.0009 diacylglycerol kinase, epsilon 64kDa 
ZNF546 1.54 0.0031 zinc finger protein 546 
LRIT3 1.54 0.0051 
leucine-rich repeat, immunoglobulin-like and 
transmembrane domains 3 
TMEM134 1.54 0.0080 transmembrane protein 134 







MRPS12 1.54 0.0183 mitochondrial ribosomal protein S12 
HIST1H4F 1.54 0.0212 histone cluster 1, H4f 
HIST1H4C 1.54 0.0259 
Jeck2013 ANTISENSE, CDS, coding, 
INTERNAL, OVCODE, OVEXON, UTR3 
best transcript NM_003542 
PNPLA3 1.54 0.0335 
patatin-like phospholipase domain containing 
3 
CALCRL 1.54 0.0341 calcitonin receptor like receptor 
UBL5 1.53 0.0000 ubiquitin-like 5 
ABCC6 1.53 0.0052 ATP binding cassette subfamily C member 6 
SEMA4B 1.53 0.0226 
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4B 
GTF2A2 1.53 0.0355 general transcription factor IIA 2 
CLPP 1.53 0.0370 
caseinolytic mitochondrial matrix peptidase 
proteolytic subunit 
HMGN3 1.52 0.0036 
high mobility group nucleosomal binding 
domain 3 
MLANA 1.52 0.0058 melan-A 
SLC16A7 1.52 0.0165 
solute carrier family 16 (monocarboxylate 
transporter), member 7 
IL33 1.52 0.0361 interleukin 33 
NCL 1.51 0.0002 nucleolin 
RPS17 1.51 0.0004 ribosomal protein S17 
CACNG7 1.51 0.0005 
calcium channel, voltage-dependent, gamma 
subunit 7 
RPL14 1.51 0.0015 
Transcript Identified by AceView, Entrez 
Gene ID(s) 9045 
IK; MIR3655 1.51 0.0016 
IK cytokine, down-regulator of HLA II; 
microRNA 3655 
DAPL1; OR7E89P 1.51 0.0076 
death associated protein like 1; olfactory 
receptor, family 7, subfamily E, member 89 
pseudogene 
ATXN1L 1.51 0.0106 ataxin 1-like 
HIST1H2BK 1.51 0.0232 histone cluster 1, H2bk 
ZFYVE16 1.51 0.0253 zinc finger, FYVE domain containing 16 
EIF3E 1.51 0.0296 
eukaryotic translation initiation factor 3, 
subunit E 
ADAM8 1.51 0.0355 
Memczak2013 ANTISENSE, CDS, coding, 







CSGALNACT1 1.51 0.0356 
chondroitin sulfate N-
acetylgalactosaminyltransferase 1 
RPS6KA3 1.51 0.0429 
ribosomal protein S6 kinase, 90kDa, 
polypeptide 3 
GTF3C5 1.50 0.0002 general transcription factor IIIC subunit 5 
ZNF155 1.50 0.0030 zinc finger protein 155 
UBE2T 1.50 0.0229 ubiquitin conjugating enzyme E2T 
HPS3 -1.50 0.0021 Hermansky-Pudlak syndrome 3 
MDM2 -1.50 0.0093 
MDM2 proto-oncogene, E3 ubiquitin protein 
ligase 
NDUFA10 -1.50 0.0169 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 10, 42kDa 
TFAP2C -1.50 0.0297 
transcription factor AP-2 gamma (activating 
enhancer binding protein 2 gamma) 
PIP5K1A -1.50 0.0299 
phosphatidylinositol-4-phosphate 5-kinase, 
type I, alpha 
SLC11A2 -1.50 0.0321 
solute carrier family 11 (proton-coupled 
divalent metal ion transporter), member 2 
ATG101 -1.51 0.0004 autophagy related 101 
NFX1 -1.51 0.0009 nuclear transcription factor, X-box binding 1 
THOC7 -1.51 0.0024 THO complex 7 
KNTC1 -1.51 0.0053 kinetochore associated 1 
ZUFSP -1.51 0.0098 
zinc finger with UFM1-specific peptidase 
domain 
CHCHD4 -1.51 0.0115 
coiled-coil-helix-coiled-coil-helix domain 
containing 4 
TMEM50B -1.51 0.0218 transmembrane protein 50B 
KLHDC7B -1.51 0.0223 kelch domain containing 7B 
CBR4 -1.51 0.0225 carbonyl reductase 4 
WDR45B -1.51 0.0232 WD repeat domain 45B 
HYOU1 -1.51 0.0255 hypoxia up-regulated 1 
TPM4 -1.51 0.0262 tropomyosin 4 
MFNG -1.51 0.0363 
MFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase 
SLC20A2 -1.51 0.0392 
solute carrier family 20 (phosphate 
transporter), member 2 
SDCBP -1.51 0.0432 syndecan binding protein 
SAP130 -1.51 0.0459 Sin3A associated protein 130kDa 
DNMT3A -1.52 0.0004 DNA (cytosine-5-)-methyltransferase 3 alpha 







SCYL1 -1.52 0.0020 SCY1-like, kinase-like 1 
BAP1 -1.52 0.0025 BRCA1 associated protein 1 
ZNF148 -1.52 0.0028 zinc finger protein 148 
RAB2A -1.52 0.0029 RAB2A, member RAS oncogene family 
NRBP1 -1.52 0.0056 nuclear receptor binding protein 1 
NSD1 -1.52 0.0248 
nuclear receptor binding SET domain protein 
1 
FAM84B -1.52 0.0333 
family with sequence similarity 84, member 
B 
BPTF -1.52 0.0338 
bromodomain PHD finger transcription 
factor 
CLASP1 -1.53 0.0003 cytoplasmic linker associated protein 1 
STIM2 -1.53 0.0009 stromal interaction molecule 2 
ZFP3 -1.53 0.0027 ZFP3 zinc finger protein 
TESC -1.53 0.0075 tescalcin 
PDE4DIP -1.53 0.0218 
Transcript Identified by AceView, Entrez 
Gene ID(s) 9659 
CAPN8 -1.53 0.0263 calpain 8 
RAB24 -1.53 0.0491 RAB24, member RAS oncogene family 
ENTPD4; LOXL2 -1.54 0.0018 
ectonucleoside triphosphate 
diphosphohydrolase 4; lysyl oxidase-like 2 
ZFX -1.54 0.0030 zinc finger protein, X-linked 
MOV10 -1.54 0.0069 Mov10 RISC complex RNA helicase 
PPP1R12B -1.54 0.0083 
protein phosphatase 1, regulatory subunit 
12B 
OPHN1 -1.54 0.0086 oligophrenin 1 
SAE1 -1.54 0.0154 SUMO1 activating enzyme subunit 1 
RALB -1.54 0.0178 
v-ral simian leukemia viral oncogene 
homolog B 
PRPSAP2 -1.54 0.0180 
phosphoribosyl pyrophosphate synthetase-
associated protein 2 
CNNM4 -1.54 0.0219 
cyclin and CBS domain divalent metal cation 
transport mediator 4 
TM2D2 -1.54 0.0414 TM2 domain containing 2 
RLF -1.54 0.0497 rearranged L-myc fusion 
RNGTT -1.55 0.0008 RNA guanylyltransferase and 5-phosphatase 
TRAFD1 -1.55 0.0022 TRAF-type zinc finger domain containing 1 
GIMAP2 -1.55 0.0097 GTPase, IMAP family member 2 
OSBPL3 -1.55 0.0180 oxysterol binding protein-like 3 







CMAS -1.55 0.0244 
cytidine monophosphate N-acetylneuraminic 
acid synthetase 
POGZ -1.55 0.0291 
Transcript Identified by AceView, Entrez 
Gene ID(s) 23126 
FAM214B -1.55 0.0347 
family with sequence similarity 214, member 
B 
CPEB2 -1.55 0.0397 
cytoplasmic polyadenylation element binding 
protein 2 
PPP2R5C -1.56 0.0000 
protein phosphatase 2, regulatory subunit B, 
gamma 
HNRNPC -1.56 0.0006 
heterogeneous nuclear ribonucleoprotein C 
(C1/C2) 
ZBED4 -1.56 0.0026 zinc finger, BED-type containing 4 
MGEA5 -1.56 0.0041 
Salzman2013 ALT_ACCEPTOR, 
ALT_DONOR, coding, INTERNAL, 
intronic best transcript NM_012215 
RPGR -1.56 0.0265 retinitis pigmentosa GTPase regulator 
SIDT1 -1.56 0.0322 SID1 transmembrane family, member 1 
ANKRD36 -1.56 0.0348 ankyrin repeat domain 36 
ATG13 -1.57 0.0000 autophagy related 13 
IP6K2 -1.57 0.0017 inositol hexakisphosphate kinase 2 
ZNF891 -1.57 0.0027 zinc finger protein 891 
CEP63 -1.57 0.0042 centrosomal protein 63kDa 
FOXP1 -1.57 0.0067 forkhead box P1 
CAPRIN2 -1.57 0.0155 caprin family member 2 
ANXA11 -1.57 0.0177 annexin A11 
TXNIP -1.57 0.0252 thioredoxin interacting protein 
CCZ1B -1.57 0.0291 
CCZ1 homolog B, vacuolar protein 
trafficking and biogenesis associated 
POMT1 -1.57 0.0375 protein-O-mannosyltransferase 1 
COG4 -1.58 0.0051 component of oligomeric golgi complex 4 
USO1 -1.58 0.0112 USO1 vesicle transport factor 
LRRC28 -1.58 0.0114 leucine rich repeat containing 28 
LMAN2L -1.58 0.0120 lectin, mannose-binding 2-like 
RINT1 -1.58 0.0152 RAD50 interactor 1 
RAB5A -1.58 0.0159 RAB5A, member RAS oncogene family 
GBF1 -1.58 0.0185 
golgi brefeldin A resistant guanine 
nucleotide exchange factor 1 
CCDC146 -1.58 0.0211 coiled-coil domain containing 146 







HHAT -1.58 0.0367 hedgehog acyltransferase 
POGZ -1.58 0.0379 
Transcript Identified by AceView, Entrez 
Gene ID(s) 23126 
MAVS -1.58 0.0438 mitochondrial antiviral signaling protein 
DPY19L3 -1.58 0.0488 dpy-19-like 3 (C. elegans) 
UBE4B -1.59 0.0001 ubiquitination factor E4B 
HDAC6 -1.59 0.0004 histone deacetylase 6 
VCPIP1 -1.59 0.0010 
valosin containing protein (p97)/p47 
complex interacting protein 1 
RBM12B -1.59 0.0012 RNA binding motif protein 12B 
SMCR8 -1.59 0.0031 
Smith-Magenis syndrome chromosome 
region, candidate 8 
TSPAN11 -1.59 0.0153 tetraspanin 11 
RGPD5; RGPD8 -1.59 0.0158 
RANBP2-like and GRIP domain containing 
5; RANBP2-like and GRIP domain 
containing 8 
OCLN -1.59 0.0161 occludin 
NDUFAF7 -1.59 0.0170 
NADH dehydrogenase (ubiquinone) complex 
I, assembly factor 7 
DNTTIP2 -1.59 0.0225 
deoxynucleotidyltransferase, terminal, 
interacting protein 2 
TERT -1.59 0.0251 
Zhang2013 ALT_ACCEPTOR, 
ALT_DONOR, coding, INTERNAL, 
intronic best transcript NM_198253 
AGO2 -1.59 0.0360 argonaute RISC catalytic component 2 
MUC13 -1.59 0.0421 mucin 13, cell surface associated 
RAB8A -1.60 0.0010 RAB8A, member RAS oncogene family 
ADNP -1.60 0.0015 activity-dependent neuroprotector homeobox 
PCMTD2 -1.60 0.0050 
protein-L-isoaspartate (D-aspartate) O-
methyltransferase domain containing 2 
NCOA4 -1.60 0.0056 nuclear receptor coactivator 4 
MATR3; 
SNORA74A; 
SNHG4 -1.60 0.0066 
matrin 3; small nucleolar RNA, H/ACA box 
74A; small nucleolar RNA host gene 4 
UBE2W -1.60 0.0096 
ubiquitin-conjugating enzyme E2W 
(putative) 
ACTR3 -1.60 0.0248 
ARP3 actin-related protein 3 homolog 
(yeast) 
CD3G -1.60 0.0306 








KCNK1 -1.61 0.0022 
potassium channel, two pore domain 
subfamily K, member 1 
FBXL20 -1.61 0.0069 F-box and leucine-rich repeat protein 20 
MED12 -1.61 0.0131 mediator complex subunit 12 
SPATA5 -1.61 0.0341 
Transcript Identified by AceView, Entrez 
Gene ID(s) 166378 
SLK -1.61 0.0346 STE20-like kinase 
MARCH8 -1.61 0.0351 membrane associated ring finger 8 
ACSS2 -1.61 0.0472 
acyl-CoA synthetase short-chain family 
member 2 
GATAD2A; 
MIR640 -1.62 0.0036 
GATA zinc finger domain containing 2A; 
microRNA 640 
EXOC7 -1.62 0.0059 
Zhang2013 ALT_ACCEPTOR, 
ALT_DONOR, coding, INTERNAL, 
intronic best transcript NM_001145297 
TRAPPC10 -1.62 0.0092 trafficking protein particle complex 10 
SEPT2 -1.62 0.0117 septin 2 
LSP1P3 -1.62 0.0172 lymphocyte-specific protein 1 pseudogene 3 
STX16 -1.62 0.0238 syntaxin 16 
CDC23 -1.62 0.0312 cell division cycle 23 
ZKSCAN1 -1.62 0.0388 
zinc finger with KRAB and SCAN domains 
1 
EHD3 -1.62 0.0496 EH domain containing 3 
DYNC1LI2 -1.63 0.0001 
dynein, cytoplasmic 1, light intermediate 
chain 2 
CD79B -1.63 0.0007 
CD79b molecule, immunoglobulin-
associated beta 
SLC44A2 -1.63 0.0079 
solute carrier family 44 (choline transporter), 
member 2 
KDM3A -1.63 0.0123 lysine (K)-specific demethylase 3A 
ZNF776 -1.63 0.0151 zinc finger protein 776 
PCNXL4 -1.63 0.0205 pecanex-like 4 (Drosophila) 
EPB41L4A -1.63 0.0237 
erythrocyte membrane protein band 4.1 like 
4A 
SRSF5 -1.63 0.0251 serine/arginine-rich splicing factor 5 
DDX23 -1.64 0.0001 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
23 
YTHDF3 -1.64 0.0021 
YTH N(6)-methyladenosine RNA binding 
protein 3 







POLR3B -1.64 0.0051 
polymerase (RNA) III (DNA directed) 
polypeptide B 
ELMO2 -1.64 0.0052 engulfment and cell motility 2 
RBM5 -1.64 0.0061 RNA binding motif protein 5 
MYLIP; MIR4639 -1.64 0.0068 
myosin regulatory light chain interacting 
protein; microRNA 4639 
MICAL2 -1.64 0.0096 
microtubule associated monooxygenase, 
calponin and LIM domain containing 2 
PRR14L -1.65 0.0006 proline rich 14-like 
NT5C2 -1.65 0.0055 5-nucleotidase, cytosolic II 
ATG2B -1.65 0.0080 autophagy related 2B 
KAT6B -1.65 0.0098 K(lysine) acetyltransferase 6B 
ZNF75D -1.65 0.0291 zinc finger protein 75D 
THAP9-AS1 -1.65 0.0478 THAP9 antisense RNA 1 
CCNC -1.66 0.0044 cyclin C 
DNAH5 -1.66 0.0065 
Transcript Identified by AceView, Entrez 
Gene ID(s) 1767 
MARCH8 -1.66 0.0185 
Transcript Identified by AceView, Entrez 
Gene ID(s) 220972 
TCHP -1.66 0.0198 trichoplein, keratin filament binding 
LOC643802 -1.66 0.0217 
u3 small nucleolar ribonucleoprotein protein 
MPP10-like 
GPR52 -1.66 0.0455 G protein-coupled receptor 52 
HSP90B1 -1.67 0.0005 
Transcript Identified by AceView, Entrez 
Gene ID(s) 7184 
RRBP1 -1.67 0.0075 ribosome binding protein 1 
CHST11 -1.67 0.0083 
Transcript Identified by AceView, Entrez 
Gene ID(s) 50515 
SORBS2 -1.67 0.0116 sorbin and SH3 domain containing 2 
AGAP9; 
CTGLF11P -1.67 0.0128 
Salzman2013 ANNOTATED, CDS, coding, 
INTERNAL, OVCODE, OVEXON best 
transcript NM_001190810; centaurin, 
gamma-like family, member 11 pseudogene 
[Source:HGNC Symbol;Acc:HGNC:23660] 
EDEM3 -1.67 0.0139 
ER degradation enhancer, mannosidase 
alpha-like 3 
ZNF200 -1.67 0.0276 
Transcript Identified by AceView, Entrez 
Gene ID(s) 7752 
CHD1 -1.67 0.0318 
chromodomain helicase DNA binding 
protein 1 







CNOT6 -1.68 0.0006 CCR4-NOT transcription complex subunit 6 
SENP6 -1.68 0.0009 SUMO1/sentrin specific peptidase 6 
ARFIP1 -1.68 0.0012 ADP-ribosylation factor interacting protein 1 
VMP1; MIR21 -1.68 0.0159 vacuole membrane protein 1; microRNA 21 




MIR6516 -1.68 0.0308 
SEC14-like lipid binding 1; small Cajal 
body-specific RNA 16; small nucleolar RNA 
host gene 20; microRNA 6516 
OSGEPL1 -1.68 0.0315 O-sialoglycoprotein endopeptidase-like 1 
TRIP11 -1.68 0.0332 thyroid hormone receptor interactor 11 
MFSD6 -1.68 0.0350 
major facilitator superfamily domain 
containing 6 
ENO1 -1.69 0.0003 enolase 1, (alpha) 
HGS -1.69 0.0005 
hepatocyte growth factor-regulated tyrosine 
kinase substrate 
FBXW2 -1.69 0.0042 F-box and WD repeat domain containing 2 
HSP90B1; 
MIR3652 -1.69 0.0063 
heat shock protein 90kDa beta (Grp94), 
member 1; microRNA 3652 
CRLF3 -1.69 0.0153 cytokine receptor-like factor 3 
MUT -1.69 0.0167 methylmalonyl-CoA mutase 
CD2 -1.69 0.0209 CD2 molecule 
SNRPA1 -1.69 0.0234 
small nuclear ribonucleoprotein polypeptide 
A 
OGFR -1.69 0.0304 opioid growth factor receptor 
STK39 -1.69 0.0376 serine threonine kinase 39 
STS -1.69 0.0380 steroid sulfatase (microsomal), isozyme S 
ABCD3 -1.69 0.0434 
Transcript Identified by AceView, Entrez 
Gene ID(s) 5825 
MPRIP -1.69 0.0452 myosin phosphatase Rho interacting protein 
FAM45A -1.69 0.0456 
Transcript Identified by AceView, Entrez 
Gene ID(s) 404636 
NAE1 -1.70 0.0011 NEDD8 activating enzyme E1 subunit 1 
FMR1 -1.70 0.0014 fragile X mental retardation 1 
DNAJC16 -1.70 0.0058 
DnaJ (Hsp40) homolog, subfamily C, 
member 16 
SEC23B -1.70 0.0139 
Sec23 homolog B, COPII coat complex 
component 
PSMD2 -1.70 0.0144 proteasome 26S subunit, non-ATPase 2 







RCC2 -1.71 0.0101 regulator of chromosome condensation 2 
TMEM8A -1.71 0.0115 transmembrane protein 8A 
GABRE; MIR224; 
MIR452 -1.71 0.0171 
gamma-aminobutyric acid (GABA) A 
receptor, epsilon; microRNA 224; 
microRNA 452 
CDRT1 -1.71 0.0204 CMT1A duplicated region transcript 1 
RAB27B -1.71 0.0340 RAB27B, member RAS oncogene family 
RCOR1 -1.71 0.0439 REST corepressor 1 
NUP153 -1.72 0.0001 nucleoporin 153kDa 
KIAA2026 -1.72 0.0001 KIAA2026 
METTL9 -1.72 0.0024 methyltransferase like 9 
ARFGEF1 -1.72 0.0061 
ADP-ribosylation factor guanine nucleotide-
exchange factor 1 (brefeldin A-inhibited) 
TBC1D3E -1.72 0.0066 TBC1 domain family, member 3E 
GDI1 -1.72 0.0127 GDP dissociation inhibitor 1 
TSPAN12 -1.72 0.0175 tetraspanin 12 
MDM4 -1.72 0.0187 MDM4, p53 regulator 
MYO5B -1.72 0.0194 myosin VB 
ARL5B -1.72 0.0218 ADP-ribosylation factor like GTPase 5B 
ARHGEF1 -1.72 0.0473 Rho guanine nucleotide exchange factor 1 
UNC13B -1.73 0.0085 unc-13 homolog B (C. elegans) 
COX18 -1.73 0.0141 
COX18 cytochrome c oxidase assembly 
factor 
CLDN4 -1.73 0.0303 claudin 4 
VPS8 -1.73 0.0304 
vacuolar protein sorting 8 homolog (S. 
cerevisiae) 
SLC25A11 -1.73 0.0435 
solute carrier family 25 (mitochondrial 
carrier; oxoglutarate carrier), member 11 
ELOVL1; 
MIR6734 -1.73 0.0478 
ELOVL fatty acid elongase 1; microRNA 
6734 
PARP15 -1.74 0.0053 
poly(ADP-ribose) polymerase family 
member 15 
SLC39A11 -1.74 0.0132 solute carrier family 39, member 11 
AGAP5 -1.74 0.0158 
ArfGAP with GTPase domain, ankyrin 
repeat and PH domain 5 
MPZL2 -1.74 0.0233 myelin protein zero-like 2 
MSL1 -1.74 0.0443 male-specific lethal 1 homolog (Drosophila) 
RNF38 -1.75 0.0051 ring finger protein 38 
SLC35A5 -1.75 0.0145 solute carrier family 35, member A5 







MLLT4 -1.75 0.0495 
myeloid/lymphoid or mixed-lineage 
leukemia; translocated to, 4 
DBNL; MIR6837 -1.76 0.0002 drebrin-like; microRNA 6837 
TRIP4 -1.76 0.0017 thyroid hormone receptor interactor 4 
EIF4EBP2 -1.76 0.0317 
eukaryotic translation initiation factor 4E 
binding protein 2 
SDHD -1.77 0.0003 
succinate dehydrogenase complex subunit D, 
integral membrane protein 
PPP1CC -1.77 0.0005 
protein phosphatase 1, catalytic subunit, 
gamma isozyme 
LYSMD3 -1.77 0.0013 
LysM, putative peptidoglycan-binding, 
domain containing 3 
IPO9 -1.77 0.0017 importin 9 
NAA35 -1.77 0.0037 
N(alpha)-acetyltransferase 35, NatC 
auxiliary subunit 
INPP5D -1.77 0.0061 inositol polyphosphate-5-phosphatase D 
DENND2D -1.77 0.0066 DENN/MADD domain containing 2D 
NCALD -1.77 0.0258 neurocalcin delta 
UCP2 -1.77 0.0286 
uncoupling protein 2 (mitochondrial, proton 
carrier) 
DCPS -1.77 0.0332 decapping enzyme, scavenger 
ZMYND8 -1.78 0.0001 zinc finger, MYND-type containing 8 
AREL1 -1.78 0.0006 
apoptosis resistant E3 ubiquitin protein ligase 
1 
SF3A3 -1.78 0.0108 splicing factor 3a subunit 3 
NEK9 -1.78 0.0208 NIMA-related kinase 9 
AGAP6 -1.78 0.0235 
ArfGAP with GTPase domain, ankyrin 
repeat and PH domain 6 
OSTM1 -1.78 0.0314 
osteopetrosis associated transmembrane 
protein 1 
MYO1D -1.78 0.0412 myosin ID 
PPFIBP2 -1.79 0.0048 
PTPRF interacting protein, binding protein 2 
(liprin beta 2) 
CFTR -1.79 0.0134 
cystic fibrosis transmembrane conductance 
regulator 
USP38 -1.79 0.0401 ubiquitin specific peptidase 38 
UTP20 -1.80 0.0039 
UTP20 small subunit (SSU) processome 
component 
PTPN3 -1.80 0.0354 
protein tyrosine phosphatase, non-receptor 
type 3 







NUDT12 -1.80 0.0497 nudix hydrolase 12 
TUFT1 -1.81 0.0013 tuftelin 1 
XDH -1.81 0.0449 xanthine dehydrogenase 
SIPA1L1 -1.83 0.0022 
signal-induced proliferation-associated 1 like 
1 
IRAK4 -1.83 0.0031 interleukin 1 receptor associated kinase 4 
PTPRCAP -1.83 0.0096 
protein tyrosine phosphatase, receptor type, 
C-associated protein 
AGAP4 -1.84 0.0094 
ArfGAP with GTPase domain, ankyrin 
repeat and PH domain 4 
FAM120A -1.84 0.0099 family with sequence similarity 120A 
CACUL1 -1.84 0.0238 CDK2-associated, cullin domain 1 
KCTD10 -1.85 0.0007 
potassium channel tetramerization domain 
containing 10 
MAP3K13 -1.86 0.0083 
mitogen-activated protein kinase kinase 
kinase 13 
MFSD10 -1.86 0.0104 
major facilitator superfamily domain 
containing 10 
MCTP2 -1.86 0.0433 multiple C2 domains, transmembrane 2 
KIAA0513 -1.87 0.0003 KIAA0513 
SLC37A1 -1.87 0.0014 
solute carrier family 37 (glucose-6-phosphate 
transporter), member 1 
DHRS1 -1.87 0.0014 
dehydrogenase/reductase (SDR family) 
member 1 
CDC42SE2 -1.87 0.0037 CDC42 small effector 2 
ANKRD13A -1.87 0.0206 ankyrin repeat domain 13A 
CATSPERB -1.87 0.0414 catsper channel auxiliary subunit beta 
TPM3 -1.88 0.0001 tropomyosin 3 
ARHGAP11B -1.88 0.0047 Rho GTPase activating protein 11B 
SLC6A14 -1.88 0.0157 
solute carrier family 6 (amino acid 
transporter), member 14 
TGM5 -1.88 0.0225 transglutaminase 5 
CTDSPL -1.88 0.0233 CTD small phosphatase like 
TMEM184A -1.89 0.0167 transmembrane protein 184A 
GLCCI1 -1.89 0.0371 glucocorticoid induced 1 
MYCBP; GJA9 -1.91 0.0001 
MYC binding protein; gap junction protein 
alpha 9 
DUSP16 -1.91 0.0067 dual specificity phosphatase 16 
TPRA1 -1.91 0.0138 








MTOR -1.92 0.0022 
mechanistic target of rapamycin 
(serine/threonine kinase) 
CCDC84 -1.93 0.0058 coiled-coil domain containing 84 
CDH26 -1.93 0.0313 cadherin 26 
USP15; MIR6125 -1.94 0.0420 
ubiquitin specific peptidase 15; microRNA 
6125 
SNX33 -1.94 0.0434 sorting nexin 33 
BROX -1.95 0.0000 BRO1 domain and CAAX motif containing 
SORBS2 -1.95 0.0231 
Transcript Identified by AceView, Entrez 
Gene ID(s) 8470 
TMX4 -1.95 0.0426 thioredoxin-related transmembrane protein 4 
NCOA3 -1.98 0.0000 nuclear receptor coactivator 3 
PIGN -1.98 0.0006 
phosphatidylinositol glycan anchor 
biosynthesis class N 
C16orf72 -1.98 0.0015 
Memczak2013 ANTISENSE, coding, 
INTERNAL, intronic best transcript 
NM_014117 
C4orf19 -1.98 0.0195 chromosome 4 open reading frame 19 
DUS2 -1.99 0.0002 dihydrouridine synthase 2 
RTN3 -2.02 0.0003 reticulon 3 
PTPN23 -2.02 0.0042 
protein tyrosine phosphatase, non-receptor 
type 23 
DIP2B -2.02 0.0167 disco-interacting protein 2 homolog B 
PPM1B -2.02 0.0305 
Memczak2013 ANTISENSE, coding, 
INTERNAL, intronic best transcript 
NM_001033556 
C2CD5 -2.03 0.0004 C2 calcium-dependent domain containing 5 
GALNT3 -2.03 0.0056 
polypeptide N-
acetylgalactosaminyltransferase 3 
PVRL2 -2.03 0.0096 
poliovirus receptor-related 2 (herpesvirus 
entry mediator B) 
KRT80 -2.05 0.0444 keratin 80, type II 
RPS6KB1 -2.06 0.0085 
ribosomal protein S6 kinase, 70kDa, 
polypeptide 1 
QSOX1 -2.06 0.0298 quiescin Q6 sulfhydryl oxidase 1 
GBA -2.06 0.0457 glucosidase, beta, acid 
NUP50 -2.07 0.0001 nucleoporin 50kDa 
OS9 -2.07 0.0262 
osteosarcoma amplified 9, endoplasmic 
reticulum lectin 








CKMT1A -2.09 0.0434 
creatine kinase, mitochondrial 1B; creatine 
kinase, mitochondrial 1A 
KIAA0430; 
MIR6506 -2.10 0.0001 KIAA0430; microRNA 6506 
STAT4 -2.10 0.0208 
signal transducer and activator of 
transcription 4 
RBM33 -2.11 0.0014 RNA binding motif protein 33 
WASL -2.12 0.0219 Wiskott-Aldrich syndrome-like 
SPECC1 -2.13 0.0005 
sperm antigen with calponin homology and 
coiled-coil domains 1 
PLPPR2 -2.13 0.0165 phospholipid phosphatase related 2 
BTN3A1 -2.14 0.0001 butyrophilin, subfamily 3, member A1 
PRKD3 -2.14 0.0174 protein kinase D3 
DICER1 -2.15 0.0000 dicer 1, ribonuclease type III 
CREBBP -2.15 0.0001 CREB binding protein 
THEMIS -2.15 0.0014 thymocyte selection associated 
PFKP -2.16 0.0036 phosphofructokinase, platelet 
AMBRA1 -2.20 0.0031 autophagy/beclin-1 regulator 1 
TMEM164 -2.20 0.0102 transmembrane protein 164 
ATP2A3 -2.23 0.0207 ATPase, Ca++ transporting, ubiquitous 
NUMB -2.25 0.0058 numb homolog (Drosophila) 
SMAP2 -2.27 0.0017 small ArfGAP2 
LIMK2 -2.27 0.0318 LIM domain kinase 2 
MAPKAP1 -2.28 0.0000 
mitogen-activated protein kinase associated 
protein 1 
FBRS -2.29 0.0164 fibrosin 
CAP1 -2.30 0.0001 
CAP, adenylate cyclase-associated protein 1 
(yeast) 
PLCB2 -2.30 0.0484 phospholipase C, beta 2 
ZBTB38 -2.33 0.0028 zinc finger and BTB domain containing 38 
FAM102A -2.33 0.0178 
family with sequence similarity 102, member 
A 
ZBTB20; MIR568 -2.34 0.0231 
zinc finger and BTB domain containing 20; 
microRNA 568 
CAPN14 -2.35 0.0194 calpain 14 
ZNF394 -2.38 0.0002 zinc finger protein 394 
RTFDC1 -2.40 0.0033 
replication termination factor 2 domain 
containing 1 
TRIM31 -2.41 0.0159 tripartite motif containing 31 







SEC16A -2.46 0.0074 
SEC16 homolog A, endoplasmic reticulum 
export factor 
CCNG2 -2.48 0.0278 cyclin G2 
SNORD89; 
RNF149 -2.50 0.0336 
small nucleolar RNA, C/D box 89; ring 
finger protein 149 
ALPK3 -2.52 0.0048 alpha kinase 3 
ATHL1 -2.55 0.0156 ATH1, acid trehalase-like 1 (yeast) 
RASGRP1 -2.60 0.0199 
RAS guanyl releasing protein 1 (calcium and 
DAG-regulated) 
TNFRSF11A -2.64 0.0000 
Transcript Identified by AceView, Entrez 
Gene ID(s) 8792 
B3GALT5 -2.67 0.0485 
UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase 5 
NLRP1 -2.76 0.0485 NLR family, pyrin domain containing 1 
LCOR -2.77 0.0001 
ligand dependent nuclear receptor 
corepressor 
SLC25A23 -2.79 0.0009 
solute carrier family 25 (mitochondrial 
carrier; phosphate carrier), member 23 
HEG1 -2.83 0.0017 
heart development protein with EGF-like 
domains 1 
SLC2A3 -2.88 0.0479 
solute carrier family 2 (facilitated glucose 
transporter), member 3 
LRMP -3.00 0.0163 lymphoid-restricted membrane protein 
SPNS2 -3.01 0.0372 spinster homolog 2 (Drosophila) 
ZDHHC18 -3.29 0.0290 zinc finger, DHHC-type containing 18 
DUSP5 -3.29 0.0431 dual specificity phosphatase 5 
TNFRSF10C -3.40 0.0444 
tumor necrosis factor receptor superfamily, 
member 10c, decoy without an intracellular 
domain 
DUSP4 -3.42 0.0027 dual specificity phosphatase 4 
WSB1 -3.59 0.0002 WD repeat and SOCS box containing 1 
GABRP -3.65 0.0047 
gamma-aminobutyric acid (GABA) A 
receptor, pi 
TMEM154 -3.84 0.0122 transmembrane protein 154 
FGL2 -3.91 0.0376 fibrinogen-like 2 
CELF2 -3.93 0.0041 
Transcript Identified by AceView, Entrez 
Gene ID(s) 10659 
CSF3R -4.67 0.0481 colony stimulating factor 3 receptor 
AMICA1 -5.07 0.0380 
adhesion molecule, interacts with CXADR 
antigen 1 
 
